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Interaction between anaemia and human immuno-deficiency virus infection 
in an asymptomatic population in South Africa 
 
By Paul Armah Aryee 
 
Anaemia is common and frequent in HIV infection and Acquired Immune Deficiency 
Syndrome (AIDS). This study was aimed at exploring the interactions between the 
effects of HIV infection and other related anaemia-causing effects (reductive 
adaptation, reduced energy/nutrient intake and inflammatory and/or metabolic 
alterations), which may be responsible for most anaemia in this population.  It is 
postulated that these interactions can heighten the risk levels for anaemia even in an 
asymptomatic HIV-infected population. The study is based on a secondary analysis of 
data from the Transition and Health during Urbanisation of South Africans (THUSA) 
survey, a population-based, cross-sectional study carried out in the North West 
Province of South Africa. Out of a sample population of 1854 ‘apparently healthy’ 
adults, aged ≥15 years, 216 (11.8%) were HIV sero-positive. A validated quantitative 
food frequency questionnaire was used to assess dietary intake and standard 
conditions and protocols used for anthropometric  and biochemical measurements. 
Anaemia was defined using WHO haemoglobin (Hb) and haematocrit (Hct) definitions. 
Univariate ANOVA statistics showed that HIV-sero-positive subjects had lower Hb, Hct, 
serum iron, ferritin, total iron binding capacity (TIBC) but higher % saturation compared 
to their sero-negative peers. However, only the differences in Hct were significant 
(p<0.001).  Anaemia prevalence was generally high but was higher though not 
statistically significant in sero-positives than sero-negatives (51.4% cf. 45.8%, 
p=0.123). Anaemia in the study population was mostly mild (about 65%), with a higher 
proportion of anaemia of chronic inflammation than iron deficiency anaemia. Vitamin a 
deficiency was significantly associated with anaemia (p=0.022). High serum total 
proteins, alanine transaminase (ALT), aspartate transaminase (AST) and low albumin 
were significantly associated with HIV sero-positivity. Predictors of anaemia in the 
study population by logistic regression modelling were settlement type (aOR,1.7;CI,1.2-
2.5;p=0.004), serum albumin (0.6;0.4-0.9;p=0.016), TIBC (1.5;1.0-2.2;p=0.008), vitamin 
E (0.6;0.4-0.9;p=0.006), serum gamma-glutamyl transferase (0.6;0.4-0.9;p=0.007), 
Direct bilirubin (0.5;0.5-1.0;p=0.0446), and abdominal skinfold (1.8;1.2-2.5;p=0.004). 
HIV infection was not a significant predictor of anaemia in this asymptomatic 
population, but the virus and related inflammatory conditions may play a crucial role in 
the development of anaemia. Where HIV and other inflammatory stressors are 
prevalent, the overall burden of anaemia could also be increased. 
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CHAPTER ONE 
1.0 GENERAL  INTRODUCTION 
The human immunodeficiency virus (HIV) is a slow acting retrovirus.  Initial infection 
with HIV may only be associated with a mild illness, and it may take years to develop 
obvious manifestations of the life-threatening disease.  The virus infects components of 
the human immune system such as CD4+ T cells, macrophages and dendritic cells.  
CD4 stands for cluster of differentiation 4, representing the glycoprotein expressed on 
the surface of helper T-cells (also called CD4+ cells), regulatory T cells, monocytes, 
macrophages, and dendritic cells.  HIV can destroy CD4+ T cells directly as well as 
indirectly, but may lie relatively quiescent in macrophages for long periods with 
intermittent reactivation.   
 
T cells are integral to a healthy immune system and impairment of their function 
increases susceptibility to secondary infection from viruses, bacteria, fungi or other 
parasites and reduces immune surveillance against cancer.  Many of the problems 
faced by people infected with HIV result from failure of the immune system to protect 
from opportunistic infections and cancers.  HIV may also attack tissues directly, such 
as the kidneys, the heart and the brain leading to morbidities such as renal failure, 
cardiomyopathy, dementia and encephalopathy.  These direct effects of HIV on tissues 
account for some of the metabolic and physiological impairments associated with the 
infection, but the virus also has important effects on nutritional status, which lead 
directly to altered metabolic function.  Together, the damaged immune system and the 
disordered metabolism increase the vulnerability of the infected person to life-
threatening infection and ill-health.  Progression of these pathologies leads to the 
condition known as acquired immune deficiency syndrome (AIDS).   
 
HIV/AIDS is considered to have emerged from sub-Saharan Africa during the mid-
twentieth century (Gao et al., 1999).  Widespread awareness of HIV followed a brief 
report in 1981 of a rare pneumonia caused by Pneumocystis jiroveci (formerly 
Pneumocystis carinii) as well as other unusual infections in 5 young homosexual men 
in Los Angeles (Centres for Disease Control and Prevention (CDC), 1981; Curan et al. 
1992; World Health Organisation (WHO), 1994).  The realisation that a significant 
epidemic was developing grew as case reports mounted and similar immune deficiency 
syndromes were described in New York, California (CDC, 1981; CDC, 1982), and 
elsewhere among homosexual men, intravenous drug users, Haitians (CDC, 1982), 
haemophiliacs (CDC, 1982), recipients of blood transfusions, infants (CDC, 1982), 
female sexual partners of infected men (Masur et al., 1982; CDC, 1983), prisoners 
(CDC, 1983), and black Africans (Clumeck et al, 1983; Piot et al, 1984; Van de Perre et   2
al. 1984).  As researchers began to describe the epidemiology and risk factors in a 
systematic way, many theories emerged regarding the cause of the ‘mysterious’ 
disease.  An infectious agent was postulated, and, in 1983, scientists led by Luc 
Montagnier at the Pasteur Institute in France first described the virus that causes AIDS, 
lymphadenopathy-associated virus - LAV (Barre-Sinoussi et al., 1983).  Confirmation 
came a year later from a team led by Robert Gallo of the United States, but they 
renamed it human T lymphotropic virus type III (HTLV-III) (Gallo et al., 1984; Levy et 
al., 1984).  After much debate, the virus was renamed human immunodeficiency virus, 
or HIV (Coffin et al., 1986).  
 
It is estimated that at the end of 2008 there were 40 million people living with HIV, and 
during the year there had been 3 million deaths from HIV with 5 million new cases 
(UNAIDS, 2008). In countries most heavily affected by HIV, such as in sub-Saharan 
Africa, life expectancy has been reduced by more than 20 years, economic growth 
slowed, and household poverty deepened (UNAIDS/WHO, 2008).  In stricken 
countries, HIV may have caused a greater loss of productivity than any other disease, 
and is likely to push an additional 6 million households into poverty (UNAIDS/WHO, 
2008).  In this sense, the emergence of HIV/AIDS has inflicted the “single greatest 
reversal in human development” in modern history (UNDP, 2005).   
 
HIV/AIDS has always been associated with the wasting syndrome, which remains a 
major manifestation of AIDS (Suttmann et al, 1995).  However, wasting may not be a 
sufficient identification of poor nutrition, especially if micronutrient status is 
compromised.  Nutrient status can be severely compromised in people with HIV/AIDS 
and low serum levels of a number of micronutrients have been reported and associated 
with disease progression (Beach et al. 1992; Baum et al, 1991; Baum et al, 1995; Tang 
and Smit, 1998; Friis and Michaelsen, 1998; Friis, 2005; Tang et al., 2005).  However, 
some caution is required in interpreting serum levels in HIV/AIDS because of the 
effects of ongoing low-grade chronic inflammation (Thurnham and Northrop-Clewes, 
2007). 
 
The introduction and availability of potent antiretrovirals (ARV) for the treatment of 
HIV/AIDS has contained the condition to an extent.  Attention has been directed to 
identifying factors that may be indicative of an increased risk of progression of clinical 
disease in both the short and the longer term.  The main indicators appear to be 
measures related directly to the virus itself or its impact, viral load and CD4 count, or 
factors related to the altered metabolic function of the host, relative weight, anaemia or 
maybe plasma albumin concentration (Morcroft et al., 1999; Shah et al., 2007).     3
Anaemia has emerged as a potentially important prognostic factor and has frequently 
been associated with HIV infection and its progress, but the causal relationship 
remains unclear.  The virus might have a direct effect on red cell precursors, but 
anaemia also commonly accompanies acute infection and low grade chronic 
inflammation, is often the result of poor nutritional status, might be related to 
medications given to treat the virus, or any combination of these and other factors.   
 
With a rising trend in the prevalence of HIV/AIDS, there is a growing consensus that 
the pandemic could constitute an important cause of anaemia (Volberging, 2000).  In 
those areas where anaemia is already a significant problem, HIV/AIDS could further 
aggravate this burden, but the relationship is neither simple nor clear and it is difficult to 
assess which interventions might be effective (Adetifa and Okomo, 2009).  In sub-
Saharan Africa, where the problems of both HIV/AIDS and anaemia have considerable 
impact and appear most intractable the evidence is least clear.  Those who are most 
sexually active are young adults and this makes them most likely to be exposed to the 
risk of infection.  They are also the most productive members of the workforce.  Hence, 
HIV/AIDS impact directly on the production, availability, stability and access to food.   
 
By reducing local or domestic food and nutrition security HIV will increase the likelihood 
of poor nutrition (Gillespie and Kadiyala, 2005).  HIV and malnutrition will interact 
negatively to have an adverse effect on the immune system (ACC/SCN, 2001).  In a 
cyclical relationship HIV increases susceptibility to secondary infections, thereby 
compromising nutritional status, whilst malnutrition itself weakens the immune system, 
thereby further exacerbating the effects of HIV (Semba and Tang, 1999, Calder and 
Jackson, 2000; Piwoz et al., 2004).   
 
It can be concluded that, though several outcomes have been associated with 
HIV/AIDS, anaemia appears to be an important marker, or risk factor for disease 
progression and mortality in persons infected with the HIV or AIDS.  This thesis 
explores the nature of the relationship between anaemia and HIV/AIDS in a population 
in South Africa as a secondary analysis of data from a cross-sectional study. 
 
1.1  OUTLINE OF THE THESIS 
The thesis has been organised into eight (8) chapters.  Chapter one, gives an overview 
of the research and describes the general framework used to explore the factors 
relating HIV infection to anaemia.  This chapter also states the rationale, aims/ 
objectives and hypothesis, and outlines the framework for developing the hypothesis in 
the study.  In Chapter 2, HIV/AIDS, anaemia and the nature of their interaction is   4
reviewed.  There is an overview of HIV/AIDS, which includes a brief historical 
perspective, an outline of its pathophysiology, epidemiology and therapeutic 
approaches.  The effects of HIV on nutrition and aspects of the complex 
interrelationships amongst HIV infection, immune processes, inflammation and nutrition 
are presented.  The nature of anaemia, its causes, pathophysiology, and other 
characteristics are also outlined.  Chapter three sets out the methodology employed for 
the study, with regards to study design, subject selection, data collection and the 
reason for selecting specific variables for secondary analyses in this thesis.  It also 
includes a description of structure adopted in addressing the hypothesis.  Of three 
results chapters, the first (chapter 4) presents and discusses the preliminary results 
consisting of the socio-demographic characteristics of the study population in relation 
to HIV infection and anaemia.  Chapter 5 presents and discusses the results on 
prevalence of anaemia and highlights effects that may serve as possible explanatory 
factors of anaemia in the study population.  Chapter 6 explores the putative interplay 
between the direct and the indirect effects of HIV on anaemia whilst elucidating 
significant predictive factors for anaemia in the study population.  Chapter 7 provides a 
general discussion of the main findings in the light of previously published work in the 
area of HIV infection and anaemia.  It also presents the limitations of the study, 
implications for public health, and recommendations for future work.  In Chapter 8 the 
main conclusions from the study are stated. 
 
1.2  HUMAN IMMUNO-DEFICIENCY VIRUS AND ACQUIRED IMMUNE 
DEFICIENCY SYNDROME 
As a slow acting virus that may take years to produce illness in its victim, HIV impairs 
the immune system reducing resistance and increasing susceptibility to infection with 
other viruses, bacteria, fungi or other parasites: so-called "opportunistic infections" (OI) 
that arise in the setting of immune impairment.  Currently there is neither a cure for 
HIV/AIDS nor a vaccine to protect against infection. 
 
For an HIV infected individual the lowering of CD4+ cell counts to < 200 cells/µL 
signifies the onset of AIDS, and greatly increased risk of OI.   The CD4+ lymphocyte 
count in the blood is used to monitor the effect of HIV on the immune system.  A CD4+ 
cell count between 600 and 1200 cells/µL is considered normal and indicates that the 
immune system has not undergone sufficient damage to put the individual at high risk 
for OI.  Such individuals are unlikely to require specific treatment.  A CD4+ count of 
<350 cells/µL indicates impairment of immune function and should prompt 
consideration for antiretroviral therapy.  When CD4+ counts fall to <200 cells/µL the 
individual is at imminent risk of serious OI or other complication and prompt treatment   5
is recommended (Dybul et al., 2002).  The time required for an HIV infected person to 
develop full blown AIDS depends on the strain and type of the virus as well as host 
factors that include age, co-infections, genetic factors, health and nutritional status 
before and during the infection (HIV/AIDS, 2004).  Antiretroviral drugs directly attack 
the virus and significantly reduce its replication in the body, thus reducing the viral load 
and slowing down the progression of the disease.  There are also therapies for the 
prevention, treatment or cure of many OI to minimise their effects or complications.   
 
Untreated HIV infection is chronic and progressive with recognisable stages.  Acute 
infection occurs when the virus is introduce into a person.  This is followed by the early 
stage during which the infected person mounts a vigorous antibody reaction to the virus 
and therefore is considered as sero-converted.  This progresses over time to the 
clinical latent HIV infection or asymptomatic phase, which is followed by the late stage 
or late symptomatic phase, when the individual can be said to have AIDS.  
 
1.3 ANAEMIA   
The term anaemia derives from a Greek word meaning “without blood”, representing a 
situation in which the number of red blood cells (RBC) or erythrocytes in the circulation 
is less than usual, and hence associated with a reduction in the haemoglobin in blood 
and its capacity to carry oxygen to the tissues.  On this basis anaemia has been 
variously defined; as a reduction in the number of circulating RBC or decreased 
haematocrit, insufficient amount of haemoglobin, or a reduction in the oxygen carrying 
capacity of the blood (Phillips and Groer, 2002).  However, limits of normality for 
haemoglobin concentration [Hb] or haematocrit (Hct) have been set by convention, 
below which anaemia is defined (See Appendix A).  These represent the usual range of 
values found in a healthy population at sea level, by age and gender 
(WHO/UNICEF/UNU, 2001).  The distribution of the haemoglobin concentration in 
healthy, fully iron-replete subjects is 120-160 g/L in women and 140-180g/L in men 
(Wintrobe, 1981).   
 
Anaemia is one of the most common and intractable nutritional problems with 
consequences for health, social and economic development (WHO/UNICEF/UNU, 
2001).  Close to 2 billion people in the world are anaemic and prevalence of anaemia is 
closely associated with poverty (Tomkins and Watson, 1989; WHO/UNICEF/UNU, 
2001).  Anaemia is a widespread public health problem associated with an increased 
risk of morbidity and mortality, especially in pregnant women and children in resource 
poor settings (WHO, 2002).   It has been identified as the second most common cause 
of disability (Murray and Lopez, 1996).  There are general, non specific symptoms   6
associated with milder degrees of anaemia, but the functional consequence of severe 
anaemia may be incapacitating.   
 
Red cells are constantly being formed and degraded within the body and, at any point 
in time, the RBC mass represents a balance between these two rates.  A reduced red 
cell mass must reflect an imbalance in the rates of production and degradation or 
destruction of RBC and/or blood loss.  
 
There are a large number of factors which can contribute to the development of 
anaemia: those which act primarily on red cell production and those that exert their 
influence through altered red cell loss.  Factors operating on red cell production would 
include poor diet and nutritional factors that limit the formation of haemoglobin or the 
production of red cells in adequate amounts.  Nutritional factors might also act to 
increase red cell destruction, for example poor vitamin E status increases red cell 
fragility and susceptibility to oxidant damage, hence increasing the likelihood of 
haemolysis.  Red cell production may be impaired by chronic disease, medications or 
other factors that impair marrow function; where RBC are produced.  Red blood cell 
destruction or losses can be increased by genetic disorders such as sickle cell disease, 
or blood loss that may be associated with some gastrointestinal helminthic infections 
(e.g. hookworms) or menstruation.  It is considered that dietary deficiencies, especially, 
iron deficiency, account for a major proportion of anaemia in many populations 
(Kraemer and Zimmermann, 2007).   
 
Irrespective of the cause, anaemia is an important indicator of both poor nutrition and 
health.  Even mild or moderate anaemia can alter the sense of well-being or the quality 
of life (QOL) of victims.  When severe, the effect of anaemia can be dramatic.  It 
increases the risk of child and maternal mortality, impairs growth and cognitive 
development in children and leads to low school performance; reduces physical 
capacity and work performance in adolescents and adults (Stoltzfus, 2001); and also 
decreases resistance to infections in affected persons.  
 
It has been suggested that much anaemia may derive from the synergy between the 
inflammatory process and its effects on the bio-availability of nutrients such as iron.  
Thus, although iron deficiency anaemia (IDA) may be the most obvious or prevalent 
form of nutritional anaemia (WHO/UNICEF/UNU, 2001), it is increasingly recognised 
that iron deficiency might be a final common pathway both for prevalent infection and 
associated nutritional problems.  Infections, together with the associated inflammation, 
interact with nutrient availability and hence may play an important role in the initiation   7
and perpetration of much anaemia (Thurnham and Northrop-Clewes, 2007).  Frequent 
exposure to endemic infections will evoke a persistent inflammatory response, thereby 
limiting iron availability for RBC synthesis (Thurnham and Northrop-Clewes, 2007).   
Infections can also lower RBC mass and haemoglobin concentrations through direct 
suppression of bone marrow synthesis and haemolysis.  Furthermore, infections may 
reduce dietary intake, impair nutrient absorption, increase nutrient utilization and 
increase losses of nutrients (Tomkins and Watson, 1989).   
 
Infections such as malaria, helminthiasis, tuberculosis (TB) and, now increasingly, 
HIV/AIDS, are among the important factors that potentially contribute to a persistent 
high prevalence of anaemia in developing regions such as sub-Saharan Africa (Lynch, 
2005; Kraemer and Zimmermann, 2007).  These infectious conditions are not 
uncommon in the region of study and have been shown to contribute to the cause of 
anaemia, especially in pregnant women (Hoque et al., 2007).  In humans malaria 
infection by Plasmodium species is associated with a reduction in haemoglobin levels, 
frequently leading to anaemia.  Though the pathogenesis of malarial anaemia is not 
very clearly understood, important factors ascribed to its occurrence include 
disordering of RBC development, intravascular haemolysis of infected RBC, together 
with destruction of both parasitized and non-parasitized RBC by macrophages (Roberts 
et al., 2005).  Gastrointestinal helminths such as Ascaris and hookworms contribute 
significantly to IDA through the feeding activities of intestinal stages leading to chronic 
blood loss into the gut.  With TB and HIV/AIDS, associations with anaemia has been 
common and many different mechanisms for anaemia, including direct and indirect 
effects on the bone marrow and body metabolic  processes, have been suggested.   
 
The presence of concurrent poverty, unsanitary conditions and inadequate health care 
increases exposure and encourages the spread of infectious diseases which may add 
to the risk of developing anaemia (Kraemer and Zimmermann, 2007).  The wave of 
rapid urbanisation sweeping across the developing world can contribute to anaemia 
through changes in nutrition or dietary patterns, associated with social, cultural, and 
economic changes intrinsic to the demographic transition (Vorster et al., 1999). 
 
Despite the emphasis placed on anaemia as a widespread problem and the efforts to 
reduce it, prevalence levels remain unacceptably high (Kraemer and Zimmermann, 
2007; WHO/UNICEF/UNU, 2001).  This is probably because the cause is more 
complex than a simple dietary deficiency.  Recognition that the aetiology of anaemia is 
often complex and multifactorial shifts the emphasis for prevention to a consideration of 
a wider range of potential causative factors that may be independent, reinforcing or   8
mutually additive.   These factors may vary depending on prevailing circumstances and 
population characteristics.  Thus to identify effective interventions to correct anaemia it 
is necessary to have a clear understanding of the individual causative factors and the 
likely complexity of their interplay.  This will then indicate the required mix of 
interventions, which may vary both absolutely and relative to each other depending on 
the circumstance.  The need to effectively address the anaemia related problems 
remains urgent, and these efforts are implicit to achieving many of the targets 
stipulated by the global Millennium Development Goals (MDG), of the United Nations 
(United Nations, 2007).   
 
1.4   HIV/AIDS AND ANAEMIA 
Anaemia is one of the more important objective measures that mark risk of clinical 
progression in HIV/AIDS (Volberding, 2002).  This is true for early as well as late 
disease, and seems to hold even if the anaemia improves subsequent to therapy with 
ARV (Volberding et al., 2004).  Anaemia in HIV/AIDS is also associated with increased 
mortality or decreased survival (Sullivan et al., 1998; Moore et al., 1998; Lundgren and 
Morcroft, 2003; O’Brien et al., 2005), which may be linked to a reduction in functional 
capacity and QOL experienced by most persons living with HIV/AIDS (PLWHA) 
(Abrams et al., 2000).  Low haemoglobin levels have been associated with 
immunosuppression (Kreuzer and Rockstroh, 1997).   
 
In HIV infection, anaemia has been identified as a prognostic marker of disease 
progression or early death, independent of CD4+ T cells and viral load (Sullivan et al., 
1998; Morcroft et al., 1999; Moyle, 2002).  Anaemia remains a statistically significant 
marker of disease progression even in the presence of therapy with ARV, and seems 
to hold even if anaemia improves subsequent to therapy (Moorcroft et al., 1999; 
Sullivan et al., 1998), regardless of CD4+ cell count, clinical AIDS, age, and the 
presence of other cell line depletions (Sullivan et al., 1998; Sullivan and Buskin, 2003).   
 
Though infection with HIV has been primarily characterised by a depletion of CD4+ T 
lymphocytes, other cell line depletions including that of erythrocytes have been 
recognised (Volberding et al, 2004).  Clinically, erythrocyte depletion characterised as 
anaemia is the most frequent manifestation, though thrombocytopaenia (platelet 
depletion) and complications of other bone marrow elements are also important (Hoxie, 
1995; Davis and Zauli, 1995; Costello, 1997).  These changes have generally been 
ascribed to impairment of the haematopoietic process, as well as to immune-mediated 
cytopaenias and altered coagulation mechanisms (Claster, 2002; Costello, 1997).   
   9
There are several epidemiological studies that suggest that the occurrence of anaemia 
tends to increase HIV disease progression and risk of death in PLWHA (Graham et al., 
1993; Sullivan et al., 1998; Mocroft et al., 1999; Semba et al., 2002; Belperio and 
Rhew, 2004), and even changes in haemoglobin that might be described as modest 
(about 1 g/dL) have been associated with a significant increased risk of death (Moyle, 
2002).  Other epidemiological studies also suggest that anaemia in HIV/AIDS is 
associated with an increased progression to dementia (McArthur et al., 1993), a 
decreased survival or increased mortality (Moore, 1999; Semba et al., 2002).   
However, some intervention studies strongly suggest that reversing anaemia can 
prolong survival by slowing down disease progression (Graham et al., 1993; Sullivan et 
al., 1998; Moore et al., 1998; Moore, 1999).  Anaemia in HIV/AIDS may therefore have 
implications for the management of the disease, which could, by and large, reflect on 
the health of the sufferer and by extension affect development and progress in the 
entire population. 
 
The signs and symptoms of anaemia may be more evident in the later stages of 
HIV/AIDS (Davis and Zauli, 1995), but they may be an early feature of the disease 
(Fleming, 1989; Street and Milliken, 1993), or may mark the onset of infection 
(Snopková et al., 2005).  Prevalence and severity of anaemia tends to increase with 
progression of the disease; being lower and often milder in the asymptomatic stage 
and higher and severer in clinical AIDS (Sullivan et al., 1998; Bain, 1999), with 
prevalence levels reaching 95% in some populations (Volberding et al., 2004).  The 
incidence and symptoms of anaemia may have been reduced with highly active 
antiretroviral therapy (HAART) (Moore, 1999b; Moore and Forney, 2002), but it remains 
a serious problem in PLWHA.  Nevertheless, its importance in the HIV infected 
population remains unexplained and, more often than not, anaemia goes undiagnosed 
in spite of its obvious clinical implications. 
 
1.5  CAUSES OF ANAEMIA IN HIV/AIDS 
The causes of anaemia in HIV/AIDS remain uncertain, but studies suggest its 
multifactorial nature (Claster, 2002; Volberding et al., 2004) with certain population 
characteristics playing an important role in its determination (Volberding and Sullivan, 
2002).  Potential causes of anaemia in HIV disease include direct HIV infection of 
hematopoietic stem cells/erythroid progenitors, immune system–mediated haemolysis, 
neoplasms, aplastic anaemia, blood loss, opportunistic bone marrow infections as well 
as deficiency of erythropoietin (Kreuzer and Rockstroh, 1997).  Nutrient deficiencies 
such as vitamin B12, folate, and iron also contribute to the development of anaemia, 
though it may be to a much lesser extent in infected persons living in developed   10
countries (Moyle,  2002), whilst medications used to treat the infection or  disease or 
associated co-morbidities can trigger anaemia (Volberding, 2000; Volberding et al., 
2004).   
 
Perhaps one of the main reasons why anaemia is very common and frequent in the 
HIV population is because its plethora of causes include the direct effects of the virus, 
which has the ability to potentiate or interplay with other anaemia inducing factors.     
HIV infection alone without any concurrent medications or co-morbidities or co-
infections can cause anaemia (Harbol et al., 1994; Claster, 2002).  A number of studies 
have shown that HIV can directly impair the survival or proliferative capacity of purified 
haematopoietic progenitor cells (Mitsuyasu, 1994; Davis and Zauli, 1995; Redd et al., 
2007).   
 
Whilst some of the factors that interplay with HIV in the cause of anaemia may be 
associated with the disease, others may remain as stressors within the population.   
Thus, the spectrum and nature of the factors causing anaemia in HIV/AIDS may be 
broad but, nevertheless, often manifest as changes in the metabolic and immunologic 
integrity of the sufferer.   
 
The chronic inflammatory nature of HIV/AIDS means a persistent immune inflammatory 
response in the body, with attendant surges in circulating cytokines and changes in 
inflammatory bio-markers (Janeway et al., 1999; Volberding, 2000; Claster, 2002).       
Opportunistic infections and other stressors associated with HIV infection can also 
induce inflammation.  With persistent inflammation there is a tendency to maintain a 
continuous hypoferaemia with a concomitant suppression of erythropoiesis (Thurnham 
and Northrop-Clewes, 2007) and an increased release of inflammatory cytokines has a 
negative effect on erythropoietin levels and/or response, leading to erythropoietic 
failure (Hambleton, 1996).   
 
Poor energy and nutrient intakes have always been recognised as part of the HIV 
infection due to changes in metabolic responses, especially as the infection progresses 
to AIDS (Bain, 1999).  The common manifestations of weight loss, altered nutrient 
profiles, specific micronutrient depletions, and fat redistribution together with altered 
endocrine function and depleted haemopoietic cell lines, reflect the body’s attempts to 
cope with the persistent effects of the virus and associated co-infections.  These 
manifestations essentially describe the consequence of inadequate food intake over 
extended periods of time, which fits the processes associated with reductive adaptation 
(Ashworth, 2001).  Thus, the consequences of reductive adaptation may be crucial in   11
restricting RBC production, as it is usually associated with the creation of an 
environment that tends to shorten the lifespan of RBC (Jackson, 2007; Barroso, 1999).  
 
In HIV infection multiple nutritional deficiencies may be common, amongst which iron 
(Fe), riboflavin (B2), folate and cyanocobalamin (B12) deficiencies may contribute to the 
reduction of haemoglobin synthesis (Volberding et al., 2004).  Other micronutrients like 
vitamins A, thiamin (B1), niacin (B3) and pyridoxine (B6) have also been implicated in 
limiting the production of RBC.  Such deficiencies may result from dietary 
inadequacies, gastrointestinal pathology, malabsorption, altered metabolic handling or 
some combination (Friis and Michaelsen, 1998; Tang and Smit, 1998, Friis, 2005).  
 
Other factors that may contribute to anaemia in HIV/AIDS include the presence of 
concurrent and endemic infections such as malaria, genetic disorders and other 
population characteristics, as well as the use of antiretroviral, antifungal or antibacterial 
agents (Hambleton, 1996; Groopman, 1998), more especially, those that have been 
noted to be myelosuppressive (Levine, 1999). 
 
Whether anaemia in HIV infection can be ascribed mainly to any specific nutrient, or to 
a reduced energy demand stemming from an altered body composition or to the 
presence of infection or inflammation or to a combination of these, is an important 
question that remains to be answered.   
 
1.6  SIGNIFICANCE OF ANAEMIA IN HIV/AIDS 
In HIV infection, underlying nutrient and energy imbalances may often manifest as a 
reduction in red cell mass (anaemia) and/or a reduction in lean body mass and/or a 
change in other physiological processes (Jackson, 2007).  The appearance of 
hypoferaemia may signify changes in the distribution of iron in response to the 
inflammatory process or changes associated with other nutrients.  These changes may 
be considered as adaptations, which help conserve energy and nutrients, or protect 
against pathogenic agents.  It remains unclear the extent to which anaemia is reflective 
of other underlying processes or is in itself a direct contributor to the pathology of HIV:.  
Although this is not the main thrust of this study, an important question that remains 
unanswered is ‘’what is the real significance of anaemia in HIV infection?’.  Could 
anaemia in the HIV/AIDS population be a marker of the processes underlying the 
infection? Alternatively, could it be protective or contribute directly to survival?  In other 
words, is there any advantage in being anaemic in HIV infection?  
 
In many poor-settings anaemia will continue as an important associate of HIV infection 
even with ART since the many factors that are responsible for its cause are combined,   12
interwoven and rife.  With improvements and scaling up of ART especially in 
developing countries the relative causes of anaemia in HIV infection may change.   
Lives of infected persons would be prolonged and maintaining QOL would become of 
utmost importance.   
 
Clearly, the reduction or treatment of anaemia, especially, in HIV/AIDS and other 
pathological conditions calls for a clearer understanding of the underlying interactive 
processes in order to facilitate the formulation and initiation of appropriate policies and 
interventions leading to a resolution or alleviation of the problem.  An assessment of 
the incidence or prevalence and determinants as well as the impact of anaemia in this 
population would be beneficial, serving as a basis for choosing preferred approaches 
for managing the disease. 
 
1.7  PROBLEM STATEMENT AND RATIONALE FOR THE STUDY 
Anaemia is a substantial public health problem, especially in poor-settings, where it 
adds to the woes of children and women of child bearing age.  In sub-Saharan Africa, 
where the prevalence of HIV/AIDS and malnutrition are high, anaemia is common 
adding to the considerable burden of morbidity and mortality.  The problem of anaemia 
in many resource-poor settings is made worse by the fact that population 
characteristics such as endemic genetic disorders and the prevalence of infections like 
malaria and helminthiasis may add to the burden of anaemia.    
 
Anaemia in HIV infection can be the product of a number of interactive causes or 
factors, and it has been difficult to determine the sequence or order of their impact in 
terms of causality.  However, it seems clear that the virus can have a direct effect 
which may alter the balance between red cell production and destruction, leading 
thereby to anaemia.  It is possible that HIV/AIDS is a major causative factor in the 
development of anaemia and that this anaemia is indicative of the likely severity or 
progression of the disorder.   
 
However, given the susceptibility to infection and nutrient deficiency, for any HIV 
infected population, there is also greater likelihood for an interplay with other factors 
which could in themselves cause or exacerbate anaemia.  It is for these reasons that 
this study postulates that HIV infected persons are more likely to be anaemic in 
comparison with uninfected persons and that those with a greater number or interacting 
combination of factors are more likely to be anaemic, or have anaemia of greater 
severity.  In other words infection with HIV can increase both the frequency and degree 
of anaemia in infected persons.   13
In a population such as the one under study, where there could be distinctive anaemia 
causing factors, establishing HIV/AIDS as an important factor related to anaemia would 
be an added step towards helping in reducing the burden of both public health 
problems.    In fact, within the region of study another important factor that could be 
contributing to the prevalence or incidence of anaemia is the process of rapid 
urbanisation occurring in the African population.  The tendency for this sweeping 
transformation to push the incidence and prevalence of HIV infection into prominence 
and to provoke other important health transformations gave the impetus for the 
Transition and Health during Urbanisation of South  Africans (THUSA) survey (see 
details in section 3.2).  The high prevalence of HIV infection in this population (South 
African Department of Health Survey, 2007), together with the presence of factors that 
could be considered as predisposing to anaemia (Vorster et al, 2000), such as poor 
dietary practices and other infectious conditions, were indicators that  influenced the 
use of the THUSA data as a source for the secondary analysis in this research. 
 
Much as anaemia is recognised as an important clinical manifestation, its real 
significance especially in HIV infection remains enigmatic and therefore a matter for 
more research and discussion.  The focus of treatment and care for PLWHA may have 
to change towards preventing or treating anaemia to maintain QOL and to enhance 
survival.  Although the management of HIV/AIDS has improved with the use of potent 
ARVs and other therapies, anaemia and poor QOL persist.  Owing to the impact of 
anaemia on the QOL of HIV infected persons, research on anaemia is beginning to 
receive increased attention, more so when evidence shows that recovery from anaemia 
can improve the QOL of HIV patients (Moore et al., 1998; Sullivan et al., 1998).  
 
Despite the multifactorial causation of anaemia in HIV/AIDS, the direct role of the virus 
in the development of anaemia as well as its anaemia potentiating capabilities raises 
important considerations.  It remains important to recognise the other processes that 
may be involved and the potential for multiple, complex interactions.  Thus, although 
HIV infected persons may be intrinsically more susceptible to anaemia in comparison 
with non-infected persons, there is the possibility that the interacting effects causing 
anaemia have special potency in HIV, varying between and within population groups, 
and with the stage of infection.  It may be that specific effects or combination of effects 
may be more predisposing to anaemia than others.  These possibilities present a basis 
for a study for exploring the interaction of important factors on the risk for anaemia in 
the HIV population.  The identification of new relationships could be useful in the 
development of novel strategies for both anaemia and HIV infection.  It is on this basis 
that the objectives of the present study were developed.    14
 1.8 STUDY  HYPOTHESIS 
The apriori hypothesis for the study postulates that, infection with HIV puts individuals 
at a significantly increased risk for becoming anaemic because of the direct effects of 
the virus and other additional and interactive indirect effects.  Thus, for HIV infected 
persons either the factors predisposing to anaemia are greater than in uninfected 
persons or the many factors add up or significantly interplay to predispose infected 
persons to anaemia.   
 
The statement of the main and the null hypotheses for this study are: 
H1: HIV infected persons are more anaemic in comparison with uninfected persons. 
H0: HIV infected persons are as likely to become anaemic as uninfected persons.  
The exposures and outcomes that were considered for addressing the main hypothesis 
included the following: 
 
Exposures 
•  HIV status (main) 
•  Anthropometry (weight, height, body mass index (BMI), lean body mass (LBM), 
lean mass index (LMI) and skin fold thicknesses) 
•  Energy intake (Plus and minus alcohol as component) 
•  Dietary micronutrients (Vitamins A, B1, B2, B3, B6, B12, C, E, zinc, iron and copper) 
•  Serum micronutrients (Vitamins A and E) 
•  Inflammatory markers:  
o  Acute phase proteins (APP) (serum total proteins, serum albumin, serum 
‘globulins’, serum ferritin and plasma fibrinogen) 
o Liver enzymes/by-product (aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), gamma glutamyl 
transferase (GGT) and bilirubin (Total and Direct)) 
 
Outcome 
•  Anaemia (Defined by [Hb], haematocrit (Hct), serum iron, serum ferritin, total iron 
binding capacity (TIBC) and % transferrin saturation)  
 
1.9  THE AIMS AND OBJECTIVES OF THE STUDY 
The essence of this research was to elucidate the risks that HIV infection may pose to 
the development of anaemia in a South African population whose exposure to HIV 
infection and other primary factors that cause anaemia may be considered as high.  In 
this study, HIV infection is considered a primary exposure together with other factors 
that may or may not be associated with the infection, such as changes in body   15
composition, poor dietary intake of energy or nutrients, as well as metabolic and 
inflammatory changes.   
 
The findings of this work might serve as a basis in later research for developing a 
scheme for identifying the interactive effects associated with anaemia in HIV infected 
persons at higher risk for developing anaemia.  Perhaps the significance of anaemia in 
the asymptomatic or early stage of HIV infection might be highlighted.  Furthermore, 
identifying factors that determine anaemia in the population could be important for 
assessing the state or progress of HIV disease and also for predicting the survival and 
QOL outcomes of PLWHA later on. 
 
The following objectives were set out to enable the exploration of the data set in order 
to achieve the purpose of the study. 
•  To characterise HIV sero-status in the study population 
•  To identify socio-demographic indicators of the study population that may relate to 
HIV status and anaemia 
•  To characterise anaemia and relate it independently with HIV status in the study 
population 
•  To explore changes in body composition, dietary energy and nutrient imbalances 
and metabolic and inflammatory alterations as possible explanatory factors for 
anaemia in the study population 
•  To explore for factors that may interplay with HIV infection and may predict 
anaemia in the study population. 
 
1.10 THE FRAMEWORK FOR THE CAUSALITY OF ANAEMIA IN THE STUDY 
POPULATION 
The proposed framework for this study, as depicted in figure 1.1 below, assumes a 
complex interaction between the factors responsible for anaemia in HIV infection.  The 
pathways show that the main exposure of HIV infection could have both a direct and 
indirect effect in upsetting the balance between red cell production and destruction and 
to precipitate anaemia.   
 
Within the context of this study, HIV status would be measured by the sero-status of 
the subjects.  However, levels of infectivity or degree of severity of infection as 
measured by HIV titres in the blood or CD4+ cell counts would probably have been 
more appropriate in accounting for the effect of the exposure on anaemia.     16 
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Nevertheless, it is strongly contended that the mere presence of the virus, because of 
its direct involvement, can make the distinction between anaemia in infected and 
uninfected persons irrespective of the stage of infection.  
 
Another consideration in the framework is the fact that a poor or inadequate energy 
and nutrient intake, which could be triggered either by a limited availability of food or 
the effects of underlying HIV and other OI on the gastrointestinal tract, can lead to 
anaemia in infected persons.  In most infections, a reduction in energy and nutrient 
intake, which can be associated with anorexia and other physiological alterations often 
induced by the infection and, often ascribable to the inflammatory process, may occur.   
In most poor- settings , social considerations such as stigma and isolation can be very 
crucial in limiting food intake.  A poor or inadequate energy and micronutrient intake, 
especially if prolonged, can lead to changes in body composition and wasting or weight 
loss, which may trigger a physiological adaptation by the body in the presence of the 
reduced energy – reductive adaptation.  Part of the reductive adaptational process is 
associated with an increased destruction of RBC as well as production of fewer and 
poorly formed cells, which may underlie the anaemia in this case.   
 
In this study energy and micronutrient intakes have been assessed and levels of their 
adequacies or inadequacies estimated.  In addition, body compositional measures 
such as BMI, LMI and skin fold thicknesses have been used to assess reductive 
adaptation.  However, considering the asymptomatic or ‘apparently healthy, disposition 
of the sero-positive  subjects, marked changes in their energy and nutrient intakes as 
well as their body compositions would not be expected to have occurred. 
 
In HIV infection as in many others, alterations in metabolic response may result in an 
increased utilisation and loss of nutrients, especially micronutrients, as they are 
required in the intermediary metabolic process and are often eliminated with other 
metabolic by-products or waste as part of the excretory process.   The physiological 
effects of HIV infection also include malabsorption and diarrhoea, which are 
concomitant with nutrient losses.  With time, nutrient imbalances may be created as a 
result of these combined effects and may eventually lead to specific nutrient 
deficiencies and oxidative stress which, by and large, have a tremendous effect of 
lowering RBC production.   
 
As the body’s integrity is challenged by the infective agent, a vigorous defence is 
invoked usually with an increase in inflammatory cytokines, such as tissue necrotic 
factor-alpha (TNF-α) and interleukin-6 (IL-6), concomitant with an increase in the   18
body’s metabolic expenditure.  The liver and other members of the reticulo-endothelial 
system (RES) are activated and a large amount of energy and nutrients are expended.  
The increased protein and nutrient turnover at this stage compromises body 
composition and, additionally, the resulting alteration in nutrient metabolism may lead 
to the development of specific nutrient deficiencies which may precipitate an oxidative 
imbalance and stress.   
 
The chronic inflammatory nature of HIV infection is likely to cause the release and 
maintenance of a persistence surge of the TNF-α, interleukin-1 (IL-1) and IL-6), more 
so when destruction of the immune system allows OI to set in.  A hyper-inflammatory 
state, with an attendant increase in protein turnover, results in alterations in the 
metabolism of acute phase proteins (APPs) as well as the maintenance of a 
hypoferaemic state and reductions in many specific nutrients in the body that are 
critical for RBC production.  Levels of some APP increase (positive APP) e.g. C-
reactive protein (CRP) and ferritin, whilst levels of others tend to decrease (negative  
APP) e.g.  ceruloplasmin and albumin.  Because the negative APP are often carriers of 
micronutrients their declining levels during the APR tends to lead to a reduction in 
plasma or serum levels of micronutrient.   
 
The measurement of cytokines are more likely to express the immune response but for 
some reasons this is cumbersome coupled with the fact that cytokines have very short 
half-lives.  Thus, APP, are often used as proxy markers to reflect these inflammatory 
responses.  The APPs CRP and α-1-acid glycoprotein (AGP) in particular, are used 
very frequently to measure acute and chronic  inflammation respectively, but in this 
study ferritin, total proteins, albumin and plasma fibrinogen, which are equally important 
proxy markers, have been used instead.   In addition the study also relies on 
measurements of liver enzymes as closely depicting inflammatory response from the 
liver. 
 
Within the causal inter-relationships between HIV infection and anaemia it is also 
suggested that factors that may not necessarily be directly ascribed to HIV but may be 
contributory to the development of anaemia in the population are recognisable. For 
instance, a limited availability of food, which is most likely to occur in any population 
whose prevailing socio-economic and environmental circumstances are such that they 
affect food security, can also induce a poor energy and nutrient intake.  The fact is that 
certain social or politico-geographic changes, such as what may pertain in war-torn 
regions can have tremendous repercussions on food supply and availability.  An 
imposition of physical restrictions or barriers on PLWHA either by upholding societal   19
norms or by the debilitating effect of the disease could limit their physical activity and 
therefore their functionality, which could subsequently lead to a reduction in their food 
intake.   
 
In populations where infectious diseases such as malaria and helminthiasis are 
common, susceptibility to anaemia can be quite high.  Furthermore, the endemicity of 
certain specific population characteristics like race, as well as hereditary traits, which 
include haemoglobinopathies (e.g. sickle cell disease) and other genetic disorders (e.g. 
glucose-6-phosphate dehydrogenase (G-6-PD) deficiency) as well as the use of 
myelosuppressive anti-microbial medications can account for the high prevalence of 
anaemia in some populations.  Unfortunately factors that would be classified as not 
related to HIV infection but likely to contribute to the overall burden of anaemia in the 
study population, as suggested above, have not been  assessed.  Although some of 
these factors may exist in the population, not being able to account for them may be 
considered as a limitation of this study.  
 
Notwithstanding the complexity in the array of causal effects, it is highly possible that a 
combined effect of infection with the virus and/or other co-infections, its associated 
nutritional, metabolic as well as inflammatory effects and other stresses related to 
these, would constitute a strong combination that could significantly determine the 
frequency and severity of anaemia in the HIV population.  The outcome of this, if 
proven, could undoubtedly place HIV infection as an important cause of anaemia.     
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CHAPTER TWO 
2.0 LITERATURE  REVIEW 
2.1    INTRODUCTION – HIV/AIDS AND ANAEMIA  
Advances in antiretroviral therapy (ART) have enabled people infected with HIV to live 
longer, making it increasingly important to understand the nature of the inter-
relationship between HIV/AIDS and anaemia because of the impact that anaemia has 
on morbidity and mortality.   
 
Estimates of the prevalence of anaemia in HIV/AIDS have varied from 1.6% to 95% 
depending on the setting (Sullivan et al., 1998; Belperio and Rhew, 2004).   Anaemia 
occurs in all stages of HIV/AIDS but prevalence tends to rise with disease progression 
(Abrams et al., 2000; Belperio and Rhew, 2004).  Thus, 66% to 85% of infected 
persons who have progressed to AIDS may have some form of anaemia (Ganser, 
1988, Hambleton, 1996).  Anaemia has not usually been considered to be a noteworthy 
complication of HIV infection, but it does appear to have significant impact both on 
QOL and on clinical outcome (Cella, 1996; Breitbart et al., 1998; Barroso, 1999; 
Abrams et al., 2000; Ludwig and Strasser, 2001; Belperio and Rhew, 2004).   
 
Several million people worldwide are infected with HIV (UNAIDS, 2006; 2008) and 
anaemia is a common manifestation of HIV/AIDS (Claster, 2002; Mildvan, 2003).   
Thus, a large percentage of those infected with the HIV will have anaemia.  Anaemia is 
a common problem throughout the world in its own right, especially in those developing 
countries where HIV is most prevalent.  Hence, in these locations the numbers with 
HIV, or anaemia, or both HIV and anaemia will be high (Lewis, 2005).  However, 
because there are multiple causes for anaemia it has been difficult to determine the 
relative contribution of HIV.  This needs to be adequately defined for populations in 
sub-Sahara Africa in order to develop evidence informed approaches to individual 
clinical and population care.   
 
Iron deficiency anaemia is one of the most common causes of anaemia worldwide (see 
below), but there is increasing concern about the uncritical use of iron supplements in 
infected individuals, in those with ongoing inflammation, or in populations where the 
risks of intercurrent infection might be high.  Therefore, to determine our current 
understanding of the problem the available literature was reviewed, drawing on any 
available systematic reviews.  The purpose was to assess the extent to which the 
aetiology of anaemia in HIV could be determined for populations living in sub-Saharan 
Africa.    21
2.2  PREVALENCE AND RISK FACTORS FOR ANAEMIA IN HIV/AIDS 
2.2.1 A SYSTEMATIC REVIEW OF THE PREVALENCE OF ANAEMIA IN HIV/AIDS -  
Belperio and Rhew (2004) carried out a systematic review of the literature to determine 
the prevalence of anaemia and its impact on the quality of life outcomes in HIV 
infection.  The review focused primarily on anaemia of chronic disease, but did not 
exclude articles dealing with iron-deficiency anaemia. 
 
The authors searched the United States (US) National Library of Medicine database 
(MEDLINE) and the Excerpta Medica database (EMBASE) for published articles on the 
prevalence and impact of anaemia in persons with HIV/AIDS.  The initial MEDLINE 
search covered January 1966 to March 2001, while the EMBASE search included 
literature from January 1974 to March 2001.  The search excluded non–English 
language and nonhuman studies, as well as editorials and abstracts.  An AIDSLINE-
Internet Grateful  Med search (January 2000 to March 2001) was also performed.   
 
Pertinent articles were selected by a predefined three stage process: title review, 
abstract review, and article review.  Investigators who were trained in the method of 
assessment worked in pairs using defined criteria to identify and select suitable 
publications.  Hand searches of bibliographies from accepted articles enabling 
identification of a limited number of additional articles were also conducted.  Accepted 
articles were classified into 2 categories: (1) the prevalence of anaemia in patients with 
HIV or AIDS and (2) the effect of anaemia on the outcomes of HIV/AIDS.   They found 
that prevalence estimates varied widely.  This variation could be related to a range of 
factors, such as progression of HIV disease, definition of anaemia, use of antiviral 
medications (particularly zidovudine), location of the study (e.g., United States vs. sub-
Saharan Africa), sex, pregnancy, injection-drug use, and age.  
 
This search was repeated to include articles published up to July 2009 to determine 
whether more recent reports on anaemia in the HIV population support the findings of 
Belperio and Rhew (2004).  A similar search strategy was adopted to ensure that the 
findings were comparable.  In all a further 11 relevant papers were identified (see 
asterisked references in tables).  For the purpose of this thesis, the results of the 
prevalence of anaemia in HIV/AIDS are considered. 
 
2.2.1.1  Results from the systematic review 
There were 42 articles (31 from Belperio and Rhew (2004) and 11 other authors) that 
reported either the incidence or prevalence of anaemia in HIV-infected patient 
populations (Tables 2.1 - 2.4).  The incidence or prevalence was related to HIV disease   22
severity and specific subpopulations of infected individuals, including pre-menopausal 
women (plus pregnant women), injection-drug users, and children.   
 
In the first consideration (Tabs 2.1a, 2.1b & 2.1c), prevalence of anaemia was 
categorised by haemoglobin thresholds for 3 separate populations: 1) hospitalised HIV-
infected patients and/or patients with AIDS, 2) HIV-infected patients with and without 
AIDS, and 3) patients with AIDS-related complex (ARC) or HIV without AIDS.  The 
definition of anaemia varied from study to study.  Taking all these variables into 
account the prevalence of anaemia was consistently higher in people with AIDS than in 
those without AIDS.  As the severity of HIV disease progressed, the prevalence of 
anaemia also increased. 
 
There were 19 studies from populations in US or Europe, 4 from Africa and 1 from Asia 
that described the prevalence of anaemia in populations of HIV-infected patients at 
various stages of HIV infection (Tabs. 2.1ab&c).   In most of the studies prevalence of 
anaemia was determined after patients were stratified on the basis of the presence or 
absence of AIDS.  Whilst some studies were retrospective analyses of surveillance 
registries, others were prospective longitudinal studies.  Despite the differing cut points 
for defining anaemia (e.g. Hb <123g/L for both sexes (Moore et al., 1991); <134 g/l 
men, <123 g/L – women (Patton, 1999); 80-140 g/L – men, 80-120 g/L – women 
(Mocroft et al., 1999)), the results clearly showed that the prevalence of anaemia was 
greater in patients with AIDS and those with lower CD4+ cell counts. 
 
In three of the largest studies (Sullivan et al., 1998; Morcroft et al., 1999; Moore et al., 
1991; 1992), evidence of the increasing prevalence of anaemia with HIV severity was 
consistently demonstrated.  In the multistate Adult and Adolescent Spectrum of HIV 
Disease Surveillance Project conducted by the CDC, haemoglobin concentrations were 
abstracted from medical reviews of 31,534 patients between January 1990 and August 
1996 (Sullivan et al., 1998).  The prevalence of anaemia varied greatly with the stage 
of HIV disease.  The 1-year incidence of anaemia (defined as a haemoglobin 
concentration <100 g/L for adults) was 3.2% in the 6,094 patients with HIV but not 
AIDS; 12.1% in the 2,579 patients with CD4+ cell counts of <200 x 10
6/L but with no 
clinical symptom of AIDS; and 36.9% for the 4,642 patients with clinical AIDS.  In all, 
22% of the anaemia cases were associated with intravenous drug use.   
 
In the EuroSIDA [Europe-wide cohort of patients with HIV with or without AIDS] study 
of a large observational, prospective cohort of European patients with HIV infection, 
6,725 patients with CD4+ lymphocyte counts and haemoglobin values were evaluated   23
for the presence of anaemia (Morcroft et al., 1999).  Patients with anaemia were more 
likely to have been diagnosed with AIDS in the 6 months before recruitment into the 
study, and patients with severe anaemia were significantly more likely to have CD4+ 
cell counts <50 x 10
6/L. 
 
The third study (Moore et al., 1991; 1992) involved a longitudinal study of anaemia in 
patients with HIV at 12 academic and community based sites across the United States.  
Between April 1987 and April 1988, zidovudine treatment was initiated in 866 patients 
with AIDS or ARC who had CD4+ cell counts <250 x 10
6/L and were enrolled in the 
study.  The prevalence of mild anaemia in patients with AIDS at enrolment was 69%, 
and the prevalence of mild anaemia in patients with ARC was 49%.  During the first 2 
years of follow-up, serious anaemia developed in 45% of patients with a baseline CD4+  
count <100 x 10
6/L and in 31% of patients with a CD4+ count >100 x 10
6/L.  The 
studies demonstrated an increasing prevalence of anaemia as HIV disease 
progresses, often in association with the use of zidovudine. 
 
In a study in the USA by Mildvan and Creagh (2007), prevalence was higher in blacks 
or persons of African descent compared to whites. Findings from two of the African 
studies (Ssali et al., 2006; Omoregie et al., 2009) also suggested that anaemia 
prevalence tended to be very high in the African population. 
 
Consistent with the results in the systematic review, earlier review studies (Zon and 
Groopman, 1987; Spivak et al., 1989) have reported similar trends in anaemia 
prevalence in other HIV/AIDS populations. 
 
In summary, the prevalence of anaemia varied widely across studies, depending on the 
degree of anaemia and stage of disease, but generally, in spite of the differing cut 
points for defining anaemia, the prevalence of anaemia was shown to increase with 
progression and severity of the HIV disease.  
 
In the second consideration, the prevalence of anaemia has been evaluated in women 
with HIV (Tab. 2.2).  Anaemia is usually more common in women than men as it is 
associated with an increased demand for menstruation and pregnancy.  Nine (9) 
relevant studies were identified (see Tab. 2.2).  Of 7 studies in which anaemia was 
evaluated in pregnant women, 5 were conducted in Africa, 1 in Europe and 1 in Asia.  
In the 5 African studies, definition of anaemia was according to or close to the WHO 
criteria, and prevalence estimates were quite high and closely similar; 82.7%, 81.7%, 
78.4%, 82.8% and 76.9% respectively (Antelman et al., 2000; Meda et al., 1998;   24
Ramon et al., 1999, Megan et al., 2005; Omoregie et al., 2007).  In 4 studies both HIV-
positive and HIV-negative pregnant women were evaluated and compared and a 
statistically significant higher prevalence of anaemia was found in the HIV-positives.   
In contrast, 2 studies conducted in Europe and USA respectively (Bucceri et al., 1997; 
Semba et al., 2002; Levine et al., 2001) estimated anaemia prevalences were much 
lower in both infected and uninfected women.  
 
The European study was from Italy, in which 151 early-stage, HIV-positive, pregnant 
injection-drug users were investigated, and showed that 27% patients were anaemic 
compared with 15% HIV-negative, pregnant injection-drug users (Bucceri et al., 1997).   
 
In the two US studies, anaemia was evaluated in populations of HIV-infected women 
(Semba et al., 2002b; Levine et al., 2001).  The first study, the Human 
Immunodeficiency Virus Epidemiology Research (HER) Study, enrolled patients from 
Baltimore, Maryland; the Bronx, New York; Providence, Rhode Island; and Detroit, 
Michigan, and examined the prevalence and cumulative incidence of anaemia in 797 
HIV-positive and 389 HIV-negative women.  The median CD4+ cell count of the HIV-
positive women was 436 ± 272 x 10
6/L.  The study established that anaemia was 
higher in the HIV-positive cohort than in the HIV-negative cohort (28.1% vs. 15.1%, 
p<0.001).  The prevalence of moderately severe anaemia (haemoglobin level <100 g/L) 
was 5.4% in HIV-positive women and 2.3% in HIV-negative women.  Estimates of 
anaemia prevalence by CD4+ cell counts were 54% for >500 x 10
6/L, 69% for 200 to 
500 x 10
6/L, and 79% for <200 + 10
6/L, demonstrating the increasing prevalence of 
anaemia with HIV disease progression in women infected with HIV.  The second study 
was the Women’s Interagency HIV Study (WIHS), in which the prevalence of anaemia 
was 37% in 2,056 HIV-positive women compared with 17% in 569 HIV-negative 
women.  The prevalence of severe anaemia was significantly greater in the HIV-
positive than in the HIV-negative women (7.2% vs. 2%, p<0.001).  Anaemia was more 
common in HIV-infected African American women than in HIV-infected white women 
(44.9% vs. 25.7%, p<0.001). 
 
From these studies it can be concluded that though there is a higher prevalence of 
anaemia in HIV-infected pregnant and non-pregnant women, it tends to increase with 
disease progression and also to be much higher in African populations.  
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Table 2.1a:  Prevalence of Anaemia in Patients with Human Immunodeficiency Virus (HIV) in Various Stages of Disease 
Prevalence Estimates of anaemia 
Study   Location  Population Measured 
Use of zidovudine 
(%) 
Definition of Anemia 
(hemoglobin, g/L)  Subgroup (if applicable)  % 
Moore et al. (1991)   USA  146 hospitalized patients with an AIDS diagnosis or 
CD4
+count of ≤200/cells x 10
6/L 
16*   <123 (both sexes)    85 
Patton (1999)   USA  516 HIV-infected adults, all stages of disease, in a longitudinal 
study of oral disease received medical care at a university 
hospital  
42.6  Men: <134  
Women:<123 
All  
  Men  
  Women  
  Asymptomatic HIV 
  Symptomatic HIV 







Mocroft  et  al.  (1999)  Europe  6,725 patients from EuroSIDA, patients with HIV with or 
without AIDS from across Europe 
Ever taken, 70–78  
Current use, 13–28 






Keller et al. (1999)  USA  86  patients  ≥50 yr hospitalized with HIV or AIDS   72 ART  Not given    77.0 
Moore et al. (1998)  USA  2,343  patients  in  various stages of disease who received 
primary care in the HIV/AIDS clinic at Johns Hopkins 
70–75  <95 (both sexes) 
80–94 (both sexes) 
70–79 (both sexes) 
65–69 (both sexes) 






Mir et al. (1989)   England  58 patients with HIV, all stages of disease, who had bone 
marrow studies performed  








Raal et al. (1988)  South 
Africa 
Patients with AIDS admitted to Johannesburg Hospital  Not reported  <120 (both sexes)    68.2 
Frontiera and Myers 
(1987) 
USA  41 male patients with end-stage AIDS undergoing bone 
marrow biopsy at the University of Colorado Health Sciences 
Center  




Zon et al. (1987)  USA  102 patients in various stages of HIV disease, including AIDS 
and ARC, at New England Deaconess Hospital  






Treacy et al. (1987)  UK  20 patients in various stages of HIV disease, including AIDS 
and ARC (14 with bone marrow biopsy) 
Not reported  Men:<140   
Women:<120 
 75 
AIDS=acquired immunodeficiency syndrome; ARC=AIDS-related complex; ART=antiretroviral therapy; EuroSIDA=Europe-wide cohort of patients with HIV with or without AIDS; Hct = haematocrit;*Includes 
zidovudine and other antiretrovirals. (Source: Belperio and Rhew, 2004)   26 
Table 2.1b: Prevalence of Anaemia in Patients with Human Immunodeficiency Virus (HIV) in Various Stages of Disease 
Prevalence Estimates of anaemia 
Study   Location  Population Measured 
Use of zidovudine 
(%) 
Definition of Anemia 
(hemoglobin, g/L)  Subgroup (if applicable)  % 
500 patients with AIDS and CD4
+count <250 cells x 10
6/L 
who first received zidovudine between Apr. 1978 and Apr. 
1998  
100  Anemia grade 1  
  Men: <133 
  Women: <120 
Anemia grade 2 <96  
Anemia grade 3 <80  







Moore et al. (1991)  USA 
366 patients with ARC and CD4
+ count <250 cells x 10
6/L 
who first received zidovudine between Apr. 1978 and Apr. 
1998 
100  Anemia grade 1  
Anemia grade 2 <96  
Anemia grade 3 <80  





Sullivan et al. (1998)  USA  31,534 HIV-infected persons in various stages of disease 
in the Adult and Adolescent Spectrum of HIV Disease 
Surveillance Project  
 
54–74  Men: <140  
Women: <120 
HIV infection, no AIDS 
  Men  
  Women  
Immunologic AIDS 
  Men  
  Women  
Clinical AIDS 
  Men  










Turner et al. (1996)   Italy  421 patients reported to the Italian  National AIDS 
Registry surviving ≥3 months after AIDS diagnosis 
28  <80  (both sexes) 
80 to <110  (both sexes) 
 17.8 
37.2 
Kozak et al. (1993)  USA  4,582 patient records with HIV-related diagnoses, with or 
without AIDS or ARC, discharged from short-stay 
Hospitals  
Not reported  ICD-9 codes 280–285   All  7.3 
Moore et al. (1992)  USA  863 patients with AIDS or ARC and CD4
+ <250 x 10
6/L 
who first received zidovudine between Apr. 15, 1978, and 
Apr. 14, 1988 
Patients with Hct <24% at baseline  














AIDS=acquired immunodeficiency syndrome; ARC=AIDS-related complex; ART=antiretroviral therapy; ICD-9= International Classification of Diseases, 9th Edition. (Source: Belperio and Rhew, 2004) 
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Table 2.1c: Prevalence of Anaemia in Patients with Human Immunodeficiency Virus (HIV) in Various Stages of Disease 
Prevalence Estimates of anaemia 
Study   Location  Population Measured 
Use of 
zidovudine (%)  Definition of Anemia (hemoglobin, g/L) 
Subgroup (if 
applicable) % 
*Harris et al. (2008)   Europe  12000 previously untreated patients with HIV-1 
infection 
Not reported  All patients (Men: <130; Women: <120) 
Mild anemia (110-<130/ 100-<120) 
Moderate anemia (80-<110/80-<100 





*Migusha et al. (2008)  Uganda  Rural cohort of 259 HIV infected persons prior 
to receiving HAART 
Not reported  Men: <120 
Women: <110 
HIV positive 







*Mildvan and Creagh 
(2007)  
USA  Multi-centre cross-sectional study: 9690 males 










1721 receiving no ART 
7252 receiving HAART 
Not reported  Anaemia 








Marked anaemia  










RNA >30000 copies 














*Ssali et al. (2006)  Uganda  and 
Zimbabwe 
3314 patients with ARC and CD4
+ count <250 
cells x 10
6/L initiating zidovudine-containing 
regimens in the DART trial 
Not reported  >9.5 
8.0–<9.5 (grade 1) 
7.0–<8.0 (grade 2)  
6.5–<7.0 (grade 3) 






*Wills et al. (2004)  USA  Retrospective study in 758 HIV infected 
persons 
Not reported  <125    30.3 
*Bushkin and Sullivan 
(2004) 














<100   10.3 








* Included from recent search 
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Table 2.2:  Studies Assessing Prevalence of Anaemia in Women Infected with Human Immunodeficiency Virus (HIV) 
Prevalence Estimates of anaemia 
Study   Location  Population Measured 






Antelman et al. 
(2000)  








Meda et al. (1998)   Burkina  Faso  218 HIV-infected pregnant women ≥18 yr at <7 months 
gestation 
<110 78.4  64.7 
Ramon et al. (1999)   Ivory  Coast  197 HIV-infected pregnant women seen at an outpatient 
clinic 
<110 81.7  68.9
# 
Bucceri et al. (1997)   Italy  151 HIV-infected pregnant injection drug-users and 164 
HIV-negative pregnant injection-drug users referred to the 
Mangiagalli Clinic in Italy 
<100 27.2  15.0
† 
Semba et al. (2002)   USA  Longitudinal study of 797 HIV-positive women and 389 HIV-







Levine et al. (2001)   USA  2,056 HIV-infected women enrolled   
in WIHS  
African American women  
 
Latinas/Hispanic women  
 























*O’Brien et al. (2005)  Tanzania  1078 HIV-positive pregnant women enrolled in a clinical trial 
of vitamin supplementation from1995–2003 
<110 








*Uneke et al. (2007)  Nigeria  815 pregnant women attending antenatal clinic  <110 





*Sinha et al., (2007)  India  467 HIV-infected pregnant women in PMTCT trials  <100 





HER Study = Human Immunodeficiency Virus Epidemiology Research Study; NA = not available; WIHS = Women’s Interagency HIV Study. 
# P<0.001 † Odds ratio, 2.1 (95% confidence interval, 1.2–3.8). (Source: Belperio and Rhew, 2004); * Included from recent search 
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Table 2.3:  Studies Assessing Prevalence of Anaemia in Injection-Drug Users Infected with Human Immunodeficiency Virus (HIV) 
Study   Location  Population Measured 




van der Werf et al. (2000)  Netherlands  Cross-sectional  study: 128 males and females  
 








Semba et al. (2001b)   USA  205 patients in Baltimore, MD  
102 patients who received HAART  






Yoong and Cheong 
(1997)  
Malaysia  49 patients attending the infectious disease unit of National 
University of Malaysia 
Not defined  81.6 
Semba et al. (2002a)   USA  Longitudinal cohort of 622 men and women evaluated between 








Semba et al. (2002b)   USA  Cross-sectional study in 136 women evaluated between 1988 
and 2000 
<120 44.1 
HAART - highly active antiretroviral therapy. (Source: Belperio and Rhew, 2004) 
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Table 2.4:  Studies Assessing Prevalence of Anaemia in Infants and Children Infected with Human Immunodeficiency Virus (HIV) 
Prevalence Estimates of anaemia 
Study   Location  Population Measured 






Adewuyi and Chitsike (1994)  Zimbabwe  46 children aged 3 mo–7 yr, admitted to the 













Ellaurie et al. (1990)  USA  Symptomatic children aged 2 mo–8 yr   <110  94.0   32.0 
Totin et al. (2002)  Uganda  165 infants aged 9 month old HIV-positive and HIV-
negative infants seen in an outpatient paediatric clinic 






Eley et al. (2002)  South Africa  60  antiretroviral-naive children aged 13–28 mo in 
various stages of disease 
Category 1 (no immunosuppression)  
Category 2 (moderate immunosuppression)  















*Clark et al. (2004)  Uganda  225 HIV infected children 9 months old  <110  91.7  NA 
NA = not available (Source: Belperio and Rhew, 2004)   31
The prevalence of anaemia has also been estimated in HIV people who inject drugs in 
5 studies (Tab. 2.3).  The ALIVE (AIDS Linked to Intravenous Experiences) study was 
a longitudinal study that enrolled 2,960 HIV-infected injection-drug users in Baltimore 
between 1988 and 1989 (Semba et al., 2001a).  Two sub-studies addressed the topic 
of anaemia in HIV-infected injection-drug users.  In one, anaemia was found in 44% of 
the 136 HIV-positive women, compared with 26% of the HIV-negative women.  The 
second ALIVE sub-study involved both male and female injection-drug users.  Of 622 
injection-drug users with HIV evaluated between 1988 and 2000, 16.1% of men and 
30.5% of women were found to be anaemic on enrolment (p<0.001).  In the 
Netherlands study, anaemia has been reported as cross-sectional prevalence rates for 
HIV-positive and HIV-negative injection-drug users, and also as part of a longitudinal 
study (van den Werf et al., 2000).  Of 128 HIV-positive injection-drug users in the 
cross-sectional study, 14.8% had anaemia, compared with 7.8% of the 232 HIV-
negative users.  Of the 158 HIV-positive injection-drug users enrolled in the longitudinal 
study, 38% had anaemia at the first visit, and an additional 26% of participants 
developed anaemia during the 3-year follow-up. 
 
Six studies were identified that evaluated the prevalence or incidence of anaemia in 
HIV-infected infants or children (Tab. 2.4). Of the 6 studies, 5 enrolled children from 
Africa, where rates of HIV infection are considerably higher than in developed 
countries.  In one study, anaemia was evaluated in 9-month-old HIV-positive and HIV-
negative infants seen in an outpatient paediatric clinic in Kampala, Uganda (Totin et al., 
2002).  Anaemia was found in 90.9% of 165 HIV-infected infants compared with 76.9% 
of uninfected infants (p<0.015).  Iron deficiency anaemia accounted for about half of 
the anaemia cases.  In Zimbabwe, anaemia was reported in 84% of children infected 
with HIV (Adewuyi and Chitsike, 1994).  Of 46 hospitalised infants and children, aged 3 
month to 7 year, 40% had normochromic normocytic anaemia, and another 40% had 
hypochromic microcytic anaemia, likely due to iron deficiency.  In 60 antiretroviral-
naïve, HIV positive infants and children, aged 13 to 38 months, attending a clinic in 
South Africa, 72% had anaemia (Eley et al., 2002).  The prevalence of anaemia was 
42% for those who were least immunosuppressed (CD4+ cell counts >500 x 10
6/L), 
and 85% in those most immunosuppressed (CD4+ cell counts <200 x 10
6/L).   Iron 
depletion was prevalent (52% had ferritin levels <10 µg/L) although IDA was present in 
only 17% of the children.  In another study in Uganda (Clark et al., 2005), anaemia 
prevalence in a cohort of 9 month old HIV infected infants was shown to be 91.7%. 
 
The impact of an active opportunistic infection on the prevalence of anaemia in HIV 
was evaluated  in a longitudinal study of 100 symptomatic paediatric patients aged 2   32
months to 8 years in the US (Ellaurie et al., 1990).  The prevalence of anaemia was 
100% in 23 patients with active opportunistic infection compared with 92% in 77 
children with no active infection.  These studies indicate that anaemia is widely 
prevalent in infants and children with advanced HIV disease especially if secondarily 
infected, in both African and the US children.   
 
2.2.1.2  Conclusions from the systematic review 
Belperio and Rhew (2004) noted the difficulty in drawing general conclusions about the 
prevalence of anaemia in people with HIV from the available literature because of the 
wide variability amongst studies and the need for standardised criteria for studies in 
this area.  Anaemia appears more common with disease progression but this is not 
clear.  Progression is variously assessed on the basis of the staging of HIV disease or 
CD4+ cell count.  In some studies all patients have been grouped together regardless 
of the extent to which they may have progressed to AIDS.  For anaemia, there is no 
consistency in the criteria used to define it, with methods and cut-offs differing amongst 
studies, and making comparisons difficult.  This may have an impact on the reliability 
and acceptance of the data, given the fact that laid down reference ranges for the 
various markers of anaemia existed (WHO/CDC, 2004).  Despite these differences, the 
highest rates of anaemia appear with advanced HIV, or AIDS, and often in patients 
receiving zidovudine.  The largest evaluation of the prevalence of anaemia to date 
(Morcroft et al., 1999) found the prevalence of anaemia for HIV-infected patients 
without AIDS to be 46% to 59% lower than in HIV-infected patients with AIDS.   
 
Most of the large studies reported from America or Europe, and the few reports from 
Africa are predominantly in pregnant women and their infants or children as these 
populations were possibly more accessible.  Indeed most of the studies in women and 
children are from Africa and here the rates of anaemia are high in non-infected 
populations and as high as 78% to 91% in those infected.  Interpretation and 
generalisability of the evidence is made difficult because HIV infection continues to 
progress to AIDS at a high rate in these groups.  Nevertheless, US data also suggest 
that anaemia is problematic in HIV-infected children.    
 
2.2.2 RISK FACTORS FOR ANAEMIA IN HIV/AIDS 
A major difficulty in drawing comparisons amongst studies is the substantial difference 
in the background factors that predispose to anaemia from one situation to another. 
 
It is usual for there to be a higher prevalence of anaemia in women than men in the 
general population (Sullivan et al., 1998), making it more difficult to assess the many   33
studies that show anaemia to be more common in HIV-infected women than infected 
men (Means, 1997; Sullivan et al., 1998; Semba et al., 2002).  The cut-off values for 
anaemia are different between the sexes, but are also different for pregnant women 
and children.  So the observation that anaemia is more likely in infected pregnant 
women (van den Broek et al., 1998) or in children (Adewuji and Chitsike, 1994) has to 
be placed in context. 
 
Amongst populations most anaemia is associated with poor diet and nutrient 
deficiencies, but dietary considerations have not been a major part of assessing the 
anaemia associated with HIV.  The commonest diet related anaemia is related to poor 
iron status, or operates through limited iron availability as the final common pathway.  
The major environmental variable that influences iron metabolism is the presence of 
infection or other ongoing inflammation.  It is seldom that sufficient account has been 
taken of the complex interplay of infections with nutrient deficiencies.  These 
interactions vary with geography and social factors and to an extent map against the 
availability of better quality diets, effective treatment with antiretroviral therapy and the 
effective management of other co-morbidities.  The use of the antiretroviral drug 
zidovudine (AZT), having low CD4+ cell counts (less than 200 cells/µl), a high viral 
load, a lower BMI as well as an increasing age have all been shown to constitute a high 
risk for developing anaemia in HIV populations (Levine et al., 2001; Creagh and 
Mildvan, 2002; Sharp et al., 1999; Semba et al., 2002).  People of African descent, 
such as African-Americans or Haitians were at one time considered to be at special risk 
of HIV/AIDS, and possibly anaemia (Sullivan et al., 1998; Volberding, 2000).  However, 
it is unclear whether these relations remain once social and nutritional factors have 
been adequately accounted for. 
 
Most studies relating HIV/AIDS to anaemia in populations from sub-Saharan Africa, 
which remains the largest HIV infected population in the world, were conducted in 
pregnant women and children populations for two main reasons. Whilst these 
population groups are the most vulnerable to HIV infection and anaemia, they are also 
easily accessible.  However, there were few studies which explored the HIV-anaemia 
relationship in adult men and non-pregnant women in sub-Saharan Africa.  There were 
no studies, separately or together, that made it possible to reliably take the major 
factors of importance into account, to assess their relative contributions directly, or 
indirectly.   
 
In many parts of the developing world patterns of ill health and morbidity relate directly 
to the demographic, epidemiological and nutrition transitions.  As populations in sub-  34
Saharan Africa become increasingly urbanised the relevance of these changing 
patterns of exposure become increasingly important in defining risk of ill-health, ill-
health itself, and opportunities for effective care.  No studies have been found that 
systematically consider all these factors or attempt to explore how they might interact 
directly and indirectly, positively and negatively, in order to draw general conclusions 
that might be applied to the adult population in sub-Saharan Africa generally, or South 
Africa specifically. 
 
In this chapter, HIV/AIDS, anaemia and the nature of their interaction is reviewed.  An 
overview of HIV/AIDS, which includes a brief historical perspective, an outline of its 
pathophysiology, epidemiology and therapeutic approaches, is given.  HIV effects on 
food and  nutrition and aspects of the complex interrelationships amongst HIV infection, 
immune processes, inflammation and nutrition are outlined.  The nature of anaemia, its 
causes, pathophysiology and identification are outlined.  This leads to a consideration 
of the relationship between HIV/AIDS and anaemia, with a review of the aetiology of 
anaemia in HIV/AIDS and the determinants of HIV infection and/or AIDS with anaemia.   
 
2.3  HIV/AIDS – BACKGROUND TO THE PANDEMIC 
Since the early 1980s the impact of HIV infection and AIDS on domestic and global 
health, social, political and economic outcomes has been substantial (UNAIDS, 2004; 
2005; 2008).  After nearly three decades the pandemic continues to challenge every 
effort (UNAIDS, 2008).  HIV/AIDS is most prevalent in sub-Saharan Africa and the 
effects are exacerbated because of interactions with other common conditions such as 
anaemia and malnutrition, wreaking havoc on families, communities and nations.   
Anaemia and malnutrition on their own tend to reduce the ability of individuals to 
acquire, consume and utilise food.  Whether the underlying cause is predominantly 
social or biological, the culmination is likely to be weight loss and poor nutritional status 
which further exacerbates any pre-existing morbid condition. 
 
The challenge for clinicians treating HIV has been how best to manage a clinically 
complex illness with limited therapeutic options.  By 1985, diagnostic serologic assays 
had been developed to test for HIV infection in asymptomatic persons, to identify new 
infections by seroconversion, and to screen donated blood (CDC, 1984).  Although 
early trials of antiviral treatments and the use of immune modulators were 
disappointing (Byers et al., 1994; Pert et al., 1986; Mildvan et al., 1991; Schooley et al., 
1990; Pedersen et al., 1990), by 1987, zidovudine (AZT, or azidothymidine), a 
nucleoside analogue reverse transcriptase inhibitor had been approved for use by the 
U.S. Food and Drug Administration (FDA) (Fischl et al., 1987).     35
The earlier excitement over the life-extending effects of the drug began to wane as 
patients treated with this single-drug therapy started to experience disease progression 
leading, in most cases, to death.  However, because there was a level of 
understanding of the epidemiology, treatment, and prophylaxis of OI associated with 
HIV-induced immune deficiency, significant life-saving advances were made, 
particularly in the areas of infection with Pneumocystis jiroveci and Mycobacterium 
avium complex (MAC) (Shafer et al, 1989; USPHS/IDSA, 1999).   
 
In resource-adequate settings, advances in the use of potent life-prolonging 
medications such as HAART and the prophylaxis and aggressive treatment of OI, has 
helped to reduce HIV to a chronic manageable condition (Moore and Forney, 2002; 
Brantley et al., 2003).  Although the medications do not cure the disease, they help 
stabilise the immune system by suppressing viral replication and indirectly help 
improve nutritional status and limit progression to AIDS (Rousseau et al., 2000).   
 
2.3.1 HIV/AIDS - EPIDEMIOLOGY  
AIDS has killed more than 25 million people since 1981, making it one of the most 
devastating epidemics in recorded history.  Despite improved access to antiretroviral 
treatment it claimed 3.1 million lives in 2005 of which half a million were children 
(UNAIDS, 2005).  The epidemic has hit hard in geographical areas where poverty and 
malnutrition are rife (UNAIDS, 2003; 2005; 2008).   
 
It is estimated that 10% of the world’s population reside in sub-Saharan Africa, but 
these populations carry two-thirds (63%) of the burden of HIV/AIDS, around 25 million 
(UNAIDS, 2005; 2008). The epidemic has resulted in a large rise in the region’s death 
toll with HIV/AIDS becoming a leading cause of mortality, accounting for well over 
three quarters of all related global deaths (UNAIDS, 2005; 2006; 2008).  The 
predominant mode of transmission in this region is heterosexual sex and over 90% of 
infected children acquire it through mother-to-child transmission (MTCT).   
 
Epidemiological data suggests that the prevalence is yet to peak in some sub-Saharan 
African countries (UNAIDS, 2003; 2005; 2006).  Since 2000, the percentage of persons 
living with HIV has stabilised, but the overall number of people living with the infection 
has increased steadily as new infections occur each year, lives are extended with ART 
and new infections outnumber deaths from AIDS (UNAIDS, 2008). 
 
In Sub-Saharan Africa, there has been a continuous increase in the proportion of 
infected females; 17.0 million in 2003, increasing to 17.5 million in 2005 and then 17.7   36
million in 2006.  However, in 2007, there has been a decline (Tab. 2.5) perhaps 
stemming from the efforts at empowering women and improving their capacities.   
Regional prevalence of the epidemic has shown variations within the same regions and 
wide variations exist at the country level where infection levels differ between areas, 
sexes and socioeconomic categories (UNAIDS 2006; UNAIDS 2008).  In sub-Saharan 
Africa, Southern Africa remains the epicentre of the global epidemic where 32% to 35% 
of persons with HIV/AIDS in the whole world reside and 38% of all global AIDS deaths 
occur (UNAIDS 2006; UNAIDS 2008).   
 
Recent developments in some South African countries show that the epidemic is non-
relenting, with levels of infection among pregnant women at 20% or higher (UNAIDS, 
2006; 2008).  In other countries a looming epidemic is eminently shown by alarming 
increases in infection, a trend that actually cuts across several regions (UNAIDS, 2003; 
2005; 2008).  The UNAIDS update report has narrowed the cause of these rising 
trends, especially, in Asia to a combination of increasing intravenous drug use and 
commercial sex (UNAIDS, 2005; 2006). 
 
Table  2.5:  Global summary of the HIV and AIDS epidemic for 2003, 2005 to 
2007 
The ranges around the estimates in this table define the boundaries within which the actual numbers lie, based on the 
best available information.  Extracted from the AIDS Epidemic Update, 2005, 2006 and 2008 (UNAIDS/WHO). 
 
2.3.1.1  The epidemiology of HIV/AIDS in South Africa  
The present THUSA study was undertaken in South Africa, where it is estimated that 















































































































(0.25-0.29)   37
(UNAIDS, 2008).  As in the rest of sub-Saharan Africa, women in South Africa are 
disproportionately affected by the epidemic and women aged 15 to 39 years are more 
likely to be infected as compared to men of the same age group, whilst males 40 years 
and above are also more likely to be infected compared to those below 40 years 
(UNAIDS, 2008; The South African National HIV Survey, 2008).  This trend is most 
likely due to a number of reasons including the fact that older men prefer to have 
sexual relationships with younger women.  
 
The prevalence of HIV in South Africa has risen steadily since 1990 to stabilise at 
18.1% in 2007.  This rise is clearly depicted in Figure 2.1 and Table 2.6 below.  The 
table (Tab. 2.6) shows that between 2001 and 2007 the estimated number of persons 
living with HIV increased from 4.7 to 5.7 million, whilst the total number of children with 
HIV increased by 130 000 (46.4%) from 150 000 in 2001 to 280 000 in 2007.  The 
number of AIDS orphans more than tripled from 400 000 in 2001 to 1 400 000 in 2007 
(Tab. 2.6). 
 
The estimated number of deaths from AIDS also increased steadily from 1990 to 2007 
(Tab. 2.6 and Fig. 2.2).  Over the period, both prevalence and deaths due to HIV have 
shown initial steep increases and subsequent stabilisation towards the end of 2005 and 
slight decline with respect to Deaths in 2006 which seems to have risen again in 2007. 
 
Table 2.6:  Estimates for HIV and AIDS in South Africa (Source: UNAIDS/WHO, 
2008) 
Category 2001  2007 
Persons living with HIV (Total)  4 700 000 (4 000 000-5 500 000)  5 700 000 (4 900 000-6 600 000) 
Adults 15+ with HIV  4 600 000 (3 900 000-5 300 000)  5 400 000 (4 700 000-6 200 000) 
Women 15+ with HIV  2 700 000 (2 300 000-3 200 000)  3 200 000 (2 800 000-3 700 000) 
Children 0-14 with HIV  150 000 (120 000 - 190 000)  280 000 (230 000-320 000) 
HIV prevalence (Adults 15 – 49)  16.9 (14.3-19.9)  18.1 (15.4-20.9) 
Death due to AIDS  180 000 (130 000-250 000)  350 000 (270 000-420 000) 
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Figure 2.1:  Estimates for Adult HIV (15-59) prevalence and number of people 
living with HIV from 1990 to 2007 in South Africa. 
 
Source: UNAIDS/WHO, 2008 
 
Figure 2.2:  Estimates for deaths due to AIDS from 1990 to 2007 in South Africa. 
 
Source: UNAIDS/WHO, 2008 
 
Provincial estimates of HIV prevalence from the South African Department of Health 
survey (2007) shown in Table 2.7 below puts Kwazulu-Natal at the highest (15.5%) and 
the Western Cape at the lowest (1.9%).     39
From table 2.7 below, it is evident that the national prevalence of HIV/AIDS bore a 
close similarity to that in the North West and Guateng provinces.  In addition, females 
and Africans were shown to have the highest prevalences with regards to gender and 
race respectively. 
 
The South African Department of Health Survey also estimated that 28% of pregnant 
women were living with HIV/AIDS in 2007.  However, prevalence levels varied from a 
low of 15.2% in Western Cape Province to a high of 39.1% in Kwazulu-Natal Province 
(South African Department of Health Survey, 2007). 
 
Table 2.7:  Provincial, gender and racial estimates for HIV prevalence in South 
Africa (Source: South African Department of Health Survey, 2007)  
Province  Number surveyed  Prevalence (%) 
Kwazulu-Natal 2  729  19.5 
Mpumalanga 1  224  15.2 
Free State  1 066  12.1 
North West  1 056  10.9 
Guateng 2  430  10.8 
Eastern Cape  2 420  8.9 
Limpopo 1  570  8.0 
Northern Cape   1 144  5.4 
Western Cape  2 204  1.9 
Sex  
Male 6  342  8.2 
Female 9  509  13.3 
Race  
African 9  950  13.3 
White 1  173 0.6 
Coloured 3  382  1.9 
Indian 1  317  1.6 
National 15  851  10.8 
 
2.3.2 HIV/AIDS - TRANSMISSION AND RISK FACTORS   
The primary method of spread of HIV infection worldwide is through sexual exposure.  
In the United States and Europe, acquisition of the virus through homosexual contact   40
remains important, and there is some evidence of increasing incidence of infection 
among young gay men and ethnic minorities (Holmberg, 1996).  In most of the 
developing world, heterosexual intercourse with an infected person is the primary mode 
of transmission, accounting for approximately 70% of the overall sexual transmission 
(Rothenberg, 1998).  Female-to-female HIV transmission has been reported, but is rare 
(Monzon and Capellan, 1987).   
 
HIV is transmitted either through direct contact of a mucous membrane with a bodily 
fluid containing the virus (such as blood, semen, vaginal fluid, and pre-seminal fluid) or 
breast milk (Gayle, 2000).  Transmission can occur because of unprotected penetrative 
sex; oral sex; blood transfusion; use of contaminated needles; exchange between 
mother and infant during pregnancy, childbirth, or breastfeeding; or other exposure to 
one of the above bodily fluids.  HIV has been isolated from blood, seminal fluid, pre-
ejaculate, vaginal secretions, cerebrospinal fluid, saliva, tears, and breast milk of 
infected individuals (Wofsy et al, 1986; Hollander and Levy, 1987; Geier et al., 1993).  
The DNA sequences of HIV-1 have been detected in pre-ejaculatory fluid (Ilaria et al., 
1992).  In genital fluids, HIV may be found in both cell-free and cell-associated 
compartments (Alexander, 1990).  Viral concentrations in tears and saliva are 
comparatively low, and there may be substances in saliva that inhibit infectivity. 
 
The use of physical barriers such as the latex condom is widely advocated to reduce 
the sexual transmission of HIV and meta-analysis has shown that their overall efficacy 
in reducing HIV transmission was 69% (Weller, 1993).  Sexual activity associated with 
exposure to infected blood increases the risk of transmission, as does the presence of 
genital ulcers and/or other sexually transmitted infections or diseases (STI/Ds) 
(Cameron et al., 1989; Greenblatt et al., 1988; Plummer et al., 1991).  In a particular 
study in an African population, serum HIV viral load was strongly associated with 
heterosexual transmission between HIV-serodiscordant sexual partners, and 
transmission was rare at viral loads <1,500 copies/mL (Quinn et al., 2000).  The risk for 
women acquiring HIV through sexual contact is greater than for men.   
 
Nonsexual HIV transmission can occur through transfusion with contaminated blood or 
blood products, injection drug use, occupational or accidental needle exposure (Cardo 
et al., 1997).  HIV transmission through transfusion of contaminated blood products 
was recognized early in the epidemic and may still remain a significant mode of 
transmission in some developing countries (CDC, 1982).  An infected mother can 
transmit the virus to the child (mother-to-child transmission, MTCT) during pregnancy, 
childbirth and breastfeeding.  MTCT occurs in approximately 25% of live births to HIV-  41
infected mothers (Connor et al, 1994) and perinatal transmission can be reduced by 
50% with antiretroviral regimens (Connor et al., 1994; Shaffer et al., 1999; Guay et al., 
1999).  Approximately one-third of cases of MTCT result from breast-feeding, and the 
risk increases with the duration of breast-feeding or partial breast feeding (Richardson 
et al., 2003). 
 
Many people who are infected remain ignorant of their HIV status and although 
asymptomatic can transmit the virus during unprotected sexual intercourse or through 
the use of contaminated needles, razors and other devices, or during labour and 
delivery or through breastfeeding.   
 
2.3.3 HIV/AIDS - VIROLOGY AND IMMUNOLOGY  
HIV is a member of the genus Lentivirus, part of the family of Retroviridae (ICTV, 
2002).  All lentiviruses have many common morphologies and biological properties.  
They can infect many animal species and are characteristically responsible for long 
duration illnesses associated with a long period of incubation (Levy, 1993).  They are 
transmitted as single-stranded, enveloped RNA viruses.   
 
Upon infection of the target-cell, their viral RNA genome is converted into a double-
stranded DNA by a virally encoded reverse transcriptase, a RNA to DNA converting 
enzyme, which is present in the virus particle.  This viral DNA, thus produced by the 
reverse transcriptase is then integrated into the cellular DNA of the host for replication 
using cellular machinery.  Once the virus enters the cell, two pathways are possible: 
either the virus becomes latent and the infected cell continues to function or the virus 
becomes active, replicates and releases a large number of virus particles which can 
infect other cells (Levy, 1993).  Steps involved in the HIV replication cycle are 
illustrated in figure 2.3 below. 
 
There are two species of HIV that infect humans; HIV-1 and HIV-2, and each of them 
has many strains.  HIV-1, which was the first to be isolated, is more virulent and easily 
transmitted, and is the source of majority of HIV infections throughout the world.  HIV-2 
is largely confined to West Africa (Reeves and Doms, 2002).   
 
HIV exhibits tropism and infects those cells that express the CD4 molecule on the 
surface (surface marker).  The entry of HIV-1 into macrophages and CD4+ cells is 
mediated through the interaction of the virion envelope glycoproteins (gp120) with the 
CD4+ surface molecule on the target cells and also with its chemokine co-receptors 
(Coakley et al., 2005).  The macrophage (M-tropic) strains of HIV-1, or non-syncitia-  42
inducing strains (NSI), use the beta-chemokine receptor, CCR5.  The virus is able to 
replicate in macrophages, which express these receptors (Coakley et al., 2005).  The 
CCR5 co-receptor is used by almost all primary HIV-1 isolates regardless of viral 
genetic subtype.    
 
Figure 2.3.  The HIV replication cycle 
 
Source: Website of the National Institute of Allergy and Infectious Diseases  
(http://www.niaid.nih.gov/daids/dtpdb/attach.htm). 
 
Macrophages play a key role in several critical aspects of HIV disease.  They appear to 
be the first cells infected by HIV and may continue to provide a reservoir for ongoing 
HIV replication when CD4+ T cells have been markedly depleted.  In the central   43
nervous system macrophages and microglial cells are the cells infected by HIV.  In 
tonsils and adenoids infected macrophages may fuse into multinucleated giant cells 
that produce copious amounts of virus (Coakley et al., 2005).  The T-tropic isolates, or 
syncitia-inducing (SI) strains replicate in primary CD4+ T-cells as well as in 
macrophages using the alpha-chemokine receptor, CXCR4, for entry (Coakley et al., 
2005).  The alpha-chemokine, SDF-1 is a ligand for CXCR4 and suppresses replication 
of T-tropic HIV-1 isolates, probably by down regulating the expression of CXCR4 on 
the surface of these cells (Coakley et al., 2005).   
 
Infection with HIV represents something of an immunological paradox, in that it induces 
a strong antiviral immune response, but simultaneously and progressively disrupting 
the ability of the immune system to respond to any new infections and antigens, 
leading ultimately to a severe immune deficiency of the cell-mediated immune system. 
 
Persons infected with HIV can show both cellular and humoral (antibody) immune 
responses to the virus, but in the great majority of infected individuals these responses 
are unable to prevent the ultimate progression of the disease.  The cellular responses 
are mediated by both CD4+ T cells and cytotoxic T-lymphocytes (CTLs or CD8 cells).  
CTLs inhibit HIV replication both directly, by recognizing and killing infected cells, and 
indirectly, by producing soluble chemokine antiviral factors (Walker et al., 1986; 
Pontesilli et al., 1998).  By direct contact the CTLs kill virally infected host cells.  This 
happens when the T-cell receptor on the surface of the CTL recognizes an epitope of 
an HIV protein bound to a major histocompatibility complex (MHC) class I molecule on 
the surface of the infected host cell.  The CTL then releases enzymes that kill the 
infected cell or through soluble factors (e.g. macrophage inflammatory protein (MIP)-1-
alpha, and MIP-1-beta), which inhibit HIV from infecting new cells by blocking their co-
receptors (Malnati et al., 2000). 
 
In viral control, CD4+ responses to HIV are important and strong HIV-specific CD4+ 
responses are usually associated with lower HIV viral loads (Rosenberg and Walker, 
1998).  The CD4+ cells respond to HIV antigens presented with MHC class II 
molecules on the surface of infected cells.  That HIV infects CD4+ cells has the 
appearance of an effective evolutionary strategy with important consequences.  Firstly, 
because productive HIV infection occurs in activated CD4+ cells, infection and killing of 
CD4+ cells that are responding to the HIV infection results in a selective decrease in 
the number of HIV-specific CD4+ cells (Rosenberg and Walker, 1998).   
 
Secondly, as HIV continues to evolve under the selection pressure of the immune   44
response of the infected individual, mutations in the viral epitopes recognized by the 
immune system enable the virus to escape the control of even broad and robust CD4+ 
and CD8 HIV-specific responses (McMichael and Rowland-Jones, 2001). 
 
The hallmark of HIV infection is, thus, the depletion of lymphocytes, which predicts an 
individual's risk for infection with opportunistic pathogens as well as other 
complications of HIV disease.  The evidence shows that both increased peripheral 
destruction and decreased production of CD4+ cells likely play a role in the decline in 
CD4+ numbers (Ho et al., 1995; Hellerstein et al., 1999; Rowland-Jones, 1999; Mohri 
et al., 2001).  This is associated with a reservoir of virus in infected macrophage 
populations, which are likely to be shed when other infected episodes stimulate 
macrophage responses.  
 
2.3.4 HIV/AIDS - CLASSIFICATIONS  
The primary or acute HIV infection stage is a period of rapid viral replication that may 
immediately follow the individual's exposure to HIV.  During primary HIV infection, most 
individuals (80% to 90%) develop a syndrome characterised by non specific flu-like 
symptoms of fever, malaise, lymphadenopathy, pharyngitis, headache, myalgia, and 
sometimes a rash (Khan and Walker, 1998).  Because of the non-specific nature of the 
symptomatology the possibility of HIV infection during the first weeks may not be 
considered, however, during this period the individual is infectious.  
 
Around three weeks after infection there is sero-conversion with a specific immune 
response to HIV-1.  This begins the clinical latency phase during which a strong 
immune response reduces the number of circulating viral particles.  Clinical latency can 
vary between two weeks and 20 years.  During this period, the individual may be 
asymptomatic with no evidence of HIV-associated clinical, immunological or nutritional 
deficiency or abnormality.  As the latency phase progresses, HIV remains active within 
lymphoid organs, where large amounts of the virus become trapped in the follicular 
dendritic cell (FDC) network.  The surrounding tissues that are rich in CD4+ T-cells also 
become infected, and viral particles accumulate in infected cells and as free virus.   
 
Individuals who have entered into this middle stage are still infectious.  During this 
phase, a high level of viral replication occurs with a concomitant high CD4+ cell 
turnover, resulting in progressive immune dysfunction which can lead to evident clinical 
disease and AIDS.  In this middle stage, laboratory evidence of immune deficiency can 
be seen even in the absence of clinical evidence.   Non-specific symptoms and variable 
fatigue may be indicative of metabolic abnormalities and there may be some loss of   45
weight, which is not usually progressive. 
At the late stage, clinical evidence of immune dysfunction is prominent and the patient 
is said to have AIDS or be actively progressing to AIDS.  Malnutrition, evident as 
weight loss is often present and may be severe.   
 
The CDC makes an important distinction between "HIV infection" and "AIDS", which 
has clinical and prognostic implications and utility in research (CDC, 1993).  The CDC 
definition of AIDS is based on a clinical criteria, including the presence of infections, 
and malignancies associated with HIV infection (CDC, 1993).   
 
The CDC also defines AIDS by a CD4+ count of <200 cells/µL or <14% of all 
lymphocytes, even in the absence of listed clinical and HIV associated conditions.  In 
line with this definition, the World Health Organization (WHO) has developed a clinical 
staging system for HIV infection (WHO, 1993).  For pragmatic purposes, this system 
weighs clinical features more heavily than laboratory evaluations, and therefore has 
practical use in resource-constrained areas where laboratory testing is not widely 
available (WHO, 1993). 
 
2.3.5 HIV/AIDS – THERAPEUTIC OPTIONS 
HIV infection is a chronic infectious disease for which treatment can limit the progress 
of the condition, without complete elimination of the virus, or cure.  Complications may 
be prevented, delayed or treated but it is still not clear whether the inexorable 
progression to AIDS can be halted.  Not all persons infected with HIV have progressed 
to AIDS, but it is generally believed that the majority will.    
 
The control of HIV viremia depends on host immune response as well as exogenous 
intervention with ARV medication.  PLWHA may also take medications to treat OI or 
other complications.  Some HIV-infected individuals use complimentary and/or 
alternative medicine (CAM) for management of their disease (Hsiao et al., 2003) 
although the evidence for their effectiveness is scanty. 
 
The advent of potent ART in 1996 led to a revolution in the care of PLWHA.  All the 
ARV currently approved by the FDA of the US work by inhibiting 1 of 3 steps in the life 
cycle of the HIV: 
1.  By blocking the reverse transcriptase (RT) enzyme.  This is the enzyme used by 
the virus to convert its RNA into DNA after it enters the cell prior to entering the 
nucleus.  All nucleoside and nucleotide analogues (NRTIs) as well as non-
nucleoside or nucleotide (NNRTIs) analogues function by interfering with or   46
inhibiting the activity of this enzyme. 
2.  By blocking the protease enzyme. Protease inhibitors (PIs) inhibit the action of the 
HIV protease, by cleaving protein products of the viral structural genes into the 
functional subunits needed to create new infectious virions. 
3.  By inhibiting fusion of the viral and host membranes.  By attaching itself to the HIV 
envelope glycoprotein gp41, fusion inhibitors prevent formation of the "hairpin" 
structure required for fusion of the HIV and host cell membranes, and thus prevent 
viral entry into the host cell. 
 
The use of ARVs has dramatically reduced morbidity and mortality, but all have low 
efficiencies with respect to elimination of the virus from resting cells, resulting in 
persistence of infection despite effective suppression (Wong et al., 1997).  All ARV 
induce drug resistance and have important side effects that challenge the need to 
develop new and more efficient medications.  In order to optimise efficacy and to limit 
the chances of drug resistance, a combination of ARVs are used, referred to as 
combination therapy or HAART.  ARV have also been associated with a range of 
adverse effects.  Some common but mild adverse effects occur in the early stages of 
ART may be transient (Montessori et al., 2004).   
 
Anaemia caused by the myelosuppressive effects of some ARV is among the more 
serious adverse effects together with peripheral neuropathy and hypersensitivity 
reactions, and metabolic disturbances such as hepatic steatosis, hyperlactataemia, 
lipodystrophy, hyperlipidaemia, glucose intolerance, bleeding disorders, osteoporosis, 
skin rash and dementia (Montessori et al., 2004).  
 
It has been suggested that immunomodulatory approaches may offer benefit in 
combination with effective ART.  IL-2, a cytokine released by activated CD4+ cells, that 
regulates T-cell proliferation and maturation, has been shown to increase CD4+ counts 
(Kovacs et al., 1996; Davey et al., 1999; Hecht et al., 2003), expand memory and naive 
CD4+ pools and decrease T-cell activation (Hecht et al., 2003) in individuals with 
controlled HIV viremia.  However, IL-2 administration has adverse effects and no 
clinical benefits of IL-2 have yet been demonstrated.  Techniques of immune 
manipulation through infusion of antigen-presenting cells that have been activated in 
vitro (Lu et al., 2003), infusion of expanded (Levine et al., 1996) or activated (Levine et 
al., 2002) CD4+ cells, and genetic manipulation of cells to induce anti-HIV CTL activity 
(Roberts et al., 1994) are also under investigation.   
 
Dietary and nutritional manipulations can themselves exert powerful effects upon   47
immune responses.  It is unlikely that sub-Saharan Africa will have the capability to 
adopt complex drug regimens in the near future, but there is the real possibility that 
improving diet might confer some benefits.  Thus, although ARV are currently seen as 
crucial fighting the HIV pandemic and prolonging lives, there is still the need to 
consider and explore the use of wider strategies that combine medical therapy, psycho-
social care and nutrition in managing the condition.  The emergence of HIV/AIDS has 
added further emphasis to the constant challenge to provide sufficient food and 
nutrition for all people, and especially to meet basic needs of people in Africa.   
 
Protease inhibitors (PIs), which prevented viral replication by inhibiting the activity of 
HIV-1 protease, were introduced in the mid-1990s, and this revolutionized the 
treatment of HIV (Hammer et al., 1997).   As the risk to developing viral resistance 
grew effective combination antiretroviral therapy became the standard of care, 
especially, in the United States and Western Europe.  Very soon thereafter, countries 
in which effective ART was available began to note sharply declining morbidity and 
mortality associated with HIV infection (Palella et al., 1998).  However, in most 
resource-poor settings, HIV/AIDS flourishes amidst poverty and disease.  In such 
places also malnutrition and infectious or communicable diseases are rife.   
 
The many challenges for care also revolve around effective treatment for malnutrition, 
wasting/weight loss and nutrient imbalances along with anaemia, but responses have 
remained largely ineffective (UNAIDS, 2005, 2006; Doukas, 1992; Sullivan et al., 1998; 
Semba and Gray, 2001; Mildvan, 2003).  Since the inception of HAART and the use of 
potent prophylactic medicines, anaemia and weight loss are still recorded in HIV 
infection but tend to be less severe and often less progressive (Volberding, 2000).   
 
Changes in the body composition, such as lipodystrophy and associated endocrine and 
metabolic consequences, have also been noted (Ware et al., 2002).  It is for these 
reasons that the need to ensure proper nutrition among persons with HIV/AIDS has to 
be considered an essential part of a coherent response to the HIV/AIDS pandemic, 
especially in Africa.  The response to this complex emergency has varied amongst 
countries and as a general commitment greater effort is needed for the prevention and 
treatment of HIV (United Nations, 2007;UNAIDS, 2008).   
 
2.3.6 HIV/AIDS – IMPACT OF THE INFECTION AND DISEASE 
HIV/AIDS has a great impact on the ability of households and communities to ensure 
food and nutrition security.  Meanwhile, achieving food and nutrition security and 
managing nutrition-related complications carry as much importance in HIV infection as   48
managing the range of complications.  For many in resource-poor environments 
achieving optimal nutritional status is a considerable challenge, which is more difficult 
for those living with HIV/AIDS.  There is evidence that HIV infection has direct 
nutritional consequences; reductions in food intake, increases in resting energy 
expenditure, nutrient malabsorption and loss, and complex metabolic alterations that 
culminate in weight loss and wasting (Babamento and Kotler, 1997; Macallan, 1999). 
 
2.3.6.1  HIV/AIDS and food and nutrition security  
Food security may be defined as “the state in which all people have both physical and 
economic access to sufficient food to meet their dietary needs for a productive and 
healthy life at all times” (Bonnard, 2002), a state which can only be achieved 
depending on food being available, accessible and utilisable by the body.  Nutrition 
security for a household is achieved when secure access to food is coupled with a 
sanitary environment, adequate health services, and adequate care to ensure a healthy 
life for all household members (Gillespie and Kadiyala, 2005).  
 
Food and nutrition insecurity has been linked to the transmission of HIV and to the poor 
outcomes associated with the HIV disease (UNAIDS/WHO, 2002; 2003; World Food 
Programme (WFP), 2004).  Widespread AIDS often occurs in the context of social and 
economic circumstances such as hunger, food and nutrition insecurity, poverty and 
poor social infrastructure.  Conversely, where the prevalence of HIV is high, all 
dimensions of food and nutrition security are affected (Committee on World Food 
Security (CWFS), 2001).   
 
In developing, transitional and developed countries alike, poor nutritional status arising 
from food and nutrition insecurity can be related to psychosocial and economic issues 
(American Dietetic Association (ADA), 2004).  Thus, lack of education, food access, 
economic support and access to health care services may increase the risk of poor 
nutrition (ADA, 2004).  HIV/AIDS and food and nutrition insecurity are entwined in a 
vicious cycle, with food insecurity heightening susceptibility to HIV exposure and 
infection, and HIV/AIDS heightening vulnerability to food insecurity (Loevinsohn and 
Gillespie 2003).  Populations that are food and nutrition insecure tend to develop 
survival strategies that expose them to greater risks of infection (Loevinsohn and 
Gillespie, 2003; Harvey, 2003).  Some may migrate to urban slums where access to 
health care services is limited and may be drawn into the drugs or sex trade, thus 
increasing their risk of exposure to infection (Loevinsohn and Gillespie, 2003; Harvey, 
2003).  Children may lose out on educational opportunities in order to support the 
family, while adults responsible for childcare become infected and die resulting in a   49
diminishing and crumbling social and economic infrastructure (Shah et al, 2002).  
Maintaining nutritional status for PLWHA becomes a daunting task, especially for the 
most vulnerable, because all aspects of food and nutrition security – availability, 
stability, access and use of food and healthcare services - are affected (CWFS, 2001).  
PLWHA have to deal with economic insecurity, social isolation and stigma, 
incarceration, limited diversity in their diets, poor cooking facilities and skills and other 
medical conditions and disabilities (ADA, 2004).  In order to improve the health and 
nutritional status of PLWHA, it is required that the barriers to food and nutrition security 
are resolved (Ontario Public Health Association Food Security Work Group (OPHA), 
2002; ADA, 2002; 2003).   
 
2.3.6.2  HIV/AIDS and nutritional status 
The case has been made for nutrition to be considered s a priority in the agenda for 
managing HIV/AIDS (WHO, 2003; WHO, 2005; ADA, 2002; 2003).  When the 
nutritional needs of the body are satisfied there is enhanced resistance and decreased 
susceptibility to any infection, including HIV-infection.  A well nourished individual is 
more likely to have a delayed onset or slower progression of clinical disease and 
greater resistance to co-infections (ACC/SCN, 1998; Williams, 1999; WHO, 2003).   
 
Given its nature, there may be early or hidden nutritional consequence in HIV before 
the presence of infection becomes evident (Beach et al., 1992; Semba and Tang, 
1999).  In apparently healthy populations, such as the THUSA population, subclinical 
inflammation can alter the acute phase response which in turn results in nutrient shifts 
and deficiency states (Thurnham and Northrop-Clewes, 2007).  As nutrients play 
critical roles in ensuring a competent immune system, the indirect effects of HIV 
infection on nutrition can further compromise immune function (WHO, 2005).   
 
Independent of HIV infection, malnutrition can lead to immune dysfunction (Nutritionally 
acquired immune deficiency – NAID) (Calder and Jackson, 2000; Keusch, 2003).  The 
maintenance of physical and chemical barriers are the first line of defence against 
infection, requiring intact skin surface and lining of the naso-oesophageal, 
gastrointestinal and urino-genital tracts (Calder and Jackson, 2000).  An inflammatory 
response or immune activation requires a high rate of cellular turnover placing an 
increased demand on nutrient and metabolite utilisation (Fraker, 1994; WHO, 2005).     
 
The availability of an appropriate mix of nutrients is necessary to optimise the 
response, enable the synthesis of immunoglobulins, acute phase proteins, cytokines 
and other cell mediators and maintain antioxidant mechanisms to protect against free-  50
radical damage (Allard et al., 1998).  Antioxidant mechanisms include enzymes with 
metals (e.g. Zn, Fe, Cu, Mn and Se) as cofactors, vitamins such as vitamins E and C, 
and small peptides like glutathione (Allard et al., 1998).   
 
Poor nutrition may express itself non-specifically as involuntary weight loss or wasting 
of body tissues (Williams, 1999) and by weakening the immune system increases the 
opportunity for virus replication and ease of other infection (Semba and Tang, 1999).  A 
well-nourished, HIV sero-positive individual with a viral load that is controlled is better 
able to cope with the effects of HIV infection and minimise the effects of immune 
compromise.  It is less clear the extent to which such an individual has significantly 
increased nutritional requirement, or if this relates at all to viral load, decline in immune 
function, specific treatment regimen, viral resistance or an active secondary infection 
(Mulligan et al., 2000).  On their own, infections, including HIV, can have adverse 
effects on nutritional status by increasing nutrient requirements that invariably lead to 
nutrient deficiencies, and which if sufficiently severe, can impair the resistance of the 
body to the infections through a reduction in immune competence (Schrimshaw and 
SanGiovanni, 1997).  Further, poor nutritional status affects the ability to cope with 
antiretroviral drugs and other medications.   
 
Figure 2.4:  Causal inter-relationship between HIV infection and nutritional status  
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The effects of HIV infection on the nutritional status of the individual may be seen as a 
causal web that follows a number of pathways depending on the stage and severity of 
the infection as illustrated in Figure 2.3 above.  Thus, an HIV infected individual who 
starts off with a reasonable nutritional status may progress to poor nutritional status as 
the infection puts extra demands on the immune system, increases the body’s demand 
for energy and nutrients, limits digestion and absorption through the gastrointestinal 
tract, or increases nutrient losses from the body.  Separately and together these 
eventually lead to a poor nutritional state and weight loss in the infected individual, 
which further weakens the immune system, affecting prognosis, QOL, and survival. 
 
2.3.6.2.1  Mechanisms for the impact of HIV/AIDS on nutritional status 
In HIV infection, nutritional status, whether marked by loss of body weight, body cell 
mass, absolute and/or relative lean body mass, or changes in albumin, pre-albumin or 
C-reactive protein, has been shown to be a significant predictor of survival in infected 
adults after adjusting for CD4+ cell counts and history of secondary events (Melchior et 
al., 1999). 
 
In general, there are changes in five major processes through which infection, including 
HIV, tends to impair the individual’s nutrition or nutritional status:  
•  Changes in nutrient intake,  
•  Changes in digestion and absorption,  
•  Changes in demand for nutrients, 
•  Changes in delivery of nutrients to tissues, 
•  Increased losses of nutrients.   
 
2.3.6.2.1.1 Changes in intake  
Infection and illness will cause nausea, vomiting and loss of appetite or anorexia, which 
with other eating difficulties lead to inadequate food intake.  People with HIV/AIDS 
most commonly eat less because of a poor appetite.  OI contribute by causing nausea, 
malaise, and fever.  Specific local infections, such as oesophageal candidiasis, may 
cause a sore mouth, stomach pain or pain during eating (AIDS Institute, 1995).   
Systemic illnesses (including HIV itself) generate a systemic acute inflammatory 
response, and  psychological conditions (such as depression) that impair patients' 
ability to nourish themselves.  Following an episode of illness, appetite may improve 
with a chance to recuperate.  The need for more food of better quality is greater at this 
time, but people with HIV/AIDS may not be able to access extra food of quality 
especially against a background of poverty and food insecurity.  In many instances, 
social considerations like stigmatisation, isolation and active drug use may play an   52
important role in limiting access to food for PLWHA (AIDS Institute, 1995).  In some 
settings, stigma leads to loss of employment, or the support of family or community.  
People too ill to work lose their jobs and farmers who are ill are unable to grow enough 
food for themselves and their dependants.  Infection with HIV/AIDS leads to a 
redirection of resources away from food to care.  There is a difficult choice between 
paying for medicine and paying for food. Care giving can divert other family member's 
time and energy away from employment or food provision. Lack of help for food 
shopping and preparation as well as lack of or inadequate food preparation and 
cooking facilities are also factors that can limit food intake in PLWHA. 
 
2.3.6.2.1.2 Changes in Digestion and Absorption  
Even when food is available, it may be poorly absorbed in persons with HIV/AIDS.  
Intestinal malabsorption and nutrient loss is common.  While severe diarrhoea and 
malabsorption may be due to OI or intestinal parasites such as cryptosporidium, some 
of the altered absorption appears to be a consequence of HIV infection itself (Kotler et 
al, 1990).  The virus can damage the intestinal villi, and inflammation resulting from the 
infection can also damage gut tissue and reduce absorption (Kotler et al, 1990).   
Frequently, small bowel transit time is accelerated, particularly among children with 
severe diarrhoea and  Intestinal mucosal digestive enzymes may be reduced or less 
active (Kotler et al, 1990).   These changes in the gut affect the body's ability to utilise 
dietary fat and carbohydrates. A study has reported that people with HIV have high 
levels of faecal fat that is unrelated to fat intake or the presence of any intestinal 
infection other than HIV itself (Hsu et al., 2005).  
 
2.3.6.2.1.3 Changes in Demand, altered delivery or increased loss  
HIV infection and replication affect metabolism in a variety of ways some of which may 
be caused by the inflammatory immune response mediated by cytokines.  Cytokines 
are chemical messengers and growth factors produced by lymphocytes and 
macrophages which mediate and regulate the inflammatory immune process (see also 
section 2.5.3.2.1).  These inflammatory immune responses begin as soon as a person 
is infected with HIV and they increase the nutrient requirements of the host.  There may 
be an increase in REE up to 10% or more during opportunistic or inter-current bacterial 
infections.  Any concomitant reduction in physical activity may mean that total daily 
energy expenditure is not changed, or even reduced (Hsu et al., 2005). 
 
There are endocrine or hormonal changes in patients with HIV/AIDS - such as 
hypogonadism, (reduced or absence of secretion of hormones from the sex glands 
which may occur in both males and females).  In males, testosterone levels in   53
particular may be depressed, accompanied by a substantial loss of muscle or LBM 
(Hsu et al., 2005). 
 
2.3.6.2.2  HIV/AIDS and the wasting syndrome 
The nutritional consequence of wasting and/or weight loss has been recognized as a 
frequent and major complication of HIV infection (Kotler et al., 1989), and is a common 
feature in PLWHA.  In HIV infection, the “syndrome of wasting” is defined by a body 
weight loss of 10% of the usual bodyweight and associated with chronic diarrhoea 
and/or fever and/or asthenia (loss of body strength) with lack of other detectable 
causes (CDC, 1987).  Wasting and/or weight loss may occur from the onset (Ott et al., 
1993) or more frequently in the later stages of HIV disease (Ysseldyke, 1991).   
As an AIDS-defining condition, wasting carries a high risk of mortality (Kotler et al., 
1989; Kravik et al, 1997; Wheeler et al., 1998; Melchoir et al, 1999).  In fact weight loss 
and muscle wasting which were unique identifying characteristics of the HIV disease 
early in the epidemic (Mhiri et al., 1992), still remain a significant clinical problem in this 
modern era of potent ARV (Wanke et al., 2000). The early days of the HIV/AIDS 
epidemic saw a rise in the syndrome of wasting even in the developed world.   
However, the inception of HAART brought an initial decline in its incidence, especially, 
in western countries, and an increase thereafter (Wanke et al, 2000).  
 
The syndrome of wasting is usually preceded by loss of appetite, repeated infections, 
weight fluctuations and changes in body composition (Babameto and Kotler, 1997).  
Wasting and loss of body weight are nearly always associated with deficiencies of 
vitamins and minerals (Babameto and Kotler, 1997).  Thus, wasting and/or weight loss 
in HIV infection develop from a number of processes that are not mutually exclusive: 
reduced food intake, nutrient malabsorption, metabolic changes, hypogonadism and 
responses to cytokines (Salomon et al., 2002).  
 
2.3.6.3  HIV/AIDS and micronutrient deficiencies 
The cyclical relationship showing that infection may lead to micronutrient deficiencies 
and that the presence of micronutrient deficiencies affects the risk of infectious 
diseases (Scrimshaw et al., 1968, Friis, 2005) reflects the complex interrelationship 
between malnutrition and infection (Semba and Tang, 1999).  In HIV infection and 
AIDS, micronutrient deficiencies may be very common, but are not necessarily evident, 
as specific signs or symptoms may often be lacking (Fawzi, 2003).   
 
Prior to the widespread use of HAART, a high prevalence of low micronutrient levels 
was noted in the HIV population (Friis, 2005).  Generally, micronutrient deficiencies are   54
common in parts of the world where access to ART is limited, such as in sub-Saharan 
Africa (Tang et al., 2005).  Epidemiological evidence indicates that low dietary intakes 
or blood levels of several vitamins and minerals may be associated with increased 
progression of HIV disease (Friis and Michaelsen, 1998; Tang et al., 1997; Tang and 
Smit, 1998).   
 
In both developed and developing populations, PLWHA tend to have decreased intake 
and absorption, increased urinary loss and low blood levels of specific vitamins 
(Vitamins A, B complex, C, E, folate and beta carotenes) and minerals (zinc, selenium 
and magnesium), in part a consequence of the acute phase response (Friis and 
Michaelsen, 1998; Tang and Smit, 1998, Friis, 2005).  Many of these micronutrients 
play defined roles in immune function and regulatory metabolic processes (Friis and 
Michaelsen, 1998; Tang and Smit, 1998).  Vitamin A, for instance, have been shown to 
play a role in the growth and function of T and B lymphocytic cells, in antibody 
responses and epithelial integrity and health (Tang et al., 1997).  Some micronutrient 
deficiencies have been associated with declining CD4+ T cell counts as well as 
increased disease progression (Pacht et al., 1997; Tang et al., 1997; Baum et al., 
1997), and also with increased risk of mortality (Semba et al., 1995a; 1995b).   
 
Some micronutrients help maintain immune function by acting as anti-oxidants (e.g. 
vitamins E, C, beta carotenes and selenium and other components like glutathione).  
They neutralise free radicals generated during the inflammatory burst (Friis and 
Michaelsen, 1998; Semba and Tang, 1999).  However, some other micronutrients like 
iron are pro-oxidants and can help to generate free radicals.  Oxidative stress results 
from an imbalance between pro- and anti-oxidant factors, either through overproduction 
of reactive oxygen species or deficiency of antioxidant protection, and this stress   
promotes HIV replication (Friis and Michaelsen, 1998; Tang et al, 2005).  In HIV 
infection and AIDS, a vicious cycle develops in which undernourished HIV-infected 
persons with micronutrient deficiencies, become further immunosuppressed and 
increased oxidative stress accelerates HIV replication and CD4+ T cell depletion 
(Semba and Tang, 1999).   
 
There have been difficulties in establishing causal relationships between specific 
micronutrient deficiencies, the transmission and adverse clinical outcomes in HIV-
infected persons.  In part this is because the pattern of deficiencies associated with HIV 
infection varies across populations and according to disease stage (Fawzi, 2003; Friis, 
2005).  Further, structured intervention studies designed to demonstrate the 
effectiveness of specific therapeutic supplementation are few and inconsistent (Tang et   55
al, 2005).  In reviewing the evidence, Tang and colleagues (2005) established that 
most studies in which the micronutrient status of the HIV/AIDS populations had been 
explored had been based upon assays for plasma or serum levels of nutrients.  The 
problem is that for most of these measures interpretation is problematic in infected 
persons where low levels do not necessarily indicate poor status, but rather they may 
be lowered as a part of the acute phase response (Tang et al., 2005).  Under such 
circumstances some micronutrients may be depleted, but others may shift between 
body compartments (Wellcome Trust and USAID, 1999).   
 
Notwithstanding these limitations, assessment of serum or plasma levels of 
micronutrients has revealed that deficiencies are likely to be common among HIV 
infected persons, especially, in those who are under-privileged and undernourished 
(Kotler and Grunfield, 1995; Liang et al., 1996).  Many of such studies have associated 
lower plasma or serum levels of vitamin A (Semba et al., 2002), vitamin E (Tang et al., 
1997a) and vitamin B12 (Tang et al., 1997b) with increased disease progression in HIV 
infection.  A low vitamin A status, in particular, is associated with increased risk of 
MTCT of HIV (Semba et al, 1994), HIV viral load in breastmilk and vaginal secretions 
(Nduati et al., 1995), progression to AIDS (Tang et al., 1993) and adult survival (Semba 
et al., 1994).  Selenium, vitamin B6, vitamin B12 and Cu deficiencies have also been 
reported in studies on HIV infected patients (Baum et al., 1991; Beach et al., 1992).  In 
a cross sectional study, Zn deficiency was observed among 23% of HIV infected 
patients (Wellinghausen et al., 1999).  In contrast, a study has shown a significant 
association between increased zinc, vitamin A and niacin intakes and the progression 
to AIDS (Tang et al., 1993).  Nevertheless, studies relating adverse effects of 
micronutrient deficiencies or lower intake seem to tip the balance of the evidence in 
favour of micronutrient supplementation. 
 
It is precisely on this basis that it was proposed that a regular supplementation with 
micronutrients in HIV/AIDS was likely to be of benefit, especially in resource-poor 
communities (Fawzi et al., 1999; Semba and Tang, 1999).  Indeed, supplementation 
trials in HIV-infected populations appeared attractive because of their affordability and 
relative ease of administration.  However, initial results have been mixed.   
 
Supplementations with vitamin A, for instance, have been beneficial for some HIV-
related outcomes, whilst for others it was unremarkable or even adverse (Tang et al., 
2005).  In infected children, supplementation with vitamin A may reduce diarrhoeal 
morbidity (Coutsoudis et al, 1995), improve immune status (Hussey et al., 1996) and 
reduce mortality (Fawzi et al., 1999).  In adults it did not have any impact on viral load   56
(Semba et al., 1998), immune status (Fawzi et al., 1998), diarrhoeal morbidity (Kelly et 
al., 1999), prenatal and postnatal morbidity in women (Kennedy et al., 2000) and MTCT 
of HIV (Coutsoudis et al., 1999; Fawzi et al., 2000).  In contrast, one study has shown 
that a high dose supplementation may even increase mortality (Tang et al., 1996). 
 
With vitamin E, supplementation may reduce oxidative stress and HIV viral load (Allard 
et al., 1998).  Late-stage oral supplementation with vitamin E, however, did not affect 
diarrhoea morbidity or mortality (Kelly et al., 1999).  With MTCT, vitamin E intake was 
associated with improving mastitis in breastfeeding women (Filteau et al., 1999), but 
similar results were found for intakes of selenium, vitamin A and beta carotene (Semba 
and Neville, 1999). 
 
The case for vitamin B12 and folate supplementation has not been clearly established 
for PLWHA but there is the need to consider these nutrients because of their potential 
interaction with HIV medications and their role in intermediary metabolism. There are 
several other micronutrients which have been associated with HIV/AIDS although the 
link or relationships between these micronutrients and the disease are not very clear. 
For instance, observational studies in industrialised countries have shown that vitamins 
B1, B2, B3, B6 and C deficiencies may be common in HIV-infected men, with a high or 
increased intake tending to slow the progression of the disease (Tang et al., 1996; 
Kanter et al., 1999). 
 
The study on selenium, which is known to play an important role in reducing oxidative 
stress, has been a limited.  However, its deficiency has been associated with HIV-
related deaths (Baum et al., 1997).  Oral supplementation of selenium to deficient 
PLWHA significantly increased antioxidant enzyme function (Delmas-Beauvieux et al., 
1996).  With regards to zinc, low serum levels have been associated with HIV disease 
progression and mortality (Baum et al., 1996), and zinc supplementation was beneficial 
in AIDS patients (Mocchegiani et al., 2000).  However, intakes over and above the 
body’s normal requirement from the diet and/or supplements were associated with 
reduced survival in HIV-infected men (Tang et al., 1996), possibly because the virus 
has its own requirement for zinc (Baum et al, 2000).  
 
Because many micronutrient deficiencies occur together, the impact of multiple 
micronutrient supplementations on HIV-related outcomes is an important consideration.  
One study showed that multiple supplements slowed disease progression to AIDS and 
deaths, especially when given with other drug therapies (Kanter et al., 1998).  In 
pregnant women, multiple micronutrient supplements appeared to have beneficial   57
effects on the offspring as well as improving the immune status of postnatal HIV-
infected women (Fawzi et al., 2000).   
 
Since HIV infection is associated with an increased oxidative stress and a subsequent 
decline in antioxidant nutrients, administering ARV might be expected to lead to 
reduction in oxidative stress and an improvement in antioxidant nutrient levels.   
However, this is seemingly not the case as the medications themselves increase 
oxidative stress and cause cellular toxicities (Tang et al, 2005).  The available data 
suggest that any improvements in the micronutrient status or antioxidant nutrient levels 
with HAART is inconsistent and may be described as modest at best (Tang et al, 
2005). 
 
With the advent of HAART, HIV has become a more manageable chronic disease, and 
concerns around metabolic changes such as lipodystrophy syndrome and others, 
together with factors that affect the QOL have taken prominence over micronutrient 
deficiencies.  Anaemia, which may manifest from many causes including the direct and 
indirect effects of the HIV, has also persisted, and remains a concern of importance 
among PLWHA (Castaldo et al., 1996; Volberding, 2000; Volberding et al., 2004).   
 
The important role played by iron in the regulation of the body’s internal milieu makes it 
a special micronutrient.  A deficiency of iron is associated with anaemia and with 
impaired immune function among others.  Iron deficiency anaemia is often prevalent 
amongst the same populations where HIV infection is common and, therefore 
administering iron supplements to such populations may appear reasonable.  However, 
some caution is required since iron can act as a pro-oxidant and possibly promote viral 
replication.  In fact some retrospective studies have suggested that a high iron status 
may hasten disease progression and increase mortality in infected adults (see section 
2.5.3.1 on iron). 
  
2.3.6.4  HIV/AIDS and anaemia  
Since several million people worldwide are infected with HIV, and anaemia is a 
common manifestation of HIV/AIDS, it follows that a large percentage of those infected 
with the HIV will have anaemia.  In developing countries, where both conditions are 
prevalent, It is likely that the numbers with both HIV and anaemia will be high (Lewis, 
2005).  Although anaemia is not historically considered a serious complication of HIV 
infection, it is now receiving much attention because of its significant impact on clinical 
outcomes and QOL (Belperio and Rhew, 2004).  HIV-infected individuals with anaemia 
are most likely to experience debilitating symptoms that may impair their functionality,   58
decrease their sense of wellbeing and affect their QOL (Cella, 1996).  Indeed, the 
impact of anaemia on the QOL and survival in HIV infection is great (Abrams et al., 
2000) as anaemia induces fatigue and other symptoms which greatly impair QOL 
(Ludwig and Strasser, 2001).  Although in HIV disease fatigue may be due to various 
factors, anaemia is a major contributor (Breitbart et al., 1998; Barroso, 1999). 
 
2.4  THE GENERAL CHARACTERISTICS OF ANAEMIA  
Anaemia is characterised by a reduction in RBC mass (Phillips and Groer, 2002). 
Haemoglobin is the major carrier of oxygen in the blood and is located within the RBC.  
Its primary function is to deliver oxygen to the tissues of the body, thereby enabling 
cellular oxidative phosphorylation and generating energy for all cellular work.  Any 
decrease in red cell mass reduces the amount of haemoglobin available and therefore 
reduces the amount and rate at which oxygen can be delivered to the tissues.  Thus, 
any limitation on this fundamental biological function, with the associated reduction in 
oxygen supply may be expected to have deleterious effects.  This state of a functionally 
significant reduction in cell mass characterises anaemia.   
 
2.4.1 THE RED BLOOD CELL OR ERYTHROCYTE 
Erythrocytes or RBC are biconcave discs approximately 7 to 8 µm in diameter 
containing approximately 300 molecules of haemoglobin.  Their average life span is 
120 days.  With ageing the content/activity of intracellular enzymes decreases, 
metabolism slows, cellular integrity fails as the plasma membrane becomes osmotically 
fragile (Sacher and McPherson, 2000; Thurnham and Northrop-Clewes, 2007).  With 
about 1% of erythrocytes being removed from the circulation daily, there is the need to 
produce the equivalent of 2,400,000 new erythrocytes per second, to maintain a steady 
state.  Senescent red cells are removed from the circulation and broken down by the 
RES, such as the spleen.    
 
Haematopoiesis refers to the production and development of erythrocytes (red blood 
cells), leukocytes (white blood cells), and thrombocytes (platelets), from common, 
pluripotent progenitor stem cells, within the tissues of the hematopoietic system, 
consisting of the bone marrow, liver, spleen, lymph nodes, and thymus gland (Sacher 
and McPherson, 2000).  Stimulation of the pluripotent stem cells by growth factors, like 
colony-stimulating factors and interleukins, give rise to myeloid stem cells that 
differentiate into erythrocytes, leukocytes, or platelets or lymphoid stem cells that 
become T- or B-lymphocytes (Sacher and McPherson, 2000).  The production and 
development of erythrocytes (erythropoiesis) takes place under the influence of at least 
four cytokines; erythropoietin, interleukin-3, granulocyte-monocyte colony-stimulating   59
factor, and monocyte-macrophage colony-stimulating factor, that stimulate precursors 
to proliferate, and differentiate to form activated erythrocytes (Sacher and McPherson, 
2000).  The primary cytokine responsible for erythropoiesis is erythropoietin, synthesis 
and/or release of which is increased, mainly from cells associated with the 
juxtaglomerular apparatus of the kidneys, under the stimulus of tissue hypoxia (Sacher 
and McPherson, 2000).  Erythropoietin in the circulation acts on the target tissue, the 
bone marrow, to stimulate the differentiation of stem cells into erythrocytes (Sacher and 
McPherson, 2000).   
 
2.4.2 MECHANISMS FOR ANAEMIA  
Anaemia occurs when the rate of RBC formation fails to keep pace with the rate of its 
degradation or loss.  According to Volberding and colleagues (2004), the three main 
mechanisms that may contribute independently or together for anaemia to occur are: 
 
•  Lower than necessary rates of RBC production (or ineffective erythropoiesis)  
•  Higher than usual rates of RBC destruction (haemolysis) or  
•  Blood loss or bleeding (haemorrhage) which could be either acute or chronic  
 
2.4.2.1  Decreased RBC production  
If the bone marrow fails to produce enough red blood cells to keep up with the body's 
needs, then anaemia will result.  Inadequate production may result from inadequate 
signal for red cell production or an unresponsive marrow or because of conflicting 
signals or if the demand for nutrients is too high or there is inadequate energy and/or 
nutrients available to meet the demand.  Common nutritional anaemias are a 
consequence of limited availability of nutrients such as iron, vitamin B12 or folates.   
Infection or inflammation can suppress RBC production.  Some pharmacological 
agents can impair RBC production, for example some drugs used for cancer 
chemotherapy or some antiretrovirals used in HIV/AIDS treatment.  Impaired renal 
function might limit the availability of erythropoietin.   
 
2.4.2.2  Increased RBC destruction 
If there is increased destruction of RBC or their life span is reduced from the usual 120 
days then it may not be possible to maintain an adequate rate of replenishment leading 
eventually to anaemia (Sacher and McPherson, 2000).  This may occur because of 
changes intrinsic to the cell itself (abnormal type of haemoglobin, e.g. sickle cell 
anaemia (HbSS), challenges from outside the cell such as infection, or destruction by 
the body's own immune system (as in autoimmune disorders and perhaps HIV/AIDS).   
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Sickle cell anaemia is a single gene defect of haemoglobin and under low oxygen 
tensions the haemoglobin  polymerises, causing the RBC to become crescent-shaped 
and making the cells more fragile, more likely to be damaged and removed from the 
circulation.  Glucose-6-phosphate-dehydrogenase (G-6-P-D) deficiency is an 
inheritable disorder in which impaired activity of the enzyme leads to cellular fragility 
and a liability to disruption under oxidative stress.  Malaria is an example of an infection 
where parasitization of the RBC leads to increased damage and loss.  
 
2.4.2.3  Blood loss or bleeding 
Bleeding or blood loss is an obvious cause of anaemia and can occur for a variety of 
reasons.  In women, there is physiological blood loss with menstruation or delivery after 
pregnancy.  Pathological blood loss, especially through the gastrointestinal tract can be 
common in enteric infection such as hook worm.  Other causes of blood loss, even if 
slight can lead to anaemia, especially when sustained over a long period of time.  This 
is more likely to lead to anaemia where the rate of blood loss exceeds the capacity for 
normal replacement, or where the bone marrow is not working properly or where the 
fragility of red cells is increased.    
  
2.4.3 CLASSIFICATION AND COMMON TYPES OF ANAEMIA  
Anaemia has been classified in many different ways, for example, based on RBC 
morphology or the aetiopathology or other specific characteristics (Breymann, 2002).  
Two systems frequently used have emphasised either aspects of RBC kinetics or 
morphology (Breymann, 2002).   
 
When RBC turnover is increased there is greater release of relatively immature forms, 
with persistence of nuclear material into the circulation, leading to an increased 
reticulocyte count.  On the other hand, morphological characterisation assesses the 
size of the RBC, reflected in the mean corpuscular volume (MCV) (Breymann, 2002).  
Red  blood cells are small in microcytic anaemia (under 80 fl); normal size (80-100 fl) in 
normocytic anaemia; and larger than normal (over 100 fl) in macrocytic anaemia.   
Microcytic anaemia results primarily from an insufficiency in haemoglobin synthesis, 
most commonly from iron deficiency, but also from other defects in haem and globin 
(thalassaemias) synthesis or toxicities that affect synthesis (e.g. sideroblastosis) 
(Breymann, 2002).  Normocytic anaemia occurs when the overall Hb levels are 
decreased, but the red blood cell size (MCV) remains normal, for example with acute 
blood loss, haemolytic anaemia, the anaemia of chronic disease/inflammation, or 
aplastic anaemia (bone marrow failure) (Breymann, 2002).  .   
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Macrocytic anaemia is primarily due to a failure of DNA synthesis with preserved RNA 
synthesis, resulting in restricted cell divisions of the progenitor cells (Breymann, 2002), 
often due to either defficiencies of vitamin B12 or folate.  The use of DNA synthesis 
inhibition drugs (e.g. AZT), can also lead to a macrocytic anaemia. 
 
Of the many different types, anaemia related either to iron deficiency or to chronic 
inflammation are more common and especially widespread in populations suffering 
from malnutrition and with a high prevalence of infectious diseases (Thurnham and 
Northrop-Clewes, 2007).  Many authorities consider that iron deficiency is the most 
important contributor to the global burden of anaemia (Krishnaswamy, 2003; Kraemer 
and Zimmermann, 2007). 
 
2.4.3.1  Iron deficiency and anaemia  
2.4.3.1.1  The functional role of iron in the body 
Iron is abundant in the earth’s crust and a feature of living organisms with versatile 
biologic activity, nevertheless human deficiency is widespread (Krishnaswamy, 2003; 
ACC/SCN, 2000).   
 
Iron fulfils several vital functional roles in biological systems.  It provides a specific 
binding site for oxygen in the haem moiety of haemoglobin found in erythrocytes and 
myoglobin in muscle and thus serves as either a carrier or storage of oxygen required 
by the tissues (Hallberg, 1982).  It is incorporated into haemoglobin within the bone 
marrow in the presence of adequate amounts of other nutrients which include vitamins 
A, B12, C, E and folate (Lubin et al., 1997).  Iron serves as part of iron-containing 
enzymes, the cytochromes, which transport electrons within cells and is an integral part 
of important enzyme systems in various tissues (FAO/WHO, 2002).  It is present in the 
liver as stored, but mobilisable iron (ferritin and haemosiderin) and is transported 
between different compartments in the body bound to the plasma protein transferrin 
(FAO/WHO, 2002).   
 
The property that gives iron its functional relevance is its ability to undergo reversible 
one electron redox (reduction/oxidation) transfer between two common oxidative 
states, Fe
2+ (ferrous) and Fe
3+ (ferric) (Aisen, 1994).  By catalysing the production of 
reactive oxygen species (unstable intermediates or oxygen species with unpaired 
electrons) or free radicals, iron plays a critical role in macrophage mediated 
cytotoxicity, providing protection against potential pathogens (Roen et al., 1995; Pacelli 
et al., 1995).   
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However, the free radicals, especially hydroxyl free radical (OH.) and superoxide (O2.) 
produced from the catalytic process with iron are also capable of causing destruction to 
cellular organic molecules such as proteins and DNA (Roen et al., 1995; Pacelli et al., 
1995). 
 
Iron is an essential nutrient for all known pathogens and many have developed 
complex mechanisms to acquire it, allowing them to thrive successfully in iron restricted 
environments (Bullen and Griffiths, 1999).  Therefore, the availability of free iron in the 
body potentially increases their virulence and also increases the potential for excessive 
free radical production (Jackson, 2007).  The human body has developed complex 
metabolic processes to absorb, transport and store iron to ensure a ready supply for 
bodily functions whilst limiting its easy availability to potential pathogens or for free 
radical formation (Lynch, 2007).   
 
Most of the iron in the body is present in the erythrocytes as haemoglobin, a molecule 
composed of four units each containing one haem group and one amino acid chain 
(globin) (FAO/WHO, 2002).  The iron-containing oxygen storage protein in the muscles, 
myoglobin, is similar in structure to haemoglobin but has only one haem unit and one 
globin chain, whilst several iron-containing enzymes, i.e. the cytochromes, also have 
one haem group and one globin protein chain (FAO/WHO, 2002).  The main iron 
storage protein is ferritin, which is stored predominantly in cells of the reticulo-
endothelial system (macrophages of the spleen, liver, bone marrow) as well as in 
skeletal muscle (Bothwell et al., 1979).  Nevertheless, all nucleated cells are able to 
synthesise ferritin for managing their intracellular iron economy.  Haemosiderin is an 
amorphous storage form of iron which is water insoluble and less rapidly available 
(Wixom et al., 1980). 
 
2.4.3.1.2  Intake and metabolism of iron 
Within and across populations, iron status may vary over a continuum from overt 
deficiency to excess, and in some pathological conditions, its distribution in various 
body compartments may be abnormal.  A normal or healthy iron status implies that red 
blood cell production occurs without being limited by the availability of iron, and iron 
reserves are sufficient to rapidly meet the demands from limited acute blood loss 
(Worwood, 1997).    
 
Under optimal nutritional conditions, iron is stored in the tissues (mainly in the RES) as 
ferritin and haemosiderin reserves, from where it is mobilised when insufficient iron is 
available to the body.  In the short term this iron is provided through release of the   63
metal from ferritin reserves.  However, the primary source of iron to the body is the diet, 
which is absorbed in both organic (haem) and inorganic (non-haem) forms through the 
gastrointestinal tract (Beard et al., 1996).  Regulation of body content is determined by 
the rate of iron absorption, as there are no regulated mechanisms through which iron 
can be lost from the body.   
 
Iron is lost passively from the body mainly through cell loss from the skin and the 
interior surfaces of the body - intestines, urinary tract, and airways.  This generates an 
estimated need of about 14 µg/kg body weight/day (Green, 1968). Though dietary iron 
requirements for normal persons are low (Andrews, 1999), the iron needs for different 
groups of people may vary widely depending on their requirements for growth or to 
meet abnormal losses.  Humans lack a regulated pathway for iron excretion and iron 
balance is achieved through tight regulation on its rate of absorption (Nicholas et al, 
2002), which ensures that any variation in the body’s needs can be met across a wide 
range of dietary intakes (Deiss, 1963).  Critical control of absorption has been linked 
recently to a peptide hormone, hepcidin, produced by the liver (Fleming and Sly, 2001; 
Ganz, 2003; Nemeth et al., 2003).   
 
Both haem iron and non-haem iron are normal constituents of the diet but their 
absorption is different (Hallberg, 1981).  The dietary sources of haem iron are mainly 
haemoglobin and myoglobin from consumption of meat, poultry, and fish.  Cereals, 
pulses, legumes, fruits, and vegetables constitute the main sources of non-haem iron.  
Absorption of haem iron from meat-containing meals varies from 10 to 40%, and is on 
average 25% (Hallberg, 1977; Hallberg et al., 1999).  Meat promotes the absorption of 
non-haem iron (Hallberg, 1979).  In contrast, calcium is the only dietary factor identified 
that influences the absorption of haem iron negatively (Hallberg, 1998). 
 
Quantitatively, non-haem iron is often the main source of dietary iron, the absorption of 
which is influenced by a number of factors other than the individual’s iron status 
(FAO/WHO, 2002).  Reducing substances that keep iron in the ferrous form must be 
present for non-haem iron to be absorbed (Wollenberg and Rummel, 1987).  Ascorbic 
acid (vitamin C) is the most potent enhancer of non-haem iron absorption with synthetic 
vitamin C increasing the absorption of iron to the same extent as the native ascorbic 
acid in fruits, vegetables, and juices (Hallberg et al., 1989).  This effect of vitamin C has 
been considered as one of its important physiological roles (Hallberg et al., 1987).   
 
Other dietary factors or ligands, such as phytates and certain iron-binding polyphenols, 
strongly bind ferrous ions and subsequently may inhibit absorption of non-haem iron   64
(Gillooly, 1983; Hallberg et al., 1989).  Phytates are found in all kinds of grains, seeds, 
nuts, vegetables, roots (e.g., potatoes), and fruits, and inhibit non-haem iron absorption 
in a dose-dependent fashion (Hallberg et al., 1989).  Phenolic compounds are a part of 
the defence system of plants against insects, animals, and humans (Brune et al., 
1989).  Some, such as those found in tea, coffee, and cocoa may contribute to 
inhibition of iron absorption (Hallberg and Rossander, 1982). 
 
Normal individuals achieve iron balance over extended periods using a combination of 
three mechanisms (FAO/WHO, 2002).  Firstly, iron derived from effete erythrocytes is 
efficiently re-utilised following degradation by the macrophages of the RES.  The iron is 
delivered by transferrin in the plasma to red blood cell precursors in the bone marrow 
or other cells for reuse.   
 
Uptake and distribution of iron in the body is regulated by the synthesis of transferrin 
receptors (TfR) on the cell surface.  This system of internal iron transport controls the 
rate of flow of iron to different tissues according to their needs and effectively limits the 
appearance of free iron and the formation of free radicals in the circulation.  Secondly, 
ferritin bound iron acts as a buffered reserve to meet immediate variation in iron 
demands.  Thirdly, iron absorption from the intestines is tightly regulated to maintain 
reserves (FAO/WHO, 2002).  Iron deficiency may develop when other factors over-ride 
the usual regulation associated with increased iron absorption (Hallberg et al., 1995).  
Of basal iron losses from the body, about half are from blood, primarily in the 
gastrointestinal tract (FAO/WHO, 2002). 
 
Iron metabolism is regulated, under normal circumstances, by iron-regulatory proteins 
(IRP) that bind to specific portions on messenger-RNA (mRNA) and protect them from 
degradation (Northrop-Clewes, 2008).  In a state of iron deficiency (ID), the IRP bind to 
mRNA and subsequently promote the expression of TfR proteins whilst repressing 
ferritin synthesis.  When levels of iron are adequate in the body, ferritin synthesis is 
promoted and iron storage predominates.  However, during the acute phase of 
inflammation, the normal control of iron metabolism is re-organised by TNF-α and IL-6 
(Northrop-Clewes, 2008).  These two cytokines are known to induce ferritin 
transcription and thereby increase ferritin levels despite the presence of reduced serum 
levels. These cytokines have been suggested to have an over-riding influence on the  
induction of ferritin mRNA compared to that from serum iron (Feelders et al., 1998), 
and serum ferritin concentrations tend to parallel the increased storage and retention 
by the RES . 
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2.4.3.1.3  Characteristics of iron deficiency and iron deficiency anaemia 
Iron deficiency accounts for about half of over 2 billion people suffering from nutritional 
anaemia.  It is prevalent worldwide with infants, children, adolescents and women of 
childbearing age constituting the vulnerable groups, and pregnant women being the 
most vulnerable (Kraemer and Zimmermann, 2007).  Usually ID occurs in three 
sequentially developing stages: depleted iron stores, iron deficient erythropoiesis and 
iron deficiency anaemia (IDA).   
 
Often ID and IDA have been incorrectly used as synonyms (FAO/WHO, 2002).  When 
a person with no mobilisable iron from reserves develops negative iron balance, an 
immediate impairment in the production of haemoglobin with a resulting decrease in 
haemoglobin and different erythrocyte indexes occurs (Wintrobe, 1981).   
 
The absence of iron stores together with signs of an iron-deficient erythropoiesis 
constitutes ID, which implies that there is an insufficient supply of iron to various 
tissues.  Initially a less than optimal level of iron available to the body leads to a 
decrease in iron stores; which may then progress to the state of ID.  It is estimated that 
this occurs at a serum ferritin level <15 µg/l (FAO/WHO, 2002).  Iron can then no 
longer be mobilised from iron stores and insufficient amounts of iron will be delivered to 
transferrin.   
 
The binding sites for iron on transferrin contain progressively less iron, characterised 
as reduced transferrin saturation (Wintrobe, 1981).  At a critical level of reduced 
transferrin saturation, the supply of iron to erythrocyte precursors fails to meet the 
demands for haemoglobin formation (Wintrobe, 1981).  The iron-transferrin complex 
binds to TfR on the cell surface and the whole complex is taken up by the cell.  The 
uptake of iron is related both to the saturation of transferrin and the number of TfRs on 
the cell surface (Harford, 1994).  There is diurnal variation in the saturation of 
transferrin making it difficult to evaluate the iron status from single determinations of 
transferrin saturation (FAO/WHO, 2002).   
 
The absence of iron stores (iron deficiency) can be diagnosed by showing that there is 
no stainable iron in the reticuloendothelial cells in bone marrow smears or more easily 
by a low concentration of ferritin in serum (<15 µg/l) (Wintrobe, 1981).  Even if absence 
of iron stores per se may not necessarily be associated with any immediate adverse 
effects, it is a reliable and good indirect indicator of iron-deficient erythropoiesis and of 
an increased risk of a compromised supply of iron to different tissues (FAO/WHO, 
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Even before iron stores are completely exhausted the supply of iron to the erythrocyte 
precursors in the bone marrow is compromised, leading to iron-deficient erythropoiesis 
(FAO/WHO, 2002).  A possible explanation is that the rate of release of iron from 
stores is influenced by the amount of iron remaining.  During the development of iron 
deficiency, haemoglobin concentration, transferrin concentration, transferrin saturation, 
soluble transferrin receptors (sTfR), erythrocyte protoporphyrin and erythrocyte indexes 
are altered (see appendix A).  All these indicators, however, show a marked overlap 
between normal and ID subjects, which makes it impossible to identify the single 
individual with mild iron deficiency by using any of these indicators (FAO/WHO, 2002).  
The diagnostic specificity then increases but the sensitivity decreases, and thus the 
true prevalence of ID is markedly underestimated if multiple diagnostic criteria are 
used.  In screening for ID, the more the number of tests used the higher is the 
diagnostic specificity but the lower the sensitivity of the procedure (FAO/WHO, 2002).  
Fortunately, a low serum ferritin (<15µg/l) is always associated with an iron-deficient 
erythropoiesis.  However, the use of serum ferritin alone as a measure will also 
underestimate the true prevalence of ID but to a lesser degree than when combined 
criteria are used (FAO/WHO, 2002).    
 
In ID, plasma iron levels are low but haemoglobin levels may remain normal (Butensky 
et al., 2004).  If ID persists, a state of IDA may develop from the depletion of marrow 
supply of iron and haemoglobin levels may decrease (Finch, 1994).  The definition of 
IDA has been based on cut-off values, and to an extent represents a statistical 
construct rather than a functional concept (Wintrobe, 1981).  By definition, the 
prevalence of IDA is less frequent than ID, which makes the use of the latter more 
specific in characterising iron nutritional status (Wintrobe, 1981).  Though imprecise, 
the IDA concept is still in use because of the ease of determining haemoglobin 
(Wintrobe, 1981).  The use of serum ferritin has improved the diagnostic accuracy of ID 
(FAO/WHO, 2002).  It is the only simple method available to detect early ID.  However, 
the practical value of using ferritin is somewhat reduced by the fact that it is a very 
sensitive acute-phase reactant which may be increased for weeks after a simple 
infection with fever for a day or two (Hulthén, 1998).  Several other conditions, such as 
alcohol use, liver as well as collagen diseases may also increase serum ferritin 
concentrations (Osler et al., 1998).   
 
Other methods (Appendix A), such as the determination of sTfR levels in plasma have 
also been recommended in the diagnosis of ID (FAO/WHO, 2002).  This method is 
mainly used in subjects who are already anaemic and it is not sensitive for the early 
diagnosis of ID.  As an advantage it is not influenced by infections.  Although the use of   67
a combination of measures, such as serum ferritin, sTfR, C-reactive protein (CRP), 
Alpha-1-acid glycoprotein (AGP) and alpha-anti-chymotrypsin (ACT) have been 
suggested to improve diagnostic accuracy, this is not always practicable in population 
studies (Cook et al., 1996; Northrop-Clewes, 2008).  In current practice, the most 
practical methods are considered to be measures of haemoglobin and ferritin, with 
some allowance made for active inflammation.  
 
2.4.3.2    Chronic inflammation and anaemia  
2.4.3.2.1  The inflammatory process and iron metabolism 
Inflammation is a general process through which the body responds to injury or 
pathogenic attack.  It is associated with the co-ordinated and regulated release of the 
inflammatory cytokines IL-1, IL-6 and TNF-α (Janeway et al., 1999).  The response is 
characterised by a series of local and systemic effects collectively referred to as the 
acute phase response (APR) (Baxendale and Gauldie, 1994).  Locally there is 
vasodilatation, platelet aggregation, neutrophil chemotaxis and the release of 
histamines, lysosomal enzymes, kinins and oxygen free radicals.  Systemic changes 
include an elevation of body temperature (fever), hormonal changes (activation of the 
adreno-pituitary system), leucocytosis (increase in white blood cell numbers), 
thrombocytosis (increase in platelet numbers), muscle proteolysis, alterations in 
intermediary metabolic substrates and changes in the hepatic or liver synthesis of 
acute phase proteins (APP) (Baxendale and Gauldie, 1994).   
 
Teleologically, the metabolic changes that occur in the liver and peripheral tissues are 
thought to provide endogenous nutrients like glucose and amino acids to fuel the 
activated immune system (Grimble, 1992).  The liver cells, in particular, respond 
specifically to IL-1, IL-6 and TNF-α, with consequential effects on the APR (Thurnham 
and Northrop-Clewes, 2007).   
 
Following infection or in the presence of an inflammatory stimulus, an APR is invoked 
by the body which starts with the release of inflammatory cytokines such as IL-1, TNF-
α, IL-6 and some IFNs which typically direct the inflammatory response (Tomkins, 
2003).  As a broad-based response to many different types of stimuli (infections and all 
kinds of tissue injury), the APR fulfils two important functions.  Firstly, it facilitates the 
inflammatory and repair processes and, secondly, it protects against the potentially 
destructive action of the inflammatory products (Baxendale and Gauldie, 1994).  Thus, 
in general, the APP produced during the process of inflammation may be functionally 
protective or anti-inflammatory, and may indicate the nonspecific presence of 
inflammation, tissue damage or endotoxins (Fleck and Myers, 1985).     68
During the APR, plasma concentrations of several nutrients and APPs are altered.   
Plasma levels of iron and zinc fall rapidly, but levels of copper tend to increase 
(Thurnham and Northrop-Clewes, 2007).  The increase in serum ferritin concentration 
parallels that of CRP, another positive APP (Feelders et al., 1998).  In recent years a 
small polypeptide known as hepcidin, synthesised and secreted from liver cells in 
response to IL-6, has been implicated in both the hypoferaemia of infection and the 
increase in serum ferritin concentration (Nemeth et al., 2003; Wrighting and Andrews, 
2006).  Although there are studies that show a correlation between inflammation, 
elevated circulating cytokines and anaemia in humans and animal models (Weinstein 
et al., 2002), the question as to whether these cytokines act alone or regulate important 
pathways for red cell production remains unanswered. 
 
2.4.3.2.2  Characteristics of anaemia of chronic inflammation  
Anaemia of chronic inflammation is an acquired hypo-proliferative disorder often seen 
in persons with systemic illnesses or inflammatory diseases, such as infection, cancer 
or autoimmune conditions.  The cause has been attributed to impaired erythropoiesis 
(Weiss and Goodnough, 2005).  First described in the 1930s, it was more fully 
characterized by Cartwright and Wintrobe in the 1950s (Cartwright, 1966).  It has been 
considered to be the second most prevalent form of anaemia after iron deficiency, and 
the most common among patients with chronic illness (Zarychanski and Houston, 
2008).   
 
In population-based studies, it has been difficult to ascertain precise estimates of the 
prevalence of ACI because many persons with anaemia are not investigated 
sufficiently to establish the cause.  Further, there are no agreed criteria for the 
diagnosis of anaemia of chronic inflammation for research purposes, and especially, in 
situations where ACI is likely to be only one of many reasons why persons might have 
anaemia (Zarychanski and Houston, 2008).  ACI varies in severity with most patients 
typically presenting with mild (> 100 g/L) or moderate (85–100 g/L) reductions in 
haemoglobin concentrations (Zarychanski and Houston, 2008).  In a minority of 
patients, there may be severe reductions in haemoglobin concentrations. 
 
ACI has features of a biologically adaptive response, being a highly coordinated and 
genetically conserved response to systemic disease (Futuyma, 2008).  Of the several 
mechanisms that may contribute independently to ACI, iron sequestration is the best 
studied.  ACI is generally characterised by low reticulocyte count, decreased survival of 
matured red cells, inhibition of erythroid progenitor cells, an increase in circulating 
inflammatory cytokines, immune activation, suppression of erythropoietin production   69
and a blunted response of red cell precursors to erythropoietin (Semba and Gray, 
2000; Claster, 2002; Zarychanski and Houston, 2008).  Another important feature of 
ACI is the occurrence of a major alteration in the distribution of iron within and between 
tissues (Butensky et al., 2004).   
 
As part of the host defence mechanism, under conditions of chronic inflammation, the 
body sequesters iron, especially in macrophages (Boelaert et al., 1996).  It has been 
suggested that this limits the availability of iron to potential pathogens, which require it 
for their own growth (Weiss, 1999).  There is limited mobilisation of iron from stores 
(Means, 1995) and a decreased absorption of iron through the gastrointestinal tract 
(Lee, 1983), which together limit the availability of iron for erythropoiesis (Means, 
2000).  Thus, the hypoferaemia associated with an inflammatory process is not 
necessarily associated with a reduced total body iron content, or a dietary iron 
deficiency, but rather a limitation on the ability to access iron (Thurnham and Northrop-
Clewes, 2007).  This redistribution of iron and limited availability of iron to metabolic 
processes can occur even when the total amount of iron in the body is normal or 
increased (Thurnham and Northrop-Clewes, 2007).  This iron sequestration is a 
hallmark of ACI that could have several beneficial effects. 
 
Early in the course of ACI, body iron stores may be normal with a mild normocytic 
anaemia resulting from the impaired iron cycling (Butensky et al., 2004).  This may 
progress to retention or accumulation of iron in the reticulo-endothelial macrophages, 
and subsequently, serum iron and serum transferrin values become low.  As time goes 
on the impaired intestinal absorption arising from the ACI would result in a reduced 
body burden of iron and hence frank iron deficiency and the anaemia becomes 
microcytic (Weinstein et al., 2002).  However, serum or plasma ferritin levels may 
remain normal or high (Weiss, 1999; Volberding, 2000).  In ACI bone marrow biopsies 
may reveal adequate or often increased iron stores with poor incorporation of iron into 
developing red cells (Weiss, 1999).   
 
Among the many other causes of anaemia in HIV infection, only ACI is involved with an 
increase in iron stores, a condition which may pose a unique problem for HIV-infected 
persons (Butensky et al., 2004).  Wider changes in the bone marrow are also a 
common feature in ACI with neutropaenia and/or thrombocytopaenia (Claster, 2002) or 
altered white cell function such as altered helper-T cell activity (Mitsuyasu, 1994; 
Volberding, 2000).  It has been suggested that in HIV infection defects of this kind 
contribute to the increased incidence of co-infections and malignancies, which can in 
their own right cause anaemia (Mitsuyasu, 1994).     70
More recent work indicates that a small peptide hormone produced in the liver, 
hepcidin, may be involved in the pathogenesis of ACI (Fleming and Sly, 2001).   
Hepcidin has intrinsic microbial activity and its expression increases in response to 
inflammation (Pigeon et al., 2001; Nicholas et al., 2002).  Hepcidin is a negative 
regulator of intestinal iron absorption and iron release by macrophages and has been 
implicated as having a central role in the regulation of iron homeostasis (Fleming and 
Sly, 2001).  The expression of the mRNA for hepcidin is up-regulated in response to 
lipo-polysaccharides (Pigeon et al, 2001) and infections (Shike et al., 2002).  Elevated 
expressions of hepcidin mRNA results in severe anaemia with the characteristics of 
ACI (Weinstein et al., 2002; Nicholas et al., 2002).   
 
The detailed molecular basis of ACI has yet to be elucidated but cytokines such as IL-
1, IL-6, TNF-α and inteferons (INFs) regulate red blood cell production and stability 
(Means, 1996; Means, 2001).  TNF-α reduces red cell synthesis and life span 
(Moldawer et al., 1989).  IL-1 inhibits the production of erythropoietin (Faquin et al., 
1992).  There is some evidence that TNF-α and IL-1 inhibit erythroid progenitor cells 
(Means et al, 1993).  Cytokines have also been associated with impaired mobilisation 
of iron from reticulo-endothelial cells (Means, 1995); IL-1 can increase ferritin synthesis 
and, with TNF-α increase ferritin secretion into plasma (Rogers et al., 1990; Tran et al., 
1997).  This tends to limit the availability of iron for erythropoiesis.  Hepcidin, as an 
iron-regulatory hormone, constitutes an important link between host defense, 
inflammation and iron metabolism.  In humans, hepcidin synthesis is markedly induced 
by infection and inflammation (Nicholas et al., 2001; Shike et al., 2002), with IL-6 as the 
key inducer of its synthesis during inflammation (Nemeth et al., 2004).   
 
2.5  INTER-RELATIONSHIP BETWEEN HIV INFECTION AND ANAEMIA 
As persons with HIV infection continue to live longer, primarily as a result of advances 
in ART, it becomes important to recognise the inter-relationship between the infection 
and anaemia particularly because of the impact that anaemia has on morbidity and 
mortality in the HIV/AIDS population.  In this regard, assessing the incidence and 
prevalence of anaemia becomes an imperative and a pre-requisite for identifying 
factors that might be contributory to the anaemia, especially, in the HIV/AIDS 
population. 
 
2.5.1 POSSIBLE AETIOLOGY OF ANAEMIA IN HIV/AIDS 
As in the normal population, the causes of anaemia in HIV infection and AIDS can be 
ascribed to many different factors (Bain, 1999; Henry, 1998; Claster, 2002).  These 
factors may act separately and/or together to tip the balance between red cell   71
production and red cell destruction or loss.  However, the anaemia of HIV has been 
noted to ensue principally as a result of a common process called erythropoietic failure 
(Moore et al., 1998; Bain, 1999), though the basis for this failure is not well understood.  
Anaemia in HIV/AIDS may also be induced or exacerbated by treatment or drug 
therapy or ART (Bain, 1999; Groopman and Itri, 1999).  The involvement of the virus 
itself has been considered as direct with other related effects described as indirect. 
 
2.5.1.1  Direct effects of HIV  
Specific HIV strains can act directly to inhibit the differentiation of stromal cells 
(progenitor cells) in the bone marrow leading to a reduction in the production of red 
cells and other bone marrow elements (Claster, 2002; Levine, 1999; Redd et al., 2007).  
The haematopoietic stem cell is the common progenitor of both the myeloid and 
lymphoid lineages in the bone marrow.  Hence, the haemato-suppressive effect on 
early progenitor cells could contribute to the anaemia and other cell line depletions in 
HIV, and to the inability of the bone marrow to reconstitute a functional pool of mature 
CD4+ T-cells (Davis and Zauli, 1995).   
 
This direct effect will contribute to an increased incidence of OI, malignancies and co-
morbidities, which constitute complications that in their own right could directly 
suppress haematopoiesis and cause or exacerbate anaemia (Volberding, 2000; 
Volberding et al, 2004).  Several opportunistic organisms that infiltrate the bone marrow 
and disrupt erythropoiesis have been associated with anaemia in HIV/AIDS. The most 
common infectious agents associated with HIV-related anaemia include 
Mycobacterium avium complex (MAC), Mycobacterium tuberculosis, Histoplasma, 
Cryptococcus, Coccidiodes, Pneumocystis carinii, Parvovirus B19 and Leishmania 
(Hambleton, 1996).  Anaemia may be directly induced in HIV by neoplasms, especially 
lymphomas, as they infiltrate the bone marrow (Sipsas et al., 1999).   
 
2.5.1.2  Indirect effects of HIV  
2.5.1.2.1  Inflammation as a possible cause of anaemia  
HIV infection and AIDS are associated with chronic inflammation, which may lead to a 
continuous release of inflammatory cytokines such as IL-1, TNF-α, IL-6 and some IFNs 
that typically direct the inflammatory response (Tomkins, 2003).  The direct effects of 
HIV on the immune system also allows OI to thrive, which also contribute to the 
sustenance of the APR.  TNF-α and other inflammatory cytokines, which may inhibit 
erythropoiesis have been suggested as the cause of anaemia associated with chronic 
disease or anaemia of chronic inflammation (Maciejewski et al., 1994; Means, 1996).  
The basis for this anaemia is that, apart from lowering blood nutrients, inflammation   72
blocks iron absorption and impairs iron utilisation, thereby lowering RBC production 
(Jackson, 2007, Thurnham and Northrop-Clewes, 2007) (see also section 2.5.3.2).   
 
2.5.1.2.2  Reductive adaptation as a possible cause of anemia 
In an infection, there is likely to be a competitive metabolic demand by the body for 
energy and nutrients (Macallan, 1998; Jackson, 2007).  To combat the infectious agent 
and maintain the body’s integrity, energy and nutrient demands of many organs are 
increased (Calder and Jackson, 2000), which eventually leads to changes in nutritional 
status (Jackson, 2007).  Whether the limited availability of food is associated with food 
insecurity from poor socio-economic and environmental factors, or the effects of HIV 
and poor appetite, a reduction in food intake, weight loss and changes in the body 
composition are likely to occur.  If prolonged or severe, loss of weight may be 
associated with other complex adaptive changes in tissues and organs characterised 
as reductive adaptation (Ashworth, 2001; Jackson, 2007).  Anaemia may appear as 
one part of the reductive adaptation response and be ascribed to the production of poor 
quality cells with a shorter lifespan, in part attributed to their existence in a challenging 
environment conferred by the presence of infection and nutritional or metabolic 
compromise (Jackson, 2007).   
 
2.5.1.2.3    Nutritional deficiencies as a possible cause of anaemia 
Like other cells, mature RBC result from the multiplication and differentiation of 
precursor, requiring the continuous availability of a full complement of nutrients and 
metabolic intermediates (Jackson, 2007).  Any limitation in one or more of these 
nutrients would impair the ability to maintain RBC production, especially when the 
demands for those nutrients directly involved in the production of haemoglobin far 
outstrip that of other cells (Jackson, 2007).  The particular need for iron for haem 
production and the unusual amino acid composition of haem and globin are important 
when considering the nutrient needs for RBC production (Jackson, 2007).   
 
Red blood cell production depends on the iron status of the individual as well as factors 
associated with ID or iron excess.  In HIV and other infections, the impact of reductive 
adaptation and the inflammatory process can result in potentially available iron being 
reduced, normal or increased (Jackson, 2007).  Within the context of reductive 
adaptation iron may accumulate in the tissues because of ineffective utilisation for red 
cell production (Golden and Ramdath, 1987; Powers and Thurnham, 1981).   
Furthermore, limited availability of other nutrients, such as vitamin A, riboflavin or 
copper, for RBC production, may also lead to an ineffective utilisation and an increase 
in stored iron (Nemeth and Ganz, 2006).  Whilst a deficiency of vitamin C is likely to   73
affect the absorption of non-haem iron in the diet (Halberg et al, 1987), a deficiency of 
vitamin B12, which is necessary for erythropoiesis and DNA synthesis, could lead to a 
reduction in RBC production (Powers and Bates, 1987).  Riboflavin deficiency can 
impose limitations on absorption and utilisation of iron (Powers and Bates, 1987), and a 
deficiency of pyridoxine (B6) may affect haem synthesis.   
 
Haem is formed from porphyrin (derived from glycine in the molar ratio of 1:4), and a 
limitation in the availability of glycine caused by micronutrient deficiencies would 
constrain its formation (Jackson, 2007).  A limitation in glycine availability also affects 
glutathione synthesis (Persaud et al., 1996), a reduction of which in RBC may enhance 
its vulnerability to oxidative stress (Jackson et al., 1987; Jackson et al., 2004).     
Additionally, limitations in the availability of other antioxidant nutrients, which have 
commonly been observed in HIV infection (Tang, 2005), may add to this enhanced 
vulnerability of RBC.  Any one of these factors, together or separately, can cause loss 
of cellular integrity and functionality in RBC, which would facilitate their premature 
removal from the circulation (Jackson, 2007). 
 
2.5.1.2.4  Other possible causes of anaemia  
A loss of cellular integrity can lead to an increased vulnerability of the RBC to 
haemolysis.  In HIV/AIDS, haemolysis of RBC could be induced by the presence of red 
cell autoantibodies or the haemophagocytic syndrome or a disseminated intravascular 
coagulation or thrombotic thrombocytopaenic purpura (Levine, 1999; Coyle, 1997; Rule 
et al., 1996; Rarick et al., 1996).  Additionally, the presence of inheritable disorders 
such as sickle cell disease, glucose-6-phosphate dehydrogenase deficiency (G6PD), 
thalassaemia and other minor or rare haemoglobinopathies which predispose to 
haemolytic anaemia may also cause or exacerbate anaemia in HIV/AIDS (Nestel, 
2002; Phillips and Groer, 2002).  Anaemia could also be induced by oxidant drugs or 
medications (including ARV, anti-fungal and anti-bacterial agents) (Volberding, 2000; 
Volberding et al., 2004).  Apart from their haemolytic effects some ARVs can also 
suppress the bone marrow and reduce erythropoiesis whilst others are particularly toxic 
to the hepatocytes (Levine, 1999).  
 
In places where malaria and helminth infections, especially hookworm, are endemic, 
they may contribute immensely to anaemia (Ssali et al., 2006).  Additionally, chronic 
anaemia in HIV infection is also associated with a decreased production of or blunted 
response to endogenous erythropoietin (Spivak et al., 1989) as well as hypogonadism 
(Dobs, 1998) which may lead to a decrease in red cell production.  
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However, and especially, as the disease progresses, a more obvious cause of anaemia 
in HIV persons, arises from the loss of blood (Volberding et al., 2004).  This may occur 
in neoplastic conditions (e.g. Kaposi sarcoma) in the gastrointestinal tract as well as 
from other gastrointestinal lesions due to opportunistic infections.   
 
2.5.2 COMMON TYPES OF ANAEMIA IN HIV/AIDS 
In PLWHA, IDA and ACI are the most common occurrences (Butensky et al., 2004).  
Though IDA may be present in HIV/AIDS, the development of anaemia in most HIV-
infected persons has often been ascribed to ACI because of the attendant reduction in 
red cell production and a suppression of reticulocyte response commonly associated 
with chronic infections (Sears, 1992; Coyle, 1997).   
 
Since HIV/AIDS is essentially an inflammatory disease, it is not surprising that ACI 
commonly occurs in both HIV-infected adult and children populations (Balbaryski et al., 
1998; Monroe et al., 2000).  Although most of these studies do not differentiate 
between IDA and ACI, findings from bone marrow evaluations confirm that ACI is of 
major occurrence in adults with HIV infection (Frontiera and Myers, 1987).   
Nevertheless, it is not uncommon to find both IDA and ACI existing together (Eley et 
al., 2002; Butensky et al., 2004). 
 
2.5.3 HIV/AIDS AND IRON METABOLISM  
Infection with HIV has been associated with profound immune deterioration as well as 
a progressive deposition of iron in tissues and organs (Boelaert, 1996).  The direct 
effects of the virus as well as the presence of chronic or acute inflammation or dietary 
inadequacies stemming from reduced intake or malabsorption could account for the 
altered iron status in infected persons (Butensky et al., 2004).   
 
Anaemia, in advanced HIV infection, has been characterised by an accumulation of 
iron in tissues and cells, which may predispose to microbial infections.  This would, as 
a matter of importance, require caution in the use of iron as a therapeutic agent or 
supplement during the management and intervention of anaemia in PLWHA.   
 
Oxidative stress, resulting from the response of the body to HIV and other infections 
and from the inflammation associated with such infections, may lead to a depletion of 
antioxidant molecules, some of which are important for the production of haemoglobin.  
Together with the inflammation, oxidative stress can lead to an alteration in iron status 
by causing an increase in red cell destruction with a concomitant sequestration of iron 
into storage as well as an attendant decrease in red cell production (Thurnham and   75
Northrop-Clewes, 2007).  Although HIV is associated with an altered iron status It is not 
very clear whether the altered iron status is due to dietary iron deficiency or a blockade 
of the iron absorption or the inflammation or process of inflammation or the relative 
contributions of these processes.  The influence of dietary iron intake on the absorptive 
regulatory process in the infected person may also be an important issue to consider 
(Thurnham and Northrop-Clewes, 2007).   
 
Although earlier studies have depicted lower prevalences for IDA in HIV-infected adult 
populations (Mir et al., 1989; Castella et al., 1990), a more recent study has confirmed 
a rising prevalence that occurs predominantly in infected women (Semba et al., 2002).  
Women together with children, who are infected with the virus, account for about half 
the anaemia seen in these population groups (Totin et al., 2002; Semba and Gray, 
2001).  The major contributors to IDA in HIV/AIDS may include inadequate dietary 
intake of iron (Hiltgartner, 1991) and malabsorption of iron, which are often associated 
with HIV disease (Castaldo et al., 1996; Tarallo et al, 1993).  In both instances, the 
inflammatory process may play a central role, in that, whilst it is known to inhibit iron 
absorption it also induces anorexia which ultimately reduces dietary iron intake 
(Beresford et al., 1971).  Clearly, in a population whose intake of iron is inadequate, 
IDA is very likely to exist irrespective of whether the inadequacy is brought about by the 
infection or socio-economic or environmental circumstances.  
 
2.6  CONCLUSIONS FROM LITERATURE REVIEW 
The main purpose of this section has been to explore the inter-relationship between 
HIV/AIDS and anaemia and the many factors that might contribute to the development 
of anaemia during HIV infection.   
 
It has been proposed that people with HIV have a greater propensity to anaemia, and 
that anaemia itself indicates a more serious clinical state.  The main hypothesis 
considered for the study was that taking all other factors into account, “HIV infected 
persons are more anaemic in comparison with uninfected persons”. 
 
In the light of the above, the literature review has provided definitions respectively for 
the main outcome of anaemia and exposure of HIV/AIDS as well as other aspects that 
relate the two.  The various effects of HIV/AIDS on the body that are most likely to be a 
part of this linkage have been considered.  In reviewing the causes of anaemia, 
emphasis has been placed on its multifactorial causation and the important, complex 
interplay amongst these factors.  HIV infection by its direct and indirect linkages with 
RBC production has been identified as a potential contributor to the public health   76
problem of anaemia.  Despite important advances in ART, anaemia in HIV remains a 
problem (Mildvan, 2003).  With improved suppression of HIV as newer therapies 
evolve, and as the lifespan of HIV-infected persons are prolonged, the risk for PLWHA 
to develop anaemia of chronic inflammation (ACI) is likely to be greater (Volberding, 
2000; Belperio and Rhew, 2004).   
 
Furthermore, the persistence, even in the HAART era, of malnutrition and other 
nutritional deficiencies (e.g. iron, vitamins A and B12 and folate deficiencies) which 
impair production of red blood cells means that anaemia has to be considered within a 
wider aetiological context in many populations.  This study seeks to focus on the role of 
HIV infection in the aetiology of anaemia and to identify the factors that interplay to 
increase the predisposition of infected persons to anaemia.  These are important 
considerations for sub-Saharan African populations where the factors that predispose 
to anaemia are multiple.   
 
In effectively tackling the HIV pandemic, it will be important to identify factors that 
exacerbate infection or affect the well-being and survival of PLWHA.  Any research 
directed at identifying those at increased risk of developing anaemia will add to the 
efforts at improving the quality of life and reducing the effects of HIV.  This study seeks 
to provide some insight to the development of anaemia in HIV//AIDS by elucidating the 
complex interactions between HIV infection and anaemia in a sub-Saharan African 
population.  
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CHAPTER THREE 
3.0 DATA  AND  METHODS 
In the previous chapter a review of the literature on HIV and anaemia highlighted the 
need to explore the relationship between these two important public health problems, 
especially, in a population where many factors intricately interplay in the relationship.  
The importance of elucidating HIV eliciting effects as likely to increase the risk of 
anaemia in the infected population is the main thrust of this research work. 
 
This chapter outlines the methodologies for capturing and analysing the data to 
address the study hypothesis.  It describes the design, sampling and data collection 
strategies.  In addition, modalities for selecting variables and the statistical tools for 
their analyses are outlined.  Lastly, a post hoc power analysis is considered for 
outcomes that presented without statistically significance between the two groups in 
the study population. 
 
3.1 INTRODUCTION 
HIV infection can be a multiple risk for anaemia because of the many effects of the 
virus that can be related to the cause of anaemia, and which may interplay in bringing 
about the condition.  In a sub-Saharan African population where factors predisposing to 
anaemia are rife, infection with HIV would significantly increase the burden already 
imposed by these factors on anaemia.  Identifying those at risk and understanding the 
nature of the interactive factors would, therefore, be an important step in gauging 
appropriate interventions or therapies.   
 
Following from the main hypothesis which stated thus, “HIV infected persons are more 
anaemic in comparison with uninfected persons”, the study objectives were set as 
follows: 
•  To characterise HIV sero-status in the study population 
•  To identify socio-demographic indicators of the study population that may relate to 
HIV status and anaemia 
•  To characterise anaemia and relate it independently with HIV status in the study 
population 
•  To explore changes in body composition, dietary energy and nutrient imbalances 
and metabolic and inflammatory alterations as possible explanatory factors for 
anaemia in the study population 
•  To explore for factors that may interplay with HIV infection and may predict 
anaemia in the study population.   78
Based on the objectives above, a series of explorative analyses, of the data set derived 
from the THUSA survey, would be employed in elucidating the various propositions in 
the study.   
 
In the next sections a brief description of the original data-set together with the 
methodology used in its collection are presented.  Variables that best fit the definitions 
of the exposures and outcomes and which may be identified in the link between HIV 
and the outcome of anaemia as well as those that may constitute effect modifiers or 
confounders are highlighted.  Finally, the various research instruments or statistical 
tools used in analysing the study data are also presented. 
 
3.2 STUDY  DATA 
The secondary data, which is subject of the analysis in this thesis, was extracted from 
the larger THUSA survey.  However, for a better understanding of the work in this 
thesis and to put in perspective the relevance of the research, a summary or overview 
of the survey and methods employed in the original data source are presented. 
 
3.2.1 THE THUSA SURVEY 
The THUSA survey was a large study that was carried out in the North West Province 
of South Africa spanning from 1996 to 1998.  The study had a major aim of monitoring 
the impact of urbanisation on the determinants of health in South Africans in order to 
provide vital information for appropriate health intervention (Vorster et al., 2000; Vorster 
et al., 2004).   
 
Apart from being an acronym for Transition and Health during Urbanisation of South 
Africans, THUSA takes its meaning from a word in the Setswana language that is 
translated as ‘help’ (Vorster et al., 2000: Vorster et al. 2005).  The actual motivation for 
the THUSA survey was the rapid process of urbanisation of, especially, Africans in 
South Africa, with its attendant acculturation and modernization (Vorster et al., 2000: 
Vorster et al. 2005).  A process that was thought to be associated with the triple burden 
of morbidity and mortality in South Africa: i.e. Infectious diseases (including HIV/AIDS); 
non-communicable diseases (NCDs); and violence and injuries.   
 
The North-West Province, where the survey was carried out, is one of the nine 
provinces of South Africa.  It is located rather centrally to the north of the country and is 
bordered by Northern Cape to the southwest, Orange Free State to the southeast, The 
Limpopo to the northeast, Gauteng to the east and to the north by 4 districts in 
Botswana (see provincial map in figure 3.1. Source: Wikimedia commons, 2006).   It   79
ranks 6th in terms of its size as well as population, which is in the region of 3.4 million 
people.  Among the languages that are predominantly spoken in the Province are 
Setswana (65.4%), which is the most widely spoken, followed by Afrikaans (7.5%) and 
then isiXhosa (5.9%).  With regards to race, the majority of inhabitants are blacks, 
constituting about 91.5% (Statistics South Africa, 2007).   
 
Figure 3.1:  Map of South Africa showing the North West Province (Source: 
Wikimedia commons, 2006) 
 
 
3.2.2 DESIGN OVERVIEW OF THE THUSA STUDY 
Beyond achieving the purpose of examining the changes in health determinants of 
Africans in the North West Province undergoing rapid urbanisation, the THUSA study 
was designed with much broader aims of informing preventive strategies, as well as 
policy and programmes, together with the purpose of identifying areas that needed 
further research (Vorster et al., 2000; Vorster et al. 2005).   
 
During the conceptual stages, a basis for developing the framework for the study was 
developed, which involved the identification from the literature of measurable potential 
exposures and outcomes for describing the determinants of health during urbanisation 
(Vorster et al., 1999).   
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A cross-sectional comparative design was adopted based on the dictating 
circumstances of limiting resources and urgency for information (Vorster et al., 2000), 
more so, the authors of the study found the use of a total randomized sampling 
technique as unnecessary as the study was not aimed at reporting the prevalence and 
risk factors of diseases (including HIV/AIDS) (Vorster et al., 2000: Vorster et al. 2005).  
Additionally, although a proportional sample stratification of subjects was planned, the 
research team was forced to adopt a disproportional stratification approach in some 
regions due to the non availability of reliable subjects.  This was due to the rigorous 
exclusion criteria which critically reduced the number of potential subjects in certain 
households.  Thus, some participants were voluntarily recruited into the study.  This 
quasi-random mode of selection may probably be a source  of potential bias to the 
study as females were more willing to volunteer.  
 
3.2.3 SUBJECT SELECTION AND EXCLUSION CRITERIA 
A community-based sample of 1854 ‘apparently healthy’ men and women, aged 15 
years and above was recruited from 37 randomly selected sites representing all health 
districts in the Province (Vorster et al., 2000).   
 
A model for sampling and subject recruitment was developed by the Statistical 
consultative Services of North West Province based on available data on the 
population density of the Province with all subjects having an equal chance of being 
selected. 
 
The subjects were stratified into five levels or stages of urbanisation. The criteria for 
categorising subjects into levels or stages were mainly on the basis of the type of 
employment or jobs they had and where they lived (housing or settlement type).   
 
The first level (level 1) comprised of typical rural people living in a traditional rural 
African village with a tribal head.  Level 2 were farm dwellers living and working in 
commercial farms; Level 3 were made up of people living in informal housing areas or 
‘squatter camps’ adjacent to all major towns and cities.  These subjects represented 
subjects in the most rapid transition phase as they moved recently into the informal 
housing areas from mainly rural areas.  These could also be described as peri-urban 
settlers.  The level 4 subjects were from the old established African townships with 
brick houses, running water and electricity available who worked as labourers in 
various institutions and industries and, finally, the level 5 subjects represented the 
upper class urban subjects who were mainly professionals (teachers and nurses), 
government employees, politicians or came from businesses/corporate industrial   81
environment (Vorster et al. 2005).  Generally, levels 1 and 2 subjects could be 
described as rural whilst level 3 was more or less transitional and the levels 4 and 5 
were considered urban (Vorster et al. 2005).  Subjects were also grouped into year of 
recruitment which spanned 1996 to 1998. 
With regards to exclusion, the criteria covered pregnant and/or lactating women, 
subjects below 15 years of age, those suffering from or diagnosed with known 
debilitating diseases or who were having an acute or chronic illness or infection 
(including HIV/AIDS, diabetes, hypertension or cardiovascular diseases (CVD), 
epilepsy, TB, etc), as well as those on any form of chronic medication, inebriated/high 
or whose body temperature was above 37.5
oC (i.e. febrile).   In addition visitors to the 
area as well as subjects who fasted for less than 8 hours were excluded. 
 
3.2.4 DATA COLLECTION 
A variety of quantitative and qualitative research techniques were employed by a multi-
disciplinary team who were trained to collect the data.  The research team comprised 
of both scientists, with Natural and Social Science backgrounds, and multilingual 
speaking field workers who collected quantitative and qualitative information through 
interviews or questionnaires at located sites (clinics or health centres).   
 
The questionnaires were specially designed or adapted and validated for the 
population under study, and the multi-lingual fieldworkers who administered them were 
specially trained to obtain information on socio-demography, anthropometry, physical 
activity, psychosocial variables and dietary intake.   
 
As much as possible each subject was interviewed in a language of his/her choice.  
Also, qualified and experienced phlebotomists and other medical staff were used in the 
collection of blood and other bodily samples from each participant on the field, and the 
samples were then transported to the laboratory for subsequent biochemical analysis.  
For the clinical assessments and screening, this was done by qualified medical staff 
trained for that purpose.  All the data was collected at specific clinics or health centres 
where subjects were asked to attend after the selection. 
 
3.2.4.1  Socio-demography physical activity and psycho-social variables 
A questionnaire on demographic, socioeconomic and other lifestyle habits including 
type of housing, access to electricity, water source, sanitation, health history, family 
structures, education, income etc was completed by the researchers and/or field 
workers.  Habitual physical activity was assessed with a physical activity questionnaire 
designed and validated for this population (Kruger et al. 2000).  Other variables that   82
served as indicators of psychological well-being were collected with a psychological 
questionnaire.  This questionnaire was based on existing scales which were adapted 
and validated for the population (Costa et al, 1992; Cohen et al. 1983).  For the current 
study socio-demographic considerations included in the analyses were sex (female or 
male), age (40 years and below or above 40 years), housing or settlement type (rural 
or urban), monthly income earnings (R1000 and lower [lower] or R1001 to 3000 
[middle] or R3001 and above [higher]), educational attainment (none to standard 6 
[lower] or std. 7 to std. 10 plus trade [middle] or std. 7 to std. 10 plus higher academic 
achievement [higher], marital status (never married or married or divorced or widowed), 
first language spoken (Tswana or Afrikaans or Xhosa or Zulu or other), smoking status 
(smoker or non-smoker) and alcohol consumption status (consumer or non-consumer). 
 
3.2.4.2 Clinical  examination 
At all field locations, two trained nursing sisters examined each subject for signs and 
symptoms of malnutrition.  Areas of examination included the thyroid, hair, skin, 
tongue, nails, glands, eyes, teeth, gums and lips.  Oral temperatures were taken with a 
clinical thermometer and blood pressure was taken at 10 minute intervals with a 
sphygmomanometer (Tycoo ®, USA) having an adjustable cuff with subjects remaining 
seated and calm.     
 
3.2.4.3 Dietary  intake 
An important goal of the THUSA study was to identify differences in dietary intakes and 
health status of a population who were at various stages of urbanisation.  In line with 
this, information on habitual dietary intake was obtained from a validated quantitative 
food frequency questionnaire (QFFQ).  Prior to the study there was a need to develop 
a culturally sensitive dietary assessment tool which was suitable for the study 
population as other groups had made similar observations in the same population 
using tools that were considered culturally insensitive (Buzzard and Sievert, 1994; 
Coates and Monteilh, 1997).  The QFFQ used in this study was first developed and 
tested for reproducibility and validity by Maclntyre and other workers (Maclntyre et al. 
2000a; Maclntyre et al. 2000b).  The processes in the development and testing for 
reproducibility and validity of the QFFQ has been fully described by MacIntyre et al., 
(2001). 
 
From the food data obtained using the QFFQ, energy and nutrient intakes were 
calculated using a computer programme approved by the Medical Research Council of 
South Africa (Tygerberg, South Africa) and based on the South African food 
composition table (Langenhoven et al., 1991).  Adjustments were made for   83
underreporting of energy intake according to the method described by Willet et al. 
(1995). Resting energy expenditure (REE) or basal metabolic rate (BMR) was 
estimated from the weight, age and gender of each subject using the Schofield 
equation (Schofield, 1985). 
 
3.2.4.4  Anthropometric measurements and indices  
Anthropometric measurements including weight, height, skin fold thicknesses and body 
circumferences (waist and hip) were taken in triplicates, by staff trained by the Institute 
of Bio-kinetics, Potchefstrooms University for Christian Higher Education (PU for CHE), 
using methods that were standardised by a specialist staff (level II Anthropologist).  In 
all cases the measuring equipment was calibrated and the necessary precautions 
taken to avoid biases.  Other anthropometric indices like BMI, waist-to-hip ratio (WHR) 
and so on were derived from earlier measurements.  For instance, BMI was derived 
from the weight and height measurements and was computed as the weight in 
kilograms divided by the height in metres squared (kg/m
2). 
 
Body weight and height  
Body weight was measured using a calibrated electronic scale (precision Health Scale, 
A+D Company, Japan) with subjects wearing light clothing.  The measurement scale 
was placed on a flat surface and zeroed.  Subjects were asked to stand on the scale 
and the readings were called out by the interviewers to the recorders.  For each 
subject, the measurements were taken three times.  
 
Height measurements were taken using an anthropometer (Invicta, 1465, UK).   
Subjects were measured standing in an erect position and with the head in a Frankfurt 
horizontal plane.  The subjects were measured with shoes or caps removed and 
readings made in a position to avoid parallax error.  This was repeated three times 
without the measurer knowing what the previous recordings were. Subject’s heights 
were measured in centimetres.  
 
Waist and Hip circumferences 
Waist circumference was measured at the narrowest area below the rib cage and 
above the umbilicus as viewed from the front while the subjects was standing in the 
anatomical position. An inelastic but flexible standard tape was used to measure the 
area at the end of a normal expiration.  The hip circumference was measured at the 
point of greatest circumference around the buttocks with the subject standing in the 
anatomical position. The same inelastic, but flexible standard tape was used. 
   84
Skinfold measurement 
The following skinfolds were measured in triplicate and the mean values were 






• Calf   
• Iliac-crest 
Standardised skinfold callipers were used (John Bull, British indicators, Ltd). 
 
Girth measurements 
An elastic, but flexible standard tape was used to measure relaxed upper arm, tensed 
upper arm, forearm, thigh – 1 cm below gluteal fold, calf and wrist girths. 
 
Body mass index (BMI) 
Subjects BMI (or Quatelet) were computed from the weight and height using the 




Waist-to-hip ratio was calculated from the measured waist circumference (in cm) 
divided by the measured hip circumference (in cm). This index provided knowledge on 
regional body fat distribution which is a valuable guide in assessing health risk for 
cardiovascular disease and diabetes (Kaplan, 1989).  
 
Body density 
Body density (BD) was calculated using the formula by Jackson et al. (1980): 
BD of women = 1.0992921 – (0.0009929 x sum of skinfolds: triceps, thigh, supra-iliac) 
+ (0.0000022 x [sum of Skinfolds: triceps, thigh, supra-iliac]
2) – (0.0001392 x age)  
 
BD of men = 1.1043 – (0.001327 x thigh skinfold) – (0.00131 x subscapular skinfold)  
 
Fat percentage  
The formulae for percent fat (%Fat) were as follows (Sloan, 1967).: 
 % fat for women = (5.03 / BD) – 4.59 
% fat for men = (4.95 / BD) – 4.5 
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Fat mass 
Fat mass (FM) was derived as follows (Mc Ardle et al., 1994): 
Fat mass = (% fat /100) x body mass 
 
Lean body mass 
Lean body mass was derived as follows (Mc Ardle et al., 1994): 
LBM = body mass – fat mass 
 
 
3.2.4.5 Biochemical  measurements 
For biochemical or laboratory determinations, fasting blood, urine and cell samples 
were collected for serum, plasma, and DNA preparation as well as for HIV testing.  For 
the purposes of this thesis only blood sample collection and analysis would be 
described.   
 
Method of blood sample collection and analyses 
A baseline blood sampling by trained personnel was preferentially carried out between 
the hours of 08:00 and 11:00 to control for the effects of environmental temperature 
and circadian rhythm on the level on variables and also to keep the period of fasting 
relative constant.  Each respondent was fasted overnight for not less than 12 hours, i.e. 
they were not allowed to eat anything between those hours.  A total of 75 ml of blood 
was drawn from the vena cephalica of each subject with sterile equipment (including 
butterfly infusion set, Johnson & Johnson, 21G 19mm needles and syringes) with no or 
minimum stasis.  These blood samples were then prepared immediately for use or 
stored appropriately.  
 
Samples collected were analysed using a large range of methods in different 
laboratories resulting in about 50 different variables indicative of nutritional and health 
status and risk for NCD.  However, for the purposes of this study descriptions of 
analysis would be restricted as much as possible to those relevant in addressing the 
study hypothesis.   
 
Sera as well as citrated or ethylenediaminetetraacetic acid (EDTA) plasma samples 
were, however, prepared in the field (4
oC) using a refrigerated centrifuge (Universal 
16R™ Hettich centrifuge, Tuttlingen, Germany).  To obtain serum, a portion of the 
whole blood collected from each subject was left for 30-60 minutes to clot, after which 
centrifugation under refrigerated conditions separated the serum from the cells.  In the 
same way anti-coagulated blood (containing citrate or EDTA) was centrifuged to obtain 
a separation between plasma and the blood cells.  Aliquots of sera and plasma were   86
then harvested into Eppendorf tubes, labelled and stored at -20
oC for 2-4 days on the 
field and subsequently transferred to a temperature of -84
oC in the laboratory pending 
further biochemical analysis.  
 
Analysis of processed blood samples involved the determination of serum proteins; 
total proteins, albumin, ‘globulins’ (obtained from the difference between total proteins 
and albumins); bilirubin (Total and Direct); electrolytes; glucose; lipids and enzymes 
using the DAX system (discrete analyzer, Technicon DAX48; Miles Inc. Diagnostic 
Division, Tarrytown, NY, USA).  Furthermore, serum micronutrients (Vitamins A, B6, B12 
and E and iron), ferritin, transferrin, as well as iron binding capacity (TIBC) and 
erythrocyte folate were determined using a number of methods which included high 
performance liquid chromatography (HPLC), immunological and colorimetric methods.   
 
With the use of standardised and portable equipment, Hct and [Hb] were determined in 
the field from EDTA-anti-coagulated blood.  Haematocrit was determined from a 
haematocrit centrifuge with its tubes (Hettich Zentrifugen; Haematocrit 24D-78532; 
Tuttlingen, Germany).  Haemoglobin was determined in a hemocue using the 
colorimetric method from Boehringer Mannheim (Germany).  Measurement of plasma 
fibrinogen was by the Clauss method using the ACL 200 (Instrumentation Laboratory, 
Milan, Italy) system.  HIV status, a parameter which was included after the study was 
over, was determined using an enzyme-immunologic method (Enzymum-Test., anti 
HIV 1+ 2+ subtype, Boehringer Mannheim, Germany).  In all the measurements, the 
protocols were followed using appropriate standards and necessary precautions were 
taken to ensure validity and accuracy (Vorster et al. 2005). 
 
3.2.5 ETHICAL CONSIDERATIONS 
Ethical approval for the study was given by the ethics committee of the North-West 
University, Potchefstroom.  However, it was conducted with the full cooperation of the 
North-West Department of Health and Social Services as well as the communities from 
which the subjects were recruited.  In compliance with the ethical norms, full 
information on the study procedure as well as its objectives were provided and 
explained to the subjects in their home language and each subject was then made to 
sign a consent form (illiterate subjects were made to sign with a cross).  Subjects 
received lunch after the glucose tolerance test and their travel expenses were paid. 
 
Further ethical approval was given by the same ethical committee for anonymous HIV 
testing of the samples after the study was completed. This meant that participants were 
not aware of their HIV status at the time of the study   87
3.3  MODALITIES FOR IDENTIFYING CONFOUNDERS AND EFFECT 
MODIFIERS 
In the epidemiological and public health context, there are several biological and social 
mechanisms that can be associated with HIV infection as an exposure and which can 
be linked to anaemia as an outcome.  There are usually two ways by which a second 
factor associated with the main exposure factor affects the outcome relationship.  It 
might either act as a confounder or as an effect modifier, or sometimes as both 
(Margetts and Nelson, 2008).  A confounder is known to distort the relationship in any 
direction, i.e. increases or decreases the association between exposure and outcome 
(Margetts and Nelson, 2008).  It does not reveal the real level of association between 
the main exposure and the outcome and it is not part of the causal pathway.  This 
means that they must be adjusted for during analyses.  On the other hand, effect 
modifiers are part of the causal pathway and must therefore be dealt with differently.  
They change the levels of risk between the main exposure and the outcome at the 
different strata of the effect modifier.  One way of dealing with them is by the use of 
stratified analysis.   
 
Stratified analysis considers each level of the effect modifier and measures the 
outcome to identify the strata with the highest level of risk.  For instance age and sex 
may have strata with a higher risk for HIV infection and anaemia, e.g. younger females 
have a higher chance of being infected because of the high risk of HIV infection 
associated with females and younger persons, and anaemic because of the 
association of females with anaemia.  It is therefore important to consider such effect 
modifiers in the analysis in order to identify such strata or groups for possible public 
health interventions.   
 
3.4  STATISTICAL RESEARCH TOOLS USED IN ANALYSES 
Selection of appropriate variables from the secondary data set would be undertaken 
and statistical analysis done using various tools described below.  Results would be 
compared between the HIV infected and uninfected groups and also between males 
and females within the two groups.  The original data has been laid out in an Statistical 
Package for Social Science (SPSS) compatible format and therefore allowed statistical 
analysis using the SPSS statistical software (version 15.0, SPSS Inc. Chicago, IL, 
USA).   
 
Normality test 
For each selected variable a normality test was first done using either a one sample 
Kolmogorov-Smirnov normality test or by plotting histograms against a normal   88
distribution curve.  A large selection of the variables were in significant agreement with 
the normal distribution curve, however, for a few others, which were skewed, values 
considered to be potential outliers (those above ±3SD) were removed before a 
semblance of normality was shown.  Variables that had few cases and were likely to 
make analysis spurious were discarded whilst skewed data were log transformed 
before analysis. 
 
Data for the HIV infected were separated from the uninfected group and each was 
considered independently of the other as they were subjected to the normality tests.  
Apart from a few HIV infected variables with low sample sizes which showed 
skewedness, the rest conformed to the previous normal determinations for data on the 
whole population.   
 
Skewed data or those that showed a semblance of normality after removing the outliers 
were log transformed.  For all outcome and exposure variables, various parametric  
and non-parametric tests as outlined below, were used appropriately to assess 
changes and differences within and between groups that were compared.  For each 
normalized variable standard descriptive statistics were presented in tables for the two 
HIV groupings as well as sub-groupings of sex where appropriate, as means with their 
95% confidence interval or as rates (percentages), and statistical comparisons were 
made between the groupings as described below. 
   
Tests of significance 
To address the hypothesis of the study and to establish a relationship between 
exposures and outcome, an independent sample t-test, chi-square, and a univariate 
analysis of variance (uniANOVA) were used where appropriate to test any differences 
between the groups for the exposure and outcome variables.  Whilst the independent 
sample t-test tested for differences between the means of the two sample populations, 
the chi-square did same for the rates or percentages derived for each population.  The 
use of a univariate ANOVA allowed the adjustment of potentially confounding socio-
demographic and anthropometric variables which served as explanatory factors for the 
effect of the exposures on the main outcome of anaemia.   
 
Pearson’s Correlation 
To establish the linear relationships between specific exposure variables on the main 
outcome of anaemia a Pearson’s correlation was applied.  A Pearson’s Correlation is a 
technique used to test the direction and strength of the relationship between two 
variables.  In other words, it’s a device to show whether any one set of numbers has an   89
effect on another set of numbers.  Correlation between two variables reflects the 
degree to which the variables are related.  When measured in a population the 
Pearson Product Moment correlation is designated by the Greek letter rho (ρ).  When 
computed in a sample, it is designated by the letter "r" and is sometimes called 
"Pearson's r."  Pearson's correlation reflects the degree of linear relationship between 
two variables.  It ranges from +1 to -1 and a correlation of +1 means that there is a 
perfect positive linear relationship between variables.  
Logistic regression analysis 
In order to explore the factors that determined or influenced the overall outcome of 
anaemia multivariable logistic regression models were employed.  These provided 
crude and adjusted odd ratios which assessed risk levels.  Using a stratified logistic 
regression model variables that were considered of importance in predicting anaemia 
in each of the significant socio-demographic strata were obtained.  
 
Logistic regression allows one to predict a discrete outcome, such as group 
membership, from a set of variables that may be continuous, discrete, dichotomous, or 
a mix of any of these.  The dependent variable in logistic regression is usually 
dichotomous, that is, the dependent variable can take the value 1 with a probability of 
success θ, or the value 0 with probability of failure 1-θ. This type of variable is called a 
Bernoulli (or binary) variable.  The independent or predictor variables in logistic 
regression can take any form.  That is, logistic regression makes no assumption about 
the distribution of the independent variables. They do not have to be normally 
distributed, linearly related or of equal variance within each group, and the relationship 
between the predictor and response variables is not a linear function.  
 
The goal of logistic regression is to correctly predict the category of outcome for 
individual cases using the most economical model. To accomplish this goal, a model is 
created that includes all predictor variables that are useful in predicting the response 
variable.  Several different options are available during model creation.  Variables can 
be entered into the model in the order specified by the researcher or logistic regression 
can test the fit of the model after each coefficient is added or deleted, called stepwise 
regression.  Stepwise regression is used in the exploratory phase of research and 
backward stepwise regression appears to be the preferred method of exploratory 
analyses, where the analysis begins with a full or saturated model and variables are 
eliminated from the model in an iterative process. The fit of the model is tested after the 
elimination of each variable to ensure that the model still adequately fits the data. 
When no more variables can be eliminated from the model, the analysis has been 
completed.     90
Deming regression analysis 
The Deming regression analysis is a method of linear regression that finds a line of 
best fit for a set of related data.  It differs from simple linear regression in that it 
accounts for error in observations on both the x- and the y-axes (Linnet, 1993).  In 
other words whereas the ordinary linear regression method assumes that only the Y 
measurements are associated with random measurement errors, the Deming method 
takes measurement errors for both axes into account.  In statistical terms the Deming 
regression analysis assumes that the co-efficient of variation of each comparative 
method is the same, i.e.   = Var(x)/Var(y) is constant across the range of values 
investigated. 
 
The Deming regression analysis is also called an "errors-in-variables regression 
analysis" or "estimating a structural relationship" (Linnet, 1993).  It is based on the 
assumption that the ratio of the variances of the errors of observations for the two 
variables is known and in which the errors are independent and normally distributed. 
 
3.5  POST HOC POWER ANALYSIS FOR INDEPENDENT DATA 
A post hoc analysis, which is arguably and generally an unacceptable method, is 
usually done on comparative data that may reach statistical significance but for which 
the comparative importance prior to the investigation were not perceptible (Margetts 
and Nelson, 2008).   
 
The weakness of many experimental studies is that the presence of an apparent 
difference between two groups may fail to reach significance as a result of 
misclassification errors in deciding which hypothesis is correct.  Such studies can be 
said to be statistically underpowered (Margetts and Nelson, 2008).  This may constitute 
a major limitation of a study, particularly one in which analyses are done on a 
secondary data source (in this case the THUSA survey).  Often with a predetermined 
sample size, there is a greater likelihood that the results would be statistically 
underpowered, particularly when the data is stratified for analysis. 
 
Statistical power relates to the sampling error and is defined as the probability that the 
null hypothesis would be rejected by a test when the alternative hypothesis is true or 
the probability of accepting the alternative hypothesis when it is true (Margetts and 
Nelson, 2008).  Inherent in any well designed experiment is the small risk of rejecting 
the null hypothesis when it is actually true, which is referred to as the Type I error or 
significance level (α), or accepting the null hypothesis when actually the alternative 
hypothesis is true (Type II error).  These two types of errors have to be contended with 
in power calculations.   Statistical power is very much dependent on the size of the   91
sample which also allows for the determination of the degree of certainty in a 
relationship in order to show significant differences between two groups (Margetts and 
Nelson, 2008), in this case between infected and uninfected persons.  The comparative 
limitation in size would also mean that potential confounders (e.g. age, gender and 
ethnicity) may not be equally distributed between the groups being compared and this 
could lead to bias and subsequent misinterpretation.  However, since the impact of any 
potential confounder could be removed by appropriate sampling or by adjusting or 
controlling for the confounders at the analysis stage, this has to be taken into 
consideration during analyses. 
 
According to the Yale University Education (2003), the factors that are likely to affect 
the statistical power of an experimental design include: 
•  The type of statistical test used in the analysis: Some tests are designed with more 
power than others and therefore may give higher significant results. 
•  The sample size: A larger sample size would provide greater power, but a very 
large sample size may not be cost effective as it would require a lot of money 
and/or time. 
•  The size of the experimental effect required: The magnitude of the difference in the 
null hypothesis would affect the power (i.e. a smaller difference would result in a 
smaller power or vice versa).   
•  The levels of errors in the experimental measurements: Errors act as ‘noise’ and 
can hide the real effects.  It is, therefore, important to ensure that a high accuracy 
and precision are achieved in an experimental design in order to reduce the noise 
and to increase statistical power.  
 
In well-designed studies the power to detect the desired effects are usually set at 80% 
(β=0.2), 90% (β=0.1) or even 95% (β=0.05) to minimize the chance of a non-significant 
test result when the effect is actually present (Margetts and Nelson, 2008).  However, a 
value of 80% is more frequently accepted. 
 
Using the given sample size and taking the two HIV groups in this study into 
consideration the power has been calculated in a post hoc analysis as outlined in 
appendix C.   
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RESULTS SECTION 
This section of the thesis presents the outcomes from the analyses of secondary data 
extracted from the original THUSA survey.   The aim of this section is to present and 
briefly discuss the findings whilst highlighting those that are important and relevant for 
addressing the main hypothesis.   
 
GENERAL INTRODUCTION  
Anaemia remains a significant marker of disease progression and survival, especially 
in HIV infection and AIDS.  In sub-Saharan Africa and many resource-poor settings, the 
rising trend of HIV infection may continue to pose a threat to the burden of anaemia, 
whilst anaemia in the HIV/AIDS population may spell disease progression, a reduction 
in survival or risk of death.  The significance of anaemia in HIV/AIDS is perhaps seen in 
the impact it has on the QOL and survival of infected persons.  To be able to 
characterise the causes of anaemia or identify persons at greatest risk for developing 
anaemia in a population is a prudent idea.  Doing so would, among other things, 
facilitate the charting of a pathway that could help prevent or target the treatment of 
anaemia as a means to effectively manage HIV disease.  
 
The overall aim of this study is to elucidate the increased risk for anaemia posed by 
HIV infection.  It is postulated that the direct effects of the virus may interact with other 
indirect anaemia-inducing effects to enhance the predisposition of infected persons to 
anaemia.  Perhaps, it is this unique direct as well as interactive effect of the virus that 
accounts for the common and frequent occurrence of anaemia in the HIV/AIDS 
population.   
 
Thus, the hypothesis for this study was stated as; “Persons infected with HIV are more 
anaemic than persons uninfected”, which served as the basis for setting up the 
modalities, outlined in the preceding sections, to address the proposition.   
 
Data for this study was taken from the THUSA survey (see Chapter 3), which was a 
cross-sectional population based study.  It broadly served as a project to help monitor 
the impact of transition or urbanisation on the determinants of health in South Africans, 
with the purpose of providing pertinent information for appropriate health interventions.  
The primary aim of this present study, undoubtedly, closely aligns with the broad aims 
of the THUSA study, as the findings from this study could highlight the increased risk 
HIV could impose on victims by making them highly susceptible to anaemia and 
generally reducing their work capacity and QOL, which could have implications for 
national development.     93
From the proposed framework for the relationship between HIV infection and anaemia 
(Fig.1), exposures or factors identified as most likely to cause or contribute to the 
cause of anaemia in sero-positive persons were considered.  These included the direct 
effects of the virus (in this study denoted by HIV sero-status) as well as indirect effects 
that can be captured under the processes of reductive adaptation, nutrient deficiencies 
and inflammatory and/or metabolic alterations, and also including a number of other 
related or unrelated socio-demographic factors that may be part of the causal link.  
 
Several variables were selected for analyses which included the following: socio-
demographic and anthropometric measurements; energy and micronutrient intakes 
derived from a record of food intakes from carbohydrate, protein and fat as main 
sources (energy from alcohol consumption was also incorporated).  Other variables 
were biochemical measurements, including levels of 2 important serum micronutrients 
(Vitamins A and E), Hb, hct, total serum proteins, serum albumin, serum ‘globulins’, 
plasma fibrinogen, total and direct bilirubin, serum Fe, TIBC, serum ferritin and % 
transferrin saturation.  In addition, levels of serum liver enzymes (AST, ALT, ALP and 
GGT), high levels of which may normally indicate insidious injury or damage to the liver 
cells or other related tissues, served as proxies to measuring inflammatory stress.    
 
In this study anaemia is defined mainly on the basis of [Hb], however, Hct and other 
more specific iron status indicators (serum Fe, serum ferritin, TIBC and % transferrin 
saturation) are also used to define various characteristics of anaemia in the study 
population. 
 
Tabulated results are, in general, compared between groups; HIV sero-negative or 
uninfected (HIV-) versus HIV sero-positive or infected (HIV+), or between subgroups; 
males versus females and anaemics versus non-anaemics.  Where results are 
presented as rates any differences between the groups would be accounted for by the 
chi-square (χ
2) statistics.  For results presented as means, a 95% confidence interval 
(95% CI) would be indicated and any differences between groups tested for using a 
univariate ANOVA before and after adjusting for significant confounders or effect 
modifiers.  Binary logistic regression models are used to predict the effect of exposures 
on the main outcome.  Each model takes into account categorical variables and adjusts 
for confounders and/or covariates.  Factors that emerge with significant predictive 
values are considered as explanatory factors.  For all statistical tests, probability values 
less than 0.05 (p<0.05) would denote statistical significance.  Results for this study 
have been presented in 3 separate chapters as outlined below in order to ensure a 
logical arrangement of findings for addressing the study hypothesis.    94
4.0  A PRELIMINARY ANALYSIS OF THE SOCIO-DEMOGRAPHIC 
CHARACTERISTICS OF THE STUDY POPULATION 
 
5.0  DETERMINATION OF HIV ASSOCIATED FACTORS THAT MAY 
SIGNIFICANTLY CONTRIBUTE TO ANAEMIA IN THE STUDY POPULATION 
 
6.0  EXPLORATIVE EVALUATION OF FACTORS THAT MAY INTERPLAY WITH 
HIV OR PREDICT ANAEMIA IN THE STUDY POPULATION 
 
In the first results chapter, baseline socio-demographic characteristics are examined 
and any associations or risk levels that may relate socio-demography with HIV infection 
and/or anaemia in the study population explored.  This preliminary analysis would 
highlight significant socio-demographic variables within the causal relationship between 
HIV and anaemia that could mask the effects of the main exposure of HIV infection on 
the outcome of anaemia.  Significant influences from such confounders or effect 
modifiers would be appropriately adjusted for or taken into consideration in the 
categorisation of persons at increased risk of anaemia.   
 
The second results chapter identifies the size of the problem of anaemia in the study 
population and explores various factors that may help explain the association of HIV 
infection with anaemia.   
 
And the third results chapter further explores for various factors that may independently 
or interactively (with HIV infection) predict anaemia in the study population.  
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CHAPTER FOUR 
4.0  A PRELIMINARY ANALYSIS OF THE SOCIO-DEMOGRAPHIC 
CHARACTERISTICS OF THE STUDY POPULATION 
4.1 INTRODUCTION 
This chapter is intended to highlight any differences in socio-demographic 
characteristics between the two HIV status groups and their sub-grouping, since these 
factors could serve as confounders or effect modifiers in the relationship between HIV 
and anaemia.  It is important to consider significant socio-demographic differences as 
explanatory factors for the relationship between HIV and anaemia and to account for 
them in subsequent analyses.   
 
In this chapter, socio-demographic data for the study population have been analysed 
and compared using basic descriptive statistics and appropriately presented in tables 
as rates (percentages).  The results generated from this cross-sectional data analysis 
does not only define the baseline socio-demographic characteristics of the study 
population but more importantly could be the basis for further longitudinal research that 
would help establish the causal relationships between HIV infection and anaemia as 
well as how these may relate to other health issues in the study population.  
 
Many socio-demographic variables may be associated with HIV infection and anaemia 
independently.  It is also very likely that associations between socio-demographic 
variables and HIV infection or anaemia may vary according to other prevailing 
environmental factors as well as specific population characteristics.  The causal 
relationship between HIV and anaemia therefore becomes a web in which all these 
factors may be considered.  
 
The socio-demographic characteristics that have been examined and presented in this 
section, in relation to HIV infection and anaemia status, include gender, age grouping, 
settlement type, educational attainment, monthly total income earned, marital status, 
first language spoken, smoking and alcohol consumption status.    
 
Whilst HIV status is based on the serological identification of viral antigens in the blood 
(HIV sero-positive, HIV+) or otherwise (HIV sero-negative, HIV-), anaemia status was 
based on the use of cut-offs for haemoglobin according to the WHO criteria (see 
Appendix A).  Persons with Hb levels below conventionally accepted cut-offs were 
classified as anaemic whilst those with Hb levels above were classified as non-
anaemic.     96
In the next section levels of association between socio-demographic variables in the 
study population and HIV and anaemia statuses, using proportions are explored. 
 
4.2  ASSESSING THE RISK FOR SOCIO-DEMOGRAPHIC FACTORS WITH HIV 
INFECTION AND ANAEMIA USING PROPORTIONS 
Tables 4.1, 4.2 and 4.3 below present summaries of the socio-demographic 
characteristics compared between HIV status grouping, gender and anaemia sub-
groupings of the study population respectively.  Chi-squared statistics have been used 
to test for any differences in proportions and any values of p<0.05 denoted statistical 
significance.   
 
From table 4.1 it is evident that out of the total of 1821 ‘apparently healthy’ adult 
subjects, whose data was included in various analyses, 216 (11.8%) were HIV sero-
positive or infected whilst the rest (1605, 88.2%) were HIV sero-negative or uninfected.  
Obviously, the prior consideration of the study population as an ‘apparently healthy’ 
one becomes questionable upon this finding.  The disproportion in subject numbers, 
between HIV sero-positive and uninfected persons can be accounted for by the 
inherent design of the original study, which was not biased towards selecting sero-
positive persons.  In fact, the original survey was not intended to measure prevalence 
of diseases (including HIV) and therefore subject selection was designed to be random.   
 
Generally, the table (Tab. 4.1) shows that though more females were recruited for the 
study than males (57.9% cf. 42.1%), there were no significant differences between 
gender proportions for the two groups (p=0.623).  Even though there was an obvious 
inherent bias that excluded pregnant women in the selection of subjects, the high 
female to male ratio could be ascribed to the willingness of females to make up the 
numbers during the selection process.  However, in terms of gender HIV prevalence, 
there were slightly more males (12.3%) who were sero-positive than females (11.5%) 
in the study population, but this difference was not significant.   
 
The table (Tab. 4.1) also shows that the HIV sero-positive population were on average 
significantly younger (p=0.001) than their uninfected counterparts with proportions of 
persons below 40 years higher in the sero-positive population than in the uninfected 
population.  This also reflected in the prevalence of HIV infection being higher in those 
aged 40 years and below (13.8%) than in those above 40 years (9.2%).   
 
It is further evident from Table 4.1 below that there were proportionately more HIV 
sero-positive persons residing in urbanised settlement types, i.e. comprising of settlers   97
in upper class areas, townships and squatter camps, than in those considered to be 
rural, i.e. settlers in typical rural areas and farms (70.4% cf. 29.7%, p<0.001).  Thus, 
HIV prevalence rates were shown to be higher in the urbanised settlement (14.5%) 
than in the rural settlement (8.3%). 
 
Table  4.1:  Socio-demographic characteristics by HIV status (All values are 
frequencies with percentages in parentheses except age in years) 
HIV status   
 
Variable  HIV-  HIV+  *p value  Total sample  % HIV+ 
Sample size (n)  1605 (100%)  216 (100%)  -  1821 (100%)  11.8% 
Male  685 (42.7%)  96 (44.4%)  781 (42.1%)  12.3% 
Sex 
Female  920 (57.3%)  120 (55.6%) 
0.623 
1040 (57.9%)  11.5% 





(33.14-36.76)  0.001  37.62  
(36.94-38.29)  _ 
15-39 yr.   919 (57.4%)  147 (68.1%)  1066 (58.5%)  13.8%  Age 
Grouping  40 and over  682 (42.6%)  69 (31.9%) 
0.003 
751 (41.5%)  9.2% 
Rural  710 (44.2%)  64 (29.7%)  773 (42.5%)  8.3%  Settlement 
type  Urban  896 (55.8%)  152 (70.3%) 
<0.001 
1048 (57.5%)  14.5% 
lower  860 (54.0%)  100 (46.3%)  960 (53.1%)  10.4% 
middle   573 (35.9%)  98 (45.4%)  671 (37.1%)  14.6% 
Highest 
Qualification 
higher  160 (10.0%)  18 (8.3%) 
0.027 
178 (9.8%)  10.1% 
lower  1185 (73.8%)  162 (75.0%)  1347 (74.0%)  12.0% 
middle   316 (19.7%)  41 (19.0%)  357 (19.6%)  11.5% 
Total 
income per 
month  higher  102 (6.4%)  13 (6.0%) 
0.945 
115 (6.3%)  11.3% 
Never married  316 (19.7%)  62 (28.7%)  368 (20.2%)  16.9% 
Married  244 (15.2%)  34 (15.7%)  278 (15.3%)  13.2% 
Divorced  13 (0.8%)  2 (0.9%)  15 (0.8%)  13.3% 
Marital 
status 
Widowed  65 (4.1%)  7 (3.2%) 
0.309 
72 (3.9%)  9.7% 
Tswana  1198 (74.6%)  153 (70.8%)  1351 (74.2%)  11.3% 
Afrikaans  32 (2.0%)  4 (1.9%)  36 (2.0%)  11.1% 
Xhosa  163 (10.2%)  27 (12.5%)  190 (10.4%)  14.2% 




Other  179 (11.2%)  27 (12.5%) 
0.104 
206 (11.3%)  13.1% 
Yes  544 (33.9%)  75 (34.7%)  619 (33.9%)  12.1%  Smoking 
status  No  1060 (66.1)  141 (65.3) 
0.819 
1201 (66.0%)  11.7% 
Yes  618 (39.9)  97 (45.8)  715 (40.6)  13.6%  Alcohol 
intake 
status  No  932 (60.1)  115 (54.2) 
0.102 
1047 (59.4)  10.9% 
*Derived from chi-squared test, p<0.05 denotes statistical significance 
 
With regards to educational attainment, a little over one half of the study population 
(53.1%) had lower status (i.e. none or up to standard (std.) 6 educational attainments), 
in other words, their educational backgrounds were considerably poor.  When 
compared to their uninfected counterparts, HIV sero-positive individuals tended to be 
highly represented in the middle level (Std. 7 to 10 (+ trade)) educational attainment, 
whilst uninfected individuals were more likely to have both lower and higher (i.e. std. 7   98
– 10 and beyond) educational attainments.  These differences were quite significant 
(p=0.027), and reflected the higher prevalence rate for HIV infection in the middle 
education attainment group (14.6%) compared to those for higher or lower educational 
attainments (10.4% and 10.1% respectively). 
 
When monthly income from all sources was considered, about three quarters (74%) of 
the study population had lower earnings (up to a thousand rands (R1000) per month), 
with about 20% and 6% earning middle (R1001 to R3000) and higher (>R3000) 
respectively.  The differences in earnings did not differ significantly between the two 
sero-status groups (p=0.945).  However, a large proportion of lower income earners  
overall may be taken as a reflection of low economic status and the fact that it defines 
a sizable proportion of the population makes it widespread.  Despite the marginal 
differences in proportions of monthly income earnings between the two sero-status 
groups, they were not significant.  There were also no differences in HIV prevalence 
rates between the income groupings.  This may probably indicate that HIV infection 
was not restricted to any particular income group and that lower income earners were 
as likely to be sero-positive as higher income earners. 
 
Table 4.1 has further shown that in spite of the low number of subjects recorded for 
marital status, HIV sero-positive subjects are proportionately higher in the never 
married (28.7% cf 19.7%) and lesser in widowed (3.2% cf 4.1%) categories compared 
with their uninfected peers, whilst proportions for married and divorced categories were 
closely similar between the two groups.  However, the observed differences were not 
significant (p=0.309).  In terms of HIV prevalence, the rates were 16.9% for never 
married, 9.7% for widowed, 13.2% and 13.3% for married and divorced categories 
respectively in the study population.   
 
For first languages spoken, a large majority (74.2%) of the entire study population 
spoke Tswana and the proportions between HIV sero-positive persons and their 
uninfected counterparts was not significantly different (p=0.104).  The proportions for 
those who spoke Xhosa, Zulu and Other as first languages were also closely similar 
between the two groups, but like with the previous comparison, the differences were 
not significant (p=0.104).  In general a high proportion spoke indigenous first 
languages, which actually reflected the indigenous ethnicities that characterised the 
study population (Statistics South Africa, 2007), and confirmed the predominance of 
Africans or blacks in the study population. With regards to HIV infection rates persons 
who spoke Xhosa (14.2%) and Other (13.1%) as first languages were proportionately 
higher.     99
When smoking status was considered, about a third (33.9%) of the study population 
were smokers and, even though the proportion of HIV sero-positive subjects who 
smoked was marginally higher compared to uninfected smokers (34.7% cf. 33.9%) the 
difference was not significant (p=0.819).  Between smokers and non-smokers there 
was also a marginal difference in the HIV prevalence rates (12.1% cf 11.7%) with that 
of smokers tending to be slightly higher but not significantly different. 
 
The proportion who consumed alcohol was shown to be higher in the HIV sero-positive 
group compared with their uninfected peers, which also reflected in a marginally higher 
HIV prevalence rate in alcohol consumers than non-consumers. Nevertheless, the 
differences were not significant. 
 
In table 4.2 below, socio-demographic characteristics between males and females of 
the two groups are compared.  From the table it is evident that both HIV sero-negative 
and sero-positive males and females are proportionately higher in the ≤40 years age 
group than in the >40 years group.  Within the groups, the differences in age grouping 
proportions between males and females are not significant.  However, HIV sero-
positive persons, irrespective of gender, have a higher proportion of younger persons 
than their uninfected counterparts, with infected females being significantly (p=0.006) 
more likely to be younger.  
 
With regards to educational attainment, proportions were slightly different for the 
various levels for between and within groups. Whilst HIV sero-positive males tended to 
be proportionately higher in the higher educational attainment category and lower in the 
lower educational attainment category than their uninfected peers, sero-positive 
females, were highly represented in the middle level as compared to their uninfected 
peers.  However, these respective differences for between and within gender groups 
were not significant.  
 
In terms of monthly total earnings, females in both groups were significantly more likely 
to be represented in the lower earning category than the middle and higher categories 
compared to their male counterparts.  When gender comparisons between infected and 
uninfected groups were considered there were no significant differences in earnings.  
 
The table (Tab. 4.2) further shows that there were no significant differences between 
sexes for each of the groups with regards to settlement type. However, HIV infected 
females like their male counterparts were significantly more likely to reside in urbanised 
settlement types compared to their uninfected counterparts (p=0.015 and p=0.001).     100
Regarding first languages spoken, table 4.2 also showed that over two-thirds (70% and 
above) of both males and females irrespective of HIV status were represented in the 
Tswana speaking category. Though fewer proportions were represented in the other 
first spoken languages, differences between gender within and between the infected 
and uninfected persons were not significant.  
 
Differences between males and females for smoking status was very significant 
(p<0.001) irrespective of HIV status, with a higher proportion of males more likely to 
smoke.  However, when gender comparisons for smoking status between infected and 
uninfected groups were considered, proportions were similar and the differences 
marginal and not significant.   
 
The trend for alcohol consumption was similar to that of smoking.  Males, irrespective 
of HIV status, were significantly more likely to consume alcohol (p<0.001) compared to 
females.  However, when sero-status groups were compared, there were no significant 
differences between genders for alcohol consumption even though proportions were 
slightly higher for the HIV infected males and females.  
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Table 4.2:  Socio-demographic characteristics by gender (Values are shown as frequencies with percentages in parentheses) 
HIV-  HIV+  Chi square (p-value)   
Characteristic  Male (a)  female (b) Male  (c)  female  (d)  a*b c*d a*c b*d 
Size (n)  685 (42.7%)  920 (57.3%)  96 (44.4%)  120 (55.6%)         
<40 yrs  396 (58.1%)  522 (56.8%)  63 (65.6%)  84 (70.0%) 
Age grouping 
≥40 yrs  285 (41.9%)  397 (43.2%)  33 (34.4%)  36 (30.0%) 
0.602 0.493 0.163 0.006 
lower  360 (52.6%)  500 (54.3%)  43 (44.8%)  57 (47.5%) 
middle  131 (19.1%)  190 (20.7%)  22 (22.9%)  34 (28.3%) 
Educational 
attainment 
   higher  187 (27.3%)  225 (24.5%)  31 (32.3%)  29 (24.1%) 
0.734 0.853 0.193 0.134 
lower  476 (69.5%)  709 (77.1%)  67 (69.8%)  95 (79.2%) 
middle  156 (22.8%)  160 (17.4%)  19 (19.8%)  22 (18.3%) 
Total income 
per month 
higher  52 (7.6%)  50 (5.4%)  10 (10.4%)  3 (2.5%) 
0.003 0.044 0.554 0.386 
rural  296 (43.2%)  414 (44.6%)  24 (25.0%)  40 (33.3%) 
Settlement type 
urban  389 (56.7%)  506 (55.0%)  72 (75.0%)  80 (66.6%) 
0.476 0.183 0.001 0.015 
Tswana  496 (72.4%)  702 (76.3%)  68 (70.8%)  85 (70.8%) 
Afrikaans  17 (2.5%)  15 (1.6%)  2 (2.1%)  2 (1.7%) 
Xhosa  79 (11.5%)  84 (9.1%)  9 (9.4%)  18 (15.0%) 





   Other  78 (11.4%)  101 (11.0%)  15 (15.6%)  12 (10.0%) 
0.331 0.465 0.107 0.355 
Never married  146 (21.3%)  170 (18.4%)  30 (31.3%)  32 (26.7%) 
Married  107 (15.6%)  137 (14.9%)  16 (16.7%)  18 (15.0%) 




   Widowed  15 (2.2%)  50 (5.4%)  1 (1.0%)  6 (5.0%) 
0.007 0.391 0.587 0.616 
Yes  386 (56.3%)  158 (17.2%)  55 (57.3%)  20 (16.7%) 
Smoking status 
No 299  (43.7%)  762 (82.8%)  41 (42.7%)  100 (83.3%) 
<0.001 <0.001 0.874  0.890 
Yes  397 (60.7%)  221 (24.7%)  62 (66.7%)  35 (29.4%)  Alcohol intake 
status  No  257 (39.3%)  675 (75.3%)  31 (33.3%)  84 (70.6%) 
<0.001 <0.001 0.269  0.263 
*Derived from chi-squared statistics, p<0.05 denotes statistical significance 
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Table 4.3:  Socio-demographic characteristics by anaemic status (Values are shown as frequencies with percentages in parentheses) 
HIV-  HIV+  Chi square (p-value)   
Characteristic  Non-anaemic (a)  Anaemic (b)  Non-anaemic (c)  Anaemic (d)  a*b  c*d  a*c  b*d 
<40 yrs  488 (57.5%)  411 (57.4%)  71 (68.3%)  74 (67.3%)  Age grouping 
≥40 yrs  360 (42.5%)  305 (42.6%)  33 (31.7%)  36 (32.7%) 
0.943 0.884 0.041 0.05 
lower  461 (54.4%)  376 (53.0%)  52 (50.0%)  47 (42.7%) 
middle  313 (36.9%)  249 (35.1%)  47 (45.2%)  50 (45.5%) 
Educational 
attainment 
   higher  74 (8.7%)  84 (11.8%)  5 (4.8%)  13 (11.8%) 
0.124 0.155 0.169 0.09 
lower  630 (74.1%)  527 (73.5%)  80 (76.9%)  80 (72.7%) 
middle  167 (19.6%)  143 (19.9%)  18 (17.3%)  23 (20.9%) 
Total income 
per month 
higher  53 (6.4%)  47 (5.8%)  6 (6.6%)  7 (6.2%) 
0.951 0.771 0.822 0.972 
rural  448 (52.7%)  250 (34.8%)  41 (39.4%)  22 (20.0%)  Settlement type 
urban  402 (47.3%)  468 (65.2%)  63 (60.6%)  88 (80.0%) 
<0.001  0.006 0.014 <0.01 
male  389 (45.8%)  280 (39.0%)  53 (51.0%)  42 (38.2%)  Sex 
   Female  461 (54.2%)  438(61.0%)  51 (49.0%)  68 (61.8%) 
0.007 0.063 0.323 0.87 
Tswana  671 (79.0%)  502 (70.1%)  76 (73.1%)  76 (69.1%) 
Afrikaans  15 (1.8%)  17 (2.4%)  1 (1.0%)  3 (2.7%) 
Xhosa  74 (8.7%)  86 (12.0%)  15 (14.4%)  12 (10.9%) 





   Other  75 (8.8%)  96 (13.4%)  10 (9.6%)  16 (14.5%) 
0.081 0.622 0.394 0.24 
Never married  178 (47.5%)  133 (52.6%)  35 (53.0%)  27 (69.2%) 
Married  147 (39.2%)  94 (37.2%)  25 (37.9%)  9 (23.1%) 




   Widowed  42 (11.2%)  21 (8.3%)  5 (7.6%)  2 (5.1%) 
0.523 0.384 0.761 0.25 
Yes  313 (36.8%)  213 (29.7%)  46 (44.2%)  28 (25.5%)  Smoking status 
No  537 (63.2%)  504 (70.3%)  58 (55.8%)  82 (74.5%) 
0.003 0.008 0.143 0.36 
Yes 335  (39.4%)   266 (37.0%)  59 (56.7%)  38 (34.5%)  Alcohol intake 
status  No 515  (60.6%)   452 (63.0%)  45 (43.3%)  72 (65.5%) 
0.340 0.003 0.007 0.61 
*Derived from chi-squared statistics, p<0.05 denotes statistical significance   103
Table 4.3 above is a comparative summary of socio-demographic characteristics 
between anaemic and non-anaemics within and between the HIV sero-status groups.  
Both non-anaemics and anaemics, irrespective of HIV status, are represented largely 
in the ≤40 year group than the >40 year group.  Age grouping differences between 
anaemic and non-anaemics were not significant within the groups but both HIV sero-
negative anaemics and non-anaemics were significantly more likely to be ≤40 years 
old, i.e. younger.   
 
For educational attainment, there were no significant differences between and within 
the sero-status groups for anaemic and non-anaemic peers and the trend was not 
different from the comparisons between HIV sero-negatives and sero-positives. 
 
Much like the HIV sero-status group comparisons total monthly earnings were similarly 
distributed between anaemics and non-anaemics.  Both anaemics and non-anaemics, 
irrespective of HIV status, were more represented in lower income category, and 
though there were marginal differences these were not statistically significant. 
 
With regards to settlement type, anaemics, irrespective of their HIV status, were 
significantly more likely to be urbanised than rural.  However, between the HIV sero-
negatives and sero-positives, both anaemics and non-anaemics in the latter group 
were significantly more likely to be urbanised. 
 
The proportion of females to males was significantly higher in the anaemics compared 
to their non-anaemic counterparts disregarding their HIV status.  However, when HIV 
status was the basis of comparison the gender differences between anaemics and non-
anaemics were not significant. 
 
Trends between anaemics and non-anaemics for first languages spoken and marital 
status were similar to those obtained when compared between HIV sero-status groups.  
Both anaemics and non-anaemics were more represented in Tswana as first language 
speaking and never married categories.  Differences between anaemics and non-
anaemics for these socio-demographic characteristics were marginal and were also 
statistically not significant. 
 
When smoking status was considered, the results showed that anaemics, irrespective 
of their HIV status were significantly less likely to smoke as compared to non-
anaemics, but the differences between anaemics and non-anaemics across the two 
HIV sero-status groups were statistically not significant.     104
In terms of alcohol consumption, the proportion of consumers was lower in both sero-
status groups. However, whilst there was no difference between sero-negative 
anaemics and their non anaemic peers, sero-positive anaemics were significantly less 
likely to consume alcohol.  Between the anaemics, HIV sero-negative persons were 
significantly more likely to consume alcohol, whilst the difference between the non-
anaemics was not significant. 
 
Summary of section 4.2 
Many socio-demographic variables were considered for analysis, which included sex, 
age grouping, settlement type, educational qualification, first language spoken, marital 
status, monthly total income, smoking status and alcohol consumption status.   
 
So far, the results have shown that the prevalence of HIV infection in the study 
population is 11.8%.  In addition, though females were higher in proportion compared 
to males; they were as likely to be infected as their male counterparts.  HIV sero-
positives were significantly more likely to be younger and also to be urbanised 
compared to their sero-negative peers.  Generally, there were more persons 
represented in the lower monthly earnings, lower educational attainment, Tswana as 
first spoken language and never married categories, with smaller proportions in the 
other categories.  Although differences between the two groups were marginal they 
were not significant.  There were also no statistically significant differences between 
the two groups for proportions who smoked or consumed alcohol, albeit, marginal 
differences were shown.   
 
With regards to gender comparisons, both males and females, irrespective of their HIV 
status, are more likely to be in the ≤40 year group, but infected persons, especially the 
females have a significantly higher tendency to be in this age group.  In terms of 
settlement type infected males and females were significantly more urbanised than 
their uninfected counterparts.  Differences between infected males and females were, 
however, not significant even though infected males were proportionately more 
represented than their female counterparts in the urbanised settlement type.  The 
comparisons between males and females for first languages spoken, educational 
attainment and marital status followed the same trend as for comparisons between the 
two sero-status groups reported earlier.  Within and between the sero-status groups, 
gender differences for these socio-demographic characteristics were marginal and not 
significant.   Females, irrespective of HIV status, were significantly more likely to be 
lower earners and less likely to smoke or consume alcohol, but between the two sero-
status groups, there were no significant gender differences in these parameters.   105
Considering socio-demographic characteristics between anaemics and non-anaemics, 
both HIV sero-positive categories were significantly more likely to be in the age group 
≤40 years.  However, within the sero-status groups there were no significant 
differences in age groupings between anaemics and their non-anaemic peers.  With 
regards to settlement type, anaemics, irrespective of the HIV status were significantly 
more likely to be urbanised.  Furthermore, infected anaemics and non-anaemics were 
significantly more likely to be urbanised compared to their uninfected counterparts.   
Within the groups females were significantly more likely to be anaemic than non-
anaemic, but gender comparisons between the groups did not show any significant 
differences for males and females respectively.  Both anaemic HIV sero-positive and 
sero-negative persons were significantly more likely to be urbanised but the non-
anaemic and anaemic infected persons showed a significant likelihood of being 
urbanised when compared to their uninfected peers.   
 
Trends for educational attainment, total monthly earnings, first language spoken and 
marital status were very similar to the earlier ones reported for sero-status and gender 
comparisons.  The differences in these socio-demographic characteristics comparing 
anaemics and non-anaemics within and between HIV statuses were marginal and not 
significant.  Anaemics, irrespective of their HIV status were also significantly less likely 
to smoke compared to non-anaemics.  However, whilst infected anaemics showed a 
significant likelihood for not consuming alcohol as compared to their non-anaemic 
counterparts, the latter were also significantly more likely to be alcohol consumers 
compared to their non-anaemic sero-negative counterparts. 
 
It is evident from the above results that some socio-demographic characteristics were 
significantly different between the two HIV sero-status groups, which are also reflected 
within the gender and anaemic status comparisons.  Clearly these significant 
differences may be indicative of influence, which means that the significant socio-
demographic characteristics could be associated with HIV infection and, therefore, may 
serve as explanatory factors in the relationship between HIV infection and anaemia in 
the study population.   
 
4.4  KEY FINDINGS - CHAPTER FOUR 
The key findings in this chapter include the following: 
•  The prevalence of HIV infection in the study population was 11.8%.  
•  HIV sero-positive persons were significantly more likely to be younger:   
Significantly, sero-positive females were more likely to be younger than males and, 
anaemics, irrespective of HIV sero-status, were also more likely to be younger.   106
•   HIV sero-positive persons were significantly more likely to be urbanised.  Sero-
positive males and females were significantly more likely to be urbanised compared 
to their sero-negative counterparts. Anaemics were generally more likely to be 
urbanised but both sero-positive anaemics and non-anaemics were significantly 
more likely to be urbanised compared to their sero-negative peers. 
•  A sizable proportion of the study population, irrespective of HIV sero-status, gender 
and anaemic status, were more likely to have lower educational attainment, earn 
lower monthly income, speak Tswana as first language and never married. 
However, compared to males, females were significantly more likely to be lower 
income earners.   
•  Females, irrespective of sero-status, were significantly more likely to be anaemic.   
•  Although there were no differences between the sero-status groups for proportions 
who smoked or consumed alcohol, males were significantly more likely to smoke or 
indulge in alcohol consumption.  Anaemics generally were significantly less likely to 
smoke, whilst seropositive anaemics in particular were less likely to consume 
alcohol compared to their non-anaemic counterparts. 
 
The next section briefly discusses the findings in this chapter in order to highlight the 
significance of socio-demographic factors as part of the link in the causal web of HIV 
and anaemia as proposed by the framework in chapter one (Fig. 1.1).   
 
4.5  DISCUSSION OF KEY CHAPTER FOUR FINDINGS 
This chapter compared socio-demographic characteristics between infected and 
uninfected groups and also between male and female as well as anaemic and non-
anaemic sub-groupings in the study population.   The main purpose was to account for 
any socio-demographic explanatory factors that may influence or modify the effects of 
HIV and other exposures on the outcome of anaemia.  In regarding these significant 
explanatory factors as confounders in the relationship between HIV and anaemia, they 
would have to be adjusted for in subsequent analyses.  Similarly, the gender related 
differences observed within and between the groups may suggest an effect modifying 
influence that may also have to be accounted for in subsequent analyses.   
 
As an initial step, it is important to point out that because the original THUSA study was 
not designed to measure prevalence of disease (Vorster et al., 2000: Vorster et al. 
2005) reference to the THUSA population as ‘apparently healthy’ is justified by the 
rigorous selection criteria that ensured that unhealthy persons took part in the study.  
However, the subsequent serological classification of a group as HIV sero-positive or   107
infected may defeat this consideration on hind sight. Much as sero-negatives or the 
uninfected population may still be ‘apparently healthy’, sero-positives would then 
essentially fall into an asymptomatic classification as they were found to be free of 
symptoms of disease.  This is important because it depicts the early stage of infection 
within the sero-positive population.  Nevertheless, this categorisation into two HIV sero-
status groups provides reasonable justification for the present study.   
 
The HIV prevalence of 11.8% in the study population may be relatively higher than the 
recently documented prevalence rates in six out of the nine provinces of South Africa 
(South African Department of Health Survey, 2007; UNAIDS/WHO, 2008), which also 
includes that for the North West Province (10.9%) (Tab. 2.7).  However, it is important 
to state that the observed HIV prevalence rate in the study is not a true representation, 
then and now, of the larger population from which the subjects have been chosen for 
several reasons. Compared to the  HIV prevalence at the time of the study, the HIV 
prevalence in the THUSA population is an underestimation of the true prevalence, 
whilst it overestimates the current provincial prevalence.   
 
Among the many reasons to suggest a possibly higher HIV prevalence in the province 
are, firstly, the targeting of an ‘apparently healthy’ population as inherent in the design 
of the THUSA study.   Because the initial selection criteria was biased towards 
excluding persons with debilitating illnesses or known medical conditions (like diabetes 
and hypertension), as well as conditions that may be HIV or AIDS defining, a number of 
potential HIV infected individuals would be missed.  In addition, subject selection also 
excluded pregnant women, children below 15 years, persons ‘under the influence’ and 
those with febrile conditions, another criteria that adds to the missing of potential HIV 
infected persons, which is likely to underestimate the actual prevalence within the 
population.  In fact, pregnant women and children constitute the most vulnerable in 
sub-Saharan Africa (including South Africa) and other poor-settings, and in these 
places HIV prevalence rates in these population groups tend to be especially high 
(UNAIDS/WHO. 2006; 2008).  However, the study prevalence  overestimates the 
current provincial prevalence, which is indicative of a gradual decline in infection rates 
in South Africa since the study was undertaken.   
 
Despite this possible mis-estimation, the level of HIV prevalence recorded in this study 
probably underscores the fact that HIV infection has been a public health problem and, 
perhaps, still remains so in the North West Province of South Africa where the study 
was undertaken, considering that the current rate is at par with the national estimated 
HIV prevalence of around 10.8%  (South African Department of Health Survey, 2007).    108
Another important consideration in this study is the identification of the stage of 
infection for HIV sero-positives.  Studies have shown that HIV disease progression is 
associated with an increased prevalence and severity of anaemia (Spivak et al., 1989, 
Belperio et al., 2004).  This means that the stage of a person’s HIV infection can be a 
very important determinant of the level or severity of anaemia.  Thus, identifying the 
stage of infected persons can be considered a very important step towards assessing 
the level of anaemia in the population.   
 
With regards to staging, guidelines have been provided by the CDC (CDC, 1993).  With 
the CDC criteria in mind, HIV infected persons in the study population could be more 
appropriately classified as stage I or asymptomatic for a number of reasons.  Firstly, 
the rigorous selection criteria ensured that those selected were ‘apparently healthy’ 
until they were serologically identified with HIV.  In addition, persons who were in other 
stages of infection would have been excluded as they would most probably have 
shown clinical signs for exclusion.  It is most likely that a large number of the infected 
subjects, if not all, were at an early stage of HIV infection as they were in a relatively 
good health, unaware of their HIV status and were enjoying a normal life as everyone 
else. 
 
Demographic surveys carried out in many countries, and especially, where the 
population is in transition and HIV is endemic, suggest that females, younger persons 
as well as urbanised settlers are more likely to be infected (UNAIDS. 2006; 2008).  The 
significant likelihood for HIV sero-positive persons in this study population to be 
younger and urbanised may lend support to this suggestion. 
 
Whilst younger persons are more likely to be involved in risky behaviours that may 
expose them to the infection, the conditions for acquiring HIV tend to be rife in urban 
areas (UNAIDS. 2006; 2008).  The general trend in certain socio-demographic 
characteristics of the study population tends to highlight the vulnerability of the study 
population not only to HIV infection but also to anaemia.   
 
In South Africa and indeed in the North West Province a rapid wave of urbanisation is 
sweeping across (Vorster et al., 1999) with attendant changes in the socio-
demographics of the population.  Urbanisation, and especially where it is rapid, often 
comes with socio-economic, nutritional and other environmental changes which may 
greatly affect income and subsequently reduce people’s ability to acquire food and 
other basic amenities (Vorster et al. 1999).  Under such circumstances younger 
persons tend to migrate from the rural areas to live in transitional or urban settlements   109
(or slums) as they seek greener pastures (UNAIDS, 2006).  Nutritional and lifestyle 
changes occur, as individuals are compelled to cope and survive.  Changes include the 
consumption of cheap or affordable and often poor quality foods, the commercialisation 
of sex and abuse of drugs including alcohol, which may influence the predisposition of 
such persons to HIV and other infections (Vorster et al., 2000).  In South Africa, these 
changes have been noted as part of a series of effects that has culminated in what is 
referred to as the ‘triple burden’ of morbidity and mortality (Vorster et al., 2000: Vorster 
et al. 2005).  
 
In this study, the general effect of urbanisation on socio-economic status is reflected in 
the very large numbers of the study population (about two-thirds) that were earning 
lower monthly incomes as well as a large majority whose educational attainments could 
be described as poor.  Indeed, poor socio-economic circumstances, such as can be 
associated with this predominantly African (black) study population, may constitute part 
of the vicious cycle that allows poverty, HIV infection and anaemia to perpetuate 
(Semba, 2003).  Apart from the higher predisposition to HIV and other infections 
conferred by this racial characteristic (Shisana et al., 2005), it is also very likely that the 
interactions between poverty, nutrition and other less perceptible racial factors could 
heighten the vulnerability of the group. 
 
With a large proportion of females, who are significantly likely to be younger, poorer, 
never married and also poorly educated, the high HIV prevalence rate in the study 
population could be reasonably explained.  Apart from their higher biological 
vulnerability to HIV infection, many socio-demographic factors associated with females, 
including the significant characteristics of being younger, lower monthly earnings and 
poorer educational attainments add to their vulnerability.  Although it has not been 
established in this study, in many poor settings and regions experiencing rapid 
transition, younger females often drop out of school and usually remaining unmarried 
have to fend for themselves.  A large number may reside in or migrate to urban slums 
in search of greener pastures and most of them may end up in sexual compromises 
often fanned by peer pressure, drugs and alcohol, which could enhance their risk to 
HIV infection (UNAIDS, 2008).  
 
Since many potential effects of HIV infection may be part of its causal relationship with 
anaemia, any factor that may affect the prevalence or severity of HIV infection or 
modify its effects within the population could be connected as an integral part of the 
linkage between HIV and anaemia.  In this study population, even though females are 
significantly more likely to be anaemic, this gender characteristic may not be   110
considered as part of the link between HIV and anaemia, because sero-positive 
females were as likely to be anaemic as their sero-negative peers.  Nevertheless, the 
reasons why females are more likely to be anaemic can be ascribed to biological 
attributes such as menstrual blood losses and pregnancy/delivery associated iron 
losses (Volberding et al., 2004) as well as poor dietary practices which tends to reduce 
iron intake.   
 
Another socio-demographic attribute of anaemics in general, as far as this study is 
concerned, is that they were more likely to reside in an urbanised settlement. 
Considering the changing nutritional and socio-demographic circumstances in a rapidly 
urbanising settlement, many young persons would have diets that are impoverished.  
They may resort to coping mechanisms which includes having fewer meals and eating 
cheaper foods often lacking in nutrients (UNAIDS, 2006).  These could eventually 
make them nutrient deficient.  In addition, socio-demographic changes could lead to 
inadequate provision of amenities as well as a deterioration of sanitation and health 
(Calder and Jackson, 2000), which would increase vulnerability to infectious diseases. 
This implies that in a rapidly urbanising environment persons who are young and poor, 
often belonging to the female population, are more likely to be nutrient deficient and 
therefore more susceptible to infectious diseases.  Altogether, these would make such 
individuals more likely to be anaemic.  Thus, the significant likelihood of infected 
persons or anaemics to reside in urbanised settlements may point to the fact that living 
in an urbanised settlement could be an important socio-demographic consideration for 
the relationship between HIV and anaemia. 
 
Perhaps other important socio-demographic attributes in the study population, which 
could be invoked to explain the association of anaemia with females is that males were 
significantly more likely to smoke and consume alcohol than females.  Smoking 
generally creates a hypoxic environment within the respiratory tract as the smoker 
continually floods the airways with carbon dioxide and other substances.  An increase 
of carboxy-haemoglobin that often ensues creates a hypoxic condition, which 
eventually serves as a stimulus for haemoglobin synthesis.  Thus, smoking may 
increase the Hb levels by about 0.3 g/dL (WHO, 2004), which tends to make smokers 
less likely to be anaemic compared to non smokers.  The finding that non-smokers in 
this study are significantly more likely to be anaemic may lend support to this assertion. 
 
With regards to intake of alcohol, some moderate levels of consumption has been 
shown to boost food intake (Yeomans, 2004), and with this may come an increase in 
nutrient intake, which may also lead to an improvement in Hb and RBC syntheses.    111
This could explain why males, who are more likely to drink, are also less likely to be 
anaemic.  The fact that sero-positive anaemics were significantly less likely to drink 
alcohol could perhaps be an added reason to explain their anaemic status.  
 
At this point, it is important to state that the socio-demographic factors considered in 
this study only form part of a constellation of factors that may relate HIV infection to 
anaemia in this population.  According to the framework for this study some factors 
other than socio-demographic are likely to cause anaemia independently or interact 
with many others to increase the susceptibility of sero-positive persons to anaemia.  
These other factors and their interplay or interaction with, especially, HIV infection, 
would be the matter for exploration in the next two chapters.     112
CHAPTER FIVE 
5.0  DETERMINATION OF HIV ASSOCIATED FACTORS THAT MAY 
SIGNIFICANTLY CONTRIBUTE TO ANAEMIA IN THE STUDY POPULATION 
In the previous results chapter, socio-demographic variables have been compared 
between HIV infected and uninfected groups as well as gender and anaemia status 
sub-groupings in the study population.  The levels of association between socio-
demographic factors with HIV infection and anaemia have also been explored.   
 
In the following sections factors that have been proposed to constitute a part of the link 
within the causal web of HIV infection and anaemia in the study population would be 
examined to see if there are any independent or interactive associations.   
 
5.1 INTRODUCTION 
Some studies have shown that HIV may directly influence the proliferation of 
erythrocyte progenitor cells to cause a reduction in RBC numbers.  Many indirect or 
side effects of HIV also tend to affect the host’s nutritional status as well as other 
metabolic processes, which may subsequently reduce RBC proliferation.  As a result of 
these effects, infection with HIV may become a multiple risk for the development of 
anaemia in a sufferer.   
 
Many biological factors can be considered as being part of the multiple causation of 
anaemia in HIV infection.  However, in this study a direct effect of the virus, depicted by 
differences in anaemia prevalences by sero-status groupings, as well as indirect effects 
that may be constituted as reductive adaption, increased nutrient deficiency and 
metabolism, and inflammation or inflammatory response, would be considered for 
exploration as part of the explanatory factors between HIV infection and anaemia.  
 
The initial explorative step in this chapter to establish an overall effect begins with the 
determination of anaemia prevalences including characteristics and relationship with 
iron status in the study population.  This would then be followed by further explorative 
analyses to establish independent risk relationships between each of the considered 
factors, as exposures with HIV infection, on the measured outcome of anaemia. 
 
The objectives set for the explorative analyses were as follows:  
•  To relate anaemia with effects of HIV (status) in the study population 
(Determination of anaemia prevalences) 
•  To relate body compositional and energy changes with HIV and anaemia statuses 
in the study population.   113
•  To relate micronutrient imbalances with HIV and anaemia statuses in the study 
population 
•  To relate inflammation with HIV and anaemia statuses in the study population 
 
5.2  RELATING ANAEMIA WITH AN OVERALL HIV EFFECT (STATUS) IN THE 
STUDY POPULATION  
In this section the independent association between HIV and anaemia is highlighted by 
the determination of sero-status prevalences and other characteristics of anaemia in 
the study population.   
 
The [Hb] and Hct cut-offs used in defining anaemia were, <13 g/dL or <12 g/dL and 
<39 or <36 for adult men or premenopausal women respectively (see table A1, 
Appendix A).  Generally accepted cut-offs for the iron status markers were also 
considered for exploring the different characteristics of anaemia in the study 
population.   
 
5.2.1  COMPARING MARKERS OF ANAEMIA BETWEEN HIV SERO-STATUS 
GROUPS AND ANAEMIA STATUS SUB-GROUPS  
The table below (Tab. 5.1) represents the summary of the results that compares the 
means of the different markers used in defining anaemia between sero-status groups 
and their anaemia sub-grouping.  
 
From table 5.1, mean levels of [Hb] and Hct were lower in the HIV infected group 
compared to their uninfected counterparts.  However, only Hct differences were 
significant (p<0.001) both before and after the significant socio-demographic 
confounders of gender, age grouping, settlement type, smoking and alcohol 
consumption, which meant that the effect of HIV infection on Hct was significant.  Both 
[Hb] and Hct remained significantly lower (p<0.001) in the anaemic compared with their 
non-anaemic peers.  Therefore, the effect of anaemia on these parameters was also 
significant. With regards to interaction between HIV and anaemia, there was no 
significant effect on Hct levels.  However, the interactive effect on [Hb] which was 
marginally significant before the adjustment became insignificant after the adjustment.  
 
Iron (Fe), TIBC and ferritin were marginally lower, whilst % transferrin saturation was 
marginally higher in the sero-positives, but there were no significant differences, even 
after adjusting for the socio-demographic confounders, between sero-positives and 
sero-negatives.     114 
Table 5.1:  Markers of anaemia and/or iron status compared between anaemic and non-anaemic sub-groups using ANOVA  
HIV- HIV+  ANOVA  (p-value) 
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However, the differences between anaemics and non anaemics were highly significant 
except for ferritin (Tab. 5.1).  This meant that whilst there was no significant effect of 
HIV infection, anaemia had a highly significant effect on these parameters.  The 
interactive effects between HIV infection and anaemia on these iron status markers 
were also not significant.  
 
In the next section the prevalence or levels of anaemia in the study population, using 
the main markers of [Hb] and Hct, and considering various sub-groupings would be 
presented.  
 
5.2.2  PREVALENCE OF ANAEMIA IN THE STUDY POPULATION 
The prevalence of anaemia, defined by both [Hb] and Hct, and some specific iron 
status markers are compared between HIV infected and uninfected groups and other 
significant socio-demographic sub-groupings.  Grades of anaemia defined by [Hb] are 
also compared between the sero-status groups.  Based on the assumption that Hct 
relates to 3 times [Hb] (Sacher and McPherson, 2000; Bain and Bates, 2001), a 
Deming regression￿￿￿þ￿￿￿￿ther than a normal linear regression fit is used to 
estimate a more realistic Hct cut-off to be used to determine anaemia prevalence. 
   
5.2.2.1  Prevalence of anaemia - defined by WHO cut-offs for Haemoglobin 
concentration and Haematocrit 
Table 5.2 below shows prevalence of anaemia in the study population (defined by [Hb] 
and Hct) and compared between HIV sero-positive and uninfected groups as well as 
within significant socio-demographic sub-groupings.  Also shown are grades of 
anaemia between sero-status groups.   
 
From table 5.2, it is evident that prevalence of anaemia was higher in HIV sero-
positives than in sero-negatives, however, the differences became significant when 
anaemia was defined by Hct cut-offs (p<0.001).  The higher prevalence in HIV sero-
positives was in agreement with prevalence values obtained for both sero-positive 
males and females, which were higher compared with those of their sero-negative 
counterparts.  This was irrespective of the marker used to define anaemia.  However, 
only HIV sero-positive females had significant Hct-defined prevalence compared to 
their sero-negative counterparts.  Irrespective of sero-status, anaemia prevalence in 
females was higher than males, which rather confirmed the earlier finding that females 
in the study population were significantly more likely to be anaemic than males.  In 
contrast, anaemia prevalences defined by Hct were generally lower compared to those 
defined by [Hb] (Tabs. 5.2).  However, the differences in prevalence between the sero-  116
status groups using the Hct definition were significant whist the [Hb] definitions were 
not.  Because of the lower but significant prevalences obtained with Hct definitions and 
considering that Hct cut-offs could relate to 3 x [Hb], There is a high likelihood that this 
relationship would deviate from what is conventionally accepted.  A DR analysis would  
therefore be used in the next section to establish cut-offs, which would be used to 
determine prevalences that may better reflect the relationship between the two 
markers.  
 
Table  5.2:  Prevalence of anaemia in socio-demographic sub-groupings and 
grades of anaemia in the study population 
[Hb] as indicator   Hct as indicator   
Category  HIV-  HIV+ Overall p  value HIV-  HIV+ Overall p  value 
Socio-demography  
All   45.8  51.4  46.4  0.123 11.2  20.0  12.9  <0.001 
Males 41.9  44.2  42.1  0.663 6.9  9.5  7.3  0.374 
Females 48.7  57.1  49.7  0.066 14.4  28.7  16.1  <0.001 
>40 yrs  45.7  51.0  46.5  0.234 10.9  20.6 12.2  0.001 
≤40 yrs  45.9  52.2  46.5  0.317 11.7  18.8  12.4  0.084 
rural 35.8  34.9  35.7  0.887 9.4  15.4  10.0  0.103 
Urban 53.8  58.3  54.5  0.307 12.6  21.8  14.0  0.003 
Non-smokers 48.8  58.6  49.6 0.024  13.7  25.0 15.0  0.001 
Smokers 40.5  37.6  40.2  0.663 6.3  10.8  6.9  0.152 
No-alcohol intake  47.2  60.9  48.7 0.006  13.4  26.8 14.9  <0.001 
Alcohol intake  44.3  39.2  43.6 0.349  8.6  11.5 9.0  0.366 
Grades of anaemia   
Mild   31.1  32.4  31.3  0.278  -  -  -  - 
Moderate 12.9  15.3  13.2  0.163  -  -  -  - 
Severe 0.7  3.2  1.0  0.009  -  -  -  - 
Statistical significance is denoted by p<0.05.  
 
Table 5.2 above also shows that, with regards to age grouping, settlement type, 
smoking and alcohol consumption statuses, anaemia prevalences (defined by [Hb]) 
were higher in HIV sero-positives except for rural settlers, non-smokers and persons 
who consumed alcohol, where prevalences were lower than in their sero-negative 
peers.  Anaemia prevalences in sero-positive non-smokers and persons who did not 
consume alcohol were significantly higher (p=0.024 and p=0.006 respectively) than for 
their sero-negative counterparts.  However, all other differences in prevalence between 
the sero-status groups were not significant.   
 
With Hct defining anaemia, prevalences for sero-positives for all the significant socio-
demographic variables were higher than for their sero-negative peers.  Almost all of the 
comparative differences were highly significant except for those between the 
categories of males, ≤40 years age grouping, rural settlers, smokers and alcohol 
consumers.  The figure below (Fig. 5.1) illustrates the comparative prevalences 
between sero-status groups as well as between socio-demographic sub-groupings.   117
Figure 5.1:  Prevalence of anaemia (defined by [Hb]) in the study population 















Using [Hb] to define anaemia clearly identified a larger proportion of individuals with 
anaemia than with Hct.  These differences have been illustrated in figure 5.2 below for 
the various demographic categories within the sero-status groups. By the WHO 
standards of defining anaemia, [Hb] is a more sensitive marker as the illustration   
below seems to confirm.  Nevertheless, there was significant agreement between the 
two markers with a partial correlation of r=0.547 (p<0.001), albeit, the Hct definition 
was more likely to show significant differences in anaemia prevalence between the   118
groups.  Despite the significant agreement shown between the two markers, the 
correlation coefficient was less than 0.8, which statistically suggests a less accurate 
expression of the relationship.  It is very likely that the normally assumed relationship, 
which estimates Hct as three times Hb (Bain and Bates, 2001; Sacher and McPherson, 
2000), does not hold for this population.  The of this assertion is explored by the use of 
a DR analysis in the next section.  Deming regression fits would then be used to derive 
cut-offs for Hct and then the  prevalence of anaemia would be determined using these 
new cut-offs.  
 
Figure 5.2:  Comparing prevalences of anaemia defined by [Hb] with those 
defined by Hct in the study population 








































Again, as illustrated in figure 5.3 below, [Hb] defined cut-offs for anaemia have been 
used to categorise 3 stages of anaemia in HIV infected and uninfected persons.  These 
values are also presented in table 5.2 above for mild, moderate and severe grades.  
The figure clearly depicts higher prevalences for mild, moderate and severe anaemia in 
the sero-positive group than in their uninfected counterparts.     119
Generally, about 31% of the overall study population were mildly anaemic (about 70% 
of anaemia), whilst 13.2% and 1% were moderately and severely anaemic respectively.  
This means that mild anaemia was the most prevalent grade of anaemia in both sero-
status groups.  Whilst the differences between the two sero-status groups for mild and 
moderate anaemia prevalences were not significant, HIV sero-positives were 
significantly (p=0.009) more likely to be severely anaemic as compared to their 
uninfected counterparts, but the numbers considered in this category were very small 
(HIV-, 11 [0.7%];  HIV+, 7 [3.2%]).  However, this tendency for severe anaemia may 
imply that HIV infection could contribute to the high levels of anaemia in the study 
population and may also be associated with its exacerbation in the sero-positive 
population.   
 




















5.2.2.2 Prevalence of anaemia - estimated from Deming regression derived 
haematocrit cut-offs 
The scatter plots below (Figs. 5.4 [a, b & c]) represent relationships between [Hb] and 
Hct for the whole study population, males and females respectively.  Regular linear 
P=0.009 
P=0.168 
P=0.273   120
regression fits are also shown alongside DR fits derived from DR analysis, which unlike 
the normal linear regression accounts for errors on both x and y axes.  The essence of 
this manoeuvre is to derive a relationship between [Hb] and Hct that better predicts one 
from the other.  
 
Apart from the differences in the predictive powers of the two regression fits in figures 
5.4b and 5.4c below, they both do not seem to be in agreement with multiplying the 
[Hb] by three to obtain an approximate Hct level as may pertain in normal clinical 
practice (Bain and Bates, 2001).  At and below the cut-off for [Hb] the Deming 
regression line estimates the ratios as close to 1:3.4 in both males and females 
(considering [Hb] cut-offs of <12 and <13 g/dL for males and females respectively as 
the x variates).  This perhaps suggests that the conventionally accepted values based 
on the 1:3 ratio is more likely to under-estimate prevalence of anaemia when Hct 
values are used.  
 
Figure 5.4a:  Scatter plot for [Hb] against Hct with regular and Deming regression 
fit lines for the whole study population 
y = 1.1695x + 27.936


















Normal fit Deming fit
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Figure 5.4b: Scatter plot for [Hb] against Hct with regular and Deming regression 
fit lines for males in the study population 
y = 0.8512x + 33.668


















Normal fit Deming fit
 
Figure 5.4c: Scatter plot for [Hb] against Hct with regular and Deming regression 
fit lines for females in the study population 
y = 1.0558x + 28.243
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From a [Hb] <13 g/dL for males, the estimated Hct cut-off of <44.33 was obtained, 
whilst [Hb] <12 g/dL for females corresponded with an Hct cut-off value of <40.72.  
These estimated cut-offs were then used as the bases for re-determining prevalences 
of anaemia in the study population.   
 
In the table below (Tab. 5.3) anaemia prevalences defined by Deming derived Hct cut-
offs have been compared between the sero-status groups and gender sub-group 
alongside prevalences estimated from [Hb} cut-offs presented earlier (Tab. 5.2).  
 
Table 5.3:  Prevalence of anaemia using Deming derived Haematocrit cut-offs 
compared with estimates from [Hb] cut-offs  
Prevalence of anaemia 
[Hb] as indicator  Deming derived Hct as indicator 
 
 
Category  HIV+  HIV-   All  P value  HIV+  HIV-  All  P value 
Males and females   51.4  45.8  46.4  0.123  53.5 41.5  42.9  0.001 
Males 44.2  41.9  42.1  0.663  50.0 39.5  40.8  0.024 
Females 57.1  48.7  49.7  0.066  56.4 42.9  44.4  <0.001 
Statistical significance is denoted by p<0.05.  
 
Evidently, the prevalences estimated from the DR analysis show that levels of anaemia 
with Hct cut-offs are closer and in most cases slightly higher in the HIV infected 
persons as compared with anaemia defined by [Hb].  On the contrary, uninfected 
persons tended to have rather lower levels of anaemia estimated by the derived Hct 
cut-offs than [Hb] cut-offs.  The differences between the 2 sero-status groups were 
however highly significant.  Generally, HIV infected persons had anaemia prevalences 
that were still higher than those of their uninfected counterparts. 
 
5.2.2.3  Prevalence of anaemia associated with iron status indicators 
In Table 5.4 below, the proportions of individuals classified as anaemic by the use of 
various cut-offs for iron status markers are shown.  The table shows that a marginally 
higher proportion of HIV infected persons compared with their uninfected peers could 
be regarded as having lower serum levels of iron (19.5% cf. 16.7%), TIBC (65.6% cf. 
61.8%), % Saturation (25.4% cf. 20.7%) and ferritin (14.8% cf. 12.4%), though the 
differences in proportions were not significant.  This implies that HIV sero-positives in 
this study population were as likely to be associated with iron deficiency related 
anaemia as sero-negatives.  Sero-positive persons were proportionately more likely to 
be iron depleted (ferritin <15 µg/L) and less likely to be iron overloaded (ferritin >100 
µg/L) though the differences were not statistically significant.  Using ferritin and [Hb] 
cut-offs together, both sero-positive and sero-negative persons were about equally 
likely to be categorised with having IDA or ACI.   
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Table 5.4:  Characteristics of anaemia in the study population using iron status 
markers and their combinations 
Percentage below cut-off point   
Parameter 
 
Cut-off point  HIV- HIV+  All  p  value 
[Hb] (g/dL)  <12 (♀)/13 (♂)    45.8 51.4 46.5 0.358 
Hct (%); WHO cut-off  <36 (♀)/39 (♂)    11.2  20.0  12.3  <0.001 
Hct (%); DR cut-off  <40.7 (♀)/44.3 (♂)  41.5 53.5 42.9 0.001 
Serum iron (µmol/L)  <9.0  16.7  19.5  17.1  0.302 
TIBC  (µmol/L)  <70  61.8 65.6 62.3 0.295 
Saturation  (%)  <15  20.7 25.4 21.3 0.126 
Iron deficiency  Ferritin <15 (µg/L)  12.4 14.8 12.6 0.307 
Iron overload  Ferritin >100 (µg/L)  38.6 36.6 38.3 0.572 
Iron deficiency anaemia  Hb<12/13(g/dL) & 
Ferritin<15(µg/L) 
8.4 10.6  8.5 0.261 




20.9 25.6 22.3 0.376 
Hct – haematocrit; DR – Deming regression; TIBC - total iron binding capacity, ♀ - female, ♂ - male.  Statistical 
significance is denoted by p<0.05.  
 
However sero-positives had a slightly higher prevalence compared to their sero-
negative peers with respect to both IDA (10.6 cf. 8.4%) and ACI (25.6% cf. 20.9%), 
even though the differences were not statistically significant. Generally, when the high 
levels of anaemia, as defined by [Hb], are considered side by side with other iron status 
parameters depicting iron depletion (low serum iron, low % transferrin saturation and 
low ferritin) and those depicting inflammatory presence (high ferritin, low TIBC), it is 
quite possible to observe that ACI is likely to be more common than IDA in the study 
population although the results do not confirm this. 
 
Summary of section 5.2 
The results in the section above show that: 
1.  Comparing the anaemia defining markers between the sero-status groups showed 
that Hct was significantly lower in the HIV sero-positives and anaemics and effects 
of both HIV infection and anaemia on this parameter was very significant, although 
the interactive effect was not.  For [Hb], serum iron, TIBC, % saturation and ferritin, 
differences between sero-positives and sero-negatives were marginal and not 
significant.  There was also no significant effect of HIV on these, but anaemia had a 
significant effect on all except ferritin.  With regards to interaction, there were no 
significant effects except [Hb] which showed a borderline significance that was lost 
after the adjustment. 
  
2.  Anaemia prevalences in the general study population, defined by both [Hb] and Hct 
cut-offs, were quite high.  However, prevalence in the HIV sero-positive group was 
rather higher irrespective of gender and age grouping for either definition.   
However, using [Hb] definition, HIV sero-positive urban settlers, non-smokers as   124
well as non-consumers of alcohol were more likely to be anaemic, whilst rural 
settlers, smokers and consumers of alcohol were less likely to be so compared to 
their sero-negative peers.  Hct definition gave contrasting results as rural settlers, 
smokers and consumers of alcohol were more likely to be anaemic than their 
uninfected peers.  Only the difference in prevalence between the groups for non 
alcohol consumers was significant, but with Hct all but the differences for males, 
≤40 year grouping, rural settlers, smokers and consumers of alcohol were highly 
significant. Only Hct defined anaemia prevalences were significantly higher.  In 
addition, HIV sero-positives were more likely to be mildly and moderately anaemic 
and significantly more likely to be severely anaemic compared to their uninfected 
peers. 
 
3.  In terms of iron status, HIV persons tended to have marginally lower levels of 
serum Fe, serum ferritin and TIBC and marginally higher % saturation than their 
uninfected counterparts.  Risk levels were, however, not significantly different, 
comparing the two groups for low serum Fe, serum ferritin and % saturation, but 
was higher and significant for lower TIBC in favour of the infected population.   
4.  Cut-offs for serum iron and ferritin levels revealed that a higher proportion of HIV 
sero-positive persons compared to their uninfected peers were more likely to be 
hypoferaemic (i.e. with low serum Fe) or hypoferritinaemic (i.e. with low serum 
ferritin levels), which made them more likely to be iron deficient.  HIV sero-positive 
persons were also more likely to be associated with hyperferritinaemia (i.e. ferritin 
levels above 100 µg/L), IDA or ACI, even though in all cases the risk levels were 
not significantly different between the two groups.  A closer look at the trends in the 
iron status markers revealed that ACI was most likely to be common than IDA in the 
study population.  
 
The implications of the above findings are that HIV infected persons in the study 
population can be considered to be more anaemic than uninfected persons, which 
could mean that infection with HIV, even at an early stage, can be independently 
associated with anaemia. 
 
The next section would begin the exploration of some factors considered as important 
and, within the constraints of the data set, could explain anaemia in the study 
population.   
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5.3  REDUCTIVE ADAPTATION AS A POSSIBLE EXPLANATION FOR THE 
ANAEMIA IN THE STUDY POPULATION 
In this section the tendency for HIV infection to cause changes in body composition 
with time as a result of metabolic and other physiological changes that may be 
associated with the infection, is explored.  The adaptive changes that may occur with 
HIV infection often affects energy balance and could have far reaching implications on 
the development of anaemia.   Changes in body composition may manifest as loss of 
weight or lean body mass and/or an energy imbalance, which by and large affects red 
cell metabolism. 
 
Table 5.5 below shows the comparative differences in body compositional 
measurements between sero-status groups in the study population.  Sero-positives 
were proportionately more likely to be lighter but taller, which also meant that they were 
more likely to have lower BMI compared to sero-negatives.  LBM and LMI were, 
however, closely similar between the two sero-status groups.   With regards to skin fold 
measurements, sero-positives tended to have lower triceps and subscapular but higher 
iliac crest, supraspinale, abdominal, thigh and calf as compared to sero-negatives.   
Clearly, the marginal differences in weight, height, and derivatives of BMI, LBM and 
LMI as well as the skin fold measurements were not significantly different between the 
two sero-status groups even when the socio-demographic confounders were adjusted 
for.  This shows that there were no significant effects of HIV infection on these 
parameters. 
 
Comparing anaemics with non-anaemics, on the other hand, showed that anaemia had 
some significant effects on BMI, LBM and some skin fold measurements.  Anaemics 
had higher BMI than non-anaemics, whilst LBM was rather higher in non anaemics 
compared with anaemics.  The effect of anaemia on BMI and LBM were rather 
significant initially, but this was lost after the adjustment.  There was also no significant 
effect of anaemia on LMI.  With regards to skin fold thicknesses, some (subscapular, 
abdominal, thigh and calf) were higher in the anaemics than the non-anaemics and 
anaemia had a significant effect, before and after socio-demographic confounders were 
adjusted for.  In terms of interactions between HIV infection and anaemia, significant 
effects were only apparent in supraspinale and abdominal skin folds only after 
adjusting for the socio-demographic confounders.  
 
The difference in BMI between anaemics and non-anaemics may be explained by 
anaemics being heavier but of similar stature as their non-anaemic peers, together with 
their comparatively lower LBM.  However, a lot of their heaviness may be attributed to   126
greater fat deposits depicted by comparatively higher skin fold thicknesses in most 
parts of the body.   
 
From the above findings it is possible to infer that, although there are no significant 
effects of HIV infection on body compositional measures, Anaemia as well as its 
interaction with HIV infection may be related with a certain level of fat deposition, 
especially, in mid sections of the body.  
 
When the two sero-status groups are compared, alterations in body compositional 
measures do not show clearly the effects of HIV in inducing reductive adaptation in the 
sero-positives.   This may possibly manifest only over a long period and for that reason 
the sero-positives may be appropriately confirmed as being at an asymptomatic or 
early stage of infection.  However, since anaemia has been associated with a 
significant alteration in some body compositional measures, it is very likely that in the 
long term anaemia in the study population could be determined in part by such body 
compositional changes. 
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Table  5.5:  Anthropometric indicators for measuring adaptational changes in the study population.  Data values are means (95% 
confidence interval – CI) 
HIV- HIV+  ANOVA  (p-value) 











(110)  Crude *Adjusted  Crude *Adjusted  Crude *Adjusted 









0.257 0.272  0.069 0.763 0.908  0.689 
Height  (cm) 
162.48  


















0.110 0.235  0.051 0.985 0.660  0.210 









0.943 0.884  0.043 0.322 0.319  0.215 











0.668 0.699  0.095 0.470 0.585  0.472 
Skin folds   









0.096 0.185  0.135 0.258 0.906  0.110 









0.241 0.398  0.037 0.810 0.585  0.093 









0.251 0.287  0.098 0.934 0.878  0.285 









0.767 0.763  0.108 0.905 0.801  0.043 









0.648 0.859  0.022 0.073 0.682  0.008 









0.338 0.427  <0.001  0.011 0.088  0.889 









0.853 0.720  0.002 0.461 0.360  0.575 
BMI – body mass index; SF – skinfold. Statistical significance is denoted by p<0.05. *Adjusted for gender, age grouping, settlement type, smoking and alcohol consumption.  
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Summary of section 5.3 
This section can be summarised as follows: 
1.  HIV sero-positives tended to be lighter and relatively shorter than their sero-
negative peers.  They also had body compositional measurements that indicated 
that they were more likely to be associated with higher fat deposits in especially the 
lower body parts. 
2.  Anaemics were more likely to have lower LBM and higher BMI because they 
tended to be heavier and also had levels of skin fold fats that were not only high but 
quite significant for lower body parts. 
3.  Interaction between HIV infection and anaemia had a significant effect only on 
abdominal skinfold. 
 
In conclusion, anaemia and to a lesser degree, its interaction with HIV infection may 
lead to alterations in body composition, which may manifests as changes in fat 
deposition in the mid section of the body or perhaps fat redistribution in, especially, the 
sero-positive population.  Associating such adaptational changes in body compositional 
measures mainly with anaemia may suggest their consideration as explanatory factors 
of anaemia in the study population. 
 
The next section would explore energy imbalances and nutrient deficiencies as 
possible causes of anaemia in the study population. 
 
5.4  ENERGY IMBALANCE AND NUTRIENT DEFICIENCIES AS POSSIBLE 
EXPLANATION FOR THE ANAEMIA IN THE STUDY POPULATION 
HIV infection, as it progresses, can lead to poor or reduced energy and nutrient 
intakes.  Infection with the virus may induce anorexia and other patho-physiological 
changes that may subsequently lead to a reduction in food intake.  HIV/AIDS is also 
associated with increased metabolic energy expenditure.  However, in spite of the 
increased metabolic expenditure, victims may eventually reduce their physical activity 
levels (PAL) in an attempt at lowering total energy expenditure, which may subsequent 
result in a reduction in food energy and nutrient intake.  The state of affairs in such a 
situation is the likely emergence of an energy imbalance and/or a nutrient deficiency, 
which by and large may result in poor or ineffective RBC production as victims may be 
deprived of essential haematinics.  
 
5.4.1 ENERGY STATUS 
In this study, total energy intake, derived from carbohydrates, proteins and fats as main 
food sources, with or without alcohol, are presented.  In table 5.6a below, the mean   129
total energy intake (including alcohol) tended to be significantly higher in the HIV sero-
positive group compared with that of their sero-negative peers, though this significance 
was lost after adjusting for socio-demographic confounders.   
 
With alcohol excluded in the estimation, there was no significant difference in energy 
intake between the two sero-status groups even after the adjustment.  This means that 
HIV infection, in this study population, has no significant effect on energy intake 
irrespective of whether alcohol is included or excluded.  Similarly anaemia did not have 
any significant effect on energy intake, even though sero-positive anaemics had 
marginally higher intakes than non-anaemics.  There was also no significant interaction 
between HIV infection and anaemia on energy intakes, which implied that sero-positive 
anaemics were not likely to have significantly higher intakes compared to their sero-
negative anaemic peers.   
 
Although proportions of food energy sources seemed marginally different between the 
two sero-status groups, these differences were statistically significant after socio-
demographic confounders were adjusted for.  This may imply an effect of HIV infection 
being confounded by socio-demographic variables.  However, there were no significant 
effects of anaemia as well as interaction between anaemia and HIV infection on the 
differences in food sources.  In terms of proportions of energy intake, carbohydrate 
food sources provided the highest in both groups and also contributed the greatest 
amount of energy (~5700KJ cf. approx. 2200KJ from fat) in their diets.   
 
Despite about 57% of the population being non-consumers of alcohol, HIV sero-
positive consumers tended to have intakes that were higher than their sero-negative 
peers, though the difference was not significant.  On the other hand anaemics had 
intakes that were significantly lower compared to non-anaemics even after socio-
demographic confounders were corrected for.  There was also a significant interactive 
effect between HIV infection and anaemia on alcohol consumption, which depicted that 
sero-positive anaemics were significantly more likely to consume lower amounts of 
alcohol. 
   130 
Table 5.6a:  Measures related to energy intake in the study population. Data values are means (95% confidence interval – CI) 
HIV- HIV+  ANOVA  (p-value) 











(108)  Crude *Adjusted Crude *Adjusted Crude *Adjusted 










0.032 0.272  0.661 0.198 0.588  0.079 










0.068 0.272  0.635 0.198 0.204  0.079 










0.091 0.023  0.065 0.243 0.416  0.393 








0.378 0.029  0.455 0.283 0.553  0.354 





















0.060 0.099  0.000 0.004 0.008  0.026 
Statistical significance is denoted by p<0.05. *Adjusted for gender, age grouping, settlement type, smoking and alcohol consumption. 
 
 
Table 5.6b:  Estimates for energy requirements and expenditure in the study population.  Data values are means (95% confidence interval – 
CI) 
HIV- HIV+  ANOVA  (p-value) 











(110)  Crude *Adjusted  Crude *Adjusted  Crude *Adjusted 








0.026 0.007  0.120 0.646 0.448  0.348 










0.530 0.644  0.821 0.696 0.729  0.643 








0.553 0.056  0.276 0.489 0.784  0.726 
PAL – physical activity level; BMR – basal metabolic rate; EAER – average estimated energy requirements. Data values are means (95% confidence interval – CI). Statistical significance is denoted by p<0.05. 
*Adjusted for gender, age grouping, settlement type, smoking and alcohol consumption.   131
In table 5.6b above mean estimates for BMR using gender specific Schofield 
equations, together with PAL estimated from activity factors ascribed to subjects in the 
study population (see appendix B) have also been shown.  Despite the marginal 
differences with PAL estimates being lower in sero-positives, there was a significant 
effect of HIV infection on this variable, even after the adjustment.  On the other hand, 
there were no differences in BMR between the two sero-status groups and the effect of 
HIV infection was not significant.  On both PAL and BMR, there were no significant 
effects of anaemia as well as effects from its interaction with HIV infection.  
 
Estimated average energy requirement (EAER), obtained as a product of PAL and 
BMR for each individual subject (see also Appendix B), are compared between the 
groups (Tab. 5.6b).  Despite showing a marginal difference between sero-status 
groups, they emerged as significant after adjusting for confounding socio-demographic 
variables.  However, effects of anaemia or its interaction with HIV infection were not 
significant on EAER. 
 
Demarcations were made for persons who were most likely to have either a poor intake 
or an intake that provided adequate energy or perhaps excess, using the gender 
derived EAER.  In table 5.7 below proportions for these demarcations are compared 
between sero-status groups as well as anaemic subgroups. 
 
Table 5.7:  Proportions with poor or adequate energy intake compared between 
groups and subgroups in the study population 
HIV-  HIV+  p-value (Chi square)   
 
 













































0.045 0.274 0.516 0.064
Poor 470   
(57.2%) 


















0.053 0.099 0.404 0.016
Statistical significance is denoted by p<0.05. 
 
Clearly, table 5.7 above shows that 50% or more of the study population were likely to 
be classified as having a poor energy intake.  Nevertheless, sero-negative anaemics 
were significantly more likely to be classified as having poor energy intakes as 
compared to their non-anaemic peers, irrespective of whether alcohol is included in the 
estimation or not.  On the other hand seropositive anaemics were rather more likely to 
fall within the adequate /excess intake category, but this was not significantly so.     132
Comparing sero-positive non-anaemics with their sero-negative peers, it was evident 
that they had similar chances of being classified as having poor intakes.  In contrast 
sero-positive anaemics were significantly less likely to fall in that category especially 
when alcohol was excluded from the estimation. 
 
In sum, HIV sero-positives have marginally higher energy intakes compared with their 
sero-negative peers.  Sero-positive anaemics are less likely whilst their sero-negative 
peers are more likely to be classified as having poor energy intakes compared to non-
anaemics.  More than 50% of the study population may be categorised as having poor 
energy intake.  
 
5.4.2 MICRONUTRIENT STATUS 
Micronutrients (i.e. vitamins and minerals) of major significance, especially to RBC 
synthesis, were compared between the groups (Tab. 5.8).  It is evident from table 5.8 
below that differences in micronutrient intakes between the sero-status groups were 
marginal and there were no significant effects of HIV infection.  Though sero-positives 
tended to have intakes that were only slightly higher for some micronutrients, intakes in 
both groups were closely similar even after adjusting for socio-demographic 
confounders.  Nevertheless, anaemics had intakes that were significantly higher for all 
except nicotinic acid, vitamin E, folate and copper.  However, the significant effect of 
anaemia on B6 and ascorbic acid were lost, whilst the effect on nicotinic acid and 
copper became significant after the adjustment.  The interactive effect of anaemia and 
HIV infection on thiamin, iron, copper and zinc before the adjustment were significant, 
and this significant effect was maintained together with vitamin B12 and nicotinic acid 
after the adjustment.  
 
Whether micronutrient intakes were adequate or not was considered to depend on 
individual requirements.  In view of this, mean levels of micronutrient intakes have been 
compared with Dietary reference intakes (DRI).  DRIs are estimates of nutrient intakes 
that are supposed to meet the requirements of a healthy population with varying 
lifestyles (Gibney et al., 2002). 
 
Tables 5.9a and 5.9b below compare micronutrient intakes with DRIs for sero-status 
groups and anaemic sub-groupings respectively.  From table 5.9a it is evident that 
mean intakes of Vitamins A for HIV sero-positive subjects were higher and highly 
significant (p<0.001) compared with DRIs, whilst intake of folate was higher but not 
significant.  On the other hand, intakes of vitamins B1, B3  and vitamin C, though 
marginally lower were not significantly different compared to the DRIs.   In a similar   133
trend, mean intakes for sero-negative subjects with respect to vitamins A, E, B2, and 
B12 were also significantly higher than DRIs.  However, unlike their sero-positive 
counterparts, intakes for folate, vitamins B1, B3 and vitamin C fell significantly below the 
DRIs.  For the mineral micronutrients, which had different DRIs for males and females, 
mean intakes for iron were marginally but significantly higher for males irrespective of 
sero-status, whilst their female counterparts had average intakes that were significantly 
lower than the DRI.  Females in either group, on the other hand, had intakes of copper 
and zinc higher than their DRIs, which like that for iron were lower compared to DRIs 
for males.  However, HIV sero-positive females had intakes that could be considered to 
be slightly high than those of their sero-negative counterparts (Table 5.9a).     134 
Table 5.8:  Intake of selected micronutrients compared between the two groups in the study population. Data values are means (95% 
confidence interval – CI). 
HIV- HIV+  ANOVA (p-value) 









Anaemic (104)  Crude *Adjusted Crude *Adjusted Crude *Adjusted 
































0.965 0.327  0.030 0.003 0.289  0.065 





















0.316 0.443  0.007 0.088 0.061  0.503 










0.977 0.355  0.008 0.022 0.477  0.012 










0.906 0.275  0.025 0.373 0.275  0.393 




















































0.062 0.408  0.084 0.052 0.042  0.011 
*ANOVA statistics adjusted for gender, age grouping, settlement type, smoking and alcohol consumption status.  Statistical significance is denoted by p<0.05.   
Data values are means (95% confidence interval – CI) 
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Table  5.9a:  Intakes of micronutrients for sero-status groups compared with 
dietary reference intakes (DRIs) 
Micronutrient 
HIV 
status  n 
Mean  
intake  DRI 
 
Mean – DRI 
 
 95% CI 
 
p value 
HIV+    214  751.10  151.10  68.63 –  233.57  <0.001  Vitamin A  
(RE/day)  HIV-    1578  735.53 
600 
135.53  101.33 –  169.74  <0.001 
HIV+    214  11.41  1.41  0.33 – 2.50  <0.001  Vitamin E 
(αTE/day)  HIV-    1578  10.76 
10 
0.74  0.44 – 1.04  <0.001 
HIV+    214  4.94  2.54  1.90 – 3.18  <0.001  Vitamin B12  
(µg/day)  HIV-    1578  4.88 
2.4 
2.48  2.23 – 2.74  <0.001 
HIV+    214  1.15  -0.05  -0.12 – 0.03  0.212  Thiamin (B1)  
(mg/day)  HIV-    1578  1.11 
1.2 
-0.09  -0.11 – -0.06  <0.001 
HIV+    214  1.41  0.41  0.30 – 0.51  <0.001  Riboflavin (B2) 
(mg/day)  HIV-    1578  1.40 
1.0 
0.40  0.36 –  0.43  <0.001 
HIV+    214  14.27  -0.73  -1.89 – 0.44  0.220  Nicotinic acid 
(B3) (mg/day)  HIV-    1578  13.48 
15.0 
-1.55  -1.89 – -1.20  <0.001 
HIV+    214  1.09  -0.41  -0.49 – -0.32  <0.001  Vitamin B6  
(mg/day)  HIV-    1578  1.09 
1.5 
-0.45  -0.48 – -0.42  <0.001 
HIV+    214  37.25  -2.85  -8.39 – 2.69  0.312  Ascorbic acid 
(C) (mg/day)  HIV-    1578  37.15 
40 
-2.86  -4.82 – -0.89  0.004 
HIV+    214  214.49  4.49  -10.37 – 19.35  0.552  Folate  
(µg/day)  HIV-    1578  204.52 
210 
-5.78  -10. 30 – -1.26  0.012 
HIV+  ♂  95  9.16  8  1.16  0.22 – 2.06  0.016 
HIV+  ♀  119  8.51  18  -9.49  -9.90 – -8.33  <0.001 
HIV-  ♂  669  9.14  8  1.14  0.83 – 1.50  <0.001 
Iron 
(mg/day) 
HIV-  ♀  889  8.89  18  -9.11  -9.76 – -9.22  <0.001 
HIV+  ♂  95  1.22  1.5  -0.21  -0.34 – -0.08  0.002 
HIV+  ♀  119  1.10  1.2  0.03  -0.12 – 0.07  0.562 
HIV-  ♂  669  1.29  1.5  -0.28  -0.32 – -0.23  <0.001 
Copper  
(mg/day) 
HIV-  ♀  889  1.17  1.2  -0.10  -0.13 – -0.07  0.102 
HIV+  ♂  95  8.86  11  -1.94  -2.83 – -1.06  <0.001 
HIV+  ♀  119  7.98  8  -0.03  -0.46 – 0.78  0.832 
HIV-  ♂  669  9.06  11  -2.14  -2.43 – -1.84  <0.001 
Zinc  
(mg/day) 
HIV-  ♀  889  8.16  8  0.16  -0.25 – 0.20  0.611 
♂ - male, ♀ -females, DRI –Dietary reference intakes (source: Gibney et al., (Eds), 2002).  Statistical significance is 
denoted by p<0.05.   
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Table 5.9b:  Comparing average Intakes of micronutrients with dietary reference 











Mean – DRI (95% CI) 
 
p value 
N-anaemic  849  694.89  600  93.38 (50.87-135.89)  0.552 
HIV-   
Anaemic  715  788.48  600  187.40 (130.91-243.81)  <0.001 
N-anaemic  104  631.51  600  31.51 (-73.12-136.14)  <0.001 
Vitamin A  
(RE/day) 
HIV+   
Anaemic  110  866.27  600  266.27 (141.80-390.73)  <0.001 
N-anaemic  829  10.91  10  0.90 (0.49-1.30)  0.077 
HIV-   
Anaemic  705  10.63  10  0.61 (0.03-2.16)  0.044 
N-anaemic  104  11.74  10  1.74 (-0.19-3.68)  <0.001 
Vitamin E 
(αTE/day) 
HIV+   
Anaemic  110  11.10  10  1.10 (0.15-1.07)  0.010 
N-anaemic  843  4.58  2.4  2.17 (1.87-2.48)  <0.001 
HIV-   
Anaemic  705  5.30  2.4  2.90 (2.47-3.32)  <0.001 
N-anaemic  104  4.30  2.4  1.90 (1.07-2.73)  <0.001 
Vitamin B12  
(µg/day) 
HIV+   
Anaemic  110  5.55  2.4  3.15 (2.19-411)  <0.001 
N-anaemic  849  1.12  1.2  -0.08 (-0.11- -0.05)  <0.001 
HIV-   
Anaemic  715  1.11  1.2  -0.10 (0.15-1.07)  <0.001 
N-anaemic  104  1.07  1.2  -0.13 (-0.23- -0.04)  0.008 
Thiamin (B1)  
(mg/day) 
HIV+   
Anaemic  110  1.24  1.2  0.04 (0.02-2.16)  0.459 
N-anaemic  854  1.38  1.0  0.37 (0.33-0.42)  <0.001 
HIV-   
Anaemic  732  1.43  1.0  0.43 (0.38-0.49)  <0.001 
N-anaemic  104  1.32  1.0  0.32 (0.18-0.46)  <0.001 
Riboflavin (B2) 
(mg/day) 
HIV+   
Anaemic  110  1.49  1.0  0.49 (0.34-0.64)  <0.001 
N-anaemic  849  13.35  15.0  -1.67 (-2.17- -1.18)  <0.001 
HIV-   
Anaemic  715  13.67  15.0  -1.36 (-1.85- -0.87)  0.723 




HIV+   
Anaemic  110  14.76  15.0  -0.24 (-1.50-1.10)  0.211 
N-anaemic  849  1.04  1.5  -0.47 (-0.51- -0.43)  <0.001 
HIV-   
Anaemic  715  1.07  1.5  -0.44 (-0.47- -0.39)  <0.001 
N-anaemic  103  1.00  1.5  -0.50 (-0.62- -0.39)  <0.001 
Vitamin B6  
(mg/day) 
HIV+   
Anaemic  110  1.19  1.5  -0.31 (-0.43- -0.19)  <0.001 
N-anaemic  849  35.72  40  -4.28 (-6.63- -1.92)  <0.001 
HIV-   
Anaemic  715  39.11  40  -0.92 (-4.23-2.43)  0.677 




HIV+   
Anaemic  110  41.93  40  1.92 (-7.23-11.08)  0.591 
N-anaemic  843  206.51  210  -3.73 (-10.14-2.68)  0.253 
HIV-   
Anaemic  710  202.64  210  -7.72 (-14.26- -1.17)  0.308 
N-anaemic  101  210.53  210  0.53 (-25.03-26.09)  0.967 
Folate  
(µg/day) 
HIV+   
Anaemic  109  218.31  210  8.31 (-7.76-24.37)  0.021 
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Comparisons of micronutrient intakes with DRIs are also shown for the anaemia sub-
groupings in Table 5.9b above.  Generally, anaemics had significantly higher intakes of 
vitamins A, B2 and B12, but sero-positives had intakes that were slightly higher than for  
anaemics were much lower than that for anaemics, but were however significantly 
higher compared to DRIs 
 
For vitamin E, the difference between intakes and DRI was marginal higher in all 
groups, but more significant in sero-positives compared to sero-negatives.  Only sero-
positive anaemics had comparable intakes to DRI for B1 and ascorbic acid, all the other 
groups had intakes that were lower and in most instances significantly so.  Intakes of 
folate compared to DRI were only marginally higher in the sero-positives, but intakes in 
anaemics were comparably higher.  On the other hand both sero-negative anaemics 
and non-anaemics had intakes lower than DRI levels.  Generally, levels of intake for B3 
and B6 were all marginally lower than DRI for all groups, but whilst the differences were 
all significant for B6, only intakes in non-anaemics were so for B3 intakes.   
 
Even though sero-status and anaemia status groupings showed higher intakes of some 
micronutrients compared to DRIs, these could well be described as marginal.   
Furthermore, with some micronutrient intake levels falling below requirements, the 
likelihood that this could lead to deficiency states that could compromise RBC 
production is suggested.  
 
Since the Micronutrient status of the population is also dependent upon their metabolic 
state, a measure of micronutrient level in blood was also considered.  From the results 
shown in table 5.10 below, it is evident that serum vitamin A and iron levels were 
marginally lower whilst vitamin E levels were similar in the sero-positives compared to 
the sero-negatives.  The differences in serum micronutrient levels between the two 
sero-status groups were not significant, and HIV infection did not have any significant 
effect on serum vitamins A and E as well as iron.  However, vitamins A and E and also 
serum iron levels were lower in anaemics compared to non-anaemics and the effect of 
anaemia on the levels of these micronutrients were very significant, especially after 
confounding socio-demographic variables were adjusted for.  In contrast, the 
interaction between HIV and anaemia did not yield any significant effect on these 
serum vitamins and mineral even after the adjustment.  This may imply that HIV 
infection does not have a significant influence on the levels of these micronutrients in 
persons who are anaemic.  
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Table 5.10:  Comparing serum micronutrient levels in the study population.  Data values are means (95% confidence interval – CI). 
HIV- HIV+  ANOVA  (p-value) 









(102)  Crude Adjusted Crude Adjusted  Crude Adjusted
Serum Vitamin A 









0.138 0.081  0.018 0.022 0.757  0.998 
Serum Vitamin E 









0.971 0.970  0.066 0.003 0.270  0.146 








0.911 0.392  <0.001  <0.001 0.984 0.718 
*ANOVA statistics adjusted for gender, age grouping, settlement type, smoking and alcohol consumption status.  Statistical significance is denoted by p<0.05.  Data values are means (95% confidence 
interval – CI) 
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The marginally lower levels of serum vitamins A and iron, in particular, observed in 
sero-positives and anaemics when compared to a tendency for higher intakes, 
especially in sero-positive anaemics (Tab. 5.9b), may suggest the influence of a 
metabolic or inflammatory presence that could lead to a deficiency state. 
 
Summary of section 5.4 
In this section the results have shown that: 
1. HIV sero-positives in general as well as sero-positive anaemics have energy 
intakes that may be considered as marginally higher than that of their sero-negative 
peers.  In addition, sero-positive anaemics are less likely to be categorised as 
having poor energy intakes, though over half of the study population were in this 
category. 
 
2.  Intakes of a number of micronutrients including vitamins, E, B2 and B12 were 
marginally higher in HIV sero-positives compared with their sero-negative peers.  
However, HIV did not have any significant effect on these intakes. When intakes 
were compared to DRIs, they were found to be marginal, with some being higher 
and others lower.  But generally sero-positive anaemics tended to have higher 
intakes compare to the other groups. HIV sero-positives also had marginally lower 
serum vitamin A and serum iron, as well as vitamin E levels that were similar to that 
of their uninfected counterparts. However, there were no significant effects of HIV 
infection on serum micronutrients.  Anaemics also had lower serum iron, vitamins A 
and E levels compared to non-anaemics, and there was a significant effect of 
anaemia both before and after adjusting for confounders. The relative higher levels 
of vitamin A and iron intakes for sero-positive anaemics, when compared with their 
comparatively lower serum levels may suggest a deficiency trait most probably 
brought about by metabolic and/or inflammatory causes.  
 
In conclusion, it is not possible to show any significant interactions between HIV and 
anaemia on energy and micronutrient status in the study population.  However, effects 
of anaemia in serum lowering vitamin A and iron levels, especially in sero-positives, 
may suggest a subtle influence of metabolic or inflammatory processes, especially 
when dietary intakes may be considered as adequate or marginal.  This lowering effect 
on the two micronutrients may have implications for anaemia in the study population.  
 
5.5  INFLAMMATION AS A POSSIBLE EXPLANATION FOR THE ANAEMIA IN 
THE STUDY POPULATION 
HIV/AIDS may not only be a chronic inflammatory disease but may also permit other   140
inflammatory influences on infected persons.  Inflammation and/or infection leads to the 
release of pro-inflammatory cytokines and a concomitant high protein turnover.   
Inflammation may also alter nutrient availability which may lead to reduced cellular 
synthesis. 
 
Cytokines tend to mark more precisely the inflammatory process.  However, in the 
absence of cytokine measurements, this study has relied on measurements of acute 
phase proteins (APP) that often parallel or relate to the release of cytokines, as well as 
measures that may be considered to indicate liver inflammation or insidious damage 
(liver enzymes and a by-product).   
 
In table 5.11 below, mean serum levels of APPs, liver enzymes as well as a specific 
by-product are compared between sero-status and anaemia groups.  With regards to 
the APPs, sero-positives were likely to have lower ferritin levels, whilst plasma 
fibrinogen levels were likely to be similar to that of sero-negatives.  However there were 
no significant effects of HIV infection on these biomarkers.  On the other hand, the 
effects of HIV infection on serum total proteins, albumin and ‘globulins’ were highly 
significant both before and after adjusting for socio-demographic confounders.  Whilst 
serum total proteins and ‘globulins’ were likely to be higher serum albumin was likely to 
be lower in the sero-positives as compared with sero-negatives.   
 
Between anaemics and non-anaemics, ferritin, plasma fibrinogen, total proteins and 
albumin were likely to be lower, whilst ‘globulins’ were likely to be higher in the 
anaemics.  However, there were no significant effects of anaemia on ferritin and 
‘globulins’.  With plasma fibrinogen a significant effect emerged after adjusting for 
socio-demographic confounders. Effects of anaemia on total proteins and albumin 
were, however very significant both before and after the adjustment.  In terms of 
interaction between HIV infection and anaemia, this effect was only significant on 
plasma fibrinogen levels after the adjustment. 
 
With regards to the liver enzymes and by-product, HIV sero-positives had lower total 
bilirubin, higher direct bilirubin and higher serum levels of ALP, GGT, ALT and AST as 
compared to sero-negatives.  However, whilst there were no significant effects of HIV 
infection on bilirubin, ALP and GGT, effects on ALT and AST were very significant both 
before and after adjusting for the confounding socio-demographic variables.  Anaemics 
were also likely to have lower bilirubin (Total and Direct) and some liver enzymes (ALP, 
ALT and AST) compared to their non-anaemic peers.  GGT was however, higher in 
sero-negative anaemics and lower in sero-positive anaemics compared with their non-  141
anaemic peers.  Except ALP and GGT levels, the effects of anaemia were very 
significant on Bilirubin, ALT and AST levels both before and after the adjustment.   
Interactive effects of HIV infection and anaemia were highly significant only on ALT and 
AST levels both before and after adjusting for the confounding socio-demographic 
factors. 
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Table 5.11:  Serum markers of inflammatory response in the study population. Data values are means (95% confidence interval – CI).  
HIV- HIV+  ANOVA  (p-value) 











(102)  Crude *Adjusted Crude *Adjusted  Crude *Adjusted 
Serum Ferritin 




















0.421 0.326  0.319 0.054 0.063  0.040 
































<0.001 <0.001  0.177 0.469  0.335  0.341 







5.75 (5.43-6.06)  6.07 (4.97-7.16)  5.38 (4.67-6.09) 











0.501 0.813  <0.001  <0.001 0.733 0.696 








0.214 0.214  0.130 0.260 0.224  0.227 








0.737 0.811  0.528 0.717 0.184  0.267 








<0.001 <0.001  0.005 0.013  0.042  0.056 








<0.001 <0.001  0.005 0.014  0.005  0.008 
*ANOVA statistics adjusted for gender, age grouping, settlement type, smoking and alcohol consumption status.  Statistical significance is denoted by p<0.05.   
Data values are means (95% confidence interval – CI) 
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In the next section the risk levels for associating high inflammatory biomarker levels 
with HIV infection in the study population would be explored using a binary logistic 
regression analysis. 
 
Summary of section 5.5 
The results in this section could be summed up as follows: 
1.  HIV sero-positive persons in the study population are significantly more likely to be 
associated with higher serum levels of total proteins and ‘globulins’ as well as lower 
levels of serum albumin than sero-negative persons.  Sero-positive persons are 
also more likely but less significantly to have lower levels of serum ferritin, plasma 
fibrinogen and total bilirubin than their sero-negative counterparts.  Additionally, 
they were more inclined to having higher levels, especially, for direct bilirubin, ALT 
and AST, as compared to their sero-negative counterparts.  There was a significant 
effect of HIV infection on serum ALT and AST. 
 
2.  Anaemics, irrespective of sero-status, were also significantly more likely to have 
lower total proteins and albumin as well as lower bilirubin (Total and Direct) and 
liver enzymes (serum ALP, GGT, ALT and AST).  However, whilst sero-positive 
anaemics had lower plasma fibrinogen, the sero-negative counterparts had higher 
plasma levels of the APP.   Anaemics also had lower liver enzymes compared to 
non-anaemics.  However, apart from GGT which was lower in the sero-positive 
anaemics, all the other liver enzymes were higher compare to that of their sero-
negative peers.  Effects of anaemia on bilirubin (Total and Direct) as well as ALT 
and AST levels were highly significant. 
 
3.  In terms of interaction, HIV sero-positive anaemics had marginal but not significant 
differences between them and their sero-negative counterparts for all but plasma 
fibrinogen serum ALT and AST, which were highly significant. 
 
The higher tendency for an increased level of total proteins and a decreased level of 
albumin, as demonstrated for sero-positives in this study population may indicate the 
influence of inflammatory stress.  Higher and significant tendencies for increased 
serum ALT and AST in both sero-positives and sero-positive anaemics may also signify 
inflammatory stress on the liver or insidious liver cell damage in a population that can 
conveniently be described as asymptomatic.  Whilst this may be as a result of the 
infection or inflammation its association with anaemia as well as its interaction with HIV 
may have implications for anaemia in the study population.  On the other hand, the 
relatively high ferritin levels in both sero-negatives and sero-positives also suggest 
inflammatory tendencies in both groups.   144
5.6  KEY FINDINGS - CHAPTER FIVE 
The following are the overall summaries for the results obtained in this chapter: 
•  HIV sero-positives had lower [Hb] and Hct levels compared to their sero-negative 
peers. However only the differences in Hct was significant.  The effects of both HIV 
infection and anaemia on Hct were also very significant, although the interactive 
effect was not. DR showed Hct was not be related to 3 times Hb.   
•  Prevalence of anaemia was generally high and most of it could be categorised as 
mild, but sero-positive prevalences were higher than those of sero-negatives.   
Differences in prevalence were only highly significant when anaemia was defined 
by Hct.  HIV sero-positive urban settlers, non-smokers as well as non-consumers of 
alcohol were more likely to be anaemic.  HIV sero-positives were more likely to be 
mildly and moderately anaemic and significantly more likely to be severely anaemic 
compared to their sero-negative peers. 
•  With iron status markers, HIV sero-positive persons were more likely but not 
significantly so to be hypoferaemic (i.e. with low serum Fe) or relatively 
hypoferritinaemic (i.e. with low serum ferritin levels) compared to their sero-
negative peers.  Sero-positives were also more likely to be classified with IDA and 
ACI, but generally ACI was more likely to be common than IDA in the study 
population. 
•  HIV infection, just like anaemia, may be associated with changes in body fat 
measures in mid body parts. HIV infection and anaemia had a significant interactive 
effect on abdominal skin fold fat. 
•  Energy intakes were marginally higher in sero-positives, and anaemic sero-
positives also had higher intakes than their sero-negative peers. They were also 
less likely to be categorised as having poor energy intakes, albeit over 50% of the 
study population could be classified as such. 
•  Micronutrient intakes were also marginally higher in sero-positives and anaemic 
sero-positives compared to their sero-negative peers.  Intakes were also marginal 
compared to DRI for a large number of micronutrients especially in sero-positives 
Regarding serum micronutrients, HIV sero-positives and anaemics were more likely 
to have lower serum levels of iron and vitamin A, whilst vitamin E levels were only 
lower in anaemics.  
•  HIV sero-positives were significantly more likely to be associated with higher serum 
levels of total proteins and ‘globulins’ as well as a lower serum levels of albumin. 
They were also likely to have levels of ferritin, plasma fibrinogen and total bilirubin 
that were lower but not significantly different from that of their sero-negative 
counterparts.  Levels of Direct bilirubin, ALT and ST levels were higher in sero-
positives, but the effects of HIV infection was significant on ALT and AST levels.   145
•  Anaemics, irrespective of sero-status, were also significantly more likely to have 
lower total proteins and albumin as well as lower bilirubin (Total and Direct) and 
liver enzymes (serum ALP, GGT, ALT and AST).  However, effects of anaemia only 
on bilirubin (Total and Direct) as well as ALT and AST levels were highly significant. 
 
The effects of anaemia and HIV infection on various parameters as explored in this 
chapter reveals the complex interactions that may exist between HIV and anaemia in 
this study population.  Thus far, subtle changes in body composition, poor energy and 
marginal micronutrient intakes, apparent serum micronutrient deficiencies coupled with 
altered APP metabolism and increasing levels of liver enzymes that may suggest 
ominous liver damage or stress, may constitute the minimum array of factors to explain 
anaemia in the study population.  However, the higher prevalence of anaemia and the 
tendency for it to be severer in sero-positives, may suggest that the effects of HIV, 
whether directly or indirectly, could have an interactive influence on the development of 
anaemia in this population.  
 
5.7  DISCUSSION OF KEY CHAPTER FIVE FINDINGS 
The hypothesis in this study presupposes that HIV infection may, directly or indirectly, 
potentiate or multiply the factors that predispose many victims to anaemia.  The aim of 
this chapter has been to resolve this postulation using various factors within the limits 
of the data available as possible explanatory factors.  The framework for the study, 
nevertheless recognises many other added factors that may be prevalent in the 
population but may not be accounted for in explaining the presence of anaemia.    
 
That HIV may directly induce anaemia has been suggested by a number of in vitro 
studies (Levine, 1999; Redd et al, 2007).  However, evidence for this direct induction of 
anaemia by the virus in individuals and populations are difficult to come by or rather 
non-existent.  Anaemia in HIV infection has also been associated with many patho-
physiologic and metabolic effects of the virus (Moyle, 2002) and other co-infections 
(Volberding et al., 2004).  In asymptomatic HIV infection, it is likely that such indirect 
anaemia inducing effects are subtle and less severe, and could account for only a 
small part of anaemia.  This may probably leave the direct effect of the virus as a major 
factor in explaining much of the anaemia.  It is, perhaps, this direct effect of HIV that 
makes its impact on anaemia great (Northrop-Clewes, 2008).   
 
Thus, the mere presence of HIV in a victim could be a major triggering factor for 
anaemia, and could make the difference between anaemia in sero-positives and sero-
negatives.  Notwithstanding, the effects of HIV in inducing anaemia can also be viewed   146
as a cascade since the many indirect and direct effects may interplay in a way that may 
enhance the development of anaemia in this population. 
 
So far findings in this chapter may suggest a role for HIV infection and its effects in the 
magnitude of anaemia in the study population.  Apart from the lower levels of [Hb] and 
Hct, which indicate a higher tendency for anaemia in HIV sero-positives, prevalence of 
anaemia, as defined by both indicators were also higher than those of their sero-
negative peers.  In addition, grades of anaemia were shown to be marginally higher in 
sero-positives coupled with a significant association of HIV infection with severe 
anaemia despite the low comparative numbers.  For a sero-positive population, which 
is essentially asymptomatic, this may strongly suggest an influence of the virus either 
directly or interacting with other factors.   
 
Anaemia induced by the HIV especially in asymptomatic persons could be mostly mild 
and subtle.  The subtlety of the anaemia induced by HIV infection in this study may be 
inferred from the marginal differences in prevalence levels between infected and 
uninfected persons, which were not significant, especially when [Hb] definitions were 
used.  This may imply that the contributions of HIV to the anaemia in the sero-positive 
group are minimal and perhaps other HIV-unrelated factors may be at play to account 
for the large part of the anaemia.  The similarly high anaemia prevalences in both sero-
status groups coupled with the lack of any significant differences may support this 
observation.   
 
Representing the control group in this study, the high anaemia prevalence recorded for 
sero-negatives could only be due to factors other than HIV infection.  This clearly 
shows that apart from HIV infection there may be other factors that are perhaps 
generally predisposing to anaemia in both sero-status populations.  Conditions such as 
malaria, helminthiasis and other infectious diseases, often associated with anaemia, 
are known to be rife in the study region (Carneiro et al., 2007) and may add to the 
burden of anaemia in the population. 
 
Another pointer in this study is the possible exacerbating effect of HIV infection, as 
shown by its significant association with severe anaemia.  This particular effect of HIV 
may be ascribed to its ability to potentiate other anaemia inducing effects; which could 
also be described as interactive.  For instance the chronic  but rather mild inflammatory 
effects of HIV infection (Jahoor et al., 1999), could potentiate the general sub-clinical 
inflammatory effects from other stressors prevalent in the population, to induce 
anaemia.  This may well explain why anaemia could be an early sign of HIV infection   147
(Fleming, 1989; Street and Milliken, 1993) or why anaemia prevalences in HIV infection 
tends to increase with disease progression (Sullivan et al., 1998; Belperio and Rhew, 
2004).  
 
Many studies have shown that anaemia prevalences are often higher in infected than 
uninfected persons irrespective of the stage of infection or whether it is assessed by 
[Hb] or Hct (Bain, 1999; Volberding, 2004; Thurnham and Northrop-Clewes, 2007; 
Nneli and Egene, 2007; Jemikalajah and Okogun 2009).  However, prevalences that 
rely on Hct definitions are often lower than those that are defined by [Hb].  This is in 
spite of the assumed linear relationship between [Hb] and Hct, which is supposed to be 
a ratio of 3:1 (Bain and Bates, 2001).  This ratio is accepted in normal clinical practice 
and is also a basis for the WHO definitions of anaemia (WHO/CDC, 2004).   
 
In this study, the significant differences obtained for anaemia prevalence between sero-
positives and sero-negatives with regards to Hct definitions, may suggest that the linear 
relationship between [Hb] and Hct deviates from the assumed one.  This finding is 
consistent with studies by Quinto et al. (2006) and Carneiro et al. (2007), who 
separately showed that the relationship did not hold for children in malarious regions.  
The use of DR fits, in this study, to derive or predict better Hct cut-offs tended to 
buttress this apparent deviation of the linear relationship between [Hb] and Hct from 
what has been assumed.  The implication is that HIV infection may have a significant 
effect on Hct which could perhaps be explained by the tendency for HIV to cause a 
decrease in RBC numbers over and above its normal production.   
 
In HIV infection absolute iron deficiency due to dietary lack or blockage and relative 
deficiency due to inflammatory effects has been observed to cause erythropoietic 
failure and eventually microcytic anaemia.  Indeed, erythropoietic failure has been 
considered as a major mechanism in the development of anaemia in HIV/AIDS 
(Volberding et al., 2004).  The HIV may not only invade and destroy erythrocyte 
progenitor cells (Levine, 1999), but its presence in the body may alter the internal 
nutrient environment and enhance the demise or destruction of RBC (Jackson, 2007; 
Thurnham and Northrop-Clewes, 2007).  In the early stages of HIV infection these 
effects may lead to a reduction in RBC numbers even as RBC production is not very 
much affected.   
 
Perhaps, another important reason for a significantly lower Hct in sero-positives may 
be because of a higher tendency for HIV infected persons to develop ACI.  Although no 
significant tendency for ACI is observed in HIV sero-positives in this study, ACI is   148
associated with an impaired utilisation of iron and often in its early course the anaemia 
is mild and normo-chromic resulting from the impaired iron cycling (Butensky, 2004).  
Generally, most anaemia in the study population has been mild but that in sero-
positives have been marginally higher, much like ACI.  Nevertheless, the lack of 
significant differences between the sero-status groups means that these may not 
explain the lower Hct in the sero-positives.  This perhaps leaves the direct effects of 
HIV on erythrocytes or erythrocyte progenitor cells as the most plausible explanation 
for the lowered Hct. 
 
With regards to prevalence of anaemia in asymptomatic HIV infection, a number of 
studies corroborate the increasing trend with advancing disease, being lower in 
asymptomatic infection and higher in AIDS (Spivak et al., 1989; Abrams et al., 2000; 
Sullivan et al., 1998).  However, most of the studies undertaken outside sub-Saharan 
Africa show comparatively lower prevalences in the asymptomatic population, whilst 
studies undertaken in sub-Saharan African populations show higher prevalences 
(Belperio and Rhew, 2004).  A considerably high anaemia prevalence as observed in 
this study, which is essentially  asymptomatic  and African, corroborates the 
observation in the study by Belperio and Rhew (2004).   
 
Although reference to the infected population in this study as asymptomatic may be 
based primarily on the design and criteria for selecting the subjects, there is reason to 
suggest that, HIV infection is at an early stage in this population.  The effects of early 
HIV infection may be contributing partly to this high level of anaemia, but other 
population factors perhaps unrelated to HIV infection may also be adding to the 
anaemia.  This may be inferred from the fact that prevalence of anaemia was equally 
high in the sero-negative population.  Indeed, the prevalence of anaemia in the study 
population as well as in each separate sero-status group suggests that anaemia in the 
study population is at a level that, by any standard, constitutes a serious public health 
problem (UNICEF/UNU/WHO, 2001).   
 
Whether HIV infection is what drives anaemia in this study population to attain public 
health relevance (McLean et al., 2007) may however be contended as the sero-
negative group also have similarly high levels of anaemia (over 40%) despite the 
absence of the infection.  Nevertheless, in a population where the prevalence of HIV 
infection has the tendency to escalate, and where the infection is likely to be 
synergised by other potential anaemia inducing factors, this minimal contribution to 
anaemia may add to the increasing magnitude of anaemia in the population.  
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Other than the direct effects of the HIV, the evidence that other factors, such as 
concurrent infections and population characteristics, may be contributing greatly to the 
high prevalence of anaemia in the sero-positive population are depicted by a number of 
epidemiological studies, which have shown significant associations between various 
factors and anaemia in the HIV/AIDS population (Sullivan et al., 1998; Volberding et al., 
2004).  From this study, an equally high anaemia prevalence in the sero-negative 
group can only suggest the importance of factors, apart from HIV infection, to the 
development of anaemia in the study population.   
 
In as much as a large number of factors have been suggested in the framework for 
addressing the hypothesis, data constraints pertaining to its secondary source, restricts 
the elucidation of certain factors as part of the causal web between HIV infection and 
anaemia as they have not been gathered.  However, in order to understand the 
reasons behind the high prevalence of anaemia in the sero-positive population and to 
place the role of HIV in perspective, the involvement of some factors, considered 
important, have been elucidated whilst others may only be conjectured based on their 
inter-relationships.  
 
The differences between the levels and characteristics of anaemia in sero-positives 
and sero-negatives in this study may not entirely be due to chance as certain respects 
have been very significant.  In trying to explain the possible reasons for the observed 
differences, the phenomenon of reductive adaptation has been invoked together with 
other plausible factors.  Reductive adaptation, which may result in significant changes 
in body composition, is most likely to occur in the latter stages of HIV infection or AIDS.  
It may manifest as weight loss, a reduction in lean body mass or changes in the 
internal milieu that could affect other bodily functions.  The effects of such changes can 
drastically reduce red cell mass as RBC production is depressed and destruction is 
enhanced (Jackson, 2007).  So far, this phenomenon may not be an obvious 
explanatory factor for anaemia in the study population since there were no significant 
differences between the sero-positives and sero-negatives with regards to a large 
number of the parameters that may depict these changes.   However, a significant 
effect of anaemia and HIV infection on fat deposition in parts of the body may suggest 
some effect of body compositional changes on anaemia even at an early stage of HIV 
infection.  
 
The effects of HIV infection could also result in food or energy and nutrient imbalances.  
Infections and inflammation can cause inadequate energy and nutrient intakes through 
anorexia and other gastrointestinal disturbances (Thurnham and Northrop-Clewes,   150
2007).  However, these often manifest at the latter stages of the infection or when 
inflammation has been persistent or chronic.  There is no doubt that energy imbalances 
and nutrient deficiencies can predispose to malnutrition (Jackson, 2007), which may 
lead to anaemia. However, considering the asymptomatic stage of sero-positives and 
the apparently healthy state of their sero-negative peers, these nutritional 
considerations could not bb taken as significant explanatory factors for anaemia in the 
study population.  In fact, sero-positive individuals as well as anaemics showed 
tendencies for being adequately nourished.  Nevertheless, lack of significant 
differences between the sero-status and anaemia groups for mean energy and 
micronutrients intakes were probably indicative of the fact that these intakes were not 
very far from normal.  
 
Though average energy and micronutrient intakes seemed close to normal 
requirements, individual intakes for a large number of persons in the study were rather 
marginal or even lower.  For sero-positives, such marginal intakes may rather express 
an inadequate intake since infection has a tendency to increase requirements (WHO, 
2003).  However, because of the widespread nature of the marginal or inadequate 
intake tendencies in the study population, other factors related to the socio-
demography and nutritional or dietary practices within the population, rather than the 
effects of HIV infection or inflammation may be plausible explanations for the poor 
intakes.   
 
The effects of poor socio-demographic characteristics on energy and nutrient intakes 
has been demonstrated in a study by Peña and Bacallao (2002), who showed a 
significant inter-relationship between poor socio-demographic factors and nutrition. It 
has also been recognised that poor socio-economic characteristics generally relate to 
food and nutrition insecurity (Gillespie and Kadiyala, 2005).  In this study, a poor socio-
demography may be inferred from levels of earnings and educational attainments in 
this study in a large section of the study population, that can only be described as poor.  
Even though these have not been related to the nutrition of the study population, it is 
quite possible that such poor socio-economic tendencies could have a strong influence 
on food intake and other dietary practices (Peña and Bacallao, 2002).  As earlier 
intimated in the previous chapter, the existence of such socio-demographic tendencies 
could be the trigger that would heighten the vulnerability of persons to nutritional 
problems and to infections such as HIV/AIDS.   
 
In this study population, poor socio-demographic conditions may have their origin in the 
wave of rapid urbanisation blowing across the region (Vorster et al., 2005).  The effects   151
of a rapid urbanisation is often accompanied by transitional changes in nutritional and 
socio-demographic structures inimical to the health of the population (Vorster et al., 
2000).  During this process, smoking, consumption of alcohol, commercial sex and 
violence are some of the increasing tendencies that heighten the vulnerability of 
individuals to nutritional problems and infectious diseases. 
  
In spite of marginal energy and nutrient intake tendencies in the study population, the 
fact that these tendencies were slightly higher in HIV sero-positives generally and sero-
positive anaemics in particular raised some important questions.  However, because 
the differences were not significant they were probably not real or due to chance. 
Nevertheless, a marginally higher dietary energy and micronutrient intake in sero-
positives could be due in part to the consumption of a significantly higher proportion of 
carbohydrate rich food sources or, perhaps, to a greater tendency for consuming 
alcohol, of which intake in moderation has been shown to boost food intake (Yeomans, 
2004).  But in the case of sero-positive anaemics, alcohol intakes may not explain the 
marginal tendencies for higher intakes over their non-anaemic peers as they were less 
likely to consume it.   
 
Apart from the above explanations, the phenomenon of hyperphagia, which may be 
common in asymptomatic HIV infection (Crenn et al., 2004), but may also occur at all 
stages of HIV infection, especially, in those with an elevated BMR (Melchoir et al., 
1993, Grunfieild et al., 1996), could be invoked as part of the explanation for higher 
intake tendencies in the sero-positive population in particular.  What makes 
hyperphagia a plausible explanation the higher BMR tendencies in sero-positives and 
seropositive anaemics compared to their peers.  This finding is buttressed by another 
study that  suggested the occurrence of hyperphagia in an HIV infected cohort whose 
BMR were marginally elevated (Macallan, 1998).  The basis for a marginally elevated 
BMR in asymptomatic HIV infection has been partly ascribed to an increased protein 
turnover (Crenn et. al., 2004) which may be linked to the release of pro-inflammatory 
cytokines such as TNF-α and IL-1 (Roubenoff et al., 2002).  In effect, inflammation 
rather than causing anorexia, could be at the core of an increased food intake, 
especially at an early stage of the infection, and sero-positive anaemics could be more 
predisposed.   
 
On the other hand, a critical examination of the differences in intakes between the 
sero-status groups, and the fact that they were marginal and not significant, may 
suggest a chance occurrence.  In view of the problematic methodology surrounding the 
assessment of diets (Margetts and Nelson, 2008), the differences in intakes between   152
the two groups could therefore be ascribed to methodological limitations.  Firstly there 
is the issue of measuring or estimating energy and nutrients from a largely variable 
intake of foods that may not be constituted entirely of a single form of energy or 
nutrient.  Secondly, intakes of foods, and especially alcohol can be highly variable, and 
especially when estimated would be an obvious source of bias (Margetts and Nelson, 
2008).  It is also possible that bias was introduced during the reporting of dietary intake, 
which is very common in vulnerable groups.  When the individuals know their status, 
which could be HIV or other, they could be prompted to over-report or under-report 
their food intakes.  Various other physical and psycho-social issues, such as being 
overweight, tend to affect the reporting of food intake.  In the case of subjects in this 
particular study they did not know their HIV status at the time of the study, but it is 
possible that these other issues could affect their reporting.  
 
For persons infected with HIV the need to maintain energy and nutrient intakes above 
what is normally required must be intended and pursued, especially, as alterations in 
metabolic and inflammatory processes brought about by the infection, create an 
increased nutritional demand.  An increase in energy and nutrient requirements may 
become even more imperative should anaemia set in.  It would therefore be expected 
that asymptomatic HIV infected persons, especially anaemics, would strive or be 
encouraged to maintain intake levels that are not less than 10% above the normal 
requirements of a healthy population, in accordance with WHO recommendations 
(WHO, 2003).  Despite the comparatively higher intakes of energy and nutrients 
observed in the sero-positive population thus does not seem to even satisfy the normal 
requirements let alone meet recommended requirements.  This poor state of energy 
and nutrient intake may therefore partly  account for the anaemia in the sero-positive 
population.  
 
Reasons for a higher prevalence and severity of anaemia in sub-Saharan African 
populations have been placed on the presence of specific population characteristics 
(Ssali et al., 2006).  Some epidemiological evidence points to the racial characteristic of 
black or African descent as a significant associate with anaemia in HIV/AIDS (Sullivan 
et al., 1998, Volberding et al., 2004).  This racial characteristic may probably explain 
the high prevalence of anaemia in the study population.  However, it is very likely that 
this racial predisposition to anaemia is based on other factors that have been 
suggested as responsible for the increased susceptibility of this group to anaemia, and 
some of which could be at play within the study population.  In the black African race 
there are certain genetic population characteristics often associated with prevalent or 
endemic environmental conditions that may confer a higher survival of the race.  For   153
instance, hereditary traits, such as G-6-PD (Calis et al., 2008) and sickle cell disease 
(Tolentino and Friedman, 2007), as well as other rare haemoglobinopathies, may have 
protective value.  Sickle cell trait, in particular, protects against specific malaria 
parasites and therefore serves as a survival strategy for most of the black race who 
reside in malaria holoendemic regions.  All these genetic traits have been associated 
with anaemia in HIV infected black persons (Volberding et al., 2004).  Additionally, 
there are aspects of nutritional and socio-cultural practises in black people that often 
reflects in their dietary preferences and choices, which may present significant risks to 
anaemia (Antelman et al., 2000, Semba, 2003). 
 
Aside from these hereditary and dietary factors, there are also socio-demographic and 
geographical circumstances, common to black Africans in particular, which may 
significantly influence the health and development of the population.  While these 
factors may have a general effect on the entire population, their presence may create 
vulnerabilities in the population or may pose a treat to particular vulnerable groups. 
Some of these socio-demographic factors, which are manifest in this study population, 
could hamper good nutrition and health of the population and invariably contribute to 
the high levels of anaemia.   
 
Black people predominantly reside in sub-Saharan Africa where malaria and other 
common infectious diseases are highly prevalent.  Although the incidence of malaria in 
the study area is quite low, it is known that high levels of other infectious diseases 
affect the nutrition and health of the population (Vorster et al., 2005).  It is the presence 
of these conditions, which prevail in most developing countries, that enhances the risk 
to anaemia (Thurnham and Northrop-Clewes, 2007).  These conditions are worsened 
by the ominous presence of poverty (Brabin et al., 2004).  Whilst poverty together with 
inadequate health care and pervading unsanitary conditions, common in much of the 
developing world, encourage the spread of diseases and expose individuals to 
anaemia and other co-morbidities (Calder and Jackson, 2000; Thurnham and Northrop-
Clewes, 2007).  Thus, the prevalence of hereditary and environmental factors 
favourable to the cause of anaemia in the black population may be compounded by 
circumstances that allow anaemia to thrive.  The causes of anaemia in such 
populations may therefore be complex and intricately interwoven.  
 
Although the factors responsible for anaemia in the study population can be said to be 
expansive, HIV infection and its effects, either directly or indirectly, remain crucial in the 
causation of anaemia.  The impact of HIV and its associated effects on anaemia may 
stem from the fact that it does not only directly cause a reduction of RBC mass, but can   154
also, through its associated inflammatory effects cause disturbances in iron metabolism 
(Butensky et al., 2004), which could subsequently lead to erythropoietic failure.   
 
For quite some time now, the idea of HIV impacting on haemopoiesis and anaemia 
through this immunological effect on iron metabolism and not necessarily through a 
genuine iron deficiency has been a point of discussion (Kreuzer and Rockstroh, 1997; 
Bain, 1999). Both the virus and the characteristic inflammation associated with the 
infection have been implicated (Butensky et al., 2004).  The ensuing ACI, that favours 
iron accumulation, has gained recognition as a more frequent occurrence.   
Nevertheless, a genuine iron deficiency and iron accumulation form the basis of two 
main types of anaemia often associated with HIV (Eley et al., 2002; Butensky et al., 
2004).   
 
This study has revealed that, a tendency for hypoferaemia or low levels of serum iron, 
consistent with the hypoferaemia that tends to occur at the onset of inflammation, even 
when iron stores seem to be normal (Thurnham and Northrop-Clewes, 2007), may be 
present.  The higher likelihood for elevated serum ferritin levels in both sero-status 
groups, buttressed by the higher proportions with ACI over IDA further supports the 
likelihood of inflammatory influences and perhaps body iron redistribution tendencies 
(Butensky et al., 2004).  Indeed, elevation of ferritin have been strongly associated with 
immune activation (Sarcletti et al., 2003), with pro-inflammatory cytokines most likely to 
be the cause of this elevation.   
 
However, whether inflammatory effects on iron can contribute to anaemia in the study 
population may depend on the expression of metabolic iron deficiency and the ability of 
individuals to maintain iron stores, which are known to be critically determined by 
absorption, loss or dietary bio-availability of iron (Thurnham and Northrop-Clewes, 
2007).  
 
For those individuals with ferritin levels below 15 µg/dL, a metabolic iron deficiency is 
not far fetched.  However, for an apparently healthy or asymptomatic population whose 
intake of iron remains close to normal requirements, it is perhaps a high intake of 
dietary blockers or the effect of an inflammatory curtain that can explain such metabolic 
iron deficiency tendencies.   Nevertheless, the higher likelihood for elevated ferritin 
levels as well as alterations in APP that are reminiscent of the inflammatory process 
strongly suggest inflammation as a significant explanatory factor to the anaemia in the 
study population.  Furthermore, the predominant prevalence of mild anaemia and ACI 
all add to the suggestion that inflammation may contribute to the cause of anaemia in   155
the study population.  This is supported by evidence from other studies that suggests 
that hypoferaemia and hyperferritinaemia induced by inflammation may be associated 
with anaemia (Thurnham and Northrop-Clewes, 2007).   
 
Changes observed in the turnover of APP as well as shifts in nutrients that often 
accompany the inflammatory process may represent inflammatory influence in the 
study population.  With the onset of an infection, injury or stress, the body normally 
evokes a rapid immune response (Kushner, 1982; Calder and Jackson, 2000), which is 
generally associated with the release of pro-inflammatory cytokines, concomitant with 
increases in positive APPs such as CRP, globulins, ceruloplasmin, fibrinogen and 
ferritin and decreases in negative APPs such as albumin, transferrin, retinol binding 
protein, lipoproteins and pre-albumin (Kushner, 1982; Schreiber, 1988; Tomkins, 2003; 
Jackson, 2007.  In this study, the tendencies for increased serum total proteins and 
decreased serum albumin may be consistent with reports that have shown the 
occurrence of similar changes in protein turnover in humans with symptomless 
HIV/AIDS (Macallan et al., 1995; Selberg et al., 1995). 
 
Such alterations in protein metabolism are not restricted to HIV infected populations 
only, but even in the absence of HIV infection, these sub-clinical markers of 
inflammation can be observed in apparently healthy populations (Thurnham et al., 
2003).  The alterations in protein metabolism may also be associated with anaemia 
irrespective of whether infection with HIV is present or not as shown by the significant 
effect of anaemia on the APP.  However, the significantly lower levels of serum total 
proteins and albumin associated with anaemia irrespective of HIV status rather 
indicates the limits to which inflammation may be influenced by anaemia.   
 
The significantly higher total proteins may suggest an increased synthesis of positive 
APP in response to an ever present threat of the virus.  However, this phenomenon 
may be a common occurrence at the onset of most infections (Meenan et al., 1992).  A 
study by Jahoor and colleagues (Jahoor et al., 1999) suggest that symptomless HIV 
infected subjects compared to uninfected controls, are able to maintain higher plasma 
concentrations and rates of syntheses of most positive APPs without a corresponding 
decrease in plasma concentration of most negative APPs, which, according to the 
authors, may represent a beneficial adaptation by the individual subjected to infection 
by the virus.  The authors also contended, based on their evidence, that subclinical 
infections, including asymptomatic HIV infection, may not be capable of eliciting a full-
blown APR (Jahoor et al., 1999). This is notwithstanding the fact that hypo-
albuminaenia occurred in the symptomless HIV infected persons (Jahoor et al., 1999)   156
and also in children with other sub-clinical infections (Morlese et al., 1996) despite 
increased rates of synthesis.   
 
The significance of lower albumin levels observed in the HIV sero-positive group may 
be similar to the hypo-albuminaemia observed in the two studies by Jahoor et al. 
(1999).  Certainly with synthesis rates not lowered any decreases or drop in the levels 
of albumin and perhaps most other negative APPs may be ascribed to something more 
than protein turnover.  Although it is possible that positive APP may be produced at the 
expense of albumin (Jackson, 2007), it is more likely that an increased trans-capillary 
escape (Fleck et al., 1985; Tomkins, 2003) is responsible for the drop.  This may 
presuppose that the effect of the inflammatory process on albumin, even if mild, is 
exerted more at increasing trans-capillary membrane losses than at altering metabolic 
or synthesis rates.  In addition, such significant lowering of albumin levels during a mild 
APR might only occur when the APR is either persistent or chronic or perhaps when 
other inflammatory stressors add on synergistically.  
 
Ferritin serves as an indicator of iron stores and also as an acute phase protein.   
However, the elevated tendencies for serum ferritin levels as seen in the study 
population could be ascribed to increased rates of synthesis as pertains during an 
inflammatory response as the levels tended to be averagely higher than normal storage 
levels.   Nevertheless, the degree to which it rises in the blood can be limited by 
underlying iron status (Northrop-Clewes, 2008) as well as the presence of 
inflammation.  Thus, the higher likelihood for ferritin levels to increase, especially, in the 
sero-negative population only shows that although the population is apparently healthy, 
sub-clinical inflammatory influences may be present.   
 
The occurrence of inflammation in the study population, as suggested by the evidence 
of altered APP, may have deleterious effects on the synthesis of haem or RBC.  This is 
especially so, where nutrients useful for RBC or haem synthesis are restricted, used up 
or lost during the process and the alterations lead to the creation of an environment 
that enhances the destruction of RBC (Jackson, 2007).  Because levels of albumin and 
other transport protein carriers, which are mostly negative APPs, are depressed during 
inflammation the levels of micronutrients (especially those carried by the transport 
proteins) are also likely to fall.  Lower levels in serum vitamins A and E observed in this 
study may be depicting this inflammatory influence, which may seem to be greatly 
exerted in the HIV sero-positives as they have a higher tendency for lower serum levels 
of these vitamins.   
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A further elucidation of inflammatory effects on anaemia in the study population was 
revealed by the levels of liver enzymes and a particular by-product, that otherwise 
would indicate an ominous presence of liver tissue damage.  The measurement of 
bilirubin (Total and direct) gave some indication of the way this haem by-product was 
handled by the RES.  A marginally lower total bilirubin and higher direct bilirubin levels 
as shown for the sero-positives and sero-positive anaemics when compared with levels 
in sero-negatives and non-anaemics might be indicative of a lower likelihood for HIV 
infection to be associated with haemolytic anaemia in this population.  In haemolytic 
anaemia, RBC are broken down and total bilirubin levels rise together with the 
unconjugated bilirubin (i.e. Total minus Direct).  The tendency for haemolytic anaemia 
to be a contributor to the anaemia in the study population would be explained by the 
possible high prevalence of haemoglobinopathies.  The significant tendencies for the 
serum liver enzymes, ALT and AST, to be elevated in sero-positive as well as in sero-
positive anaemics compared to their peers, may also elucidate inflammatory effects.  
Both HIV and anaemia can alter the metabolic properties of the liver and other related 
cells, and considering the significant interactive effect between HIV and anaemia, it 
stands to reason that inflammatory stress could lead to damage of liver cells and spill 
over of enzymes.  An indication of ominous hepato-cellular damage in HIV infected 
subjects who are essentially asymptomatic portrays HIV infection as capable of 
interacting with other effects to exert a detrimental influence even at an early stage.   
 
Though HIV infection alone can significantly increase the tendency for liver damage 
(Richardson et al, 1994; Sulkowski, 2008), the likelihood that it does so by interacting 
with or potentiating other stressors is high.  In HIV infected populations, a close 
occurrence of HIV and other viral opportunistic infections, including viral hepatitis 
(Richardson et al, 1994; Sulkowski, 2008) as well as ARV toxicities (Sulkowski and 
Benhamou, 2007), form the bases for most liver damage.  Generally, excessive intake 
of alcohol, especially at levels considered to be hazardous, has been linked to liver 
damage (Bellantani et al., 1997).  Such excessive intakes have also been associated 
with an increased risk of liver damage in HIV infected persons (Chaudhry et al., 2009).  
Furthermore, the effects of alcohol in damaging the liver may be enhanced in black 
persons (Stranges et al., 2004).  In this study, HIV sero-positives, who were black, 
were more likely to consume alcohol but in quantities that may be considered less 
hazardous.  Despite the absence of information on viral hepatitis and ARV toxicity 
statuses for this population, the presence of some predisposing factors coupled with 
their HIV sero-positivity may be considered as important explanatory factors for the 
increased tendencies of serum ALT and AST.   
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In sum, HIV infection and its many eliciting effects can be very important in evoking 
changes within the body of its victim that may be associated with body composition, 
nutritional status, or the body’s immunological response in relation to metabolism of 
proteins and nutrients.  External or environmental stresses unrelated to the infection 
may also exert their influence on the effects of the virus.  Together, all these factors 
may eventually determine the development of anaemia in the infected population.   
However, in asymptomatic infected persons, the viral effects may be mild, and yet the 
persistence of these effects may prime other potential anaemia-inducing effects to 
significantly alter RBC metabolism and predispose to anaemia.  The effects of HIV and 
anaemia on many of these factors have been shown as independent or interactive.  
However the inter-relationships between all these factors together without necessarily 
considering the level at which they may be acting to cause anaemia is what the next 
chapter seeks to explore.    159
CHAPTER SIX 
6.0  EXPLORATIVE EVALUATION OF FACTORS THAT MAY INTERPLAY WITH 
HIV OR PREDICT ANAEMIA IN THE STUDY POPULATION 
So far, results in the preceding chapters can lead to the conclusion that though 
anaemia in the study population is high, it is higher in HIV sero-positives compared to 
sero-negatives.  In addition, the causes of high anaemia prevalences may be attributed 
to a number of factors that may include the virus as well as possible changes brought 
about by the infection and/or inflammation, alterations in body composition, energy or 
nutrient deficiencies, and perhaps a number of other factors not identified in this study.  
The association of HIV infection with a higher prevalence and severer grade of 
anaemia may suggest an independent effect of HIV or its presence to potentiate or 
interplay in the cause of anaemia by other factors.    
 
It is in view of this possible interactive effects of the HIV with factors that could predict 
anaemia in the study population that this chapter seeks to elucidate. 
 
6.1 INTRODUCTION 
In this chapter, the hypothesis which states that, ‘HIV infected persons are more 
anaemic in comparison with uninfected persons’ would be explored by partial 
correlations between the possible explanatory factors and markers of anaemia, whilst 
adjusting for confounding socio-demographic variables.  Furthermore, factors that are 
more likely to predict anaemia in the study population would be identified using various 
multivariable logistic regression models. 
 
The objectives set to achieve the above goals are as follows: 
•  To show the extent to which HIV infection may interplay with markers of body 
composition, energy and micronutrient intakes, serum micronutrients and levels of 
inflammatory bio-markers that may possibly explain anaemia in the study 
population 
•  To identify significant factors or effects that may predict anaemia in the study 
population using binary regression modelling 
 
The next sections would explore the extent to which individual factors identified in the 
previous chapters could interactively constitute significant determinants of anaemia in 
the study population.  Partial correlations would be used to explore for any 
relationships between HIV and anaemia using the variables independently against 
indicators of anaemia whilst adjusting for confounding socio-demographic variables.   
This would be followed by the use of various logistic regression (LR) models to explore   160
for significant predictors of anaemia within each sero-status group and also within each 
strata of the significant socio-demographic variables. 
 
6.2  EXPLORING THE RELATIONSHIP BETWEEN SIGNIFICANT FACTORS AND 
MARKERS OF ANAEMIA IN THE STUDY POPULATION BY PARTIAL 
CORRELATIONS 
Tables 6.1a, b and c below show summarised outcomes for the partial correlations 
between factors that are likely to be associated with anaemia (using [Hb] and 
haematocrit definitions) in the study population. 
 
Considering anthropometric variables (Tab. 6.1a), abdominal weight and calf skin folds 
measurements showed significant negative or inverse correlation coefficients (r) with 
[Hb] only in sero-negatives.  However, r with abdominal skinfold and weight  were 
rather weak.  On the other hand correlations with other anthropometric variables were 
either marginal or not significant.  An inverse correlation can be interpreted as a 
relationship where a variable increases as the other on which it may be dependent 
decreases.  For instance, in this case weight as well as abdominal and calf skinfolds 
would increase with a decreasing [Hb], i.e. with progressing anaemia.  The implication 
here nay be that, in sero-negatives, anaemic persons are more likely to have higher 
weights or abdominal or calf skin folds and vice versa. 
 
With dietary energy and micronutrients (Tab 6.1b), correlation coefficients for thiamin, 
riboflavin and folate intakes against [Hb] in sero-positives were also inverse and very 
significant.  Most others were however very weak and also not significant. This also 
implies that a lower [Hb] level is most likely to be associated with higher intakes of 
these micronutrients in this study population. 
 
From table 6.1c, correlation coefficients (r), for serum vitamin A was positive and 
significant with [Hb] in sero-positives, whilst in sero-negatives it was only marginally 
significant with Hct.   Serum vitamin E levels were also significantly and positively 
correlated with [Hb] and Hct in HIV sero-positives, and with [Hb] in HIV sero-negatives 
Similarly, correlations between serum iron and either [Hb] or Hct were positive and 
highly significant in HIV sero-positives, but in the sero-negatives though r was positive 
it was only significant against Hct.  Positive and significant r values were also revealed 
for TIBC against [Hb] only in sero-positives, whilst r values for % transferrin saturation 
against [Hb] and Hct were also positive in sero-positives. 
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Table 6.1a:  Partial correlations between anthropometric variables against [Hb] 
and haematocrit as possible determinants of anaemia in the study 
population 
Haemoglobin  Haematocrit 
Variables  HIV-  HIV+  HIV-  HIV+ 
r  -0.087  -0.078  0.041  0.046 
p  0.032  0.414  0.313  0.629 
Weight   n-1  608  109  608  109 
r  -0.035  -0.156  0.037  0.060 
p  0.389  0.102  0.358  0.529 
Height  n-1  608  109  608  109 
r  -0.060  0.019  0.060  -0.060 
p  0.139  0.846  0.142  0.535 
Triceps skin fold  n-1  608  109  608  109 
r  -0.078  0.090  0.069  -0.045 
p  0.055  0.348  0.090  0.636 
Subscapular skin fold  n-1  608  109  608  109 
r  -0.059  0.012  0.072  -0.036 
p  0.147  0.903  0.076  0.710 
Iliac crest skin fold  n-1  608  109  608  109 
r  -0.040  0.083  0.074  0.063 
p  0.327  0.387  0.068  0.510 
Supraspinale skin fold  n-1  608  109  608  109 
r  -0.088  0.034  0.071  0.059 
p  0.029  0.727  0.078  0.540 
Abdominal skin fold  n-1  608  109  608  109 
r  -0.120  -0.030  0.027  -0.007 
p  0.003  0.754  0.509  0.941 
Thigh skin fold  n-1  608  109  608  109 
r  -0.002  -0.190  0.017  0.036 
p  0.953  0.046  0.671  0.706 
Total energy intake  n-1  608  109  608  109 
r  -0.117  -0.039  0.008  0.069 
p  0.004  0.685  0.843  0.472 
Calf skin fold  n-1  608  109  608  109 
Correlation statistics corrected for sex, age grouping and settlement type. r = correlation coefficient, p = statistical 
probability and n-1 is degrees of freedom  
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Table  6.1b:  Partial correlations between dietary intake variables against [Hb] 
and haematocrit as possible determinants of anaemia in the study 
population 
Haemoglobin  Haematocrit 
Variables  HIV-  HIV+  HIV-  HIV+ 
r  -0.029  -0.113  -0.016  -0.061 
p  0.275  0.108  0.536  0.390   
Dietary Vitamin A   n-1  1454  201  1454  201 
r  0.046  -0.036  0.015  -0.043 
p  0.077  0.609  0.578  0.544 
Dietary Vitamin E  n-1  1454  201  1454  201 
r  -0.002  -0.102  0.018  0.037 
p  0.945  0.146  0.482  0.596   
Dietary Vitamin B12   n-1  1454  201  1454  201 
r  -0.024  -0.144  -0.017  -0.052 
p  0.362  0.040  0.522  0.463 
Dietary Thiamin (B1)   n-1  1454  201  1454  201 
r  -0.032  -0.137  0.019  -0.051 
p  0.229  0.051  0.460  0.472 
Dietary Riboflavin (B2)  n-1  1454  201  1454  201 
r  -0.017  -0.086  0.015  0.053 
p  0.512  0.223  0.560  0.454 
Nicotinic acid (B3)   n-1  1454  201  1454  201 
r  -0.046  -0.036  -0.019  -0.018 
p  0.080  0.607  0.467  0.797   
Dietary Vitamin B6   n-1  1454  201  1454  201 
r  -0.010  -0.055  0.056  0.034 
p  0.694  0.435  0.033  0.633 
Dietary Ascorbic acid   n-1  1454  201  1454  201 
r  0.015  -0.138  0.039  -0.064 
p  0.567  0.049  0.137  0.366   
Dietary Folate   n-1  1454  201  1454  201 
r  0.011  -0.119  -0.007  -0.017 
p  0.684  0.091  0.802  0.805 
Dietary Iron  n-1  1454  201  1454  201 
r  0.017  -0.075  -0.017  -0.005 
p  0.529  0.285  0.514  0.944 
Dietary Copper   n-1  1454  201  1454  201 
r  -0.019  -0.113  0.020  0.060 
p  0.463  0.108  0.442  0.392   
Dietary Zinc   n-1  1454  201  1454  201 
Correlation statistics corrected for sex, age grouping and settlement type. r = correlation coefficient, p = statistical 
probability and n-1 is degrees of freedom  
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Table  6.1c:  Partial correlations for biochemical variables against [Hb] and 
haematocrit to show  predictive value for anaemia in the study 
population 
Haemoglobin  Haematocrit 
Variables  HIV-  HIV+  HIV-  HIV+ 
r  0.140  0.090  0.152  0.133 
p  0.075  0.003  0.053  <0.001 
Serum Vitamin A   n-1  161  1127  161  1127 
r  0.299  0.119  0.044  0.093 
p  <0.001  <0.001  0.577  0.002 
Serum Vitamin E  n-1  161  1127  161  1127 
r  0.101  0.189  0.194  0.245 
p  0.200  <0.001  0.013  <0.001 
Serum Fe  n-1  161  1127  161  1127 
r  -.132  -0.083  -0.031  0.019 
p  0.094  0.005  0.696  0.522 
TIBC  n-1  161  1127  161  1127 
r  0.100  0.186  0.118  0.200 
p  0.203  <0.001  0.133  <0.001 
% Transferrin saturation  n-1  161  1127  161  1127 
r  -0.045  0.016  0.036  0.077 
p  0.566  0.601  0.646  0.009 
Serum ferritin  n-1  161  1127  161  1127 
r  -0.088  0.154  -0.124  0.213 
p  0.266  <0.001  0.116  <0.001 
Serum total Protein   n-1  161  1127  161  1127 
r  0.161  0.167  0.203  0.237 
p  0.040  <0.001  0.009  <0.001   
Serum  Albumin     n-1  161  1127  161  1127 
r  0.145  0.041  0.075  0.069 
p  0.066  0.167  0.339  0.021 
Plasma Fibrinogen  n-1  161  1127  161  1127 
r  0.054  0.083  0.174  0.128 
p  0.495  0.005  0.027  <0.001 
Total bilirubin  n-1  161  1127  161  1127 
r  0.128  0.200  0.139  0.150 
p  0.102  <0.001  0.077  <0.001 
Direct bilirubin  n-1  161  1127  161  1127 
r  0.143  0.009  0.055  -0.012 
p  0.044  0.739  0.439  0.652 
Serum ALP  n-1  196  1388  196  1388 
r  -0.006  -0.005  -0.069  0.020 
p  0.931  0.858  0.332  0.467 
Serum GGT  n-1  196  1388  196  1388 
r  0.062  0.034  0.063  0.118 
p  0.389  0.209  0.376  <0.001 
Serum ALT  n-1  196  1388  196  1388 
r  0.016  -0.001  0.022  0.030 
p  0.824  0.982  0.760  0.261 
 Serum AST  n-1  196  1388  196  1388 
Correlation statistics corrected for sex, age grouping and settlement type. r = correlation coefficient, p = statistical 
probability and n-1 is degrees of freedom  
 
With regards to the APPs, a correlation coefficient for ferritin, even though was weak, 
was positive and significant against Hct in only the sero-positives.  There emerged a 
strong positive correlation between total proteins against both [Hb] and Hct only in the 
sero-positives, whilst serum albumin showed strong positive r as well against both 
indicators for both sero-negatives and sero-positives.  With plasma fibrinogen a weak   164
positive but significant r was shown against Hct only in the sero-positives.  When the 
liver enzymes and bilirubin were analysed, both total and direct bilirubin showed a 
direct significant correlation with [Hb] and Hct in sero-positives whilst in the sero-
negatives there was a significant direct correlation only with Hct.  For the liver 
enzymes, apart from the positive significant correlation between ALP and [Hb] in sero-
negatives and also between ALT and Hct in sero-positives, all others were not 
significantly correlated.  
 
Summary of section 6.2 
This section may be summarised as follows: 
1.  Weight, abdominal or calf skin folds may be considered as negative significant 
determinants of anaemia in the sero-negative population or in other words sero-
negative anaemic persons are more likely to have higher weights, abdominal or calf 
skin folds. 
2.  High thiamin, riboflavin and folate intakes may be positive significant determinants 
of anaemia in sero-positives in this study population 
3.  Serum vitamins A and E may be significant positive determinants of anaemia in the 
sero-positive and to some extent in the sero-negative population. Similarly, serum 
iron, TIBC and % transferrin saturation were considered as positive determinants of 
anaemia in the sero-positive population. Whilst serum ferritin was weak and 
positive, total proteins and albumin were rather strong and positive  determinants in 
the sero-positives, whilst albumin was a positive and significant determinant in the 
sero-negatives. 
4. Total and direct bilirubin were considered significant positive determinants of 
anaemia in the sero-positives, much like serum ALT, whilst serum ALP was a 
determinant of anaemia in the sero-negatives 
 
In the next section, various multivariable logistic regression models would be applied to 
explore for significant factors that may interactively predict anaemia in the study 
population. 
 
6.3  PREDICTORS OR DETERMINANTS OF ANAEMIA BY MULTIVARIABLE 
LOGISTIC REGRESSION MODELLING 
To identify variables that were more likely to interplay between HIV and anaemia and 
which could significantly predict anaemia in the study population, backward stepwise 
likelihood ratio (LR) logistic regression models were applied to each of the groups and 
also to the significant socio-demographic strata.  Each model, except for the strata,   165
incorporated all variables considered as possible explanatory factors for anaemia 
together with significant socio-demographic variables that served as covariates. 
 
6.3.1  PREDICTORS OF ANAEMIA IN THE STUDY POPULATION  
Table 6.2 below is a summary of the outcomes from the regression models for factors 
within the study as well as the sero-positive and sero-negative populations 
respectively.   
 
The numbers included in each respective adjusted model were 1365 out of 1845 
(79.4%) in the first, 179 out of 216 (86.6%) in the second and 1187 out of 1605 (69.3%) 
in the third.  Cases that had missing values for any of the variables in the model were 
excluded.  Also, variables included in each model were all categorical and included 
socio-demographic variables that served as co-variates for adjustment.  Furthermore, a 
Nagelkerke R squared value was included to show how much of the variability in each 
model was accounted for by the interacting variables – the closer the value is to 1 the 
more the model is explained by the interaction.  Variables at each step of the analyses 
were excluded in order of significance with those removed earlier tending to have lower 
significance compared to those removed later, which represented an estimate of the 
degree to which the variable was likely to be significant as a predictor of anaemia.   
 
The table (Tab.6.2) also lists the variables that depicted higher probabilities and 
emerged as significant in predicting anaemia.  In the general study population these 
were; Urbanisation, Serum albumin, Serum vitamin E, Plasma fibrinogen, Serum GGT, 
TIBC, Direct bilirubin and Abdominal skinfold.  In the model applied to the infected 
group, the significant factors emerging were; Serum albumin, Serum globulins, Serum 
vitamin E, Serum AST, Smoking status, BMI, Mass, Stature, Supraspinale skin fold and 
LMI.  Whilst the model for the uninfected group yielded Urbanisation, Serum total 
proteins, Serum vitamin E, Serum GGT and Abdominal skinfold as the most significant 
determinants.   
 
Table  6.2:  Summary of significant predictors of anaemia in the study 











Settlement type, Serum albumin, Serum 
vitamin E, Plasma fibrinogen, Serum GGT, 
TIBC, Direct bilirubin, Abdominal skinfold  0.256 
HIV sero-
positive group  179/216 
Serum albumin, Serum globulins, Serum 
vitamin E, Serum AST, Smoking status, BMI,  
Mass, Stature, Supraspinale skin fold, LMI  0.350 
HIV sero-
negative group  1187/1605 
Settlement type, Serum total proteins, Serum 
vitamin E, Serum GGT, Abdominal skinfold  0.257   166
Tables 6.3, 6.4 and 6.5 below respectively present crude odds ratios (OR) and 
adjusted OR (aOR) for the significant variables which emerged for models applied to 
the study population, sero-positive group and sero-negative group respectively.  Whilst 
the crude OR accounted for the risk levels for each variable independently, aOR 
accounted for the interactive effect of all the variables in the model and their 
relationship with each other.  Odds ratios greater than 1 denoted a greater likelihood or 
probability for association with the outcome and vice versa. 
 











95% CI of aOR 
low 715  Serum 
albumin  high 650 
0.589 (0.002)  0.635 (0.016)  0.439–0.918 
Rural 539  Settlement 
type  Urban  826 
1.658 (0.001)  1.708 (0.004)  1.182–2.466 
low 706 
TIBC  high 659 
1.356 (0.002)  1.506 (0.028)  1.044–2.173 
low 664 
Vitamin E  high 701 
0.715 (0.002)  0.603 (0.006)  0.419–0.864 
low 705 
serum GGT  high 660 
0.896 (0.008)  0.613 (0.007)  0.430–0.875 
low 876  Plasma 
fibrinogen  high 489 
0.697 (0.065)  0.607 (0.010)  0.415–0.886 
low 856  Direct 
bilirubin  high 509 
0.831 (0.041)  0.695 (0.046)  0.486–0.994 
low 673  Abdominal 
skinfold  high 692 
1.753 (<0.001)  1.768 (0.002)  1.235–2.531 
Backwards-stepwise logistic regression analyses with anaemia (dependent variable).  Odds ratios (OR) have been 
adjusted for other variables in the model P values less than 0.05 denoted statistical significance. 
 
Table 6.3 above shows that settlement type, TIBC and abdominal skin folds are 
significant indirect determinants with aOR that are greater than 1.  This means that 
Urban settlement type, high TIBC and abdominal skin folds are strong predictors of 
anaemia in the study population. It can also be inferred from the table that low serum 
albumin, vitamin E, serum GGT, plasma fibrinogen and direct bilirubin are strong 
predictors of anaemia as well in the study population. 
 
From table 6.4 below, female sex,  non-smoking, high serum ‘globulins’, serum AST, 
BMI, stature and LMI as well as low serum albumin, vitamin E, weight and supraspinale 
skin fold all predicted anaemia in the sero-positive group.  
 
With regards to the significant predictors of anaemia in the sero-negative population, 
table 6.5 below has shown emerging variables as urban settlement type, high 
abdominal skin fold as well as low serum total proteins, serum vitamin E and serum 
GGT.   167
Table 6.4:  Significant predictors of anaemia in the HIV sero-positive group by 















95% CI of aOR
Male 74 
Sex  female 104 
4.053 (0.001)  3.557 (0.001)  1.410–9.412 
low 128  Serum 
albumin   high 50 
0.706 (0.006)  0.753 (0.051)  0.037–24.107 
low 70  Serum 
globulins  high 108 
5.449 (0.033)  7.402 (0.001)  5.857–87.486 
low 117 
Vitamin E  high 61 
0.532 (0.135)  0.051 (0.001)  0.009–0.284 
low 83 
Serum AST  high 95 
1.971 (0.023)  0.017 (0.001)  0.002–0.179 
yes 76  Smoking 
status  No 102 
1.246 (0.432)  12.034 (0.004)  2.174–66.607 
low 81  Body mass 
index  high 97 
5.344 (0.067)  22.092 (0.018)  1.693–288.216 
low 117  Weight 
  high 61 
0.044 (0.007)  0.058 (0.018)  0.006–0.610 
low 54  Height 
  high 124 
7.445 (0.008)  42.894 (0.004)  3.227–570.152 
low 97  Supraspinale 
skin fold  high 81 
0.612 (0.061)  0.116 (0.044)  0.014–0.943 
low 77  Lean mass 
index  high 101 
2.603 (0.002)  12.898 (0.015)  1.659–100.261 
Backwards-stepwise logistic regression analyses with anaemia (dependent variable). Odds ratios (OR)  have been 
adjusted for other variables in the model.  P<0.05 denoted statistical significance. AST – aspartate transaminase 
 
Table  6.5:  Significant predictors of anaemia in the sero-negative group - 















95% CI of 
aOR 
Urban 695  Settlement 
type  Rural 492 
2.086 (<0.001)  1.852 (0.002)  1.249–2.747 
low 581  Serum total 
proteins  high 606 
0.791 (0.017)  0.585 (0.007)  0.396–0.865 
low 571  Serum vitamin 
E  high 616 
0.624 (0.034)  0.670 (0.044)  0.453–0.990 
low 561 
Serum GGT  high 626 
0.770 (0.061)  0.667 (0.036)  0.456–0.974 
low 587  Abdominal 
skin fold  high 600 
1.768 (<0.001)  1.771 (0.003)  1.212–2.589 
Backwards-stepwise logistic regression analyses with anaemia (dependent variable). Odds ratios  (OR) have been 
adjusted for other variables in the model.  P<0.05 denoted statistical significance. GGT – gamma glutamyl transaminase 
 
A comparative binary regression analysis was also used to identify predictors of 
anaemia between sero-positive and sero-negative anaemics using all variables as 
before. (Tab. 6.6).  Out of 828 cases, 612 (73.9%) were included in the model whilst 
the rest were excluded for missing values.  The significant predictive variables, from 
table 6.6 below, when the two anaemic groups were taken into consideration were; Age   168
grouping ≤ 40 years together with high serum total proteins, serum ‘globulins’, and iliac 
crest skin fold as well as low serum albumin, plasma fibrinogen and supraspinale skin 
fold. 
 
Table  6.6:  Significant predictors of anaemia comparing seropositive and 
seronegative anaemics using logistic regression modelling 
 
Variable 







95% CI of aOR 
≤40 yrs  438  Age grouping 
  >40 yrs  174 
0.434 (0.002)  0.362 (0.039)  0.138–0.950 
low 313  Serum total proteins 
high 219 
5.665 (<0.001)  7.203 (0.002)  2.058–25.159 
low 437  Serum albumin 
  high 175 
0.342 (0.006)  0.217 (0.005)  0.075–0.625 
low 210  Serum globulins 
high 332 
3.775 (0.007)  4.942 (0.022)  1.253–19.488 
low 447  Plasma fibrinogen 
  high 165 
0.410 (0.045)  0.294 (0.024)  0.102–0.853 
low 217  Iliac crest skin fold 
high 315 
3.987 (0.003)  4.482 (0.019)  1.274–15.775 
low 449  Supraspinale skin 
fold  high 163 
0.355 (0.146)  0.177 (0.007)  0.050–0.630 
Backwards-stepwise logistic regression analyses with anaemia (dependent variable). Odds ratios have been adjusted 
for other variables in the model.  P<0.05 denoted statistical significance. 
 
In the next section, significant predictors of anaemia within the strata of the significant 
socio-demographic variables would be explored. 
 
6.3.2 PREDICTORS OF ANAEMIA WITHIN SIGNIFICANT SOCIO-
DEMOGRAPHIC STRATA  
To further identify interacting variables that could predict anaemia within each strata of 
the significant socio-demographic predictors in the study population, a stratified forced 
entry logistic regression analysis was undertaken.  The forced entry strategy was 
adopted because the backward LR model yielded smaller sample sizes at the end of 
the stratified adjustment, which would make the statistical analysis highly 
underpowered. 
 
Table 6.7 below represents the summary for the forced entry binary logistic model for 
the stratified significant socio-demographic variables of sex, settlement type, age 
grouping, smoking status and alcohol consumption status..   
 
Many important and significant predictors of anaemia are common within each sero-
status group as the analyses has shown.  In view of this, the variables for predicting 
anaemia within the socio-demographic strata were considered for the entire study 
population without considering HIV status.  For instance in males, high energy intake,   169
abdominal skinfold and serum ferritin as well as low serum vitamin E, plasma 
fibrinogen, serum GGT, and direct bilirubin were significant in predicting anaemia, 
whilst for females, urban dwelling type, non smoking, high TIBC together with a low 
serum albumin constituted significant predictors of anaemia.   
 
Within the settlement type strata, there were no significant predictors for rural dwellers.  
However, for their urban counterparts, anaemia was predicted by high serum iron and 
TIBC as well as low serum albumin, serum vitamin E, plasma fibrinogen and direct 
bilirubin.    
 
The age grouping strata also showed urban settlement type, non-smoking, high serum 
ferritin, TIBC and abdominal skin fold together with low serum vitamin E and direct 
bilirubin as major predictors of anaemia in persons who were 40 years and below. For 
those who were above 40 years the significant predictors were urban settlement type, 
high stature as well as low serum total proteins, plasma fibrinogen and serum GGT.   
 
For smokers significant predicting variables included high stature, abdominal skin fold 
and LMI as well as low serum vitamin E plasma fibrinogen and direct bilirubin whilst for 
non-smokers they were urban settlement type together with low serum albumin and 
serum iron.  
 
With regards to alcohol consumers there were a large number of predictive variables 
for anaemia.  These included; high energy intake, TIBC, % transferrin saturation, 
serum ferritin and abdominal skin fold as well as low serum vitamin E, plasma 
fibrinogen, serum GGT, serum iron and direct bilirubin.  On the other hand non-
consumers of alcohol had significant predictors of anaemia which included, urban 
settlement type, high mass or weight and a low serum GGT. 
 
Within the various significant socio-demographic strata, anaemia was most likely to be 
predicted by urban settlement type, low serum vitamin E, low plasma fibrinogen and 
low direct bilirubin in 5; low serum GGT, high TIBC and high abdominal skin fold in 4; 
low serum albumin, high serum ferritin, serum iron (both high and low) and smoking 
status (both smoker and non-smokers) in 3. The rest of the factors predicted anaemia 
in either 2 strata or 1 stratum. 
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Table 6.7:  Predictors of anaemia in significant socio-demographic strata  (aOR with probabilities in parentheses) 
Socio-demographic strata 
Sex  Settlement type  Age grouping  Smoking status  Alcohol consumption status 
 
 
Significant predictors male female  rural  Urban  40 years and 
below   
Older than 
40 years  smokers  Non -
smokers  Consumers  Non 
consumers 
Urbanisation  - 
2.005 




(0.015)  - 
2.434  
(0.002)  - 
2.026  
(0.023) 
Serum vitamin E  0.580 




0.003)  - 
0.439 
(0.008)  - 
0.451  
(0.004)  - 
Plasma fibrinogen  0.436 
(0.004)  -  - 
0.585 




(0.006)  - 
0.523  
(0.028)  - 
Direct bilirubin  0.475 




(0.002)  - 
0.538 
(0.042)  - 
0.378  




(0.006)  -  -  -  - 
0.482 





Abdominal skinfold  2.532 
(0.001)  -  -  - 
2.106  
(0.039)  - 
2.120 
(0.026)  - 
3.383  
(0.050)  - 
Serum ferritin  1.905 
(0.025)  -  -  - 
2.330  
(0.015)  -  -  - 
2.645  
(0.018)  - 
Serum albumin  - 
0.444 
(0.006)  - 
0.546 
(0.025)  -  -  - 
0.488  
(0.016)  -  - 
Total iron binding 
capacity  - 
1.915 




(0.004)  -  -  - 
1.764  
(0.001)  - 
Smoking status  - 
3.737 




(0.002)  -  -  -    - 
Serum iron  -  -  - 
1.714 




(0.005)  - 
Energy intake  2.472 
(0.012)  - -  -  -  -  -  - 
2.393  
(0.029)  - 




(0.024)  -  -  - 
Serum total proteins  -  -  -  -  - 
0.410 
(0.032)  -  -  -  - 
Lean mass index  -  -  -  -  -  - 
2.306 
(0.041)  -  -  - 
% saturation  -  -  -  -  -  -  -  - 
4.098  
(0.001)  - 
Weight  -  -  -  -  -  -  -  -  - 
1.845  
(0.006) 
Forced entry binary logistic regression analyses with anaemia as dependent variable. Odds ratios have been adjusted for other variables in the model.  P<0.05 denoted statistical significance.   171
Summary of section 6.3 
The results in the above section have shown that: 
1.  Within the study population urban settlement type, high TIBC and abdominal skin 
folds as well as low serum albumin, vitamin E, serum GGT, plasma fibrinogen and 
direct bilirubin were significant predictors of anaemia.  In the sero-positive group, 
female sex,  non-smoking, high serum ‘globulins’, serum AST, BMI, stature and LMI 
as well as low serum albumin, vitamin E, weight and supraspinale skin fold all 
predicted anaemia.  In the sero-negative population, urban settlement type, high 
abdominal skin fold as well as low serum total proteins, serum vitamin E and serum 
GGT were the significant predictors.  However, between the HIV infected and their 
uninfected anaemic peers, significant predictors were; age grouping ≤ 40 years 
together with high serum total proteins, serum ‘globulins’, and iliac crest skin fold as 
well as low serum albumin, plasma fibrinogen and supraspinale skin fold. 
2.  Within the male socio-demographic strata, high energy intake, abdominal skinfold 
and serum ferritin as well as low serum vitamin E, plasma fibrinogen, serum GGT, 
and direct bilirubin were significant in predicting anaemia, whilst for females, urban 
dwelling type, non smoking, high TIBC together with a low serum albumin 
constituted significant predictors of anaemia. In the rural settlers there were no 
significant predictors.  However, for their urban counterparts, anaemia was 
predicted by high serum iron and TIBC as well as low serum albumin, serum 
vitamin E, plasma fibrinogen and direct bilirubin  When age grouping was 
considered, urban settlement type, non-smoking, high serum ferritin, TIBC and 
abdominal skin fold together with low serum vitamin E and direct bilirubin predicted 
anaemia, whilst for those who were aged above 40 years, significant predictors 
were urban settlement type, high stature as well as low serum total proteins, 
plasma fibrinogen and serum GGT.  For smokers, significant predicting variables 
included high stature, abdominal skin fold and LMI as well as low serum vitamin E 
plasma fibrinogen and direct bilirubin whilst for non-smokers they were urban 
settlement type together with low serum albumin and serum iron.  In alcohol 
consumers predictive variables included; high energy intake, TIBC, % transferrin 
saturation serum ferritin and abdominal skin fold as well as low serum vitamin E, 
plasma fibrinogen, serum GGT, serum iron and direct bilirubin.  For non-consumers 
of alcohol significant predictors of anaemia included, urban settlement type, high 
weight and a low serum GGT. 
 
The results in this section demonstrate the complexity of factors that may be 
responsible for anaemia within the study population and especially for persons infected 
with HIV.  Whilst some of the factors are not uniquely ascribable to HIV infection there   172
are, however, those that can be related to an increase in metabolic and/or inflammatory 
response, which may then be given consideration as more likely to interactively predict 
anaemia in the HIV infected population in this study. 
 
6.4  KEY FINDINGS - CHAPTER SIX 
In this results chapter the key findings were as follows:  
1.  High weight, abdominal and calf skin folds as well as high thiamin, riboflavin and 
folate intakes are significant determinants of anaemia in the sero-positive 
population.  In addition low serum vitamins A and E may be significant 
determinants of anaemia in the sero-positive and to some extent in the sero-
negative population. Similarly, serum low iron, TIBC and % transferrin saturation 
are positive determinants of anaemia in the sero-positive population, whilst high 
serum ferritin is a weak and high total proteins and low albumin are rather strong 
determinants in the sero-positives  Low albumin is also a significant determinant in 
the sero-negatives.  Low total and direct bilirubin were also considered significant 
determinants of anaemia in the sero-positives, much like serum ALT, whilst serum 
ALP was a determinant of anaemia in the sero-negatives. 
2.  Within the study population, some variables commonly predicted anaemia,  whilst a 
few were restricted to particular groups.  Among the significant but more common 
predictors were urban settlement type, high serum total proteins, high abdominal 
skin fold as well as low albumin and low vitamin E.  Between sero-positives and 
sero-negatives, age grouping ≤ 40 years together with high serum total proteins, 
serum ‘globulins’, and iliac crest skin fold as well as low serum albumin, plasma 
fibrinogen and supraspinale skin fold were more likely to predict anaemia.   Within 
significant socio-demographic anaemia was most likely to be predicted by urban 
settlement type, low serum vitamin E, low plasma fibrinogen and low direct bilirubin. 
 
In sum, the results presented in this chapter demonstrate that determinants of anaemia 
may be common between sero-positives and sero-negatives as well as between 
different socio-demographic strata within the study population.  However, the unique 
predictive strengths of other variables in particular groups may suggest other unrelated 
factors that have potential to add to or significantly interplay in determining anaemia in 
the study population.      
 
6.5  DISCUSSION OF KEY CHAPTER SIX FINDINGS 
In this chapter, the significant factors that may determine the inter-relationships 
between HIV infection and anaemia and significantly predict anaemia in the study 
population have been explored using various multivariable logistic regression models.    173
The models used in the various analyses may closely demonstrate interplay between 
various factors including HIV infection as well as other potentially anaemia-eliciting 
factors, including those that may not be associated with the infection, but may pose a 
significant risk to the development of  anaemia in infected persons.     
 
The previous chapters highlighted various factors as likely to explain anaemia in the 
study population.  From the analyses in this chapter it can be observed that the 
commonalities of factors between the sero-status groups and the various socio-
demographic strata, in causing or contributing to the cause of anaemia are vast.   
 
Although HIV infection can be linked to anaemia (Sullivan et al., 1998; Volberding, 
2000; Moyle, 2002), in this study in particular, there are many factors that seem to 
suggest that this linkage is quite weak.  Apart from the asymptomatic character 
proffered on the sero-positive group, it is also very likely that many other factors 
unrelated to HIV infection but prevalent within the population could significantly 
contribute to the cause of anaemia. 
 
Even though it remains speculative at this point, there are a number of factors other 
than HIV infection peculiar to sub-Saharan Africa and other resource-poor settings that 
may tend to predispose to or exacerbate anaemia (McLean et al., 2007).  Many of 
these endemic conditions, such as poverty and malnutrition, have been known to 
heighten the burden of HIV/AIDS (UNAIDS, 2006; 2008).  
 
It may be argued that, even at an apparently asymptomatic population, inflammatory 
responses to HIV infection and perhaps to other stressors can be crucial in determining 
the balance between RBC synthesis and destruction or loss.  Such inflammatory 
tendencies may be identified in the significant relationships between increased total 
serum proteins, high serum ferritin and low serum albumin and [Hb] and the strengths 
of their prediction of anaemia in various study population groups. 
 
One may also allude to the overwhelming predictiveness of urban settlement as more 
likely to buttress the inflammatory tendencies.  The rapidity at which urbanisation is 
occurring in the study region coupled with the transitional changes that accompany it, 
may create conditions that could be associated with an increase in inflammatory stress.  
The creation of urban slums is likely to breed poverty and malnutrition.  Insanitary 
conditions and infectious disease may also be rife and looming and may, perhaps, be 
aggravated by other conditions such as limited access to health care that together 
would heighten the vulnerability of persons to both HIV/AIDS and anaemia.    174
The emergence of low serum albumin, low serum vitamin E levels and perhaps low 
TIBC as significant determinants of anaemia in the study population and especially in 
the sero-positives, may be reflecting an imbalance in nutrients similar to what happens 
during the  inflammatory process.  In this study such tendencies in sero-positives, could 
have been caused by the presence of the HIV and perhaps also primed by the 
presence of other inflammatory stressors.  The fact that this may be happening in an 
asymptomatic HIV seropositive population who are most likely to be at the early stages 
of the infection shows that either inflammatory stress at this stage is high or an 
apparently  mild HIV effect potentiates the effects of other inflammatory stressors.   
 
The predictive significance of low vitamin E and TIBC may also reflect an enhanced 
inflammatory response or oxidative stress. It has been shown that immunological 
changes associated with HIV and other infections may tend to decrease micronutrient 
levels as their transport protein levels are depressed (Tomkins, 2003).  However, the 
significant effects of HIV on haematopoiesis and RBC metabolism could as well 
increase the utilisation and metabolic loss of these micronutrients, as confirmed by 
significant associations between HIV infection and micronutrient deficiencies reported 
in some studies (Tang et al., 1997a; 1997b; Tang and Smit, 1998; Tang et al., 2005; 
Friis, 2005).   Irrespective of cause, a tendency for vitamin E deficiency (Traber and 
Kamal-Eldin, 2007) can be associated with anaemia as it may be associated with 
oxidative stress.   
 
Significantly, urbanised settlement type and low vitamin E could be considered as more 
likely to predict anaemia in the study population, whilst females, low serum albumin, 
and high serum total proteins reflect the HIV sero-positive predictors. The implications 
for these predictive factors could be very relevant in public health terms, considering 
that both HIV and anaemia could have serious public health consequences in this 
population.  Though, generally accepted as very vulnerable to HIV infection, females 
are highly likely to be anaemic because of socio-economic and other biological 
reasons.  With both HIV and anaemia presenting as serious threats to females, it would 
be prudent to give a serious attention to this gender group as far as policies in 
addressing issues surrounding these threats are concerned.  It is also a recognised 
fact that urbanisation comes with some socio-demographic and nutritional changes that 
more often than not are inimical to the health and survival of the most vulnerable. 
Vulnerability to HIV and anaemia can be heightened by poverty and inadequate and 
inappropriate education, which may commonly be associated with transitional (squatter 
camps) or residence in urban slums. 
   175
Low vitamin E as a significant predictor of anaemia may simply be highlighting the 
general importance of the pervasive inflammatory tendencies, which is likely to 
precipitate oxidative stress both within the infected and uninfected populations.   
Although oxidative stress has not been actually determined in this study, higher 
tendencies and predictive value of low vitamin E levels with anaemia within the study 
population may be considered as significantly reflecting oxidative stress levels within 
the population.   
 
It may be inferred from the findings that anaemia in this asymptomatic HIV sero-
positive population is more likely be associated with alterations in serum protein levels 
that may signify inflammatory influence, and most likely determined by the influence of 
an ever present virus interacting with other potential stressors.   176
CHAPTER SEVEN 
7.0 GENERAL  DISCUSSION 
The results from various analyses employed to address the hypothesis of this study 
has been outlined and discussed in the preceding three chapters.  The first part 
elucidates the baseline socio-demographic characteristics that could serve as 
explanatory factors in the relationship between HIV infection and anaemia, which is 
followed by the examination of various factors as possible explanatory factors for 
anaemia in the study population. Lastly, factors that may interplay with HIV infection 
and could significantly predict anaemia in the study population have been explored.  
 
In this general discussion chapter findings that are considered as key in this study, 
which may be pertinent in addressing the main hypothesis will be discussed in the light 
of the evidence from literature relating HIV/AIDS to anaemia.  From this, relevant 
conclusions drawn would be outlined.  The limitations of the study will also be 
highlighted, whilst implications of the findings for public health will be derived and 
suggestions or recommendations made for future work in this study area. 
 
7.1  KEY STUDY FINDINGS 
The key findings in this study are summarised as follows: 
•  Prevalence of HIV infection in the study population was 11.8%.  
•  HIV sero-positive persons were significantly more likely to be ≤40 years, i.e. 
younger:  sero-positive females were more likely to be younger than males and, 
anaemics, irrespective of HIV sero-status, were also more likely to be younger. 
•    HIV sero-positive persons, irrespective of gender and anaemia status, were 
significantly more likely to be urbanised.   
•  Over half of the study population, irrespective of HIV sero-status, gender and 
anaemia status, were more likely to have lower educational attainment, earn lower 
monthly income and speak Tswana as first language.  
•  Females, irrespective of sero-status, were significantly more likely to be lower 
income earners and more likely to be anaemic.   
•  Males were significantly more likely to smoke or indulge in alcohol consumption.  
Anaemics generally were significantly less likely to smoke, whilst seropositive 
anaemics in particular were less likely to consume alcohol compared to their non-
anaemic counterparts. 
•  HIV sero-positives had lower [Hb] and Hct levels compared to their sero-negative 
peers. The effects of both HIV infection and anaemia on Hct were very significant, 
but the interactive effect was not.   
•  Prevalence of anaemia was generally high and most of it could be categorised as   177
mild, but sero-positive prevalences were higher and significant with Hct defining 
anaemia, than those of sero-negatives.  HIV sero-positives were more likely to be 
mildly and moderately anaemic and significantly more likely to be severely 
anaemic.  HIV sero-positive urban settlers, non-smokers as well as non-consumers 
of alcohol were more likely to be anaemic.   
•  HIV sero-positive persons were more likely to be hypoferaemic (i.e. with lower 
serum Fe) or relatively hypoferritinaemic (i.e. with lower serum ferritin levels) 
compared to their sero-negative peers.  Sero-positives were also more likely to be 
classified with IDA and ACI, though ACI was more likely to be common than IDA in 
the study population. 
•  HIV infection, much like anaemia, may be associated with changes in body fat 
measures in mid body parts, independently and interactively especially on 
abdominal skin fold fat. 
•  Energy and micronutrient intakes were marginally higher in sero-positives and 
anaemic sero-positives than their peers. Over 50% of the study population could be 
classified as having poor energy intakes.  Intakes were generally marginal 
compared to DRI.  HIV sero-positives and anaemics were more likely to have lower 
serum levels of iron and vitamin A, whilst vitamin E levels were only lower in 
anaemics. 
•  HIV sero-positives had significantly higher serum levels of total proteins and 
‘globulins’ as well as a lower serum levels of albumin. Levels of Direct bilirubin, ALT 
and AST levels were higher in sero-positives, but the effects of HIV infection was 
significant on ALT and AST levels. 
•  Anaemics, irrespective of sero-status, were also significantly more likely to have 
lower total proteins and albumin as well as lower bilirubin (Total and Direct) and 
liver enzymes (serum ALP, GGT, ALT and AST).  However, effects of anaemia only 
on bilirubin (Total and Direct) as well as ALT and AST levels were highly significant. 
 
7.2  DISCUSSION AND GENERAL IMPLICATIONS OF KEY FINDINGS 
In most regions of the world, especially in places that have been hardly hit by 
HIV/AIDS, efforts to stem the tide of the pandemic has met with a lot of difficulties 
(UNAIDS, 2006; 2008).  Similarly, in places where anaemia is a serious public health 
problem, prevalences have hardly declined despite the numerous programmes aimed 
at reducing it.  Because of the way they influence each other, there is a need to 
address these two global problems with a multidimensional approach as their causation 
and effects may not only be related but also interactive.  Both HIV/AIDS and anaemia 
have important nutritional implications for victims and the population at large, which 
makes it imperative to place nutrition at the core of addressing them.     178
HIV/AIDS is inextricably linked with the nutrition of the victim, and problems associated 
with nutrient losses and increased nutrient utilisation mostly emanate from an 
increased metabolism and/or inflammation, inadequate food intake and oxidative stress 
(Babamento and Kotler, 1997; Bogden et al., 2000) due to the infection.  The 
interaction between HIV/AIDS and nutrition is of particular significance, especially in 
many sub-Saharan African countries where malnutrition and infectious diseases may 
occur simultaneously, sequentially or repeatedly in infected persons, and may 
contribute towards the acceleration of HIV disease (Semba and Tang, 1999; Anabwani 
and Navario, 2005).  The cycling between malnutrition and endemic infectious diseases 
in most of such regions, which are often resource-limited, may also be reinforced by 
population characteristics in the development of anaemia in the population (Ssali et al, 
2006). 
 
In asymptomatic HIV infection, the effects of the virus on the nutritional status and 
metabolic alterations in victims may be mild.  Nevertheless, the occurrence of anaemia 
in asymptomatic or symptomless HIV infected populations is just not mythical, but 
levels are more often higher than in the uninfected populations (Spivak et al., 1984; 
Costello, 1988; Hoxie, 1995; van Den Broek et al., 1998).   In the infected population, 
prevalence of anaemia remains much higher in sub-Saharan African countries than in 
developed countries (Belperio and Rhew, 2004), and levels within asymptomatic 
populations follow a similar trend  (van Den Broek et al., 1998; Ayisi et al., 2000; 
Mlisana et al., 2008).  The high anaemia prevalences in this apparently asymptomatic 
population, which tends to be significantly higher than that of sero-negatives using Hct 
definitions may be consistent with the findings of the earlier studies. 
 
In this study, prevalence of anaemia in both infected and uninfected populations of 
around 50% may have serious public heath implications, however, it is perhaps the 
tendency for anaemia and its exacerbated forms to be associated with HIV infection 
which should draw attention to the contribution HIV infection could be making to 
anaemia in an environment where anaemia may already be a burden.  In fact, the 
significantly higher anaemia prevalence between sero-positives and sero-negatives, 
when Hct definitions are considered coupled with the significant association of severe 
anaemia with HIV infection, albeit numbers were low, may suggest that, even in 
asymptomatic infection, HIV can exert a significant impact on the numbers of RBC.  
However, whether this impact of HIV is due to its direct influence or to its associated 
eliciting effects or to an interplay between these direct and indirect effects cannot be 
clarified because of the limitations of the data. 
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Whilst the comparative differences in levels of asymptomatic HIV related anaemia 
between developed countries and developing countries may suggest different mixes or 
potencies of aetiological factors, it also highlights the fact that the impact of the 
infection might be greater in developing populations.  In this study, an equally high 
prevalence of mild and moderate anaemia is demonstrated in the sero-negative as in 
the sero-positive population, which indicates that factors other than HIV are also at play 
in inducing anaemia within the study population.  It is therefore possible that these 
other factors may add to or interact with the effects of HIV to contribute to its greater 
impact on anaemia in the sero-positive population.  Though the elucidation of these 
other factors are constrained by the limitations of the study data, the unique importance 
of HIV in either directly or indirectly enhancing the predisposition of infected persons to 
anaemia may be conjectured from a number of factors inferring from certain population 
characteristics in the study. 
 
Among the many socio-demographic characteristics that have been demonstrated to 
be associated with anaemia in populations including PLWHA are sex (female), age 
(being older), race (black), use of ARV and antiviral myelosuppressive medication (e.g. 
AZT), CD4+ cell count (<200 cells/µl), viral load (increased), intravenous drugs (users) 
and many others (Sullivan et al., 1998; Volberding et al., 2004).  Those factors that 
closely relate with HIV disease state or severity such as CD4+ cell count and viral load 
may constitute viral effects or HIV-related effects which could mark more precisely the 
direct involvement of the virus in causing anaemia in an infected population.  On the 
other hand, the socio-demographic determinants may be regarded as HIV-unrelated 
and therefore more generally considered as explanatory factors of anaemia for the 
entire study population, unless they differ significantly between the two population 
groups.  However, any significant link or association with HIV infection would enable 
socio-demographic and other HIV-unrelated determinants to be constituted as 
significant explanatory factors for differences in levels and characteristics of anaemia 
between infected and uninfected populations.  Unfortunately, HIV-related 
characteristics like CD4+ cell count and viral load were not available for consideration 
as significant determinants of anaemia in the infected population because they were 
not measured.  With regards to the HIV-unrelated factors, the socio-demographic 
characteristics of sex (female) and race colour (black), which may be associated with 
anaemia, were not significantly different between HIV ser-positive and sero-negative 
groups, and therefore may only be used in explaining part of the anaemia in both study 
population groups.  
 
As significant predictors of anaemia in the entire study population, female sex and   180
urbanised residence type together with the predominant black racial characteristic may 
constitute important explanatory variables for the high levels of anaemia in the entire 
population.  In a population where female proportions tend to be higher than that of 
males this population characteristic may assume some importance in partly explaining 
the high prevalence of anaemia within the population, especially, when it constitutes a 
significant determinant of anaemia (Sullivan et al., 1998; Volberding et al., 2004).   
Whilst the female characteristic is associated with anaemia because of biological 
predispositions, the black race has been associated with anaemia for other reasons 
that may be considered as either biological or social.   
 
Associating anaemia with females may be largely attributed to menstrual blood loss 
and to the drains on iron stores that occur with pregnancy and delivery (Volberding et 
al., 2004).  On the other hand, the black racial group, who predominantly reside in or 
have their ancestral roots in sub-Saharan Africa, have been associated with certain 
population specific characteristics, which may have survival significance, but may also 
be significantly predisposing to anaemia (Ssali et al., 2006).  In populations where HIV 
infection is high these population specific characteristics may serve as important 
priming or potentiating factors for anaemia.  These characteristics include endemic and 
rare genetic disorders like sickle cell disease, thalassaemias and G-6-P-D, (Sullivan et 
al., 1998; Volberding et al., 2004), which by themselves may predispose to anaemia.   
Although these characteristics were not assessed in the study population, a higher 
tendency for haemolytic anaemia, may be an indication of the presence of such 
characteristics. 
 
As part of the characteristics of black populations that may explain anaemia in the 
population, dietary considerations associated with certain nutritional and/or cultural 
practices, which tend to limit the availability of iron for RBC production, have been 
suggested (Semba, 2003).  The effects of such a population specific characteristic can 
often be compounded by the prevalence of environmental conditions that are inimical 
to the maintenance of good nutrition and health, which may further enhance the 
predisposition of individuals to anaemia.  For instance, a poor socio-economic 
dispensation often associated with rapid urbanisation and changes in demography, 
could essentially depict levels of poverty and therefore a basis for the dietary 
alterations that are likely to lead to low RBC production.   In this study such 
circumstances are reflected in the poor average income earnings and educational 
attainments in a large section of the study population.  This tendency for poverty to 
prevail, which could most probably be ascribed to the rapid urbanisation process in the 
population (Vorster et al., 2000), may underlie the poor dietary energy and   181
micronutrient intakes observed in a large section of the population.   
 
The potential for pervasive poverty to increase prevalence of HIV/AIDS in the region 
(UNAIDS, 2008) coupled with the presence of unrelenting infectious diseases (Vorster 
et al., 2000), may serve to explain the adverse changes in health and nutrition in the 
study population.  The significant association of anaemia with urbanisation in the study 
population simply buttresses the role for these changing socio-demographic and 
associated factors in causing anaemia.  This is against the background that residence 
in urban transition or slum is more likely to be associated with a high prevalence of 
unsanitary conditions and other vices which could encourage the spread of diseases 
including HIV and expose individuals to anaemia and other co-morbidities (Calder and 
Jackson, 2000; Thurnham and Northrop-Clewes, 2007).  Obviously as a strong 
predictor of both HIV infection and anaemia, the urbanised stratum would be most 
appropriate for targeting as a public health intervention strategy.   
 
Subclinical levels of endemic infectious diseases or helminthic infestation may 
constitute a potential cause of anaemia in the study population although indicators of 
such conditions were not assessed in this study.  In sub-Saharan Africa and many 
developing countries, including the study location, the presence of endemic malaria, 
helminthic and respiratory infections have been suggested to contribute to the 
predisposition of persons to anaemia (van Eijk et al., 2001; Muhangi et al., 2007).  It is 
possibly for these reasons that countries and regions that account for the very high 
global prevalences of anaemia, all fall within the zones where such infectious diseases 
and other causes of inflammatory stress abound (McLean et al., 2007).   
 
Endemic infectious diseases, including HIV infection, may have specific ways by which 
they influence the development of anaemia, but nevertheless, they all generally tend to 
activate an inflammatory response which, more often than not, deprives victims of 
nutrients such as iron, whilst creating conditions within the body that may impair RBC 
production or increase its destruction (Jackson, 2007; Northrop-Clewes, 2008).   
 
However, since the APR is a broad based response to many inflammatory stressors 
and not necessarily restricted to infections (Thurnham and Northrop-Clewes, 2007), it 
means that inflammatory influences in the study population may still be present without 
overt infection.  Such sub-clinical inflammatory effects cannot be overlooked in 
explaining the anaemia in the study population, and especially in the uninfected group 
who were considered to be ‘apparently healthy’.  In fact, pro-inflammatory cytokines 
released during inflammation could significantly contribute to the initiation and the   182
continued presence of anaemia (Thurnham and Northrop-Clewes, 2007), more so in 
populations where exposure to inflammatory stress is especially high.  Associated with 
the inflammatory response is a rapid fall in plasma concentrations of several nutrients 
(though a few may increase in concentration), which occurs irrespective of nutritional 
status (Thurnham and Northrop-Clewes, 2007).  Additionally, the inflammatory 
response is also characterised by sequestration of iron and zinc and a reordering of the 
metabolic processes in the liver resulting in an increased formation of positive APPs at 
the expense of negative APPs (Jackson, 2007).  During the inflammatory process 
serum ferritin levels tend to rise to levels that parallel that of CRP (Feelders et al., 
1998), an APP which has often been used to mark acute inflammation.   
 
The evidence for the presence of inflammatory stressors in the study population, apart 
from HIV, may lie in the tendencies for hypoferaemia and, especially, 
hyperferritinaemia in both infected and uninfected populations.  This may be buttressed 
by the attribution of most anaemia in the two populations to ACI, which also tends to 
have hypoferaemia and hyperferritinaemia as significant features (Thurnham and 
Northrop-Clewes, 2007).  In addition, both populations have shown characteristics 
associated with hepatic metabolic protein and nutrient alterations that often accompany 
the inflammatory response.  However, these inflammatory effects may seem to have 
been more pronounced in the sero-positives. Since such tendencies strongly suggest 
inflammatory influence, it may follow that the hypoferaemia and perhaps the lower 
serum micronutrients characterised in the study population are not necessarily genuine 
dietary iron or nutrient deficiencies, but most likely may represent iron redistribution or 
nutrient conservation tendencies associated with the inflammatory process (Tomkins, 
2003; Thurnham and Northrop-Clewes, 2007).    
 
More recently, the hypoferaemia and hyperferritinaemia associated with inflammation 
have been attributed to the effects of hepcidin, a small hepatic-secreting polypeptide, 
produced through induction by the inflammatory cytokine IL-6 on hepatocytes (Nemeth 
et al., 2003; 2004; Nemeth and Ganz, 2006).  Hepcidin regulates iron metabolism by 
inhibiting iron adsorption from the intestines, iron recycling by macrophages and iron 
mobilisation from hepatic stores (Thurnham and Northrop-Clewes, 2007).  The essence 
of the nutrient and iron redistribution during inflammation have been thought to be 
protective; first against the effects of infection either by conserving nutrients or creating 
an environment that is not conducive for the survival of the invading pathogen 
(Thurnham and Northrop-Clewes, 2007), and secondly as anti-inflammatory, protecting 
against the potential pro-oxidant effects of iron and the exacerbation of tissue damage 
at the sites of inflammation (Thurnham, 1990; Thurnham, 1997).  There is also some   183
evidence to show that hypoferaemia might promote macrophage cytotoxicity (Rouault 
and Klaussner, 1996; Domachowske, 1997), though in iron deficient individuals it may 
be associated with a reduction in lymphocyte proliferation and activation (Brock and 
Mulero, 2000). 
 
In the short term, changes in the levels of biomarkers of nutritional status during the 
inflammatory process may be considered detrimental though probably minimal (Beisel, 
1998), but as a way of conserving nutrients or keeping them away from invading 
pathogens, it may be especially beneficial (Thurnham and Northrop-Clewes, 2007).   
However, in the long term hypoferaemia during a persistent infection or poor 
nourishment can further reduce nutrient levels and worsen an existing nutrient 
deficiency or impair tissue function (Thurnham and Northrop-Clewes, 2007).  These 
changes create conditions within the body that may increase the risk of anaemia by 
impairing RBC synthesis and/or shortening their lifespan (Jackson, 2007).   
 
The overall risk of anaemia during the inflammatory process may, however, be 
dependent on the presence of a metabolic iron deficiency as determined by the ability 
of the individual to maintain iron stores through iron absorption, iron loss and the 
dietary intake of bioavailable iron (Thurnham and Northrop-Clewes, 2007).  Maintaining 
normal iron stores can be very difficult for persons under chronic inflammatory stress 
as the inflammatory process, and specifically hepcidin, is known to restrict iron through 
its main regulatory route of absorption (Cox and Halsall, 2003).  Although assessing 
hepcidin levels may have been very useful in showing the effects of inflammation as 
well as the occurrence of iron maldistribution, the observed tendencies for shifts in 
APPs and nutrients that are characteristic of the inflammatory process may be good 
indicators of inflammation in the study population.   
 
Nevertheless, apart from the inhibitory actions of hepcidin on iron absorption, other 
limitations on absorption and utilisation of iron could have been imposed either by 
riboflavin deficiency stemming from a poor dietary intake of diary products (Powers and 
Thurnham, 1981), or consumption of large components of substances (like phytates) in 
the diet that bind to iron (Halberg, 1981; 1982; Halberg et al., 1997).  Although these 
dietary limitations have not been established for the study population, a previous study 
that analysed the dietary intakes in this population (Vorster et al., 2004) suggests the 
likelihood that such poor dietary practices with combined effects of infection and 
inflammation may be mediating the anaemia in the study population.   
 
In many developing countries and poorly-resourced settings such combined influences   184
from infection, inflammation and poor dietary practices are known to contribute to the 
high prevalence of anaemia (WHO, 2001).  In addition, the anaemia emanating from 
such influences often tend to be mild, but nevertheless remains a major public health 
problem in these poor settings (Stoltzfus, 1997).  The largely mild anaemia in this study 
population coupled with the preponderance of ACI may therefore be considered as 
being consistent with the suggestion that infection and inflammation and perhaps poor 
dietary practices are important in the aetiology of anaemia in the study population.   
 
Though the effects of a mild but persistent anaemia can carry some adverse 
consequences (such as impairing cognitive capacity in children as well as increasing 
delivery of pre-term babies and reducing capacity to work in all persons) (Stoltzfus, 
1997; Black et al., 2004), the health risks associated with such mild anaemia are much 
lower compared to moderate and severe forms (Thurnham and Northrop-Clewes, 
2007).  Considering that mild anaemia comes with a comparatively lower health risk 
and has other beneficial effects may presuppose that most anaemia in this ‘apparently 
healthy’ study population could be an advantageous strategy (Thurnham and Northrop-
Clewes, 2007) or perhaps an adaptive, beneficial response to an underlying disease 
state, especially, in the HIV infected population (Zarychanski and Houston, 2008).  If 
these assertions are acceptable then a high prevalence of mild anaemia as is apparent 
in the study population or as may occur in any population with predominant 
inflammatory causes may have implications for iron therapy.  This may be particularly 
important considering that the approach to addressing anaemia in many such settings, 
which are often poorly-resourced, have centred mostly on supplementation with iron or 
iron therapy.  This approach at solving the problem of anaemia and iron deficiency has 
often been undertaken due to the misconception of equating iron deficiency to anaemia 
(Thurnham and Northrop-Clewes, 2007). 
 
Administering iron as therapy in circumstances where inflammatory tendencies exist 
has been known to increase vulnerability to infections (Prentice, 2008).  Much of the 
evidence for this helped in shaping the WHO Guidelines for Treatment of Severely 
Malnourished Children, which recommended the withholding of iron therapy to 
malnourished children until wide-spectrum antibiotics have been used to control 
bacterial infections, especially in malaria endemic areas (Prentice, 2008).  More 
recently the Pemba trail (Sazawal, 2006) gave impetus for further caution in iron 
supplementation programmes to prevent iron deficiency in infants and young children 
in malaria-endemic areas (WHO, 2007).   
 
Though it has been argued that the detrimental effects of iron therapy were confined to   185
iron replete subjects (Stoltzfus, 2007), the need to weigh the balance of effects before 
any such interventions, as suggested by Prentice (2008), is very pertinent.  In HIV and 
other viral infections iron may play a number of roles including its ability to increase the 
proliferation of the viral agent (Drakesmith and Prentice, 2008). There is also evidence 
to suggest that elevated ferritin levels or iron stores strongly predict disease severity 
and earlier mortality in HIV infected persons (McDermid et al., 2007; Rawat et al., 
2008).  Together with studies that may relate the occurrence of iron accumulation in the 
tissues of infected persons to an increase in viral replication (Boelaert et al., 1996; 
Weiss, 1999), the need for caution in administering iron as therapy for infected persons 
especially with anaemia becomes imperative.  
 
Another important consideration in this interrelationship between anaemia, iron 
metabolism and HIV infection is vitamin A deficiency.  Vitamin A deficiencies have 
been associated with both HIV infection (Fawzi, 2003; Friis, 2005) and anaemia 
(Fishman et al., 2000; Dreyfuss et al., 2000; Gamble et al., 2004).  Vitamin A deficiency 
may increase the risk of iron deficiency and anaemia particularly because it alters the 
absorption, storage and release or transport of iron to the marrow (Semba and Bloem, 
2002) by enhancing the inflammation-induced sequestration of iron as well as other 
responses to infections that tend to increase the risk to anaemia.  Epidemiological 
surveys show that the prevalence of anemia is high in populations affected by vitamin 
A deficiency in developing countries whilst improvement of vitamin A status has 
generally been shown to reduce anaemia (Semba and Bloem, 2002; Thurnham and 
Northrop-Clewes, 2007).  However, the influence of vitamin A deficiency on anaemia 
can be complicated by concurrent chronic infectious disease as they may alter both the 
distribution of vitamin A and iron independently or impact directly on the vitamin A-iron 
pathway.  The significant tendencies for anaemic HIV infected persons in the study 
population to be vitamin A deficient may therefore be attributed to the influence of 
perhaps the virus as well as the pervasive inflammatory tendencies conferred by the 
virus and other inflammatory stressors within the population.  Clearly, if adequate 
supplementation of vitamin A can ameliorate iron deficiency anaemia in deficient 
individuals, especially, residing in places where causes of inflammation abound 
(Kolsteren et al., 1999; Semba et al., 2001) then there is a possibility that HIV infected 
persons who are iron deficient may benefit from such interventions.  
 
Regardless of the magnitude of factors that may be collectively responsible for 
anaemia in the study population, the significant differences in anaemia prevalence 
between the infected and uninfected populations as well as the tendencies for 
exacerbated anaemia, a lower [Hb] and a significantly lower Hct, significantly higher   186
serum total proteins and globulin levels and lower serum albumin levels in the infected 
population, may buttress the greater impact of HIV, and perhaps its potential interactive 
effects, on anaemia.  Even though it has been suggested earlier that the inflammatory 
effects of HIV can induce anaemia, it is perhaps its ability to directly destroy stromal or 
erythrocyte precursor cells (Davis, and Zauli, 1995; Levine, 1999; Redd et al., 2007) 
and also suppress the bone marrow (Hambleton, 1996) that is crucial for 
haematopoiesis.  These direct effects may be distinguished from the concurrent effects 
of medication, OI and nutritional deficiency.   
 
The inflammatory effects of HIV infection, much like most other infections, are 
mediated by inflammatory cytokines (Means, 1995; 2000).  However, HIV, by virtue of 
its persistence and ability to proliferate rapidly makes it a perpetual or chronic 
inflammatory disease.  Even with potent ARV the virus remains undefeated being able 
to mutate and remain quiescent in latent reservoirs.  Researchers are coming to a 
general consensus that the formidable impact of HIV on a large number of health 
outcomes, including anaemia, in the infected population is due to inflammation (Wohl, 
2009).  Whilst inflammation in HIV infection is not a cause of disease, it may result from 
the HIV and other stressors like those related to co-infections and/or therapy.  It is 
perhaps the collective influence from these stressors that would determine the total 
burden of inflammation in an individual and which may enhance the inflammatory 
effects of  a mild HIV infection.  Such inflammatory effects in HIV infection have been 
significantly linked with a reduction in erythropoietin synthesis and response (Spivak et 
al., 1989) and deficiencies of several vitamins (Volberding et al., 2004), which have all 
been associated with anaemia.  
 
The combined effects of all the factors that can be ascribed to HIV constitute a great 
arsenal for the virus in inducing anaemia in infected persons but, more often than not, 
have been regarded as more likely to manifest in advancing HIV disease or AIDS.  
Nevertheless, associating asymptomatic HIV infection with significant levels of anaemia 
such as in this study and others (Hoxie, 1995; van Den Broek et al., 1998; Ayisi et al., 
2000), may indicate the significant ability of the virus on its own to predispose victims to 
anaemia, more especially, when the effects of HIV are considered independently of 
concurrent inflammation and medications (van Den Broek et al., 1998).  Nevertheless, 
the significant effects of the HIV on anaemia in a population may only be assumed to 
be independent of inflammatory influences since the mere presence and tenacity of the 
virus, even in apparently health victims, is accompanied by mild, atypical (Jahoor et al., 
1999) and persistent inflammatory responses. Even if undetectable at times the 
inflammatory influences from HIV may still be pervasive, which is why the infection is   187
designated as chronic.   The results in this current study, which has similarities in terms 
of the outcome of anaemia with the study by van Den Broek and colleagues, depicts a 
possibility of inflammatory influence on anaemia in asymptomatic HIV infection.   
 
In both studies CD4+ cell counts and other indicators of disease progression were not 
available.  Furthermore, clinical examinations to exclude cases that might fulfil the 
definitions of AIDS, as well as the apparently healthy state conferred by the selection 
criteria allowed subjects to be categorised as asymptomatic.  On the other hand there 
were differences in the subjects and markers of inflammation.  Whilst pregnant women 
were the subjects and CRP was the only inflammatory marker used in the van Den 
Broek study, the current study excluded pregnant women and children and relied on 
several other APPs (serum total proteins, ferritin, globulins, albumin and plasma 
fibrinogen) as well as proxy markers (serum GGT, ALP, ALT and AST) as indicators of 
inflammation.   
 
Measuring CRP may be important for marking acute inflammation as it tends to rise 
and fall sharply with inflammation (Northrop-Clewes, 2008).  This should make its use 
alone as highly unsuitable for marking chronic inflammation.  In any ‘apparently 
healthy’ HIV infected population, the measurement of a chronic but considerably mild 
inflammation (Jahoor et al., 1999) with CRP may not yield a significantly noticeable 
difference between infected and uninfected groups as the van Den Broek study has 
confirmed.  The APR of HIV infection, especially in asymptomatic persons, would 
require a marker that can measure the sustained presence of the stimulus or even long 
after the stimulus is removed.   Because of the extensive influence of inflammation on 
iron status, the use of ferritin with other APPs has been recommended (WHO, 2004).   
Increases in ferritin levels are not only induced by cytokines (Kobune et al., 1994), but 
the rise in ferritin levels tend to parallel that of CRP (Feelders et al., 1998), confirming it 
as an APP.  However, levels of ferritin and some other APPs fluctuate much slower 
and may remain active during the APR (Northrop-Clewes, 2008).  Marking 
inflammation with serum ferritin and the other APPs in the present study has revealed 
that, even in an apparently healthy population, inflammatory tendencies, which may not 
be obvious, can still be noted.  The shifts in the APPs used in this study, i.e. serum 
ferritin, plasma fibrinogen, serum globulins and albumins, were consistent with changes 
in plasma proteins associated with the APR.  
 
However, serum ferritin acts as an indicator of iron stores and so the degree to its rise 
is influenced by the underlying iron status of the individual (Northrop-Clewes, 2008).  
What is notable is that inflammatory tendencies were depicted in the uninfected   188
population as well inferring from the higher ferritin and plasma fibrinogen levels, but 
nevertheless, the overall effects of inflammation on anaemia seem to have been 
accentuated in the infected population. Though anaemia in infected persons was 
associated with comparatively lower serum ferritin and plasma fibrinogen levels 
albumin levels were much lower.  In addition, anaemic infected persons had similar 
risks levels for liver enzymes as their uninfected peers.  Since this may suggest a 
lowered tendency for insidious damage to the liver, it may be consistent with the 
suggestion that the most type of anaemia in this population is protective and perhaps 
an adaptive strategy.  In addition, the lower ferritin and fibrinogen levels and the 
significantly lower albumins may presuppose that the body of infected persons may 
place a premium on producing materials for defending itself against the infection to the 
detriment of synthesising transport proteins (Jahoor et al., 1999) and perhaps 
haemoglobin resulting in the higher predisposition to anaemia.   
 
It is more appropriate to suggest at this point that the lower ferritin levels in the infected 
anaemics could be due to the restrictions placed on its synthesis as a result of the low 
serum iron levels, which may have resulted from either, the inflammatory blockage of 
absorption or dietary restrictions or both. The implication here is that in HIV infection 
anaemia is more likely to occur in persons who are iron deficient irrespective of the 
cause of the iron deficiency.  This ties in well with the greater tendencies for iron 
deficiency, IDA and ACI as defined in the study and more likely to be associated with 
the infected population.  
 
Whatever the mechanism that lowers serum albumin levels, hypo-albuminaemia may 
have significance in the development of anaemia as albumin may constitute a major 
protein reserve usually available for meeting hepatic syntheses as well as haem and 
RBC production to meet the rapidly changing demands of the body for oxygen carriage 
and energy synthesis (Jackson, 2007), especially when the body’s metabolism is 
altered.  Although a poor nutritional status could account for the reduced levels of 
serum albumin, much of this lowered effect could have been due to cytokine regulation 
or leakage into the interstitial space during the inflammatory process (Tomkins, 2003).  
The link between hypo-albuminaemia and anaemia in HIV infected persons has been 
shown in a study by Shah and colleagues (Shah et al., 2007), which also suggested 
that both albumin and haemoglobin could serve as important markers of HIV disease 
progression.  
 
In this comparative study it is important to recognise that a number of the factors 
compared between the infected and uninfected population, including exposure   189
variables used to assess inflammation, serum micronutrients as well as iron status and 
some outcome variables that classified anaemia, were not significantly different 
statistically, and as revealed by post hoc power calculations (Appendix C) were highly 
underpowered.  Important considerations that may have determined this under-
powering of comparative statistics were the effect sizes and the sample sizes.  Having 
been predetermined from the use of a secondary data source, there is a high 
probability that an adequately powered study could have provided clearer and more 
conclusive answers to the propositions in this study.  However, even for those which 
presented with statistically significant differences, there is an absolute need to be 
cautious in their interpretation as statistical significance does not always connote 
biological significance.   
 
On the other hand, there is some possibility that outcomes with biological significance 
may not necessarily result in statistical significance.  A biological significance is 
important and becomes imperative when differences in biological parameters relate to 
physiological or functional differences, and in cases where statistical significance is not 
obtained, a biological significance must be explored and results interpreted 
accordingly.  
 
 For instance, differences observed in serum levels of albumin and globulins between 
infected anaemics and their uninfected counterparts were very significant (p<0.001).  
However, whether the real differences obtained between the two sero-status groups by 
comparing the mean values of albumin (2.28g/l) and globulins (6.63g/l) have any 
biological significance is another issue worth considering.  Even though the mean 
values of serum albumin in both groups were within the lower fringes of normal, lower 
levels are associated with fatal risks (Goldwasser and Feldman, 1997) and in HIV 
infected persons it marks changes in early infection and disease progression (Feldman 
et al., 2003).  Graham and colleagues (2007) showed that every 1 g/l reduction in 
serum albumin was accompanied by a 13% increase in disease progression.  Thus in 
this study, the differences in serum albumin levels between the two groups can be said 
to have both statistical and biological significance.  In effect, the grand impact of HIV 
and its attendant effects on the victim as well as its potential to interplay with other 
anaemia-inducing effects in the environment may be considered most plausible in 
explaining differences in the prevalence of anaemia and its exacerbated forms between 
the two groups in the study population.  The significant differences between the 
infected and uninfected populations in inflammatory markers, coupled with that of 
anaemia as measured by Hct and exacerbated forms, strongly suggest that HIV 
infection may induce inflammation even in asymptomatic infection that is perhaps   190
potent enough to influence the development of anaemia in the infected population.  
 
7.3  LIMITATIONS OF THE STUDY 
The study has been presented with a number of limitations some of which can be   
related to the limitations inherent in the design of the original THUSA survey from 
which secondary data was obtained.   These limitations generally have determined, to 
a very large extent, the interpretations to the outcomes in this study and calls for 
caution in relating these findings to the wider country and provincial populations as well 
as to the general HIV/AIDS population. 
 
The design of the THUSA study, which was a cross sectional collation of data on 
dietary intake, nutritional status and other variables of health, socio-demographic and 
lifestyle characteristics in an African population (precluding the identification of HIV 
status), made it appropriate for characterising or observing the study population with 
respect to the different parameters measured.  It would therefore allow for the 
description of the study population in terms of how certain exposures may relate to 
outcomes without any control over any exposure of interest (Margetts and Nelson, 
1997).  Thus, it may provide a snapshot of the prevalence of a condition in the study 
population.  Such a design also allows the exploration of relationships between 
exposures and outcomes but does not allow the determination of causality between 
them (Margetts and Nelson, 1997).  Thus, the relationships proposed in the present 
study may not necessarily indicate causality.   
 
Since the outcome and exposures are dynamic phenomena, it would have also been 
more appropriate to use a cohort or longitudinal study to establish a causal pathway 
between the exposures and anaemia in the study population.  Nevertheless the 
outcome results from this study could serve as a basis for further work in a specially 
designed longitudinal study to establish causality.  
Another important limitation was imposed by the exclusion criteria, also inherent from 
the THUSA study design.  Since the original survey was not intended to address the 
current objective, many potential HIV infected subjects were excluded.  The exclusion 
of pregnant women and children as well as individuals who may have signs associated 
with HIV is a cause for this limitation.  According to the UNAIDS (2006 and 2008), 
pregnant women and children, especially in regions where the pandemic is unrelenting, 
are the most vulnerable population groups with very high prevalences of HIV infection. 
Thus, any measure of HIV prevalence in the study population may not truly represent 
prevalence in the entire Province or country, which therefore limits any generalisations 
based on study outcomes to the entire population.  By extension, the under-  191
representation of infected persons compared to their uninfected peers is the 
consequence of this limitation, which is probably the basis for statistical under-
powering in some of the comparative analyses and especially in those where 
stratification of data by socio-demographic characteristics were done.  This has been 
confirmed in post hoc power calculations.  
 
The cross-sectional quasi-random design also meant that potential confounders or 
effect modifiers such as age and sex could have been a source of bias, especially as 
they were not equally distributed between the two groups being compared, which could 
lead to spurious interpretations concerning the findings.  However, to address the 
problem of bias, adjustment controls have been made for these potential confounders 
in the analyses of data. 
 
The use of a prevalent cohort of HIV-seropositive persons whose duration of infection 
was not known, further limited the extent to which the interactions between HIV and 
anaemia could be explained.  The difference in study objectives precluded the inclusion 
of variables that could be described as HIV related, such as date of initial infection, 
CD4+ cell counts, viral load (or antigen titres), opportunistic infection and medications 
and drugs, which have been shown to be associated with anaemia in the HIV/AIDS 
population (Volberding et al.,, 2004).  Thus, knowing the sero-status of subjects was 
not enough to indicate duration or degree of exposure to the virus for subsequent 
adjustments in analyses.  This limitation hampered the categorisation or staging of 
infected subjects according to the CDC criteria, and in according risks to these 
categories as well as for making adjustments during analyses.  The importance of this 
limitation becomes apparent when HIV is related directly to anaemia, specifically 
because HIV has a direct involvement in the causation of anaemia and more so 
because higher levels and severer anaemia are associated with advanced HIV 
disease.   
 
Since data for this study was based on a secondary source, there was a limit to the 
availability and use of relevant data to address the current hypothesis.  Apart from the 
absence of data to assess duration and intensity of the infection, most variables were 
adapted for answering the various propositions in this study.  This meant that whilst 
some data were inadequate some others were considered more as proxies.  For 
instance, since HIV infection is recognised as a chronic inflammatory disease, and 
inflammation may be associated with anaemia, data on inflammatory cytokine levels 
(e.g. TNF-α, IL-1, IL-6 or INF-γ) would have been most appropriate to mark 
inflammation.  On the other hand, since the use of markers that closely parallel the   192
release of inflammatory cytokine (such as  CRP or α-anti-chymotrypsin – ACT or AGP) 
are accepted they could have been used.  This notwithstanding important acute phase 
proteins (serum ferritin, plasma fibrinogen, serum globulins and serum albumin) as well 
as serum liver enzymes (GGT, ALP, ALT, AST and LDH), which were close proxies, 
were selected as marking inflammation and/or increased metabolism in the study 
population.  Results from the use of these variables may not necessarily be conclusive.  
In addition, some data for depicting micronutrient deficiencies were inadequate (serum 
vitamin B6 and B12), leading to under-powering and constraining of statistical 
interpretations.   
 
In general, the effects of HIV on energy and nutrient intake is based on the argument 
that the infected population are asymptomatic, and  because HIV related factors that 
are likely to affect food intake such as anorexia, and other gastrointestinal disturbances 
have not been accounted for, a poor dietary energy and micronutrient intake could not 
be associated with the infection.  There is also likelihood that other factors that are 
beyond the scope of this study, but which may have influences on the relationship 
between HIV infection and anaemia (such as physical activity levels) could limit the 
interpretations of the findings in this study. 
 
7.4  IMPLICATIONS OF THE STUDY FOR PUBLIC HEALTH 
There is no doubt that HIV/AIDS is an important public health problem especially in 
most developing countries and resource-poor settings where it continues to advance. 
In most such places anaemia prevalences are often high and HIV infection may be an 
important aetiological factor.  The factors that relate HIV infection to the problem of 
anaemia are many and may be considered as either HIV–related or HIV–unrelated.  
However, nutrition and inflammation may be at the heart of these two problems, which 
calls for paying attention to both nutrition and the causes of inflammation in addressing 
the problems.  
 
The findings in this study add to the suggestion that HIV has a significant and crucial 
role in the development and exacerbation of anaemia, HIV/AIDS may add to the 
problem of anaemia, especially, in regions where its prevalence is on the rise, and 
other factors that may prime both problems abound.  It also adds to the suggestion that 
the aetiology of anaemia in HIV infection, and even in asymptomatic infection, may be 
multifactorial and chronic inflammation might be an important contributor.  This calls for 
an ‘all hands on deck’ approach to addressing the problem.  Essentially, for any public 
health effort to be effective in controlling anaemia in HIV/AIDS or anaemia and 
HIV/AIDS, it must be geared toward an integrated focus and tailored to meet the   193
particular needs and opportunities within the country or region where the problem is 
(Kraemer and Zimmermann, 2007).   
 
Many public health programmes have failed to address the problem of anaemia 
because they have not only failed to recognise its multifactorial cause among other 
reasons, and often programmes are designed with the assumption that iron deficiency 
is the sole cause of anaemia.   
 
The importance of inflammation as an aetiological factor of anaemia in HIV infection, as 
well as in a population, which may not only be resource poor, but may have undefeated 
infectious diseases and infestations that provoke inflammation, has been highlighted in 
this study.  In many instances administration of iron as supplements or treatment for 
anaemia, in individuals or populations with inflammatory tendencies, has often met with 
adverse effects or unresponsiveness.  Inflammation may even be the major factor 
restricting haematinics to the bone marrow and reducing erythropoiesis.  The strategy 
for addressing anaemia in this context would be to identify the inflammatory causes 
and addressing them as a primer or an adjunct to the main treatment.  The control of 
endemic malarial, helminthic infestations and other infectious diseases, especially in 
vulnerable groups, must be part of the integrated approach as well as ensuring that 
poverty, unsanitary conditions and inadequate health care, all of which encourage the 
spread of disease, are tackled appropriately. 
 
As part of the integrated approach, it is important to recognise individuals or 
populations that may be particularly vulnerable to poor nutrition.  Despite this study 
showing a large proportion of the study population as most likely undernourished, HIV 
infected persons, because the disease places a higher burden on their nutritional 
requirements, can be considered to be more vulnerable.  If there is any need to provide 
supplements in this group for anaemia, then ameliorating inflammation as has been 
demonstrated with vitamin A administration (Thurnham and Northrop-Clewes, 2007) 
must be considered.  Otherwise, food based approaches that aim at dietary 
diversification and meeting requirements for RBC production must be targeted. 
 
 In most of the developing world where HIV and anaemia coexist as major problems 
standard treatment and care of patients for, especially, these two conditions are 
restricted to just a few due mainly to poor resources.  Even where treatment is 
available, the two conditions are considered independently.   This study has shown that 
there is a very high possibility that being infected with HIV would result in the victim 
becoming anaemic or if anaemia was present prior to the infection it was likely to   194
worsen with infection.  Indeed, anaemia may even be the first sign of the infection, 
which means that once a person has been diagnosed as being HIV positive an 
assessment of anaemia must be required.  In such poor settings, a simple assessment 
of anaemia could also be used to monitor the progress of the disease since anaemia is 
a useful marker of disease in infected persons. 
 
Considering that current efforts are geared toward scaling up of ART and care in 
resource-poor settings, it becomes imperative that anaemia is included in the central 
issues in initiating therapy as well as in choosing which medications to administer.   
Clearly, anaemia being an independent risk factor for disease progression and survival 
is potentially a good indicator of rapid clinical deterioration in HIV infected persons, 
especially in resource-poor settings.  In times when efforts to eradicate the virus 
through various therapies is not yielding, it would be a prudent idea to consider the 
prevalence of anaemia in patients awaiting HAART particularly with regards to the 
choice of medication as certain ARVs have been known to induce or exacerbate 
underlying anaemia.   
 
Anaemia has remained a common and prevalent public health problem in South Africa 
among women and children especially (Eley et al., 2002).  With HIV and other 
infectious diseases remaining undefeated in the population, anaemia is more likely to 
become a bigger problem, which would invariably add to the increasing health burden.  
If the increasing trend should continue, then both HIV and anaemia are likely to have a 
detrimental impact on the socio-economic development of the country.  The approach 
to controlling these problems, as has been reiterated would lie in an integrated 
approach, which places inflammation and nutrition at the core of the solution. 
 
Although there may be many aetiological factors responsible for low iron status in HIV 
infection, the possible deleterious effects of iron administration as part of the treatment 
of iron deficiency and anaemia should be given critical consideration.  While the 
relationship between infection/inflammation and iron status remain contentious, the 
association of iron overload in HIV infection with increased susceptibility to the virus 
and other OI (Boelaert et al., 1996) should invoke caution in the liberal administration of 
iron therapy or prophylaxis in infected populations.   
 
7.5  RECOMMENDATIONS FOR FUTURE WORK 
The nature of this study provides many opportunities for research to further elucidate or 
clarify some of the issues raised.  Primarily, there is a need for a longitudinally 
designed research that would address the causality of asymptomatic HIV infection and   195
anaemia.  This should look at the direct effects of the virus on erythropoiesis, the HIV-
related effects as well as the HIV-unrelated effects, both of which may include 
inflammation and other co-infections.   
Where resources and time are important constraints, and there is a need for a cross-
sectional study, then the design should include the collection of data on more 
appropriate measures of exposures and outcomes. The need to measure, for instance, 
HIV disease intensity by CD4+ and viral load as well as inflammation by more specific 
inflammatory markers including cytokines and/or APPs as well as hepcidin must be 
included in order to establish causality. 
 
It is important to also measure the environmental stressors and take into consideration 
other potential and competing causes of anaemia in the entire population.  These may 
include OI and endemic infections (Malaria, helminthic infestations, etc) as well as 
genetic disorders (sickle cell disease, thalassaemias, G-6-PD, etc) in order to account 
for their contributions or to include them in the causal inter-relationship between HIV 
and anaemia.  The particular influence on anaemia provided by the inflammatory 
effects of the virus must not be underestimated.  Similarly, the inflammatory stresses 
provided by sub-clinical endemic infections like malaria and helminthic infestations 
must be taking into account. 
 
The ultimate aim for identifying persons at high risk for anaemia in a population would 
be to help in charting appropriate treatment pathways or institute appropriate 
interventions especially for those who may belong to the vulnerable population.   
Therefore, any future work must take into consideration steps at identifying the different 
sub-groupings within the population that may be highly vulnerable to anaemia.  This 
may be particularly important for public health intervention and for a cost-effective 
intervention approach. 
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CHAPTER EIGHT 
8.0 CONCLUSIONS 
In this study the inter-relationships between HIV infection and anaemia has been 
explored.  The hypothesis was that ‘HIV infected persons are more anaemic compared 
to their uninfected counterparts’.  In considering that HIV infected persons were 
significantly more likely to be associated with anaemia (indicated by Hct) as well as 
mild, moderate and severe forms of anaemia demands the acceptance of the 
hypothesis.  This would make HIV infection in asymptomatic individuals a very 
significant determinant of anaemia, especially, in the study population. 
 
The high levels or prevalence of anaemia in both study population groups presupposes 
that HIV alone is not responsible for anaemia in the population, and considering the 
observed inflammatory tendencies, inflammation generally can be said to be 
contributory to the public health significance of anaemia in the study population.  In 
drawing the framework for this study a large number of intermediary factors were 
considered as likely to be part of the inter-relationship between HIV infection and 
anaemia.  The direct effect of the virus, though not measured, was considered crucial 
in the linkage as were effects associated with inflammation.  Indeed, the combine 
effects of inflammation perhaps emanating from different inflammatory stressors 
(including the HIV) and producing changes in body nutrients and proteins that may be 
described as subtle but effective in the long run may be considered as significant 
determinants of anaemia in the study population. 
 
Tendencies for nutrient deficiencies, especially, in iron and vitamin A, which were more 
likely in the infected population, could be considered as due to the effects of 
inflammation since inflammation is known to cause a redistribution or alteration in the 
production of transport proteins for these micronutrients.  This further buttresses the 
significant influence of inflammation in determining anaemia in the study population. 
 
The effects of HIV in this asymptomatic population were not significantly expressed as 
changes in food intake and body composition, perhaps because the infection was at its 
early stages.  Thus, factors that may lead to a reductive adaption such as anorexia and 
a reduction in lean body mass were not clearly distinguishable.  These were, therefore, 
not considered to significantly contribute to or determine anaemia as the study has 
shown.  In spite of the limitations of this study, the evidence points to the fact that HIV 
infection, even in asymptomatic individuals, serves as a significant risk for developing 





ASSESSMENT OF ANAEMIA   
Since iron deficiency is the most important and widespread micronutrient deficiency 
associated with nutritional anaemia, assessing iron status is very valuable and most 
crucial for identifying nutritional anaemia (Biesalski and Erhardt, 2007).  Generally, 
however, most of the methods represent an assessment of the functional capacity of 
the blood.   
 
Although some clinical indicators for iron deficiency, such as chronic fatigue as well as 
dietary assessments of intake (haem and non-haem) have been used to assess 
anaemia, the most relied upon are, however, laboratory or biochemical measurements.  
 
By far, the most common of these measurements are Hb and Hct determinations from 
erythrocytes and whole blood.  These measurements have helped screen anaemia and 
putative iron deficiencies as they reflect the largest iron compartment in the body 
(Biesalski and Erhardt, 2007).  They can be quite easy and inexpensive to run and very 
essential, especially, in the diagnosis of nutritional anaemia.  However, the 
measurement of Hb and/or Hct is not very sensitive or specific, especially, for detecting 
iron deficiency (Cook, 2005).  Therefore to better evaluate iron status and identify most 
forms of anaemia, it has been agreed to measure Hb, ferritin and sTfR, complemented 
with indicators of acute or chronic infections, which has rendered the procedure quite 
difficult and comparatively expensive (Biesalski and Erhardt, 2007).  Descriptions of 
some measurements used to indicate anaemia in the population are presented below. 
 
ASSESSMENT OF ANAEMIA BY WHO CRITERIA 
Haemoglobin (Hb):  Haemoglobin is the iron containing pigment in the RBC that 
carries oxygen from the lungs to the cells of the body for metabolism.  Hb is composed 
of two pairs of globin chains and four haem groups containing ferrous iron.  It is 
commonly measured by automated spectrophotometry in which the red cell is lysed 
and the Hb concentration is determined by measuring the iron-containing pigment.  Hb 
thus provides a direct measurement of the oxygen carrying capacity of the blood.   
 
Haemoglobin concentration is a relatively easy and inexpensive measurement 
involving the dilution of only a small amount (about 20µl) of whole blood in Drabkins’ 
reagent and measuring the absorption at 540 nm with a spectrophotometer.  The 
amount of Hb in the RBC is measured in grams per decilitre (g/L) of blood.   
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When the concentration of Hb in the blood falls to a level where oxygen carriage is 
compromised anaemia is said to occur.  In healthy persons the Hb levels may show 
wide variations, but generally, adult men tend to have higher values than women and 
children (Sacher and McPherson, 2000).  Based on conventional cut-off values 
(WHO/UNICEF/UNU, 2001), Hb levels have been used to distinguish between anaemic 
and non-anaemic persons, as well as between stages of anaemia, i.e. mild, moderate 
and severe, in the population (see Tables A1 & A2 below).   
 
There are a number of conditions that influence Hb concentration.  For instance, sex, 
age and pregnancy as well as race (being of African descent may lower the Hb levels 
by about 0.5 to 1.0 g/dL); smoking also can increase it by about 0.3 to 0.7 g/dL whilst 
living in an altitude may increase it for up to about 2.0 g/dL (Gibson, 2005).   
 
Haematocrit (Hct):  Also known as the packed cell volume (PCV), Hct is the ratio of 
the volume of packed RBCs to the total blood volume.  When whole blood is 
centrifuged or spun it separates into two main layers, the blood cells and plasma.   
Between the RBCs and plasma is a layer, the buffy coat layer.  This constitutes approx. 
1% and consists of white blood cells and platelets and is therefore not calculated as 
part of the PCV.  Thus the RBCs make up around 99% of the cells and the rest are 
white cells and platelets.  The haematocrit is reported as a percentage or a ratio.  Hct 
can be determined either by automated blood-counters or by microhaematocrit (or 
spun) readings.  In the case of automated complete blood count equipment, the Hct is 
a calculated percentage derived from the product of two red cell indices: the red blood 
cell count and the average size of red blood cells (also referred to as the mean 
corpuscular volume, or MCV).  In healthy adult individuals the red blood cells constitute 
approx. 40-48%, i.e. less than half of the blood, whereas newborns may have 
haematocrits of up to 60% (Soldin et al., 1995).   
 
In contrast to Hb, Hct provides an indirect measurement of the body's oxygen-carrying 
ability.  Cut-off values have been determined for defining anaemia in a healthy 
population (WHO/UNICEF/UNU, 2001) (see Table A1 below).   
 
Haemoglobin and Hct continue to be the hallmark laboratory parameters for monitoring 
and managing anaemia in most patients.  Because of a seemingly close correlation 
between Hb concentration and Hct in normal conditions, these two have been used 
interchangeably and, roughly, the Hct has been estimated as three times the Hb 
concentration (Sacher and McPherson, 2000).  Despite the seemingly close correlation 
between Hct and Hb concentration in measuring anaemia it remains even less   199
sensitive compared to Hb (Biesalski and Erhardt, 2007).  However, different studies 
have shown that the two parameters are not comparable, but that they have their 
separate applications (Graitcer et al., 1981; Young et al., 1986).  
 
The tables below (Tab. A1 & A2) depict the WHO recommended cut-offs for measuring 
anaemia and graded form respectively for different population groups.  The cut-offs are 
based on measurements in a healthy population at sea level, and ranges from 110 g/L 
or  33 in pregnant women and children below 5 years to 130 g/d or 39 in adult men, for 
[Hb] and  Hct respectively. 
 
Table  A1: Normally used haemoglobin and haematocrit cut-offs to define 
anaemia in healthy persons living at sea level (WHO/UNICEF/UNU, 
2001). 
Age or sex group  Haemoglobin below (g/dL)  Haematocrit below (%) 
Children 6 to 59 months    11.0  33 
Children 5 – 11 years  11.5  34 
Children 12 – 14 years  12.0  36 
Non-pregnant women  12.0  36 
Pregnant women  11.0  33 
Men 13.0 39 
 
 
Table A2: Normally used haemoglobin cut-offs to define stages of anaemia in 
healthy persons living at sea level (WHO/UNICEF/UNU, 2001). 
Age or sex group  Mild  Moderate  Severe 
Children 6 to 59 months    10.0-10.9  7.0-9.9  <7.0 
Children 5 – 11 years  10.0-11.4  7.0-9.9  <7.0 
Children 12 – 14 years  10.0-11.9  7.0-9.9  <7.0 
Non-pregnant women 15 years 
plus  10.0-11.9 
7.0-9.9 
<7.0 
Pregnant women 15 years plus  10.0-11.9  7.0-9.9  <7.0 
Men 15 years plus  12.0-12.9  9.0-11.9  <9.0 
 
According to the WHO, since Hb values change significantly with altitude, formulas are 
available to make adjustments for these changes to define anaemia at different 
altitudes. 
 
OTHER MEASUREMENTS FROM ERYTHROCYTES (RBC) 
RBC count: This is the total number of erythrocytes or RBCs measured in a cubic   200
millimetre (mm
3) of blood and often denoted by millions of RBCs per mm
3, which 
represents the density of blood cells in whole blood.  A low RBC count indicates 
anaemia whilst a higher than normal count may indicate an overproduction or 
polycythaemia.  Under normal circumstances RBC counts are higher in men than in 
women.  Whereas overhydration can lower the RBC count dehydration is noted to have 
the opposite effect (Sacher and McPherson, 2000).   
 
Reticulocyte count:  This is a measure of the number of immature RBCs that have 
been released from the source of production (bone marrow) into circulation.  After their 
release from the bone marrow, reticulocytes take between 4 to 5 days to mature.  The 
reticulocyte count gives an indication of how well the bone marrow is functioning or 
responding to erythropoietin.  A normal reticulocyte count is from 0.5% to 2.5% and a 
low count may signify bone marrow failure or depressed erythropoietin synthesis 
(Sacher and McPherson, 2000).   
 
Mean corpuscular volume (MCV):  This refers to the relative volume or size of the 
RBCs.  When the MCV is low the RBCs are said to be microcytic or smaller than 
normal and when MCV is high then they are macrocytic or larger than normal.  The 
normal volume of RBCs ranges from 80fL to 98fL (Sacher and McPherson, 2000). 
 
Mean corpuscular haemoglobin (MCH) and Mean corpuscular haemoglobin 
concentration (MCHC):  The MCH is a measure of the average amount of Hb in the 
RBCs whilst the MCHC refers to that in a single RBC.  Low MCH or MCHC signifies 
hypochromic (pale colour) RBCs whereas high MCH or MCHC suggests that the RBCs 
are hyperchromic.  Normal MCH values range from 28 to 32 fL and MCHC values from 
32 to 36 fL (Sacher and McPherson, 2000). 
 
MEASUREMENTS OF IRON STATUS 
Serum iron:  Iron levels measured in serum constitute an indirect assessment of iron 
status as most of the iron is in transit.  Serum iron levels must therefore be evaluated 
side by side with serum transferrin, serum transferrin saturation and serum ferritin 
(Leclair, 1997).  A low serum iron level may indicate iron deficiency whereas a high 
serum iron level may be indicative of iron toxicity (Sacher and McPherson, 2000)...  
 
Serum ferritin: Ferritin is an iron-phosphate-protein complex made by the intestinal 
mucosa when iron combines with apoferritin (a protein produced by the liver).  Thus, 
iron is accumulated as ferritin which is primarily stored in the reticulo-endothelial cells 
of the liver, spleen and bone marrow (Sacher and McPherson, 2000).  Ferritin is   201
currently the most important indicator of iron status as serum concentrations tend to 
correlate well with iron stores.  It is the most sensitive in determining iron status as it 
shows a decrease even in the first stage of iron deficiency (Biesalski and Erhardt, 
2007).  Whilst a low ferritin level indicates storage iron depletion, a high value is not 
necessarily a sign of good iron status as infections and, especially, inflammation 
increases its levels.  Thus, it is very important to also measure parameters of acute and 
chronic infections in order to distinguish persons whose ferritin levels might be elevated 
by infection.  Parameters for indicating acute or chronic infection have included the use 
of C-reactive protein as well as Alpha-1 glycoprotein (AGP) (Biesalski and Erhardt, 
2007; Northrop-Clewes, 2008).  Cut-off values for serum ferritin are not very clear cut 
but have been set around 10 to 30 µg/L and values below 10 or 15 µg/L are certainly 
more indicative of iron deficiency (Biesalski and Erhardt, 2007; Northrop-Clewes, 
2008). 
 
Serum transferrin/transferrin saturation: Serum transferrin measures the amount of 
transferrin, an iron-binding globulin in the blood that is responsible for binding and 
transporting iron.  Transferrin levels increase as the plasma levels of iron drops (iron 
deficiency) and decreases during chronic illnesses and in hypoproteinaemic states 
(Sacher and McPherson, 2000).  Serum transferrin saturation on the other hand is a 
measure or calculation to indicate how much iron is available for Hb synthesis.  It is 
calculated from the measurements of serum iron and total iron binding capacity (TIBC), 
which is a measure of the available sites for iron binding in the blood.  The calculation 
is obtained by dividing the iron concentration by the TIBC and multiplying by 100 to 
express as a percentage (i.e. serum transferrin saturation = serum iron/TIBC x 100).   
Values should be at least 20% to ensure that there is enough iron in the blood to meet 
the requirements of Hb synthesis.  Any values that fall below this mark may indicate 
iron deficiency (Sacher and McPherson, 2000). 
 
Soluble transferrin receptors (sTfR):  Transferrin receptors (TfR) are transmembrane 
protein receptors that bind and internalise transferrin, thereby delivering iron to the 
cytosol (Beguin, 2003).  Mostly found on erythroid progenitor cells, TfR expression is 
increased to facilitate iron uptake when a cell needs iron.  Proteolysis of these 
membrane receptors leads to the soluble monomers that can be measured in plasma 
and serum and referred to as sTfR.  STfR concentration which marks a need for iron or 
erythropoietic activity is elevated in iron deficiency.  Unlike the other measures of iron 
status, sTfR is not affected by chronic disease or inflammation (Beguin, 2003).   
Because sTfR concentrations tend to increase in the second stage of iron deficiency, 
after the iron stores are exhausted and Hb concentration is still above the cut-off, it is a   202
less sensitive parameter than ferritin but more sensitive than Hb (Biesalski and Erhardt, 
2007).  Unfortunately it has no internationally standardised method of assessment and 
it is still very expensive. 
 
Zinc protoporphyrin (ZnPP):  During iron deficiency the iron in protoporphyrin can be 
replaced by zinc, which can be measured by specific methods (Biesalski and Erhardt, 
2007).  The replacement of iron by zinc happens in the second stage of iron deficiency 
even before Hb levels fall under the cut-off values, which makes ZnPP a more sensitive 
parameter than Hb (Biesalski and Erhardt, 2007).  However, it is important to keep in 
mind when measuring ZnPP that lead can increase its levels in the blood (Biesalski 
and Erhardt, 2007). 
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APPENDIX B 
 
DEFINING AND ESTIMATING ENERGY REQUIREMENTS AND IMBALANCES IN 
THE STUDY POPULATION 
The recommended level of dietary energy and nutrient intake for a population group is 
the mean requirement of healthy, well-nourished individuals who constitute that group.  
For most nutrients, a certain excess of intake will not be harmful. Thus, when dietary 
recommendations are calculated for these nutrients, the variation among individuals in 
a population group is taken into account, and the recommended level of intake is then 
estimated as the amount that will meet or exceed the requirements of practically all 
individuals in the group.  This recommended level of intake, usually stipulated as the 
mean intake value plus two standard deviations (Mean + 2SD), can be satisfied with an 
average balanced diet.  However, for dietary energy, this approach is not applicable 
because intakes that exceed requirements will produce a positive balance, which may 
lead to overweight and obesity in the long term.   
 
DIETARY ENERGY INTAKE 
Experts have agreed that the best descriptor of the dietary energy intake that could be 
safely recommended for a population group is the estimated average energy 
requirement (EAER) of that group, whose derivation is illustrated in figure B1 below 
(WHO, 1985).    
 
Within the range of energy and nutrient intakes in a population, any levels that fall 
below the estimated average requirements are not likely to meet the body’s demands 
for these nutrients, which would make such intake levels inadequate.  This would mean 
that, any persons having such intake levels may be considered as having poor intakes. 
In contrast, persons whose intakes fall above the EAER have a higher probability of 
excessive intakes which could have detrimental consequences if maintained with time. 
 
Estimating poor or inadequate intake – Usual energy intake versus requirements  
In free-living, healthy and well-nourished adults, energy requirements are equivalent to 
total energy expenditure (TEE), and these requirements are estimated for meeting the 
energy demands of the body for basal metabolism (BMR), metabolic response to food 
and physical activity (PA).  In the absence of experimental data, energy requirements 
of adults can be calculated from factorial estimates of habitual TEE (FAO/WHO/UNU, 
1985).  This takes into account  body size, body composition and habitual PA 
irrespective of the geographic, cultural and economic background of the population.  
Among population groups of a given age and gender, BMR is relatively constant. 
Consequently, habitual PA and body weight are the main determinants for the diversity   204
in energy requirements of adult populations with different lifestyles (James and 
Schofield, 1990).   
 
Figure B1: Probability that a particular energy intake is inadequate or excessive 
for an individual* 
 
* Individuals are randomly selected among a class of people or a population group. The two probability curves overlap, 
so the level of energy intake that assures a low probability of dietary energy deficiency is the same level that implies a 
high probability of obesity owing to dietary energy excess.  Source: WHO, 1985. 
 
BMR estimated from age, gender-specific predictive equations (Schofield, 1985, see 
below) based on the average body weight of the population as well as PAL values 
calculated for individuals within the population based on their occupation or physical 
activity, and lifestyle characteristics were used to estimate TEE and subsequently the 
average energy requirement for the population.   
 
The Schofield Equation  
This is a method of estimating the basal metabolic rate (BMR) in calories of adult men 
and women.  It is commonly used by dieticians as a means of estimating the total 
calorie intake required to maintain current body mass. This figure can then be used to 
design a dietary regime that places the subject in calorie deficit or surplus, depending 
on whether weight loss or gain is the intended clinical outcome.   205
Men: 
10 - 17 years BMR = 17.7 x W + 657  SEE = 105 
18 - 29 years BMR = 15.1 x W + 692  SEE = 156 
30 - 59 years BMR = 11.5 x W + 873  SEE = 167 
Women: 
10 - 17 years BMR = 13.4 x W + 692  SEE = 112 
18 - 29 years BMR = 14.8 x W + 487  SEE = 120 
30 - 59 years BMR = 8.3 x W + 846   SEE = 112 
Key: W = Body weight in Kilogram; SEE = Standard error of estimation 
The SEE value means the calculated BMR could be this number of calories out, in 
other words either too many or too little.  As an example, if you are very muscular and 
possess more lean weight than an average person of the same height and weight, then 
you may have to add the SEE value to the BMR calculated. The simple reason is more 
lean weight means more calories needed. 
 
Table B1 below is a summary of the estimated means for both PAL and BMR for the 
two groups, which also show disparities between the sexes.   
 
Table B1:  Mean estimates for PAL and BMR compared between the HIV sero-
status groups and sexes in the study population 
Variable 
HIV 
status  n  Mean  95% CI 
#t  
(p value) 




HIV+    216  1.594  1.575 – 1.613 




(0.270)  0.001 
Males  779  1.605  1.595 – 1.615 




(<0.001)  0.008 
PAL (Estimated 
by lifestyle) 
Total  1819 1.592  1.586 - 1.599  -  -  - 
HIV+    214  6.19  6.08 - 6.29 






Males  766  6.52  6.47 - 6.57 








Total  1790 6.16  6.12 - 6.20  -  -  - 
#t – derived from Independent samples t-test statistics.  *F – derived from univariate ANOVA statistics which adjusted for 
gender, age grouping and settlement type.  Statistical significance is denoted by p<0.05.  Eta squared values represent 
the proportion of the variance explained by the exposure. 
 
Although the estimated mean PAL difference between males and females was 
significant (p<0.001), mean estimates between the two groups, which took into 
consideration the gender disparity and proportions, showed that the infected subjects 
had a slightly higher value than their uninfected counterparts even though the   206
difference was not significant even after adjusting for the socio-demographic 
confounders.  With regards to the mean BMR estimated for the groups, table B1 above 
shows also that males had a significantly higher BMR than females (p<0.001).   
However, in comparing the two HIV groups, and considering gender disparities and 
proportions, infected persons tended to have a marginally higher estimated BMR than 
their counterparts, but again the difference was not significant after the adjustment for 
age grouping and settlement type were considered.   
 
From the Schofield equation (TEE or EAER = BMR x PAL) energy requirements were 
calculated for males and females with gender disparities and disproportions in mind.  
The estimated EAERs for both males and females were derived as follows: 
 
EAER (males) = 6.52 x 1.605 = 10.465 MJ/day (i.e. 10465KJ/day), and  
EAER (females) = 5.89 x 1.583 = 9.324 MJ/day (i.e. 9324 KJ/day) 
 
From these derived values, subjects for whom intakes fell below their respective 
gender specific EAER estimates were classified as having poor intakes, whilst those 
whose intakes were equal to or above the EAERs were classified as more likely to 
have adequate or excess energy intakes.   
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APPENDIX C 
CALCULATION OF POST HOC POWER FOR MAIN HYPOTHESIS 
The power calculations in this section are based on the observed effects and only 
comparative results that were not significant would be used.  However, power 
calculations were ignored for effects that are based on very small sample sizes as 
these were more obviously underpowered. 
 
The main hypothesis which states that ‘HIV infected persons are more anaemic in 
comparison with uninfected persons’ has several components.  It presupposes that HIV 
infected persons are more likely to be anaemic as they are also more likely to have 
poor energy and micronutrient intakes, have an increased inflammatory response and 
metabolism leading to lower serum micronutrients and also marked by higher levels of 
positive APP and lower levels of negative APP.  It is these attributes that are 
suggested, together with the direct effects of the virus, to interactively predispose 
infected persons more to anaemia, as the attributes can induce anaemia by 
themselves. 
 
The continuous exposure variables compared between the two HIV groups were as 
follows: 
• Energy  intake 
•  Anthropometry (BMI and LMI) 
•  Serum micronutrients (Vitamins A and E) 
•  Serum/Plasma APP (Total proteins, albumin, globulins, fibrinogen, ferritin) 
•  Liver enzymes (s-ALP, s-GGT, s-ALT, and s-AST) 
 
The equation used for the post hoc power calculation for the continuous variables has 
been derived from the equation for sample size calculation and is described in Margetts 




n = 2 (Z1-α/2 + Z1-β)
2          
=
  
2 (Z1-α/2 + Z1-β)
2         (1) 
(d*/σ)
2               f
2 




By rearranging equation (1) 
f = (Z1-α/2 + Z1-β)√
2/n                                                  (2) 
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And then from equation (2) eqn. (3) is derived as follows: 
Z1-β = f√
n
/2 - Z1-α/2                    ( 3 )  
Where;  Z1-β = Power component 
n = sample size and, 
Z1-α/2 = 1.96 
 
The tables below (Tabs. C1-C3) summarises the derivation of post hoc power (1-β) 
from a list of variables required for calculating the power for each variable that was not 
significantly different between the HIV infected and uninfected groups. 
 
Table C1 










BMI   LMI  
N 212  212  212  212 
d*
 
648.38 437.64  0.10  0.01 
Σ
 
3519.05 3274.62  1.00  1.00 
f (d*/σ)
 











-0.07 -0.57  -0.93  -1.85 
Power (1-β)  47.2 28.4  17.6  3.2 
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Table C2 




Serum Vitamin A  Serum Vitamin E   Plasma Fibrinogen  Serum Ferritin 
N  202 201 210  216 
d*
 
2.11 0.09 0.10  15.11 
Σ
 
15.72 3.11  1.14  106.85 
f (d*/σ)
 













-0.61 -1.67 -1.14  -0.50 








Haemoglobin s-ALP    s-GGT  S-LDH 
N 214  209  209  209 
d*
 
0.32 3.24 3.60  6.57 
Σ
 
2.17 37.58  104.62  33.60 
f (d*/σ)
 





















Power (1-β)  33.4 14.0 5.4  61.6 
 
It is obvious from the post hoc power calculations shown in the tables above that the 
study was generally underpowered (below 80%) for showing any significant differences 
between the two groups for the variables considered.  Given the effect sizes (d*) 
obtained for the various parameters, increasing the sample size (n) could have possibly 
increased the power for the differences to be significant, but as to whether the effect 
sizes were biological significant was also another issue to consider.    
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